{"trials":[{"id":5930,"nct_id":"NCT07818564","title":"Pilot Study on the Effects of Psilocybin on Belief Updating and Insight Formation","sponsor":"Brown University","registry_url":"https://clinicaltrials.gov/study/NCT07818564","tracker_url":"publication.php?id=5930","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-10","last_update_date":"2026-10-08","start_date":"2026-11","primary_completion_date":"2027-11","completion_date":"2027-11","study_type":"INTERVENTIONAL","phases":["PHASE1"],"enrollment":{"count":24,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"BASIC_SCIENCE","masking":"TRIPLE"},"conditions":["Phase I"],"interventions":[{"name":"Psilocybin (Usona Institute)","type":"DRUG"},{"name":"Inactive Placebo (Usona Institute)","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"989968603bde40ea62cec15821beab8b75357cd99d372a1c9c6f3bbeebc55d37","facility":"Brown University School of Public Health","city":"Providence","region":"Rhode Island","country":"United States","lat":41.823990000000002,"lon":-71.41283}],"countries":["United States"]},{"id":5746,"nct_id":"NCT07721467","title":"Neuroplasticity Enhancement From Cognitive Training Reinforced by Psilocybin (NECTAR) in Aging and Alzheimer's Disease","sponsor":"National Institute on Aging (NIA)","registry_url":"https://clinicaltrials.gov/study/NCT07721467","tracker_url":"publication.php?id=5746","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-10-06","last_update_date":"2026-10-08","start_date":"2026-10-13","primary_completion_date":"2030-12-31","completion_date":"2030-12-31","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":200,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"OTHER","masking":"NONE"},"conditions":["Alzheimer's Disease"],"interventions":[{"name":"Psilocybin","type":"DRUG"},{"name":"Cognitive Training","type":"OTHER"}],"substances":["psilocybin"],"sites":[{"key":"28a3d9c38002b595ae213eb3bb81b2024aaf1d5bdcc3b9fd3ac81fe627252323","facility":"National Institute of Aging, Clinical Research Unit","city":"Baltimore","region":"Maryland","country":"United States","lat":39.290379999999999,"lon":-76.612189999999998}],"countries":["United States"]},{"id":3621,"nct_id":"NCT06386003","title":"Psilocybin-Assisted Massed Cognitive Processing Therapy for Chronic Posttraumatic Stress Disorder: An Open-label Trial","sponsor":"Unity Health Toronto","registry_url":"https://clinicaltrials.gov/study/NCT06386003","tracker_url":"publication.php?id=3621","status":"ACTIVE_NOT_RECRUITING","status_label":"Active, not recruiting","status_verified_date":"2025-12","last_update_date":"2026-10-06","start_date":"2026-06-01","primary_completion_date":"2028-01","completion_date":"2028-06","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":15,"type":"ESTIMATED"},"design":{"allocation":"NA","intervention_model":"SINGLE_GROUP","primary_purpose":"TREATMENT","masking":"NONE"},"conditions":["Post Traumatic Stress Disorder","PTSD","Chronic PTSD"],"interventions":[{"name":"Psilocybin","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"f8718ebbb2d22b3721ee7415ff50f53592161a61926e613b38dcc6395cbf5438","facility":"St. Michael's Hospital, Unity Health Toronto","city":"Toronto","region":"Ontario","country":"Canada","lat":43.706429999999997,"lon":-79.39864}],"countries":["Canada"]},{"id":3490,"nct_id":"NCT07570654","title":"A Phase 2b/3, Multicentre, Randomised, Double-blind, Controlled Trial, With an Open Label Extension, to Investigate the Efficacy, Safety, and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder","sponsor":"COMPASS Pathways","registry_url":"https://clinicaltrials.gov/study/NCT07570654","tracker_url":"publication.php?id=3490","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-04","last_update_date":"2026-10-06","start_date":"2026-09","primary_completion_date":"2028-11","completion_date":"2029-09","study_type":"INTERVENTIONAL","phases":["PHASE2","PHASE3"],"enrollment":{"count":300,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"QUADRUPLE"},"conditions":["PTSD - Post Traumatic Stress Disorder","PTSD","PTSD Symptoms","PTSD, Post Traumatic Stress Disorder"],"interventions":[{"name":"COMP360 psilocybin","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"ddc0834a1890df449d67ca69d92e76e6f1b5160403493ab29dfc1c2e1aed69c6","facility":"FL","city":"Miami","region":"Florida","country":"United States","lat":25.774270000000001,"lon":-80.193659999999994},{"key":"4b235d9fa455f60193f31a0d89a5dee284e9661ca9046ed4a1e57536aca09d6f","facility":"FL","city":"Orlando","region":"Florida","country":"United States","lat":28.538340000000002,"lon":-81.379239999999996},{"key":"a3f3b33aa62b155795dadc7cd5bdf343b9f66b44bc44a2ad0d5ee5fa338c2557","facility":"IL","city":"Chicago","region":"Illinois","country":"United States","lat":41.850029999999997,"lon":-87.650049999999993},{"key":"dbbb51357e4d710396c355b1f980917dd53615a81be8d319622d67aba5bb4e0e","facility":"MN","city":"Eden Prairie","region":"Minnesota","country":"United States","lat":44.854689999999998,"lon":-93.470789999999994},{"key":"c3798f7e7cf15a4eef1a10f53d46184aaf3eec07c5a23828e9e7a968feadf7db","facility":"NE","city":"Lincoln","region":"Nebraska","country":"United States","lat":40.799999999999997,"lon":-96.666960000000003},{"key":"1d793527c906ffb5c84860c6577d23027344e23eb25b29e2b74f8a07d64f5514","facility":"NV","city":"Las Vegas","region":"Nevada","country":"United States","lat":36.174970000000002,"lon":-115.13722},{"key":"6214ddb8e0d6a9b9b5b4cd7c9be7f1b1f04d1f4f17ff5715a68f589a0d3c671a","facility":"NY","city":"New York","region":"New York","country":"United States","lat":40.714269999999999,"lon":-74.005970000000005},{"key":"593189837e8532b432a369deaaa9a95dd6d9069e9ee0f7d4f302734d14cb430e","facility":"BC","city":"North Vancouver","region":"British Columbia","country":"Canada","lat":49.316360000000003,"lon":-123.06934}],"countries":["United States","Canada"]},{"id":3608,"nct_id":"NCT06041152","title":"Does Psilocybin Change Synaptic Density in the Brains of Patients With Amnestic Mild Cognitive Impairment","sponsor":"Centre for Addiction and Mental Health","registry_url":"https://clinicaltrials.gov/study/NCT06041152","tracker_url":"publication.php?id=3608","status":"COMPLETED","status_label":"Completed","status_verified_date":"2026-09","last_update_date":"2026-10-05","start_date":"2023-11-27","primary_completion_date":"2026-02-19","completion_date":"2026-02-19","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":10,"type":"ACTUAL"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"OTHER","masking":"QUADRUPLE"},"conditions":["Amnestic Mild Cognitive Impairment"],"interventions":[{"name":"Psilocybin","type":"DRUG"},{"name":"Placebo","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"bf2adfb756d244974a952f7c5c58e6f72f66cbbd5ba63e61a8b987fa1820f128","facility":"Centre for Addiction and Mental Health","city":"Toronto","region":"Ontario","country":"Canada","lat":43.706429999999997,"lon":-79.39864}],"countries":["Canada"]},{"id":3555,"nct_id":"NCT07227909","title":"NeuroGuard: Psilocybin Trial for Preventing Chemo-induced Neuropathy","sponsor":"M.D. Anderson Cancer Center","registry_url":"https://clinicaltrials.gov/study/NCT07227909","tracker_url":"publication.php?id=3555","status":"NOT_YET_RECRUITING","status_label":"Not yet recruiting","status_verified_date":"2026-09","last_update_date":"2026-10-05","start_date":"2026-11-04","primary_completion_date":"2029-01-31","completion_date":"2031-01-31","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":83,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"SUPPORTIVE_CARE","masking":"NONE"},"conditions":["Psilocybin","Neuropathy"],"interventions":[{"name":"Psilocybin (drug)","type":"DRUG"},{"name":"Standard of Care (SOC)","type":"OTHER"}],"substances":["psilocybin"],"sites":[{"key":"3a46b1d6e7fd8e6d4ac3522c52ea258b11d52f64ed81a85f442fdb36db5182f6","facility":"MD Anderson Cancer Center","city":"Houston","region":"Texas","country":"United States","lat":29.763280000000002,"lon":-95.36327}],"countries":["United States"]},{"id":5969,"nct_id":"NCT07852832","title":"Open-label, Single-arm fMRI Study Evaluating the Effects of Psilocybin on Craving in Nicotine Dependence.","sponsor":"University of British Columbia","registry_url":"https://clinicaltrials.gov/study/NCT07852832","tracker_url":"publication.php?id=5969","status":"NOT_YET_RECRUITING","status_label":"Not yet recruiting","status_verified_date":"2026-09","last_update_date":"2026-10-01","start_date":"2027-01","primary_completion_date":"2027-12","completion_date":"2028-01","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":3,"type":"ESTIMATED"},"design":{"allocation":"NA","intervention_model":"SINGLE_GROUP","primary_purpose":"BASIC_SCIENCE","masking":"NONE"},"conditions":["Nicotine Dependence"],"interventions":[{"name":"Psilocybin (drug)","type":"DRUG"}],"substances":["psilocybin"],"sites":[],"countries":[]},{"id":3686,"nct_id":"NCT07610135","title":"PRISMatic: A Phase 1b Randomized, Double-Armed, Parallel-Group, Placebo-Controlled Trial of Psilocybin Efficacy With or Without Pimavanserin Pretreatment","sponsor":"Johns Hopkins University","registry_url":"https://clinicaltrials.gov/study/NCT07610135","tracker_url":"publication.php?id=3686","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-09","last_update_date":"2026-10-01","start_date":"2026-10-30","primary_completion_date":"2028-06","completion_date":"2028-12","study_type":"INTERVENTIONAL","phases":["PHASE1","PHASE2"],"enrollment":{"count":20,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"BASIC_SCIENCE","masking":"QUADRUPLE"},"conditions":["Mood (Psychological Function)","Well Being","Mood","Healthy"],"interventions":[{"name":"Psilocybin","type":"DRUG"},{"name":"Pimavanserin","type":"DRUG"},{"name":"Inactive Placebo","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"9d7c1530695da1e0dbe5d0029c61521b74c434cedec820dcadef26feb9ead43e","facility":"Johns Hopkins Center for Psychedelic and Consciousness Research","city":"Baltimore","region":"Maryland","country":"United States","lat":39.290379999999999,"lon":-76.612189999999998}],"countries":["United States"]},{"id":3660,"nct_id":"NCT07332143","title":"The Safety and Acceptability of Psilocybin With Support and With Massed Prolonged Exposure Therapy for PTSD","sponsor":"Emory University","registry_url":"https://clinicaltrials.gov/study/NCT07332143","tracker_url":"publication.php?id=3660","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-09","last_update_date":"2026-10-01","start_date":"2026-06-08","primary_completion_date":"2027-03","completion_date":"2027-03","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":150,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"NONE"},"conditions":["PTSD"],"interventions":[{"name":"psilocybin","type":"DRUG"},{"name":"Supportive Therapy","type":"BEHAVIORAL"},{"name":"Prolonged Exposure Therapy","type":"BEHAVIORAL"}],"substances":["psilocybin"],"sites":[{"key":"8d12e2a0185c4db904e4654a720cc76843665c984d8a6666af2af6398451abcf","facility":"Emory University Hospital","city":"Atlanta","region":"Georgia","country":"United States","lat":33.749000000000002,"lon":-84.387979999999999}],"countries":["United States"]},{"id":3693,"nct_id":"NCT07360301","title":"Consciousness and Psilocybin Effects on Well-Being: The CoPEWell Study","sponsor":"University of Wisconsin, Madison","registry_url":"https://clinicaltrials.gov/study/NCT07360301","tracker_url":"publication.php?id=3693","status":"NOT_YET_RECRUITING","status_label":"Not yet recruiting","status_verified_date":"2026-06","last_update_date":"2026-09-29","start_date":"2026-10","primary_completion_date":"2028-02","completion_date":"2028-02","study_type":"INTERVENTIONAL","phases":["PHASE1"],"enrollment":{"count":120,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"BASIC_SCIENCE","masking":"DOUBLE"},"conditions":["Well-Being, Psychological","Psychedelic Experiences"],"interventions":[{"name":"Psilocybin","type":"DRUG"},{"name":"Saline Placebo","type":"OTHER"},{"name":"Clonidine","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"0fef037c24d643378aa9f37a26412f8308ddc2ac490d10c8ef10ee242ac4bfb8","facility":"University of Wisconsin","city":"Madison","region":"Wisconsin","country":"United States","lat":43.073050000000002,"lon":-89.401229999999998}],"countries":["United States"]},{"id":5845,"nct_id":"NCT07610369","title":"The Efficacy of Psilocybin Therapy for Depression in Parkinson's Disease","sponsor":"Yale University","registry_url":"https://clinicaltrials.gov/study/NCT07610369","tracker_url":"publication.php?id=5845","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-09","last_update_date":"2026-09-28","start_date":"2026-07-10","primary_completion_date":"2030-07","completion_date":"2030-07","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":40,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"QUADRUPLE"},"conditions":["Depression","Parkinson's Disease (PD)"],"interventions":[{"name":"Psilocybin (drug)","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"ce511e3de8dae05034afdb25043c5e28d581eecc32497eda1b36dd3837c67ae4","facility":"Yale University","city":"New Haven","region":"Connecticut","country":"United States","lat":41.308149999999998,"lon":-72.928160000000005}],"countries":["United States"]},{"id":3705,"nct_id":"NCT07449351","title":"Effects of Psilocybin Microdosing on Cognition, Mood and Quality of Life: A Pilot Study","sponsor":"Yale University","registry_url":"https://clinicaltrials.gov/study/NCT07449351","tracker_url":"publication.php?id=3705","status":"NOT_YET_RECRUITING","status_label":"Not yet recruiting","status_verified_date":"2026-06","last_update_date":"2026-09-24","start_date":"2026-10-01","primary_completion_date":"2028-04-01","completion_date":"2028-04-01","study_type":"INTERVENTIONAL","phases":["EARLY_PHASE1"],"enrollment":{"count":20,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"BASIC_SCIENCE","masking":"DOUBLE"},"conditions":["Psychedelic Microdosing Effects on Mood, Cognition, Subjective Well-being and MRI"],"interventions":[{"name":"Psliocybin","type":"DRUG"},{"name":"Placebo","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"2a5127e58b092bb500853eb27d6f1063d5c783b90322382c367deb6192edd0bc","facility":"Olin Neuropsychiatry Research Center","city":"Hartford","region":"Connecticut","country":"United States","lat":41.763710000000003,"lon":-72.685090000000002}],"countries":["United States"]},{"id":3529,"nct_id":"NCT06299319","title":"Evaluating the Feasibility, Clinical Effects, and Safety of Psilocybin-assisted Psychotherapy for Treatment-resistant Obsessive-compulsive Disorder: An Open-label Clinical Trial","sponsor":"Centre for Addiction and Mental Health","registry_url":"https://clinicaltrials.gov/study/NCT06299319","tracker_url":"publication.php?id=3529","status":"COMPLETED","status_label":"Completed","status_verified_date":"2026-03","last_update_date":"2026-09-24","start_date":"2024-09-01","primary_completion_date":"2026-09-04","completion_date":"2026-09-04","study_type":"INTERVENTIONAL","phases":["PHASE1"],"enrollment":{"count":10,"type":"ACTUAL"},"design":{"allocation":"NA","intervention_model":"SINGLE_GROUP","primary_purpose":"TREATMENT","masking":"NONE"},"conditions":["Obsessive-Compulsive Disorder"],"interventions":[{"name":"Psilocybin","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"bf2adfb756d244974a952f7c5c58e6f72f66cbbd5ba63e61a8b987fa1820f128","facility":"Centre for Addiction and Mental Health","city":"Toronto","region":"Ontario","country":"Canada","lat":43.706429999999997,"lon":-79.39864}],"countries":["Canada"]},{"id":3440,"nct_id":"NCT07296094","title":"Psilocybin-Assisted Psychotherapy for the Treatment of Severe Alcohol Use Disorder: A Double-Blind, Dose-Comparison Concurrent Control Randomized Trial","sponsor":"Brigham and Women's Hospital","registry_url":"https://clinicaltrials.gov/study/NCT07296094","tracker_url":"publication.php?id=3440","status":"NOT_YET_RECRUITING","status_label":"Not yet recruiting","status_verified_date":"2026-09","last_update_date":"2026-09-24","start_date":"2026-11-15","primary_completion_date":"2029-12-01","completion_date":"2030-02","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":36,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"QUADRUPLE"},"conditions":["Alcohol Use Disorder"],"interventions":[{"name":"Psilocybin","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"ea17498fc8f1ee10ccde7d5207d959cb8f2fd7095ee234897659fb05d1422118","facility":"Brigham and Women's Hospital","city":"Boston","region":"Massachusetts","country":"United States","lat":42.358429999999998,"lon":-71.05977}],"countries":["United States"]},{"id":3455,"nct_id":"NCT06988319","title":"Psilocybin for Chronic Pelvic Pain (CPP) in Women: A Pilot Feasibility Study","sponsor":"Oregon Health and Science University","registry_url":"https://clinicaltrials.gov/study/NCT06988319","tracker_url":"publication.php?id=3455","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-09","last_update_date":"2026-09-23","start_date":"2026-11-01","primary_completion_date":"2027-12-31","completion_date":"2027-12-31","study_type":"INTERVENTIONAL","phases":["PHASE1"],"enrollment":{"count":15,"type":"ESTIMATED"},"design":{"allocation":"NA","intervention_model":"SINGLE_GROUP","primary_purpose":"TREATMENT","masking":"NONE"},"conditions":["Chronic Pelvic Pain"],"interventions":[{"name":"Psilocybin (Usona Institute)","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"c0770de3d29c4c5f32a2af8475f2c25f664dc150eb0612e3bad6f32b5afb5313","facility":"Oregon Health & Science University","city":"Portland","region":"Oregon","country":"United States","lat":45.523449999999997,"lon":-122.67621}],"countries":["United States"]},{"id":5953,"nct_id":"NCT07833761","title":"ADEPT: Augmenting DBT Effectiveness With Psilocybin-Assisted Therapy","sponsor":"University of Minnesota","registry_url":"https://clinicaltrials.gov/study/NCT07833761","tracker_url":"publication.php?id=5953","status":"NOT_YET_RECRUITING","status_label":"Not yet recruiting","status_verified_date":"2026-09","last_update_date":"2026-09-22","start_date":"2026-12-01","primary_completion_date":"2029-12-31","completion_date":"2030-12-31","study_type":"INTERVENTIONAL","phases":["PHASE1"],"enrollment":{"count":18,"type":"ESTIMATED"},"design":{"allocation":"NA","intervention_model":"SINGLE_GROUP","primary_purpose":"TREATMENT","masking":"NONE"},"conditions":["Borderline Personality Disorder","Borderline Personality Pathology","Depressive Symptoms","Emotion Dysregulation","Suicidal Ideation"],"interventions":[{"name":"Psilocybin","type":"DRUG"},{"name":"Psilocybin-Assisted Therapy With Dialectical Behavior Therapy","type":"BEHAVIORAL"}],"substances":["psilocybin"],"sites":[{"key":"463b7eaf2831972976c6ab2249631d9a0d7323ad764555861eab134acf615949","facility":"M Health Fairview DBT Program","city":"Minneapolis","region":"Minnesota","country":"United States","lat":44.979970000000002,"lon":-93.263840000000002},{"key":"3999afea2dfc9e525a89b295c634b8873c7c49f65315ca0aa8ba0398d13bf73b","facility":"M Physicians St. Louis Park Clinic","city":"Saint Louis Park","region":"Minnesota","country":"United States","lat":44.948300000000003,"lon":-93.348010000000002}],"countries":["United States"]},{"id":5872,"nct_id":"NCT07774702","title":"Psilocybin in the Treatment of Methamphetamine Use Disorder","sponsor":"Peter Hendricks","registry_url":"https://clinicaltrials.gov/study/NCT07774702","tracker_url":"publication.php?id=5872","status":"NOT_YET_RECRUITING","status_label":"Not yet recruiting","status_verified_date":"2026-09","last_update_date":"2026-09-21","start_date":"2027-02-01","primary_completion_date":"2032-02-01","completion_date":"2032-02-01","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":42,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"QUADRUPLE"},"conditions":["Methamphetamine Use Disorder"],"interventions":[{"name":"Psilocybin (single oral capsule administered at one of two dose levels, Dose A or Dose B; specific doses withheld during conduct).","type":"DRUG"},{"name":"Manualized cognitive behavioral therapy platform (2 preparation + 2 integration sessions).","type":"BEHAVIORAL"}],"substances":["psilocybin"],"sites":[{"key":"7ce22b002e53ab5c3978b99f32427c645bc1173311a77a8658068ba9bbf879bc","facility":"University of Alabama at Birmingham","city":"Birmingham","region":"Alabama","country":"United States","lat":33.520659999999999,"lon":-86.802490000000006}],"countries":["United States"]},{"id":3575,"nct_id":"NCT07210112","title":"Efficacy of Psilocybin and Trazodone Combination in Treatment-resistant Depression: a Randomized Controlled Proof-of-concept Study (PSILOTRAZ)","sponsor":"Centre Hospitalier St Anne","registry_url":"https://clinicaltrials.gov/study/NCT07210112","tracker_url":"publication.php?id=3575","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-06","last_update_date":"2026-09-21","start_date":"2026-06-30","primary_completion_date":"2029-12-31","completion_date":"2030-06-30","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":112,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"QUADRUPLE"},"conditions":["Depression - Major Depressive Disorder","Treatment-resistant Depression (TRD)"],"interventions":[{"name":"Psilocybin 25 mg per os","type":"DRUG"},{"name":"Trazodone 5mg","type":"DRUG"},{"name":"Trazodone 30 mg","type":"DRUG"},{"name":"Placebo of psilocybin","type":"DRUG"},{"name":"Placebo of trazodone","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"20f0c712ea58b6615610fe11e7cff939bcc55adfffcd8761309ca251e8acfc7d","facility":"GHU Paris Psychiatrie and Neurosciences","city":"Paris","region":"","country":"France","lat":48.853409999999997,"lon":2.3488000000000002}],"countries":["France"]},{"id":3495,"nct_id":"NCT07516405","title":"A Multicenter Phase 1 Safety and Tolerability Trial of Psilocybin in Healthy Older Adults","sponsor":"University of Colorado, Denver","registry_url":"https://clinicaltrials.gov/study/NCT07516405","tracker_url":"publication.php?id=3495","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-09","last_update_date":"2026-09-16","start_date":"2026-04-01","primary_completion_date":"2028-03","completion_date":"2028-03","study_type":"INTERVENTIONAL","phases":["PHASE1"],"enrollment":{"count":40,"type":"ESTIMATED"},"design":{"allocation":"NA","intervention_model":"SINGLE_GROUP","primary_purpose":"TREATMENT","masking":"NONE"},"conditions":["Healthy Volunteer","Older Adults (65-85 Years)"],"interventions":[{"name":"Psilocybin (Usona Institute)","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"43d57f1d479805418491a2b4e825f4a61463da217d6483cb15a9c517f345d284","facility":"University of California San Francisco (UCSF) Department of Neurology","city":"San Francisco","region":"California","country":"United States","lat":37.774929999999998,"lon":-122.41942},{"key":"0473ab642c74b3812c946daf78fe3c51c20132227d55cd3b18f186955bf391f2","facility":"University of Colorado Anschutz Medical Campus","city":"Aurora","region":"Colorado","country":"United States","lat":39.729430000000001,"lon":-104.83192},{"key":"2392816208ad8a6692839d858f70a09054f7ea063608cc805707f539d666e13b","facility":"Emory University Brain Health Center","city":"Atlanta","region":"Georgia","country":"United States","lat":33.749000000000002,"lon":-84.387979999999999},{"key":"6f007287e1a63fa09fd71b03e4e4b72f285c5af84c8385a3eed252bc9a13b363","facility":"Dana-Farber Cancer Institute","city":"Boston","region":"Massachusetts","country":"United States","lat":42.358429999999998,"lon":-71.05977},{"key":"22268aacd3575a268c889e749c8576127c9bff8a9e8343b4058a94d77d976383","facility":"University of Nebraska Medical Center","city":"Omaha","region":"Nebraska","country":"United States","lat":41.256259999999997,"lon":-95.940430000000006},{"key":"bf586d38e3cc5e261d1c6e575c24ec47a2175ffd3a3a156c666afe314b54f80c","facility":"New York University Langone Health, Center for Psychedelic Medicine","city":"New York","region":"New York","country":"United States","lat":40.714269999999999,"lon":-74.005970000000005}],"countries":["United States"]},{"id":5935,"nct_id":"NCT07820033","title":"Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) Therapy for Patients With Advanced Cancer: A Randomized Controlled Trial","sponsor":"University Health Network, Toronto","registry_url":"https://clinicaltrials.gov/study/NCT07820033","tracker_url":"publication.php?id=5935","status":"NOT_YET_RECRUITING","status_label":"Not yet recruiting","status_verified_date":"2026-09","last_update_date":"2026-09-15","start_date":"2026-09-14","primary_completion_date":"2028-12-30","completion_date":"2029-07-30","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":46,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"SUPPORTIVE_CARE","masking":"TRIPLE"},"conditions":["Advanced Cancer","Stage IV Solid Tumor Cancer","Stage IV Sarcoma of Bone","Stage IV Lymphoma","Stage IV Melanoma","Endocrine Cancer"],"interventions":[{"name":"Psilocybin (25mg)","type":"DRUG"},{"name":"Psilocybin (1mg)","type":"DRUG"},{"name":"PEARL Therapy","type":"OTHER"}],"substances":["psilocybin"],"sites":[{"key":"94f32ec7d881a5dcad883b92fb978930f07259cffee3dda1527eba86a2d3e8bc","facility":"University Health Network","city":"Toronto","region":"Ontario","country":"Canada","lat":43.706429999999997,"lon":-79.39864}],"countries":["Canada"]},{"id":3709,"nct_id":"NCT07180108","title":"PRoMiSS: Psilocybin and the Role of Music in Set and Setting","sponsor":"Johns Hopkins University","registry_url":"https://clinicaltrials.gov/study/NCT07180108","tracker_url":"publication.php?id=3709","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-09","last_update_date":"2026-09-15","start_date":"2025-08-12","primary_completion_date":"2028-06","completion_date":"2028-08","study_type":"INTERVENTIONAL","phases":["PHASE1"],"enrollment":{"count":100,"type":"ESTIMATED"},"design":{"allocation":"NA","intervention_model":"SINGLE_GROUP","primary_purpose":"BASIC_SCIENCE","masking":"NONE"},"conditions":["Psilocybin","Music Intervention"],"interventions":[{"name":"Psilocybin (high dose)","type":"DRUG"},{"name":"Playlist 1","type":"BEHAVIORAL"},{"name":"Playlist 2","type":"BEHAVIORAL"},{"name":"Playlist 3","type":"BEHAVIORAL"},{"name":"Playlist 4","type":"BEHAVIORAL"},{"name":"Playlist 5","type":"BEHAVIORAL"}],"substances":["psilocybin"],"sites":[{"key":"fdeccc6664a6555feb9443c7f9547c8dc94264e878e864489fd4b43c0a16451a","facility":"Center for Psychedelics and Consciousness Research in the Behavioral Biology Research Center","city":"Baltimore","region":"Maryland","country":"United States","lat":39.290379999999999,"lon":-76.612189999999998}],"countries":["United States"]},{"id":3607,"nct_id":"NCT07607938","title":"Targeting Reward Circuits: Psilocybin as a Novel Therapy for Residual Anhedonia","sponsor":"NYU Langone Health","registry_url":"https://clinicaltrials.gov/study/NCT07607938","tracker_url":"publication.php?id=3607","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-09","last_update_date":"2026-09-15","start_date":"2026-09","primary_completion_date":"2030-08-01","completion_date":"2030-09-30","study_type":"INTERVENTIONAL","phases":["PHASE1"],"enrollment":{"count":90,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"TRIPLE"},"conditions":["Anhedonia","Emotional Blunting"],"interventions":[{"name":"Psilocybin","type":"DRUG"},{"name":"Placebo","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"f013c15d8112693910d9bf055f39dc54c2a9c3749b21ac7dacc4c09c7de423df","facility":"NYU Langone Health","city":"New York","region":"New York","country":"United States","lat":40.714269999999999,"lon":-74.005970000000005}],"countries":["United States"]},{"id":3600,"nct_id":"NCT06943573","title":"Psilocybin-Assisted Therapy for Treatment-Resistant Depression in Bipolar II Disorder: A Randomized Controlled Trial","sponsor":"Lakshmi N Yatham","registry_url":"https://clinicaltrials.gov/study/NCT06943573","tracker_url":"publication.php?id=3600","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-08","last_update_date":"2026-09-15","start_date":"2026-06-15","primary_completion_date":"2028-12","completion_date":"2028-12","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":90,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"QUADRUPLE"},"conditions":["Bipolar II Depression"],"interventions":[{"name":"psilocybin (25 mg)","type":"DRUG"},{"name":"psilocybin 1mg micro-dose","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"b080767d21c0ebe8aea0aba1c3f1a88355bed0e01997cb41cb5704abd0b086dc","facility":"Djavad Mowafaghian Centre for Brain Health","city":"Vancouver","region":"British Columbia","country":"Canada","lat":49.249659999999999,"lon":-123.11933999999999},{"key":"aa8f99cb753e6ee68d3c63b2cdb1b7e7d90b1680cb84bc239d625d80bd4e6c8b","facility":"Department of Psychiatry, University of Ottawa, The Ottawa Hospital","city":"Ottawa","region":"Ontario","country":"Canada","lat":45.411169999999998,"lon":-75.698120000000003},{"key":"ab54d44984a52b7a2aba12f9808b881d3f2fa4a702669885a0a10983ba498e39","facility":"Department of Psychiatry, University of Toronto, University Health Network,","city":"Toronto","region":"Ontario","country":"Canada","lat":43.706429999999997,"lon":-79.39864}],"countries":["Canada"]},{"id":5931,"nct_id":"NCT07818720","title":"A Phase 1b Study to Evaluate the Safety and Tolerability of MLS101 Treatment for Premenstrual Dysphoric Disorder (PMDD)","sponsor":"MycoMedica Life Sciences PBC","registry_url":"https://clinicaltrials.gov/study/NCT07818720","tracker_url":"publication.php?id=5931","status":"NOT_YET_RECRUITING","status_label":"Not yet recruiting","status_verified_date":"2026-09","last_update_date":"2026-09-14","start_date":"2026-12","primary_completion_date":"2027-09","completion_date":"2027-12","study_type":"INTERVENTIONAL","phases":["PHASE1"],"enrollment":{"count":32,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"QUADRUPLE"},"conditions":["Premenstrual Dysphoric Disorder ( PMDD)","PMDD"],"interventions":[{"name":"MLS101 psilocybin","type":"DRUG"},{"name":"Placebo capsules","type":"DRUG"}],"substances":["psilocybin"],"sites":[],"countries":[]},{"id":3525,"nct_id":"NCT07565493","title":"Psilocybin Administration With 5-HT1a Blockade","sponsor":"Johns Hopkins University","registry_url":"https://clinicaltrials.gov/study/NCT07565493","tracker_url":"publication.php?id=3525","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-09","last_update_date":"2026-09-14","start_date":"2026-08-12","primary_completion_date":"2028-06-15","completion_date":"2028-06-15","study_type":"INTERVENTIONAL","phases":["EARLY_PHASE1"],"enrollment":{"count":18,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"CROSSOVER","primary_purpose":"BASIC_SCIENCE","masking":"TRIPLE"},"conditions":["Psychedelic Effects in Healthy Volunteers"],"interventions":[{"name":"Pindolol","type":"DRUG"},{"name":"Placebo","type":"DRUG"},{"name":"Psilocybin","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"5694dcf845a6c481e3dda16b85afa7a73d3936087eefe461fcc9694177d080de","facility":"Center for Psychedelics and Consciousness Research","city":"Baltimore","region":"Maryland","country":"United States","lat":39.290379999999999,"lon":-76.612189999999998}],"countries":["United States"]},{"id":3684,"nct_id":"NCT06200155","title":"TRIP - TReatment to Improve Depression and/or Anxiety Using Psilocybin-Assisted Psychotherapy in Patients With Advanced Cancer on Maintenance Therapy","sponsor":"M.D. Anderson Cancer Center","registry_url":"https://clinicaltrials.gov/study/NCT06200155","tracker_url":"publication.php?id=3684","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-09","last_update_date":"2026-09-11","start_date":"2024-04-16","primary_completion_date":"2026-12-31","completion_date":"2026-12-31","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":48,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"SUPPORTIVE_CARE","masking":"QUADRUPLE"},"conditions":["Depression, Anxiety","Psilocybin-Assisted Psychotherapy","Advanced Cancer"],"interventions":[{"name":"Psilocybin","type":"DRUG"},{"name":"Niacin","type":"OTHER"}],"substances":["psilocybin"],"sites":[{"key":"3a46b1d6e7fd8e6d4ac3522c52ea258b11d52f64ed81a85f442fdb36db5182f6","facility":"MD Anderson Cancer Center","city":"Houston","region":"Texas","country":"United States","lat":29.763280000000002,"lon":-95.36327}],"countries":["United States"]},{"id":3479,"nct_id":"NCT06615908","title":"A Randomized Double-blinded Controlled Trial for the Treatment of Persisting Symptoms After Concussion With Psilocybin-assisted Therapy: A Safety and Feasibility Trial","sponsor":"University of Calgary","registry_url":"https://clinicaltrials.gov/study/NCT06615908","tracker_url":"publication.php?id=3479","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-09","last_update_date":"2026-09-09","start_date":"2025-05-27","primary_completion_date":"2027-06-30","completion_date":"2027-12-30","study_type":"INTERVENTIONAL","phases":["PHASE1"],"enrollment":{"count":40,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"QUADRUPLE"},"conditions":["Persisting Symptoms After Concussion"],"interventions":[{"name":"Psilocybin","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"43d6a4c1bec6b0da7fbcdcf29f22e29eb9ee146f88b69aa1d4bc718a46bed666","facility":"University of Calgary","city":"Calgary","region":"Alberta","country":"Canada","lat":51.050109999999997,"lon":-114.08529}],"countries":["Canada"]},{"id":3452,"nct_id":"NCT07386730","title":"A Double Blind, Randomized Trial Investigating the Safety, Feasibility, and Mechanisms of Psychedelics in Healthy Older Adults With Low Well-being as Moderated by Biomarkers for Preclinical Alzheimer's Disease","sponsor":"Jennifer Mitchell","registry_url":"https://clinicaltrials.gov/study/NCT07386730","tracker_url":"publication.php?id=3452","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2025-12","last_update_date":"2026-09-09","start_date":"2026-06-01","primary_completion_date":"2030-02","completion_date":"2030-02","study_type":"INTERVENTIONAL","phases":["PHASE1"],"enrollment":{"count":80,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"TRIPLE"},"conditions":["Anhedonia in Healthy Volunteers","Older Adults (50-90 Years)"],"interventions":[{"name":"Psilocybin (drug)","type":"DRUG"},{"name":"Dextromethorphan (DXM)","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"52bc2180526f10b62a5aca748b84f9b3b723aee40e4b7ba311fbe63f85e74ca8","facility":"University of California San Francisco, Sandler Neuroscience Building","city":"San Francisco","region":"California","country":"United States","lat":37.774929999999998,"lon":-122.41942}],"countries":["United States"]},{"id":3511,"nct_id":"NCT06885996","title":"Psilocybin-assisted Therapy for Post-Traumatic Stress Disorder in Survivors of Intimate Partner Violence","sponsor":"University of Calgary","registry_url":"https://clinicaltrials.gov/study/NCT06885996","tracker_url":"publication.php?id=3511","status":"NOT_YET_RECRUITING","status_label":"Not yet recruiting","status_verified_date":"2026-09","last_update_date":"2026-09-08","start_date":"2026-10-01","primary_completion_date":"2028-08-01","completion_date":"2029-08-01","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":76,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"QUADRUPLE"},"conditions":["Post Traumatic Stress Disorder PTSD","Intimate Partner Violence (IPV)"],"interventions":[{"name":"Psilocybin","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"43d6a4c1bec6b0da7fbcdcf29f22e29eb9ee146f88b69aa1d4bc718a46bed666","facility":"University of Calgary","city":"Calgary","region":"Alberta","country":"Canada","lat":51.050109999999997,"lon":-114.08529},{"key":"43285f7204d9fc6f3ca9d5dde05a28e488488aa9f5a73593374801c5dfe5dfe0","facility":"The University of British Columbia - Okanagan Campus","city":"Kelowna","region":"British Columbia","country":"Canada","lat":49.883069999999996,"lon":-119.48568}],"countries":["Canada"]},{"id":3651,"nct_id":"NCT05546658","title":"Effects of Psilocybin in Obsessive Compulsive Disorder","sponsor":"Johns Hopkins University","registry_url":"https://clinicaltrials.gov/study/NCT05546658","tracker_url":"publication.php?id=3651","status":"ACTIVE_NOT_RECRUITING","status_label":"Active, not recruiting","status_verified_date":"2026-09","last_update_date":"2026-09-04","start_date":"2022-11-28","primary_completion_date":"2026-12-30","completion_date":"2027-09-12","study_type":"INTERVENTIONAL","phases":["EARLY_PHASE1"],"enrollment":{"count":35,"type":"ACTUAL"},"design":{"allocation":"RANDOMIZED","intervention_model":"CROSSOVER","primary_purpose":"TREATMENT","masking":"NONE"},"conditions":["Obsessive-Compulsive Disorder"],"interventions":[{"name":"Psilocybin","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"b1b7385307b2710c76b5175c36619a7edcaff39e015a0a2e8cb2e1b125a2f6bb","facility":"Johns Hopkins University School of Medicine","city":"Baltimore","region":"Maryland","country":"United States","lat":39.290379999999999,"lon":-76.612189999999998}],"countries":["United States"]},{"id":3604,"nct_id":"NCT04123314","title":"Pilot Study of Serotonin 2A Receptor (5-HT2A) Agonist Psilocybin for Depression in Patients With Mild Cognitive Impairment or Early Alzheimer's Disease","sponsor":"Johns Hopkins University","registry_url":"https://clinicaltrials.gov/study/NCT04123314","tracker_url":"publication.php?id=3604","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-09","last_update_date":"2026-09-04","start_date":"2021-03-24","primary_completion_date":"2027-06-30","completion_date":"2027-09-30","study_type":"INTERVENTIONAL","phases":["EARLY_PHASE1"],"enrollment":{"count":20,"type":"ESTIMATED"},"design":{"allocation":"NA","intervention_model":"SINGLE_GROUP","primary_purpose":"TREATMENT","masking":"NONE"},"conditions":["Depressive Symptoms","Depression","Alzheimer Disease","Mild Cognitive Impairment"],"interventions":[{"name":"Psilocybin","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"9d7c1530695da1e0dbe5d0029c61521b74c434cedec820dcadef26feb9ead43e","facility":"Johns Hopkins Center for Psychedelic and Consciousness Research","city":"Baltimore","region":"Maryland","country":"United States","lat":39.290379999999999,"lon":-76.612189999999998}],"countries":["United States"]},{"id":3590,"nct_id":"NCT06355414","title":"Psilocybin and Affective Function in Chronic Lower Back Pain Depression","sponsor":"Johns Hopkins University","registry_url":"https://clinicaltrials.gov/study/NCT06355414","tracker_url":"publication.php?id=3590","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-09","last_update_date":"2026-09-04","start_date":"2024-04-22","primary_completion_date":"2026-12-30","completion_date":"2026-12-30","study_type":"INTERVENTIONAL","phases":["PHASE1"],"enrollment":{"count":40,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"TRIPLE"},"conditions":["Chronic Low-back Pain","Depression"],"interventions":[{"name":"Psilocybin","type":"DRUG"},{"name":"Methylphenidate","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"b1b7385307b2710c76b5175c36619a7edcaff39e015a0a2e8cb2e1b125a2f6bb","facility":"Johns Hopkins University School of Medicine","city":"Baltimore","region":"Maryland","country":"United States","lat":39.290379999999999,"lon":-76.612189999999998}],"countries":["United States"]},{"id":3552,"nct_id":"NCT06989957","title":"Psilocybin and MDMA for Post-traumatic Stress Disorder (PTSD)","sponsor":"Johns Hopkins University","registry_url":"https://clinicaltrials.gov/study/NCT06989957","tracker_url":"publication.php?id=3552","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-09","last_update_date":"2026-09-04","start_date":"2025-09-17","primary_completion_date":"2028-08","completion_date":"2029-08","study_type":"INTERVENTIONAL","phases":["PHASE1"],"enrollment":{"count":40,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"DOUBLE"},"conditions":["Posttraumatic Stress Disorder"],"interventions":[{"name":"Psilocybin","type":"DRUG"},{"name":"MDMA","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"9d7c1530695da1e0dbe5d0029c61521b74c434cedec820dcadef26feb9ead43e","facility":"Johns Hopkins Center for Psychedelic and Consciousness Research","city":"Baltimore","region":"Maryland","country":"United States","lat":39.290379999999999,"lon":-76.612189999999998}],"countries":["United States"]},{"id":3436,"nct_id":"NCT06430541","title":"Study of Psilocybin Assisted Psychotherapy to Address Fear of Recurrence in Patients Diagnosed With Early-stage Breast Cancer and Ovarian Cancer in Remission","sponsor":"University of Colorado, Denver","registry_url":"https://clinicaltrials.gov/study/NCT06430541","tracker_url":"publication.php?id=3436","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-09","last_update_date":"2026-09-04","start_date":"2024-11-21","primary_completion_date":"2026-12","completion_date":"2028-12","study_type":"INTERVENTIONAL","phases":["PHASE1"],"enrollment":{"count":20,"type":"ESTIMATED"},"design":{"allocation":"NA","intervention_model":"SINGLE_GROUP","primary_purpose":"SUPPORTIVE_CARE","masking":"NONE"},"conditions":["Breast Cancer","Ovarian Cancer"],"interventions":[{"name":"Psilocybin","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"9d73c96f237ac68fbda3d911e4b1f4df70d78bffe439fcbd3af6fdd7e0b5b445","facility":"Outpatient CTRC","city":"Aurora","region":"Colorado","country":"United States","lat":39.729430000000001,"lon":-104.83192},{"key":"26536ff41048bd47e18a2ae19bf7955b33e3305e2417d2a442cc3e762d6f37db","facility":"University of Colorado Cancer Center","city":"Aurora","region":"Colorado","country":"United States","lat":39.729430000000001,"lon":-104.83192}],"countries":["United States"]},{"id":3687,"nct_id":"NCT04932434","title":"Psilocybin Therapy for Depression and Anxiety in Parkinson's Disease: a Pilot Study","sponsor":"Joshua Woolley, MD, PhD","registry_url":"https://clinicaltrials.gov/study/NCT04932434","tracker_url":"publication.php?id=3687","status":"COMPLETED","status_label":"Completed","status_verified_date":"2026-08","last_update_date":"2026-09-03","start_date":"2021-08-15","primary_completion_date":"2024-12-31","completion_date":"2024-12-31","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":12,"type":"ACTUAL"},"design":{"allocation":"NA","intervention_model":"SINGLE_GROUP","primary_purpose":"TREATMENT","masking":"NONE"},"conditions":["Parkinson Disease","Depression","Anxiety"],"interventions":[{"name":"Psilocybin therapy","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"7f09a842484186a75c6232177464293472d56c43d4d49f24f37efcb6c9cbbbb8","facility":"University of California, San Francisco","city":"San Francisco","region":"California","country":"United States","lat":37.774929999999998,"lon":-122.41942}],"countries":["United States"]},{"id":5892,"nct_id":"NCT07791901","title":"High vs. Low-Dose Group-Based Psilocybin-Assisted Therapy (PAT) With or Without Mindfulness-Based (MB) Preparation and Integration for Demoralization in Adults With Advanced Cancer (PAT-MIND): A Pilot Feasibility 2x2 Factorial Multisite Trial","sponsor":"University of Calgary","registry_url":"https://clinicaltrials.gov/study/NCT07791901","tracker_url":"publication.php?id=5892","status":"NOT_YET_RECRUITING","status_label":"Not yet recruiting","status_verified_date":"2026-08","last_update_date":"2026-09-02","start_date":"2026-10-30","primary_completion_date":"2027-12-20","completion_date":"2027-12-31","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":60,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"FACTORIAL","primary_purpose":"TREATMENT","masking":"QUADRUPLE"},"conditions":["Advanced Cancer","Demoralization","Existential Distress","Psychological Distress"],"interventions":[{"name":"PEX010 25 mg psilocybin","type":"DRUG"},{"name":"PEX010 5 mg psilocybin","type":"DRUG"},{"name":"Standard Psilocybin-Assisted Therapy","type":"BEHAVIORAL"},{"name":"Mindfulness-Based Psilocybin-Assisted Therapy","type":"BEHAVIORAL"}],"substances":["psilocybin"],"sites":[{"key":"69ac64288af5cb5338ec5bcb6ba08a6b7fa1b82e6ac1e239ced6fb2bbb2fb97e","facility":"Arthur Child Comprehensive Cancer Centre","city":"Calgary","region":"Alberta","country":"Canada","lat":51.050109999999997,"lon":-114.08529},{"key":"dc3875179cb830724fc5f84413b98d92146b4b6cbbf28f85a160567e32905d2c","facility":"Providence Care Hospital","city":"Kingston","region":"Ontario","country":"Canada","lat":44.229759999999999,"lon":-76.480980000000002}],"countries":["Canada"]},{"id":3587,"nct_id":"NCT06349083","title":"Neurobehavioral Mechanisms of Psilocybin-assisted Treatment for Alcohol Use Disorder","sponsor":"NYU Langone Health","registry_url":"https://clinicaltrials.gov/study/NCT06349083","tracker_url":"publication.php?id=3587","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-08","last_update_date":"2026-09-02","start_date":"2026-09-01","primary_completion_date":"2030-05","completion_date":"2030-05","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":200,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"DOUBLE"},"conditions":["Alcohol Use Disorder"],"interventions":[{"name":"Psilocybin","type":"DRUG"},{"name":"Inactive Placebo","type":"OTHER"},{"name":"Supportive therapy sessions","type":"BEHAVIORAL"}],"substances":["psilocybin"],"sites":[{"key":"f013c15d8112693910d9bf055f39dc54c2a9c3749b21ac7dacc4c09c7de423df","facility":"NYU Langone Health","city":"New York","region":"New York","country":"United States","lat":40.714269999999999,"lon":-74.005970000000005}],"countries":["United States"]},{"id":3558,"nct_id":"NCT06768944","title":"The Role of the Subjective Experience in Supporting Positive Effects Following Psilocybin: a Randomized, Controlled Clinical Trial Using Risperidone in Healthy Adults","sponsor":"University of Calgary","registry_url":"https://clinicaltrials.gov/study/NCT06768944","tracker_url":"publication.php?id=3558","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-05","last_update_date":"2026-09-02","start_date":"2026-05-15","primary_completion_date":"2027-12","completion_date":"2028-01","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":128,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"FACTORIAL","primary_purpose":"OTHER","masking":"QUADRUPLE"},"conditions":["Investigating the Importance of the Subjective Psychedelic Experience"],"interventions":[{"name":"Psilocybin high-dose","type":"DRUG"},{"name":"Psilocybin low-dose","type":"DRUG"},{"name":"Risperidone 1 MG","type":"DRUG"},{"name":"Placebo","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"43d6a4c1bec6b0da7fbcdcf29f22e29eb9ee146f88b69aa1d4bc718a46bed666","facility":"University of Calgary","city":"Calgary","region":"Alberta","country":"Canada","lat":51.050109999999997,"lon":-114.08529}],"countries":["Canada"]},{"id":3522,"nct_id":"NCT06814522","title":"Psilocybin-Assisted Therapy for Physician Well-Being and Burnout: Feasibility, Safety, Clinical Effectiveness and Biomarkers of Response [PAT-B (Psilocybin-Assisted Therapy for Physician Well-Being and Burnout)]","sponsor":"University of California, San Diego","registry_url":"https://clinicaltrials.gov/study/NCT06814522","tracker_url":"publication.php?id=3522","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2025-11","last_update_date":"2026-09-02","start_date":"2025-01-13","primary_completion_date":"2028-06","completion_date":"2028-08","study_type":"INTERVENTIONAL","phases":["PHASE1","PHASE2"],"enrollment":{"count":30,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"SINGLE"},"conditions":["Burnout","Burnout, Healthcare Workers"],"interventions":[{"name":"Psilocybin, [3-[2-(dimethylamino)ethyl]-1H-indol-4-yl] dihydrogen phosphate","type":"DRUG"},{"name":"Real-time Biofeedback","type":"DEVICE"}],"substances":["psilocybin"],"sites":[{"key":"2e7548466e831b567e38ef1e8fdd7baae3817e9b4e2a89bc35dca43d64edbecb","facility":"UC San Diego","city":"San Diego","region":"California","country":"United States","lat":32.715710000000001,"lon":-117.16472}],"countries":["United States"]},{"id":3544,"nct_id":"NCT06225232","title":"An 8-week Phase 2 Clinical Trial to Evaluate the Safety, Tolerability and Efficacy of Psilocybin-assisted-psychotherapy in Adults With Cannabis Use Disorder: A Proof-of-Concept Study","sponsor":"McMaster University","registry_url":"https://clinicaltrials.gov/study/NCT06225232","tracker_url":"publication.php?id=3544","status":"ACTIVE_NOT_RECRUITING","status_label":"Active, not recruiting","status_verified_date":"2026-08","last_update_date":"2026-08-31","start_date":"2025-03-21","primary_completion_date":"2026-12","completion_date":"2026-12","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":16,"type":"ESTIMATED"},"design":{"allocation":"NA","intervention_model":"SINGLE_GROUP","primary_purpose":"TREATMENT","masking":"NONE"},"conditions":["Cannabis Use Disorder, Moderate","Cannabis Use Disorder, Severe"],"interventions":[{"name":"Psilocybin combined with Psychotherapy","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"51a9a92a0508b764f9a4517d8d60933b3ee3ba0964375b23c07f442f64b82278","facility":"MacAnxiety Research Centre","city":"Hamilton","region":"Ontario","country":"Canada","lat":43.250109999999999,"lon":-79.849630000000005}],"countries":["Canada"]},{"id":5893,"nct_id":"NCT07792538","title":"Psilocybin-Assisted Psychotherapy for Posttraumatic Stress Disorder in Military Veterans: A Pilot Feasibility Study","sponsor":"ARQ National Psychotrauma Centre","registry_url":"https://clinicaltrials.gov/study/NCT07792538","tracker_url":"publication.php?id=5893","status":"NOT_YET_RECRUITING","status_label":"Not yet recruiting","status_verified_date":"2026-08","last_update_date":"2026-08-28","start_date":"2026-12","primary_completion_date":"2028-12","completion_date":"2028-12","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":12,"type":"ESTIMATED"},"design":{"allocation":"NA","intervention_model":"SINGLE_GROUP","primary_purpose":"TREATMENT","masking":"NONE"},"conditions":["Posttraumatic Stress Disorder (PTSD)"],"interventions":[{"name":"Psilocybin-assisted Psychotherapy","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"3a56bfcfdf7e421572987bf0738f148704d0626c5f1a8add94a738b0edf2d3c0","facility":"ARQ National Psychotrauma Centre / ARQ Centrum'45","city":"Oegstgeest","region":"","country":"Netherlands","lat":52.18,"lon":4.4694399999999996}],"countries":["Netherlands"]},{"id":3481,"nct_id":"NCT04959253","title":"A Randomised, Placebo Controlled Trial of Psilocybin in Treatment Resistant Depression: A Feasibility Study","sponsor":"King's College London","registry_url":"https://clinicaltrials.gov/study/NCT04959253","tracker_url":"publication.php?id=3481","status":"COMPLETED","status_label":"Completed","status_verified_date":"2021-06","last_update_date":"2026-08-28","start_date":"2021-06-21","primary_completion_date":"2024-12-18","completion_date":"2024-12-18","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":60,"type":"ACTUAL"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"QUADRUPLE"},"conditions":["Treatment Resistant Depression"],"interventions":[{"name":"Psilocybin assisted therapy","type":"COMBINATION_PRODUCT"},{"name":"Placebo assisted therapy","type":"COMBINATION_PRODUCT"}],"substances":["psilocybin"],"sites":[{"key":"2af82304b750e5e49e9f89c722d44575fe6978541c1a1e315e0c160897006053","facility":"Clinical Research Facility, King's College Hospital","city":"London","region":"London","country":"United Kingdom","lat":51.50853,"lon":-0.12573999999999999}],"countries":["United Kingdom"]},{"id":3540,"nct_id":"NCT07211438","title":"Evaluating the Role of Psilocybin Monitors in Psilocybin Therapy for Treatment Resistant Depression: A Pilot Randomized Clinical Trial","sponsor":"Centre for Addiction and Mental Health","registry_url":"https://clinicaltrials.gov/study/NCT07211438","tracker_url":"publication.php?id=3540","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-07","last_update_date":"2026-08-21","start_date":"2026-07-03","primary_completion_date":"2028-07","completion_date":"2029-01","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":40,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"QUADRUPLE"},"conditions":["Treatment-Resistant Depression"],"interventions":[{"name":"Psilocybin","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"61ce79cfaa08fedbb10711df8d7c73a357fd5df0b146e4b4ff109a1f1ba7fd39","facility":"Toronto Western Hospital (University Health Network)","city":"Toronto","region":"Ontario","country":"Canada","lat":43.706429999999997,"lon":-79.39864},{"key":"bf2adfb756d244974a952f7c5c58e6f72f66cbbd5ba63e61a8b987fa1820f128","facility":"Centre for Addiction and Mental Health","city":"Toronto","region":"Ontario","country":"Canada","lat":43.706429999999997,"lon":-79.39864}],"countries":["Canada"]},{"id":3515,"nct_id":"NCT07306364","title":"Psilocybin in Chronic Low Back Pain: An Integrative Study of Lab-Based Mechanisms and Real-World Physical Therapy Outcomes","sponsor":"Yale University","registry_url":"https://clinicaltrials.gov/study/NCT07306364","tracker_url":"publication.php?id=3515","status":"NOT_YET_RECRUITING","status_label":"Not yet recruiting","status_verified_date":"2026-08","last_update_date":"2026-08-19","start_date":"2026-10","primary_completion_date":"2029-06","completion_date":"2029-06","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":45,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"SUPPORTIVE_CARE","masking":"QUADRUPLE"},"conditions":["Chronic Low Back Pain (CLBP)","Physical Therapy","Psilocybin"],"interventions":[{"name":"Psilocybin 10 mg","type":"DRUG"},{"name":"Psilocybin 25 mg","type":"DRUG"},{"name":"Niacin 100 mg","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"27df3ff2008239e64bf38e6c56f8f5e8652612b4aa9bff987d4ba0f94be975b1","facility":"Connecticut Mental Health Center","city":"New Haven","region":"Connecticut","country":"United States","lat":41.308149999999998,"lon":-72.928160000000005}],"countries":["United States"]},{"id":3501,"nct_id":"NCT05220046","title":"An Exploratory Pilot Study of Palliadelic Treatment to Reduce Psychological Distress in People With Pancreatobiliary and Other Advanced Gastrointestinal Cancers","sponsor":"University of Nebraska","registry_url":"https://clinicaltrials.gov/study/NCT05220046","tracker_url":"publication.php?id=3501","status":"COMPLETED","status_label":"Completed","status_verified_date":"2025-12","last_update_date":"2026-08-19","start_date":"2023-04-10","primary_completion_date":"2025-11-17","completion_date":"2025-11-17","study_type":"INTERVENTIONAL","phases":["PHASE1"],"enrollment":{"count":18,"type":"ACTUAL"},"design":{"allocation":"NON_RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"SUPPORTIVE_CARE","masking":"NONE"},"conditions":["Pancreas Cancer","Biliary Tract Cancer","Psychological Distress","Gastrointestinal Cancer"],"interventions":[{"name":"Psilocybin","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"22268aacd3575a268c889e749c8576127c9bff8a9e8343b4058a94d77d976383","facility":"University of Nebraska Medical Center","city":"Omaha","region":"Nebraska","country":"United States","lat":41.256259999999997,"lon":-95.940430000000006}],"countries":["United States"]},{"id":5742,"nct_id":"NCT07719088","title":"An Examination of Psilocybin Effects on Biomarkers of Longevity, Healthy Aging, and Purpose in Life","sponsor":"Charles Raison","registry_url":"https://clinicaltrials.gov/study/NCT07719088","tracker_url":"publication.php?id=5742","status":"NOT_YET_RECRUITING","status_label":"Not yet recruiting","status_verified_date":"2026-08","last_update_date":"2026-08-17","start_date":"2026-12","primary_completion_date":"2028-04","completion_date":"2028-12","study_type":"INTERVENTIONAL","phases":["PHASE1"],"enrollment":{"count":50,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"OTHER","masking":"DOUBLE"},"conditions":["Aging","Longevity","Biomarkers of Aging"],"interventions":[{"name":"Psilocybin (Usona Institute)","type":"DRUG"}],"substances":["psilocybin","psilocin"],"sites":[{"key":"e6baef990fbeb7d39fe3ae6170b4504d185d11acfac4b251c03198f2bd0ccd03","facility":"Vail Health Behavioral Health","city":"Edwards","region":"Colorado","country":"United States","lat":39.64499,"lon":-106.5942}],"countries":["United States"]},{"id":3626,"nct_id":"NCT07169747","title":"The Therapeutic Potential of Psilocybin in Anorexia Nervosa in Young Adults","sponsor":"Region Skane","registry_url":"https://clinicaltrials.gov/study/NCT07169747","tracker_url":"publication.php?id=3626","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-05","last_update_date":"2026-08-14","start_date":"2026-07-20","primary_completion_date":"2027-10-01","completion_date":"2027-10-01","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":40,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"NONE"},"conditions":["Anorexia Nervosa"],"interventions":[{"name":"Psilocybin","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"277ec95effb37a499f97d6fb82da461e2d3790bb840eb8be0d307666a1a93593","facility":"Psykiatrikliniken, Baravägen 1","city":"Lund","region":"","country":"Sweden","lat":55.705840000000002,"lon":13.193210000000001}],"countries":["Sweden"]},{"id":3602,"nct_id":"NCT06450210","title":"Safety for Home Administration of Microdose Psilocybin Use","sponsor":"Johns Hopkins University","registry_url":"https://clinicaltrials.gov/study/NCT06450210","tracker_url":"publication.php?id=3602","status":"COMPLETED","status_label":"Completed","status_verified_date":"2026-08","last_update_date":"2026-08-14","start_date":"2024-12-06","primary_completion_date":"2026-07-31","completion_date":"2026-07-31","study_type":"INTERVENTIONAL","phases":["PHASE1"],"enrollment":{"count":17,"type":"ACTUAL"},"design":{"allocation":"RANDOMIZED","intervention_model":"SEQUENTIAL","primary_purpose":"OTHER","masking":"SINGLE"},"conditions":["Psychedelic Experiences"],"interventions":[{"name":"psilocybin trihydrate","type":"DRUG"},{"name":"Placebo","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"e3da1ce8cb4b14f80a762b6f6cadb84535f4c69b15786b698ef1c7179aa721b3","facility":"5510 Nathan Shock Drive","city":"Baltimore","region":"Maryland","country":"United States","lat":39.290379999999999,"lon":-76.612189999999998}],"countries":["United States"]},{"id":3472,"nct_id":"NCT07226232","title":"A Multi-site Randomized Controlled Trial of Psilocybin for Treatment-Resistant Depression (TRD) in Veterans","sponsor":"VA Office of Research and Development","registry_url":"https://clinicaltrials.gov/study/NCT07226232","tracker_url":"publication.php?id=3472","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-08","last_update_date":"2026-08-14","start_date":"2026-08-03","primary_completion_date":"2030-12-02","completion_date":"2031-06-30","study_type":"INTERVENTIONAL","phases":["PHASE3"],"enrollment":{"count":240,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"QUADRUPLE"},"conditions":["Major Depression"],"interventions":[{"name":"Psilocybin","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"1094674cfb576eb3aba9c610abfa1ec8007d88c3fc30323de895b78b257dc9ca","facility":"Birmingham VA Medical Center, Birmingham, AL","city":"Birmingham","region":"Alabama","country":"United States","lat":33.520659999999999,"lon":-86.802490000000006},{"key":"36ded30328be4e5de016f706a8efcb9e2ce3181d513bae1f031f8c88931e15dd","facility":"Tuscaloosa VA Medical Center, Tuscaloosa, AL","city":"Tuscaloosa","region":"Alabama","country":"United States","lat":33.20984,"lon":-87.56917},{"key":"673eee709be8746b7b99358264e9a830cab9eff575766127a823456961139800","facility":"VA Portland Health Care System, Portland, OR","city":"Portland","region":"Oregon","country":"United States","lat":45.523449999999997,"lon":-122.67621},{"key":"5bc04aa77be1370761183e8a64f2c2e1129ef67efc98b5f6610da73065ccb37c","facility":"Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA","city":"Philadelphia","region":"Pennsylvania","country":"United States","lat":39.952379999999998,"lon":-75.163619999999995},{"key":"cf2d4c3f9eed8457b9a5ca21d741ba54a1b036d130efd17e977384b0d89a5133","facility":"VA Puget Sound Health Care System Seattle Division, Seattle, WA","city":"Seattle","region":"Washington","country":"United States","lat":47.606209999999997,"lon":-122.33207}],"countries":["United States"]},{"id":3678,"nct_id":"NCT06692192","title":"Role of Experience, Conscious Awareness, and Plasticity in Psilocybin's Behavioral Effects - Follow-Up Study (The RECAP 2 Study)","sponsor":"University of Wisconsin, Madison","registry_url":"https://clinicaltrials.gov/study/NCT06692192","tracker_url":"publication.php?id=3678","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-03","last_update_date":"2026-08-13","start_date":"2025-08-07","primary_completion_date":"2027-12","completion_date":"2027-12","study_type":"INTERVENTIONAL","phases":["PHASE1"],"enrollment":{"count":60,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"BASIC_SCIENCE","masking":"TRIPLE"},"conditions":["Psilocybin"],"interventions":[{"name":"Psilocybin","type":"DRUG"},{"name":"Midazolam","type":"DRUG"},{"name":"Saline","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"72b096fd9021c9bfd550d9d949b2594137c212c14110e7c00e66d39b5f8101eb","facility":"UW School of Medicine and Public Health","city":"Madison","region":"Wisconsin","country":"United States","lat":43.073050000000002,"lon":-89.401229999999998}],"countries":["United States"]},{"id":3562,"nct_id":"NCT06899165","title":"Processing Intergenerational Trauma With Psilocybin-Assisted Therapy","sponsor":"Rachel Yehuda","registry_url":"https://clinicaltrials.gov/study/NCT06899165","tracker_url":"publication.php?id=3562","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-08","last_update_date":"2026-08-13","start_date":"2026-08-28","primary_completion_date":"2029-05-31","completion_date":"2030-01-02","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":100,"type":"ESTIMATED"},"design":{"allocation":"NA","intervention_model":"SINGLE_GROUP","primary_purpose":"TREATMENT","masking":"NONE"},"conditions":["Psychological Stress","Depression","Anxiety"],"interventions":[{"name":"Psilocybin","type":"DRUG"},{"name":"Integration sessions","type":"BEHAVIORAL"}],"substances":["psilocybin"],"sites":[{"key":"41d7ef563025697eae67dcbab6ec20d0cf94934cb7a21f3999e9b581e150f205","facility":"The Parsons Research Center for Psychedelic Healing","city":"New York","region":"New York","country":"United States","lat":40.714269999999999,"lon":-74.005970000000005}],"countries":["United States"]},{"id":3539,"nct_id":"NCT06247839","title":"The Effects of Psilocybin on Self-Focus and Self-Related Processing in Major Depressive Disorder","sponsor":"Sharmin Ghaznavi","registry_url":"https://clinicaltrials.gov/study/NCT06247839","tracker_url":"publication.php?id=3539","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-08","last_update_date":"2026-08-13","start_date":"2024-09-10","primary_completion_date":"2028-06-30","completion_date":"2028-06-30","study_type":"INTERVENTIONAL","phases":["PHASE3"],"enrollment":{"count":20,"type":"ESTIMATED"},"design":{"allocation":"NA","intervention_model":"SINGLE_GROUP","primary_purpose":"TREATMENT","masking":"NONE"},"conditions":["Major Depressive Disorder"],"interventions":[{"name":"Psilocybin","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"ae85e9f90db4bd1845b2a9817e008d4a625ffc046123c8a22344695349c7e230","facility":"Athinoula A. Martinos Center for Biomedical Imaging","city":"Charlestown","region":"Massachusetts","country":"United States","lat":42.377870000000001,"lon":-71.061999999999998}],"countries":["United States"]},{"id":3485,"nct_id":"NCT06853912","title":"PsiloStudy: A Phase 2 Single-site, Double-blind, Placebo-controlled, Randomized Clinical Trial With an Open-label Extension Phase to Examine the Safety, Subjective Experiences, Acute Effects, and Suitability of Psilocybin Combined With Psychological Support (Psi-PS) for Military Veterans and First Responders With Co-occurring Alcohol Use Disorder (AUD) and Posttraumatic Stress Disorder (PTSD)","sponsor":"Nathan Brashares Sackett","registry_url":"https://clinicaltrials.gov/study/NCT06853912","tracker_url":"publication.php?id=3485","status":"ACTIVE_NOT_RECRUITING","status_label":"Active, not recruiting","status_verified_date":"2026-08","last_update_date":"2026-08-13","start_date":"2025-06-01","primary_completion_date":"2026-11-01","completion_date":"2027-06-01","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":40,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"DOUBLE"},"conditions":["Alcohol Use Disorder (AUD)","PTSD"],"interventions":[{"name":"Psilocybin 25 mg","type":"DRUG"},{"name":"Maltodextrin (Placebo)","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"7de3d89eed44865c013d4553fc6090d54c7c067dbeedefce79bfea681d8b54c2","facility":"University of Washington Center for Novel Therapeutics in Addiction Psychiatry","city":"Seattle","region":"Washington","country":"United States","lat":47.606209999999997,"lon":-122.33207}],"countries":["United States"]},{"id":3674,"nct_id":"NCT06801041","title":"TRIPS - Treatment to Improve Depression and/or Anxiety Using Psilocybin-assisted Psychotherapy in Cancer Survivors","sponsor":"M.D. Anderson Cancer Center","registry_url":"https://clinicaltrials.gov/study/NCT06801041","tracker_url":"publication.php?id=3674","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-08","last_update_date":"2026-08-12","start_date":"2025-05-23","primary_completion_date":"2027-03-31","completion_date":"2029-03-31","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":20,"type":"ESTIMATED"},"design":{"allocation":"NA","intervention_model":"SINGLE_GROUP","primary_purpose":"SUPPORTIVE_CARE","masking":"NONE"},"conditions":["Depression","Anxiety","Cancer"],"interventions":[{"name":"Psilocybin","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"cc8da94c896719bab57ed8dd47266c0ce0664ad555799300d442f1fe89aa2942","facility":"The University of Texas M. D. Anderson Cancer Center","city":"Houston","region":"Texas","country":"United States","lat":29.763280000000002,"lon":-95.36327}],"countries":["United States"]},{"id":3581,"nct_id":"NCT06706232","title":"Acceptability & Safety of Two Sequential Doses of Psilocybin in Bipolar Disorder II Depression and Suicidality","sponsor":"The University of Texas Health Science Center, Houston","registry_url":"https://clinicaltrials.gov/study/NCT06706232","tracker_url":"publication.php?id=3581","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-07","last_update_date":"2026-08-12","start_date":"2025-07-07","primary_completion_date":"2027-08","completion_date":"2027-08","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":10,"type":"ESTIMATED"},"design":{"allocation":"NA","intervention_model":"SINGLE_GROUP","primary_purpose":"TREATMENT","masking":"NONE"},"conditions":["Bipolar II Disorder","Depression, Bipolar","Suicidality"],"interventions":[{"name":"Psilocybin","type":"DRUG"},{"name":"Therapeutic Support","type":"BEHAVIORAL"}],"substances":["psilocybin"],"sites":[{"key":"da2bda06c1b463bdcf59130477fd36b92915811ee4ac0f0c25eafb7329fb0cb9","facility":"The University of Texas Health Science Center at Houston","city":"Houston","region":"Texas","country":"United States","lat":29.763280000000002,"lon":-95.36327}],"countries":["United States"]},{"id":3574,"nct_id":"NCT06827054","title":"Low-Dose Psilocybin Therapy for Palliative Care Patients With Chronic Cancer Pain Requiring Opioids","sponsor":"Roswell Park Cancer Institute","registry_url":"https://clinicaltrials.gov/study/NCT06827054","tracker_url":"publication.php?id=3574","status":"NOT_YET_RECRUITING","status_label":"Not yet recruiting","status_verified_date":"2026-08","last_update_date":"2026-08-12","start_date":"2026-09-15","primary_completion_date":"2027-05-05","completion_date":"2027-05-05","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":20,"type":"ESTIMATED"},"design":{"allocation":"NA","intervention_model":"SINGLE_GROUP","primary_purpose":"SUPPORTIVE_CARE","masking":"NONE"},"conditions":["Hematopoietic and Lymphatic System Neoplasm","Malignant Solid Neoplasm"],"interventions":[{"name":"Biospecimen Collection","type":"PROCEDURE"},{"name":"Functional Magnetic Resonance Imaging","type":"PROCEDURE"},{"name":"Interview","type":"OTHER"},{"name":"Psilocybine","type":"DRUG"},{"name":"Psychotherapy","type":"BEHAVIORAL"},{"name":"Questionnaire Administration","type":"OTHER"}],"substances":["psilocybin"],"sites":[{"key":"d8fb28c671742199166f748836eb0aaf7f93725796222ed3a6857bd2ec7ed639","facility":"Roswell Park Cancer Institute","city":"Buffalo","region":"New York","country":"United States","lat":42.886450000000004,"lon":-78.878370000000004}],"countries":["United States"]},{"id":3426,"nct_id":"NCT06969170","title":"A Phase 2a, Placebo-Controlled Randomized, Double-Blind Trial to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Psilocybin Oral Solution in Adults With Generalized Anxiety Disorder","sponsor":"Claudio N Soares","registry_url":"https://clinicaltrials.gov/study/NCT06969170","tracker_url":"publication.php?id=3426","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-08","last_update_date":"2026-08-12","start_date":"2025-05-16","primary_completion_date":"2027-12-31","completion_date":"2028-12-30","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":50,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"SINGLE_GROUP","primary_purpose":"HEALTH_SERVICES_RESEARCH","masking":"QUADRUPLE"},"conditions":["Generalized Anxiety Disorder (GAD)"],"interventions":[{"name":"Psilocybin (drug)","type":"DRUG"},{"name":"Placebo","type":"OTHER"}],"substances":["psilocybin"],"sites":[{"key":"5e54e3832bb9c4f6cddd3eeefc9951bb04903d8e26aedf819b29aa11a2e0c418","facility":"Kingston General Health Research Institute","city":"Kingston","region":"Ontario","country":"Canada","lat":44.229759999999999,"lon":-76.480980000000002}],"countries":["Canada"]},{"id":5852,"nct_id":"NCT07756736","title":"Psilocybin Recovery Intervention for Stopping Methamphetamine Use","sponsor":"Nicky Mehtani, MD, MPH","registry_url":"https://clinicaltrials.gov/study/NCT07756736","tracker_url":"publication.php?id=5852","status":"NOT_YET_RECRUITING","status_label":"Not yet recruiting","status_verified_date":"2026-08","last_update_date":"2026-08-11","start_date":"2026-11","primary_completion_date":"2029-04","completion_date":"2029-06","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":30,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"QUADRUPLE"},"conditions":["Methamphetamine Use Disorder","Human Immunodeficiency Virus (HIV)"],"interventions":[{"name":"Psilocybin 5 mg","type":"DRUG"},{"name":"Psilocybin 25 mg","type":"DRUG"},{"name":"Motivational Support","type":"BEHAVIORAL"}],"substances":["psilocybin"],"sites":[{"key":"351f97e654e4dc3c5a6bc97464ad09c9791a304ed6d742edf0ae41f3b33c137a","facility":"UCSF at Zuckerberg San Francisco General Hospital","city":"San Francisco","region":"California","country":"United States","lat":37.774929999999998,"lon":-122.41942}],"countries":["United States"]},{"id":3523,"nct_id":"NCT06656702","title":"Effects of Psilocybin in Patients With Amyotrophic Lateral Sclerosis","sponsor":"Johns Hopkins University","registry_url":"https://clinicaltrials.gov/study/NCT06656702","tracker_url":"publication.php?id=3523","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-08","last_update_date":"2026-08-11","start_date":"2025-04-09","primary_completion_date":"2027-01-30","completion_date":"2027-07-01","study_type":"INTERVENTIONAL","phases":["EARLY_PHASE1"],"enrollment":{"count":24,"type":"ESTIMATED"},"design":{"allocation":"NA","intervention_model":"SINGLE_GROUP","primary_purpose":"TREATMENT","masking":"NONE"},"conditions":["Amyotrophic Lateral Sclerosis"],"interventions":[{"name":"Psilocybin","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"9d7c1530695da1e0dbe5d0029c61521b74c434cedec820dcadef26feb9ead43e","facility":"Johns Hopkins Center for Psychedelic and Consciousness Research","city":"Baltimore","region":"Maryland","country":"United States","lat":39.290379999999999,"lon":-76.612189999999998}],"countries":["United States"]},{"id":3642,"nct_id":"NCT06512194","title":"An Investigation of Strategies to Understand and Optimize the Antidepressant Effects of Psilocybin (The OPTIMIZE Study)","sponsor":"Charles Raison","registry_url":"https://clinicaltrials.gov/study/NCT06512194","tracker_url":"publication.php?id=3642","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-08","last_update_date":"2026-08-10","start_date":"2025-05-13","primary_completion_date":"2029-05","completion_date":"2029-05","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":141,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"QUADRUPLE"},"conditions":["Depression"],"interventions":[{"name":"Psilocybin","type":"DRUG"},{"name":"Transcutaneous Auricular Vagus Nerve Stimulation (taVNS)","type":"DEVICE"},{"name":"Sham taVNS","type":"DEVICE"}],"substances":["psilocybin"],"sites":[{"key":"e6baef990fbeb7d39fe3ae6170b4504d185d11acfac4b251c03198f2bd0ccd03","facility":"Vail Health Behavioral Health","city":"Edwards","region":"Colorado","country":"United States","lat":39.64499,"lon":-106.5942}],"countries":["United States"]},{"id":3532,"nct_id":"NCT05711940","title":"A Phase III, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With Treatment-resistant Depression","sponsor":"COMPASS Pathways","registry_url":"https://clinicaltrials.gov/study/NCT05711940","tracker_url":"publication.php?id=3532","status":"ACTIVE_NOT_RECRUITING","status_label":"Active, not recruiting","status_verified_date":"2026-04","last_update_date":"2026-08-10","start_date":"2023-02-14","primary_completion_date":"2025-11-13","completion_date":"2026-12","study_type":"INTERVENTIONAL","phases":["PHASE3"],"enrollment":{"count":572,"type":"ACTUAL"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"QUADRUPLE"},"conditions":["Treatment Resistant Depression"],"interventions":[{"name":"Psilocybin","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"e9edfb74a78777f36bdfaa262be65a39985de4f9f95f1206871c1a7ff9a9c980","facility":"Lighthouse Psychiatry Scottsdale","city":"Gilbert","region":"Arizona","country":"United States","lat":33.352829999999997,"lon":-111.78903},{"key":"8c8cc924d99dc7a2acac00ca041c949244f6efbdaecea0e276cd138f1f9f4a45","facility":"Clinical Innovations, Inc.","city":"Bellflower","region":"California","country":"United States","lat":33.881680000000003,"lon":-118.11700999999999},{"key":"33cd083fccf6bfafedb17e1ca5bcb5536d1a7eb0d006049da3c7f262774714ec","facility":"M3 Wake Research","city":"Encino","region":"California","country":"United States","lat":34.159170000000003,"lon":-118.50118999999999},{"key":"3956987c0538c47320e7e3cb786388fb4df67930ced721b44fcf2ab583c65ac8","facility":"The Regents of the University of California - San Diego","city":"La Jolla","region":"California","country":"United States","lat":32.847270000000002,"lon":-117.27419999999999},{"key":"b1132fa91c6c49bf3a7b5fc89a57fb89b94ff271a2081e8352dd7bd5a7ea4f1c","facility":"Kadima Neuropsychiatry Institute","city":"La Jolla","region":"California","country":"United States","lat":32.847270000000002,"lon":-117.27419999999999},{"key":"433890853c30fd15b198d52a519a62c71d8f0aa70ec3feaec3b4706dec634558","facility":"CalNeuro Research Group, Inc","city":"Los Angeles","region":"California","country":"United States","lat":34.052230000000002,"lon":-118.24368},{"key":"9d75c9d391d2e052ce5d2a8d26f61fee174796b13686fbc553967949c7f16d71","facility":"Catalina Research Institute, LLC","city":"Montclair","region":"California","country":"United States","lat":34.077509999999997,"lon":-117.68978},{"key":"0bce40827ee3d733ae9e503a880619077ca6e8de0dd17a87c7648da3a2ea4f92","facility":"Piedmont Hospital Neuroscience Centre","city":"Oakland","region":"California","country":"United States","lat":37.804369999999999,"lon":-122.27079999999999},{"key":"0ecf4347c0490c2eb9d05276c5439c505d2af8ab93b342747f51f471f3f2f8b5","facility":"ATP Clinical Research, Inc.","city":"Orange","region":"California","country":"United States","lat":33.787790000000001,"lon":-117.85311},{"key":"2d348620aff9bffb0740d1c6f653cba6346fb9e4be97ffcdd65f37a4facef711","facility":"CITrials","city":"Riverside","region":"California","country":"United States","lat":33.95335,"lon":-117.39615999999999},{"key":"f716f4334d80fcccdf2abeb47aec4330b37ff6c101c75c28a0c50d78e79fe16e","facility":"Lumos Clinical Research Center","city":"San Jose","region":"California","country":"United States","lat":37.339390000000002,"lon":-121.89496},{"key":"04fc45375356ec7e141d1e661bbe958521ad9595143bf914dac40e8e4038f89b","facility":"Syrentis Clinical Research","city":"Santa Ana","region":"California","country":"United States","lat":33.745570000000001,"lon":-117.86783},{"key":"50c13e63ee1fe4325b40dc6b409f9002d59ae4e7e4879bf350dcad72bc996f6d","facility":"Stanford University","city":"Stanford","region":"California","country":"United States","lat":37.424109999999999,"lon":-122.16607999999999},{"key":"f3f64a43e6e1393672512aff6e67e13509591b6e56ca2fda56ce8c242f43e72d","facility":"ASCLEPES Research Centers","city":"Thousand Oaks","region":"California","country":"United States","lat":34.170560000000002,"lon":-118.83759000000001},{"key":"a827f194bf451373f242dff28ca06d6f968576ec23131c98663006604196ff34","facility":"Pacific Clinical Research Management Group, LLC","city":"Upland","region":"California","country":"United States","lat":34.09751,"lon":-117.64839000000001},{"key":"1d86b7161c444a07e40f263de72732b54d755691bf3a60669016463f215c75dd","facility":"Innovative Clinical Research, Inc.","city":"Lauderhill","region":"Florida","country":"United States","lat":26.140360000000001,"lon":-80.213380000000001},{"key":"a61751b7d865072b2f31bf6e4ab9c9ce7ae37384fb363d60648104de17c1289c","facility":"Central Miami Medical Institute, LLC","city":"Miami","region":"Florida","country":"United States","lat":25.774270000000001,"lon":-80.193659999999994},{"key":"9e85535b6cebd5a4a1d90f25b70eda855eeb4de9eac52adb675e9c49740bdea8","facility":"Behavioral Clinical Research, Inc.","city":"Miami Lakes","region":"Florida","country":"United States","lat":25.908709999999999,"lon":-80.308660000000003},{"key":"69ca07bfacaf4b2aa725899b657d5f8cab7f1c88c3d64b1257c6f236ea3cd818","facility":"Health Synergy Clinical Research","city":"Okeechobee","region":"Florida","country":"United States","lat":27.243929999999999,"lon":-80.82978},{"key":"d254863966539613f9cf8b8bbf09c480ffe63cbd290d96eff3edb91423fba06c","facility":"Clinical Neurosciecne Solutions, Inc. dba CNS Healthcare","city":"Orlando","region":"Florida","country":"United States","lat":28.538340000000002,"lon":-81.379239999999996},{"key":"8b79eabaace5e2d9634e903d05c134f3463c515b9149f7f1110f7075f2855415","facility":"APG Research, LLC- Advanced Psychiatric Group","city":"Orlando","region":"Florida","country":"United States","lat":28.538340000000002,"lon":-81.379239999999996},{"key":"886add41555cb1260c6a674de26b8977c2837edb5094cf381bd33852ca06f8d6","facility":"University South Florida","city":"Tampa","region":"Florida","country":"United States","lat":27.947520000000001,"lon":-82.458430000000007},{"key":"e8272b61efc64a56598c46b640aaa7fe71b04a3bc669ca520458edb6dd768d81","facility":"Stedman Clinical Trials","city":"Tampa","region":"Florida","country":"United States","lat":27.947520000000001,"lon":-82.458430000000007},{"key":"96291c327c4e7434938b601c55622ac50098458d497e0741666ccdbb17afbff1","facility":"Health Synergy Clinical Research, LLC","city":"West Palm Beach","region":"Florida","country":"United States","lat":26.715340000000001,"lon":-80.053370000000001},{"key":"4e53967735fae7ab4ea818a325ed6321cb8d90d0439b5d344989cf76f7773501","facility":"Atlanta Center for Medical Research","city":"Atlanta","region":"Georgia","country":"United States","lat":33.749000000000002,"lon":-84.387979999999999},{"key":"2ee722b6641f2fb2181d7c449b187717e0152f3d6240301acbae668f2a017496","facility":"iResearch Atlanta","city":"Decatur","region":"Georgia","country":"United States","lat":33.774830000000001,"lon":-84.296310000000005},{"key":"6e7e87e6abd6f29f724f49ce28a3a34c25e5c1c49b95f77a93f8b41e6c15e026","facility":"Rush University Medical Center","city":"Chicago","region":"Illinois","country":"United States","lat":41.850029999999997,"lon":-87.650049999999993},{"key":"ddad76cc8ac3eabdf04d8d630a084814244b8b4bc8c26a47c3e9a8a5a1a06dea","facility":"Uptown Research Institute, LLC","city":"Chicago","region":"Illinois","country":"United States","lat":41.850029999999997,"lon":-87.650049999999993},{"key":"f7a1cbf92391beae3f7562af92296c53808e6d5b6e24800d0300caa67e059deb","facility":"Psychiatric Medicine Associates","city":"Skokie","region":"Illinois","country":"United States","lat":42.033360000000002,"lon":-87.73339},{"key":"694ca0b3448bdcdf992374f9b82f3bf5ea4a8de1d62177bd65c019ba6e3e7276","facility":"Harvard Medical School - McLean Hospital","city":"Belmont","region":"Massachusetts","country":"United States","lat":42.39593,"lon":-71.178669999999997},{"key":"0cbc44fd437f048ccec8b77bcab3642524094c01439c857c0d93b1df2c3c5792","facility":"Adams Clinical - Boston (Copley Clinical)","city":"Boston","region":"Massachusetts","country":"United States","lat":42.358429999999998,"lon":-71.05977},{"key":"3def80915b7bdc5d973f5b43fbe6e47d92c9a910c88c6ef98de29a0648309c43","facility":"University of Massachusetts Medical School","city":"North Worcester","region":"Massachusetts","country":"United States","lat":42.316760000000002,"lon":-71.817570000000003},{"key":"46862561f48050c28d5929604cd7310f7dd5b980451df606b91dec8b5a5e4842","facility":"Adams Clinical - Boston","city":"Watertown","region":"Massachusetts","country":"United States","lat":42.370930000000001,"lon":-71.182829999999996},{"key":"82a991cbba0edc55429e1bf37c9e8fb9198d616ade8204136d57fb15035be0c0","facility":"Michigan Clinical Research Institute PC","city":"Ann Arbor","region":"Michigan","country":"United States","lat":42.277560000000001,"lon":-83.740880000000004},{"key":"5077e7a11120073a05fb9c15ef1570a81e7dc68801a62a7c2dab56e77135317a","facility":"University Of Michigan Comprehensive Depression Center","city":"Ann Arbor","region":"Michigan","country":"United States","lat":42.277560000000001,"lon":-83.740880000000004},{"key":"1f57eba4506ead7dbe85ee58d44522b9adb00f7badf8acc2a19177cbd78523d7","facility":"Institute for Integrative Therapies","city":"Eden Prairie","region":"Minnesota","country":"United States","lat":44.854689999999998,"lon":-93.470789999999994},{"key":"bfc0abfee7b8d0aaf77701419fbafff26c77912e4386a5188e7182a2774725c2","facility":"St. Charles Psychiatric Associates - Midwest Research Group","city":"Saint Charles","region":"Missouri","country":"United States","lat":38.783940000000001,"lon":-90.481229999999996},{"key":"552a38e810ea599cab40e1a06262965439884f4f1ad26494072c517e71b41307","facility":"Alivation Research, LLC.","city":"Lincoln","region":"Nebraska","country":"United States","lat":40.799999999999997,"lon":-96.666960000000003},{"key":"ade48b4a9a79751c77c933de17f5be45d01a947eb4f6d0c0ae3d9779c9e993cc","facility":"Hassman Research Institute","city":"Berlin","region":"New Jersey","country":"United States","lat":39.791229999999999,"lon":-74.929050000000004},{"key":"0c6bbeedba8c2a5fa6e104bd9e3665edd400539cd709bc37e3b4c82a359254ae","facility":"Princeton Medical Institute","city":"Princeton","region":"New Jersey","country":"United States","lat":40.34872,"lon":-74.659049999999993},{"key":"4345cef85b3822f2a99a14204b9552b865c0a12a0081b0e155f454d8c0a0a130","facility":"Bio Behavioral Health","city":"Toms River","region":"New Jersey","country":"United States","lat":39.95373,"lon":-74.197919999999996},{"key":"bd484b86c9be7b53a1d38ad00e616619475eb6359e7b6f182f9ea4debf82b795","facility":"Dent Neurosciences Research Center, Inc.","city":"Amherst","region":"New York","country":"United States","lat":42.978389999999997,"lon":-78.799760000000006},{"key":"454515776b11d66402a152efa7f552f15b988e79b979ac8eed8fdeb01fb5a56e","facility":"Fieve Clinical Research, Inc","city":"New York","region":"New York","country":"United States","lat":40.714269999999999,"lon":-74.005970000000005},{"key":"99b8a84c837f6982e0917263a833f5aaea72f1851b9e6a259d714d169d25020a","facility":"Spectrum Neuroscience and Treatment Institute","city":"New York","region":"New York","country":"United States","lat":40.714269999999999,"lon":-74.005970000000005},{"key":"fb0809cdceec9619af9370ddd68999ba673fdb0632c5c9bc83beb431ea41f3e9","facility":"Adams Clinical - New York","city":"New York","region":"New York","country":"United States","lat":40.714269999999999,"lon":-74.005970000000005},{"key":"9f6dd6c250948ab5fb811774c2613bdc33238e29b80a54c99b31bd3b33684089","facility":"New York State Psychiatric Institute","city":"New York","region":"New York","country":"United States","lat":40.714269999999999,"lon":-74.005970000000005},{"key":"63cb8ba1c0094238eb4400cf5d93d9ae1b0820b3cd87f1ab2138f6949151ef5a","facility":"Richmond Behavioral Associates","city":"Staten Island","region":"New York","country":"United States","lat":40.562330000000003,"lon":-74.139859999999999},{"key":"8e138c4de81ac1f637dfa268b2b7800f8c82a961092c6100c7104b78ff3379a7","facility":"Adams Clinical - New York","city":"The Bronx","region":"New York","country":"United States","lat":40.849850000000004,"lon":-73.866410000000002},{"key":"987d4adb7e469b7ed36a06dbc91030981ca591af195c9a0ab2e02bba8a0d3972","facility":"University of Cincinnati, Department of Psychiatry & Behavirol Neuroscience","city":"Cincinnati","region":"Ohio","country":"United States","lat":39.127110000000002,"lon":-84.514390000000006},{"key":"40cbc17a430b6e762b1e9940acf93d8e293eda7f6847081b1ec74eccfcf6cd0c","facility":"Cleveland Clinic - Lutheran Hospital","city":"Cleveland","region":"Ohio","country":"United States","lat":41.499499999999998,"lon":-81.695409999999995},{"key":"be9155272f1c03899bfc66b211e217f90f72de646b7740cb75ea8391a13624e9","facility":"The Ohio State University","city":"Columbus","region":"Ohio","country":"United States","lat":39.961179999999999,"lon":-82.99879},{"key":"1c7438c2dd393f89a6984bc7c2d5a57e87c15ed5673114f3fdc806a7cb34c3cf","facility":"Suburban Research Associates","city":"Media","region":"Pennsylvania","country":"United States","lat":39.916780000000003,"lon":-75.387690000000006},{"key":"e95c6b8b499957a645809625007b3fd78455d1c8129ea67ceb51c5b53dd1fa04","facility":"The University of Texas at Austin - Dell Medical School","city":"Austin","region":"Texas","country":"United States","lat":30.267150000000001,"lon":-97.74306},{"key":"2acd481bb65f8fe1401b23689fc66e5da5978643601ea8445106082c8eabda7e","facility":"Houston Clinical Trials, LLC","city":"Bellaire","region":"Texas","country":"United States","lat":29.70579,"lon":-95.458830000000006},{"key":"02e37a9dd5948eceb65538ae90a46d1cc8b78982d21801b0bb6af3b10db5ed93","facility":"Relaro Medical Trials","city":"Dallas","region":"Texas","country":"United States","lat":32.783059999999999,"lon":-96.806669999999997},{"key":"7979f0993e76394286f5f03480f284ac50f3a19e17fd47d46e59665648ddf36d","facility":"Center for Depression Research and Clinical Care","city":"Dallas","region":"Texas","country":"United States","lat":32.783059999999999,"lon":-96.806669999999997},{"key":"0b557b40f24420f1abfb13544f507f9566ad0a580efeb5c49cb6773bccbd80ec","facility":"North Texas Clinical Trials","city":"Fort Worth","region":"Texas","country":"United States","lat":32.725409999999997,"lon":-97.320849999999993},{"key":"560f71dbdc782a70c5d785def2d529c405284ce56896efe30bc0b3d4f5029454","facility":"Brain Health Consultants and TMS Center","city":"Houston","region":"Texas","country":"United States","lat":29.763280000000002,"lon":-95.36327},{"key":"2028352f21415dc4d425b3e11ace95ea8cc08d2a2f26d289e61fe059c3ff3068","facility":"HCA Healthcare Research Institute - Medical City Green Oaks Hospital","city":"Plano","region":"Texas","country":"United States","lat":33.019840000000002,"lon":-96.698890000000006},{"key":"096867127180fe96e9a72bbcc7520d5592abe8032d4645482a93afa580e47078","facility":"Cedar Clinical Research","city":"Draper","region":"Utah","country":"United States","lat":40.52467,"lon":-111.86382},{"key":"fab2f83593e00e9a8526694e34435936cebf031dae3f2b19e723b5f14f9df830","facility":"The University of Utah - Huntsman Mental Health Institute","city":"Salt Lake City","region":"Utah","country":"United States","lat":40.760779999999997,"lon":-111.89105000000001},{"key":"852acd88a3554f9543812fc58a1da1761ef5d1428172d7159bdaf5ebc0afa09c","facility":"Seattle Neuropsychiatric Treatment Center","city":"Seattle","region":"Washington","country":"United States","lat":47.606209999999997,"lon":-122.33207},{"key":"ef60aa0dae20a9ed5c10cd4ce8482a706f4cbac6a5114b39c05228e620e8feb3","facility":"Diex Recherche Sherbrooke Inc.","city":"Québec","region":"B.C.","country":"Canada","lat":46.812280000000001,"lon":-71.21454},{"key":"7cb13038e1e3fe5eec551c8cb3f2e6cf8dc1c0100a214c236093feb7b9a1200f","facility":"Medical Arts Health Research Centre, Kamloops","city":"Kamloops","region":"British Columbia","country":"Canada","lat":50.66648,"lon":-120.3192},{"key":"b6145ff487ffb39fe26ce240998c399fbf6f9a455da2b4bd7a6baefc497639eb","facility":"Okanagan Clinical Trials","city":"Kelowna","region":"British Columbia","country":"Canada","lat":49.883069999999996,"lon":-119.48568},{"key":"fe34fdf0374170a77a8ea2f65e782f299897a6fc4f3888c7477dc463f4716995","facility":"Medical Arts Research Group - Penticton","city":"Penticton","region":"British Columbia","country":"Canada","lat":49.480620000000002,"lon":-119.58584},{"key":"3ea0145b1ddfed5da3fbe6e87c0d7cbfae4890db632cc0458ddbe08bcbd9e83c","facility":"Chatham-Kent Clnical Trials Centre","city":"Chatham","region":"Ontario","country":"Canada","lat":42.412239999999997,"lon":-82.184939999999997},{"key":"cbbb447c4fbad7764f06801cb01f1c736fa64961a1055d544bc07f4c33f05dc5","facility":"St. Michael's Hospital","city":"Toronto","region":"Ontario","country":"Canada","lat":43.706429999999997,"lon":-79.39864},{"key":"2846642b890b09da9f32cb5c27a53f14767c23a4d2f66d979dc0e0c46d5d4cb3","facility":"Centre for Addiction and Mental Health (CAMH)","city":"Toronto","region":"Ontario","country":"Canada","lat":43.706429999999997,"lon":-79.39864},{"key":"77dadecab9166a9daade5e3e4f5bab68b6201a9a4540a27546ed6ebd4bfbe01a","facility":"Centre for Neurology Studies","city":"Vancouver","region":"","country":"Canada","lat":49.249659999999999,"lon":-123.11933999999999},{"key":"cb8b817ff4fec9a087d8b86e30c73c54c24590b44ec0e883af2f7ceff9126dc6","facility":"Medical Arts Research Group","city":"Vancouver","region":"","country":"Canada","lat":49.249659999999999,"lon":-123.11933999999999},{"key":"d389d3900cc088a27974b2b5e13fc6f9ec37fc5b84a0948484673de1d44e47a5","facility":"National Institute of Mental Health","city":"Klecany","region":"","country":"Czechia","lat":50.175989999999999,"lon":14.411479999999999},{"key":"f91ac90932e665e7ecb3557e93b058f71655e686f92803689e1521f8dff9d84c","facility":"Neuroterapie KH Sro","city":"Kutná Hora","region":"","country":"Czechia","lat":49.948390000000003,"lon":15.26816},{"key":"b520016f9fb54cabf32fa9c005e80e49e6d316199594e35758680b6dc1ab5dc4","facility":"Psychiatric Ambulance","city":"Ostrava","region":"","country":"Czechia","lat":49.834650000000003,"lon":18.282039999999999},{"key":"d0f30b3dfe1a1430d239837af8087c86194996403bf342f41034f7cc173a8be4","facility":"A-Shine s.r.o.","city":"Pilsen","region":"","country":"Czechia","lat":49.74747,"lon":13.37759},{"key":"850755de8392406d920407e1a3c7b061e13ce0e6877ec4330e16e1b3581bfd9d","facility":"Psychedelicka klinika, s.r.o.","city":"Prague","region":"","country":"Czechia","lat":50.088039999999999,"lon":14.42076},{"key":"f17868226437efe220461a8dd69049d4795b3d7e10f0e247300b6f793eadf002","facility":"Institut Neuropsychiatricke Pece","city":"Prague","region":"","country":"Czechia","lat":50.088039999999999,"lon":14.42076},{"key":"bda21da2d259f22bc767e1bc16b14a0821d454f141c4df055bf56b1860147b38","facility":"Aalborg Universitetshospital-Psykiatrien Region Nordjylland","city":"Aalborg","region":"","country":"Denmark","lat":57.048000000000002,"lon":9.9186999999999994},{"key":"d6c34b0a3f2673cd992a7856bae0e50b1af86d935e249c027b580253ee59c5a0","facility":"Ghu-Centre Hospitalier Sainte Anne, Centre de Recherche Clinique","city":"Paris","region":"Paris","country":"France","lat":48.853409999999997,"lon":2.3488000000000002},{"key":"b0e7944fe5a90e12e71e461ffc91c42b04b7ae31031157eddab865ffef09f92a","facility":"Centre Hospitalier Universitaire de Nimes (CHU) - Hopital Universitaire Caremeau","city":"Nîmes","region":"","country":"France","lat":43.836649999999999,"lon":4.3578799999999998},{"key":"9a01801daca00ce24f1fab7f819e88260759bb8c60020463a724ade136a7c9f3","facility":"Universite Paris VI Pierre et Marie Curie - Hopital de La Salpetriere - Centre Emotion - USR 3246 (CNRS UMR 7593)","city":"Paris","region":"","country":"France","lat":48.853409999999997,"lon":2.3488000000000002},{"key":"a303bb5bfeff1483534543f03a9a65bedb06203041eed68e4ee3ff361dc4f99e","facility":"Centre Hospitalier Sainte Anne - Clinique des Maladies Mentales et de l'Encephale (CMME)","city":"Paris","region":"","country":"France","lat":48.853409999999997,"lon":2.3488000000000002},{"key":"13f3a02a08766157b3539561920a498408109806a88f798e97a5adb902b9ad83","facility":"Charite-Universitaetsmedizin Berlin","city":"Berlin","region":"","country":"Germany","lat":52.524369999999998,"lon":13.41053},{"key":"3d01600f8989a888092f754f642cc599a43330af3d400f38b4e840a702fe0dc5","facility":"Johann Wolfgang Goethe-Universitaet Frankfurt am Main - Klinik fuer Psychiatrie, Psychosomatik und Psychotherapie","city":"Frankfurt","region":"","country":"Germany","lat":49.683329999999998,"lon":10.533329999999999},{"key":"8b2daea5a7b3526bd77a6a99df1437437456f49d29ce3a49f27cc2d7918d1fd9","facility":"ZiP Campus Luebeck","city":"Lübeck","region":"","country":"Germany","lat":53.868929999999999,"lon":10.687290000000001},{"key":"1936d05fa8ae325b9934cffa0a0c3f08afa8e902d6fe3597cf7ffaec91b70308","facility":"Tallaght University Hospital","city":"Dublin","region":"","country":"Ireland","lat":53.333060000000003,"lon":-6.2488900000000003},{"key":"0f1e596cf73c48035fda8f4a649ac2cdba597ec02171f6c16aa85986f90c1399","facility":"La Nua Day Hospital Mental Health Centre","city":"Galway","region":"","country":"Ireland","lat":53.272449999999999,"lon":-9.0509500000000003},{"key":"27d7b4df35cb1e0b4d4349418e100597b52afe044578477ac7a1e36059b373ba","facility":"University Medical Center Groningen","city":"Groningen","region":"","country":"Netherlands","lat":53.219169999999998,"lon":6.5666700000000002},{"key":"c556803ea8e3be024939cd9c5b7ff7483d45f2a121453ccabc7afce367e79d59","facility":"Leids Universitair Medisch Centrum (LUMC) (Leiden University Medical Center) - Leiden Institute for Brain and Cognition (LIBC)","city":"Leiden","region":"","country":"Netherlands","lat":52.158329999999999,"lon":4.4930599999999998},{"key":"f27ca47bafc0beaaf1789d6d3ec8ed39dd2973eb988250dcf49e358e580ca35a","facility":"Universitair Medisch Centrum Utrecht (UMC Utrecht)","city":"Utrecht","region":"","country":"Netherlands","lat":52.090829999999997,"lon":5.1222200000000004},{"key":"65033108f2c921e6730b66e12ab86bd21a5830fe2456f05939665d6c1f15c600","facility":"Promente - Ośrodek Badań Klinicznych","city":"Bydgoszcz","region":"","country":"Poland","lat":53.1235,"lon":18.007619999999999},{"key":"d8588dddc2ec49af487209955c5c215697b2b789578db619a235a9fa0af36f7d","facility":"Uniwersyteckle Centrum Kliniczne, Klinika Psychiatrii Doroslych","city":"Gdansk","region":"","country":"Poland","lat":54.352269999999997,"lon":18.64912},{"key":"c96bda844dce2ee72d4741e6f70e1e7c3259ada70b947a164873839ebf52b359","facility":"Centrum Badan Klinicznych PI-House Sp. z o.o.","city":"Gdansk","region":"","country":"Poland","lat":54.352269999999997,"lon":18.64912},{"key":"59233ce7d6f2edef71f68bf51536799ac6a65f87692ff4369de3bf18f425914d","facility":"Hospital Clinic de Barcelona","city":"Barcelona","region":"","country":"Spain","lat":41.38879,"lon":2.1589900000000002},{"key":"46ad5618c3314b159e772e81bf17466910fb4af8aeb31aea469b663c4c645362","facility":"Parc Sanitari Sant Joan de Deu (Sant Joan de Deu Serveis de Salut Mental)","city":"Barcelona","region":"","country":"Spain","lat":41.38879,"lon":2.1589900000000002},{"key":"1ddb4bb3723fd7ceec0c9c2cdbafbb15107fe722952f9927a48a2eb3c1bff9d7","facility":"Hospital Universitario Fundacion Jimenez Diaz","city":"Madrid","region":"","country":"Spain","lat":40.416499999999999,"lon":-3.7025600000000001},{"key":"1e1b6ece04c7ea00924126f7b00e7cbae908840ee7eb0b316cb13e1cb711dd04","facility":"FIDMAG Hermanas Hospitalarias","city":"Sant Boi de Llobregat","region":"","country":"Spain","lat":41.34357,"lon":2.0365899999999999},{"key":"72b144f6dc83ba4a6ecf1f2ac2446fbfd27a9310097e956a77537b55d3eb07e0","facility":"Hospital Universitario Río Hortega de Valladolid","city":"Valladolid","region":"","country":"Spain","lat":41.655410000000003,"lon":-4.7235300000000002},{"key":"2b7b823bf3529da5f066168b504e02a29094c3ea0f7f9163307d91e79cff6fc8","facility":"Hospital Provincial de Zamora - Servicio de Psiquiatria","city":"Zamora","region":"","country":"Spain","lat":41.506329999999998,"lon":-5.7445599999999999},{"key":"f1a0a09fe583f21e302bf05e9ee655cd07aeca8a7eb5aac4b2cfec53e3a42234","facility":"Vuxenpsykiatrimottagningen","city":"Landskrona","region":"","country":"Sweden","lat":55.870800000000003,"lon":12.830159999999999},{"key":"c5c94dd70cd248ae3b8db5ad4cc50a4e910e3809eb4f086106edd7fb1c27a170","facility":"Lunds Universitet - Medicinska Fakulteten (Lund University Faculty of Medicine)","city":"Lund","region":"","country":"Sweden","lat":55.705840000000002,"lon":13.193210000000001},{"key":"1270a8c8958350af2f41db348de64da361ff0a6a3ae2b248ea8f4b4aa0810db6","facility":"ClinSmart Sweden AB","city":"Solna","region":"","country":"Sweden","lat":59.360039999999998,"lon":18.000859999999999},{"key":"8b7e818100b36f2a138b6da62aa3927916f36a260d8e14b9e1b511c61e7be21a","facility":"Hälsoklustret","city":"Stockholm","region":"","country":"Sweden","lat":59.32938,"lon":18.068709999999999},{"key":"502f7a9b486836f86f1c7723e897f8177e5e3b58de30c687b8695cd68684206a","facility":"Cornwall Partnership NHS Foundation Trust","city":"Bodmin","region":"Cornwall","country":"United Kingdom","lat":50.471510000000002,"lon":-4.7243000000000004},{"key":"ed7e594baca236a584b788fcf56a8d9d89ea2c9c1d9c2a2e93c47bb7892b1cbb","facility":"Abraham Cowley Unit - Surrey and Borders Partnership NHS Foundation Trust","city":"Chertsey","region":"","country":"United Kingdom","lat":51.388120000000001,"lon":-0.50782000000000005},{"key":"e1f0e3386129e61cb94fc070476723cc82a349226837177f359093b6504f5ede","facility":"St. Pancras Clinical Research","city":"Chester","region":"","country":"United Kingdom","lat":53.1905,"lon":-2.8918900000000001},{"key":"0e5481c54547720b8f9020635efd953371452d6d017f7f73c704a4b19a0ae2b1","facility":"Grounded Research Hub - Rotherham Doncaster & South Humber NHS Foundation Trust","city":"Doncaster","region":"","country":"United Kingdom","lat":53.522849999999998,"lon":-1.1311599999999999},{"key":"261e4850c7da0eb533cf912b4586297e7d085bcb73610f105b3bfd1c1af443bf","facility":"Clinical Research Facility, Royal Devon and Exeter Hospital","city":"Exeter","region":"","country":"United Kingdom","lat":50.723599999999998,"lon":-3.5275099999999999},{"key":"1a2807daf5cce5445b24431f5172ed03cbadc8702a144d7594f49f64b6a752a2","facility":"Fulbourn Hospital - Cambridgeshire And Peterborough NHS Foundation Trust","city":"Fulbourn","region":"","country":"United Kingdom","lat":52.182830000000003,"lon":0.22045999999999999},{"key":"2af6f49013d0328846d4ce8ee776c303f013ff687e95fd27fa857af0c681008b","facility":"St. Pancras Clinical Research","city":"London","region":"","country":"United Kingdom","lat":51.50853,"lon":-0.12573999999999999},{"key":"02475861c29cbd1b1474d35fe0bd7a2b64282baf79d491e44fc0514393cc6e2b","facility":"King's College London - Institute of Psychiatry, Psychology","city":"London","region":"","country":"United Kingdom","lat":51.50853,"lon":-0.12573999999999999},{"key":"8242b5f25a78f0691cea6b91e224fec590627e484a1125e0e6f474a7065690b8","facility":"Clerkenwell Health","city":"London","region":"","country":"United Kingdom","lat":51.50853,"lon":-0.12573999999999999},{"key":"d517f8dc8bece9df440ed5c67f9a803fdf173dc503e1a2699e9a50011514fa52","facility":"Cumbria, Northumberland, Tyne and Wear NHS Foundation Trust - Wolfson Research Centre","city":"Newcastle","region":"","country":"United Kingdom","lat":54.218040000000002,"lon":-5.8897899999999996},{"key":"01791a48325340ca7a8860be5bc049e6ef8d1bc9e07caf8546c3677942beff75","facility":"University Of Nottingham/Nottinghamshire Healthcare Trust, Institute Of Mental Health","city":"Nottingham","region":"","country":"United Kingdom","lat":52.953600000000002,"lon":-1.1504700000000001},{"key":"b2005f3755ff2b9b0e437b0c0a95409768810e849ab1c6907d0037e7560c4663","facility":"The Warneford Hospital- NIHR Clinical Research Facility","city":"Oxford","region":"","country":"United Kingdom","lat":51.752220000000001,"lon":-1.25596},{"key":"728ba7211bd103ada604bafdb7d6dd131aad2f3d1da71c9bffb43a70f1956e5a","facility":"Sheffield Health and Social Care NHS Foundation Trust","city":"Sheffield","region":"","country":"United Kingdom","lat":53.38297,"lon":-1.4659}],"countries":["United States","Canada","Czechia","Denmark","France","Germany","Ireland","Netherlands","Poland","Spain","Sweden"]},{"id":3531,"nct_id":"NCT07251491","title":"Safety, Tolerability, Outcomes of Psilocybin for Depression (STOP Depression) in Veterans With Spinal Cord Injury","sponsor":"James J. Peters Veterans Affairs Medical Center","registry_url":"https://clinicaltrials.gov/study/NCT07251491","tracker_url":"publication.php?id=3531","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-08","last_update_date":"2026-08-10","start_date":"2026-08-06","primary_completion_date":"2028-03-01","completion_date":"2028-03-01","study_type":"INTERVENTIONAL","phases":["PHASE1","PHASE2"],"enrollment":{"count":30,"type":"ESTIMATED"},"design":{"allocation":"NON_RANDOMIZED","intervention_model":"SEQUENTIAL","primary_purpose":"TREATMENT","masking":"TRIPLE"},"conditions":["Spinal Cord Injury","Depression - Major Depressive Disorder","Veteran"],"interventions":[{"name":"Psilocybin (Usona Institute)","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"1b2819d4a8ca62168bb131d84bf5a2039f0800c02db6394dd76a4e6af80edf2c","facility":"James J. Peters Department of Veterans Affairs Medical Center","city":"The Bronx","region":"New York","country":"United States","lat":40.849850000000004,"lon":-73.866410000000002}],"countries":["United States"]},{"id":3521,"nct_id":"NCT05624268","title":"A Phase III, Multicentre, Randomised, Double-blind, Placebo-controlled Study to Investigate the Efficacy, Safety, and Tolerability of COMP360 in Participants With Treatment-resistant Depression","sponsor":"COMPASS Pathways","registry_url":"https://clinicaltrials.gov/study/NCT05624268","tracker_url":"publication.php?id=3521","status":"COMPLETED","status_label":"Completed","status_verified_date":"2026-08","last_update_date":"2026-08-10","start_date":"2023-01-24","primary_completion_date":"2025-05-28","completion_date":"2026-04-15","study_type":"INTERVENTIONAL","phases":["PHASE3"],"enrollment":{"count":258,"type":"ACTUAL"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"QUADRUPLE"},"conditions":["Treatment Resistant Depression"],"interventions":[{"name":"Psilocybin","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"24261169bb3b882e44d0ce9b6db12a1a4ae03b8ce73f9ae22b19e94bba90d4a6","facility":"ProScience Research Group","city":"Culver City","region":"California","country":"United States","lat":34.021120000000003,"lon":-118.39646999999999},{"key":"53861f064c1a9f43fa47a00fa75810394fc0ced2e11c6ce351983a26424f1a9c","facility":"Collaborative Neuroscience Network, LLC","city":"Garden Grove","region":"California","country":"United States","lat":33.773910000000001,"lon":-117.94145},{"key":"b1132fa91c6c49bf3a7b5fc89a57fb89b94ff271a2081e8352dd7bd5a7ea4f1c","facility":"Kadima Neuropsychiatry Institute","city":"La Jolla","region":"California","country":"United States","lat":32.847270000000002,"lon":-117.27419999999999},{"key":"1a66f6c1641f91b527ea1da596b436f437b6ca8cc333273f5ca35ea9e309b7aa","facility":"University California San Diego","city":"La Jolla","region":"California","country":"United States","lat":32.847270000000002,"lon":-117.27419999999999},{"key":"121fe8aeeee077fbeb52e9f1471bca271c42bfce67b02ad50d65b709ab003cf0","facility":"California Center for Psychedelic Therapy","city":"Los Angeles","region":"California","country":"United States","lat":34.052230000000002,"lon":-118.24368},{"key":"433890853c30fd15b198d52a519a62c71d8f0aa70ec3feaec3b4706dec634558","facility":"CalNeuro Research Group, Inc","city":"Los Angeles","region":"California","country":"United States","lat":34.052230000000002,"lon":-118.24368},{"key":"d7932aa60824f8d82cc579d74b2be467daab59ad9a4864aedfc27e57410e1e44","facility":"Clarity Clinical Research, LLC","city":"Los Angeles","region":"California","country":"United States","lat":34.052230000000002,"lon":-118.24368},{"key":"0ecf4347c0490c2eb9d05276c5439c505d2af8ab93b342747f51f471f3f2f8b5","facility":"ATP Clinical Research, Inc.","city":"Orange","region":"California","country":"United States","lat":33.787790000000001,"lon":-117.85311},{"key":"f9d7ad3ab662ab0b636e2440c3619194c78a3ee16acda243a8d5fab2004d0226","facility":"Artemis Institute for Clinical Research","city":"San Diego","region":"California","country":"United States","lat":32.715710000000001,"lon":-117.16472},{"key":"f716f4334d80fcccdf2abeb47aec4330b37ff6c101c75c28a0c50d78e79fe16e","facility":"Lumos Clinical Research Center","city":"San Jose","region":"California","country":"United States","lat":37.339390000000002,"lon":-121.89496},{"key":"50c13e63ee1fe4325b40dc6b409f9002d59ae4e7e4879bf350dcad72bc996f6d","facility":"Stanford University","city":"Stanford","region":"California","country":"United States","lat":37.424109999999999,"lon":-122.16607999999999},{"key":"f3f64a43e6e1393672512aff6e67e13509591b6e56ca2fda56ce8c242f43e72d","facility":"ASCLEPES Research Centers","city":"Thousand Oaks","region":"California","country":"United States","lat":34.170560000000002,"lon":-118.83759000000001},{"key":"f8afd960bd569f417d33b370afd03dc4522d769a952965e6473c16317b2cbbcc","facility":"Comprehensive Psychiatric Care","city":"Norwich","region":"Connecticut","country":"United States","lat":41.524259999999998,"lon":-72.075909999999993},{"key":"d254863966539613f9cf8b8bbf09c480ffe63cbd290d96eff3edb91423fba06c","facility":"Clinical Neurosciecne Solutions, Inc. dba CNS Healthcare","city":"Orlando","region":"Florida","country":"United States","lat":28.538340000000002,"lon":-81.379239999999996},{"key":"81ea1f75d333518f039c11053765aac0c019b1120b8bbb0f1ef8f6e0180d1a82","facility":"APG Research, LLC","city":"Orlando","region":"Florida","country":"United States","lat":28.538340000000002,"lon":-81.379239999999996},{"key":"d1d1c12c20d14ca7af6aae7288edc9b1215a68aef339f77dd7037ed8e1070490","facility":"DMI Health Care Group, Inc","city":"Tampa","region":"Florida","country":"United States","lat":27.947520000000001,"lon":-82.458430000000007},{"key":"f330e51df71fdf4b1b4b45c55554f01d0670d6ccd46b9114a1cb1c99138ec54b","facility":"Meridien Research/Accel Research","city":"Tampa","region":"Florida","country":"United States","lat":27.947520000000001,"lon":-82.458430000000007},{"key":"cbc52ccc3240d2384c67bd70f459ee87227d85c7f149a1d0d89c35f236bc92da","facility":"Psych Atlanta","city":"Atlanta","region":"Georgia","country":"United States","lat":33.749000000000002,"lon":-84.387979999999999},{"key":"dddfebfd7c55fd6887c90ed4c4d9ddf35cec45fa0565c30783730eb960b19056","facility":"Emory University","city":"Atlanta","region":"Georgia","country":"United States","lat":33.749000000000002,"lon":-84.387979999999999},{"key":"ddad76cc8ac3eabdf04d8d630a084814244b8b4bc8c26a47c3e9a8a5a1a06dea","facility":"Uptown Research Institute, LLC","city":"Chicago","region":"Illinois","country":"United States","lat":41.850029999999997,"lon":-87.650049999999993},{"key":"bc376e1e0a696ea23f74184c3639e3209c4cf2754b05d49dcebccf226428bc05","facility":"Sheppard Pratt Health System","city":"Baltimore","region":"Maryland","country":"United States","lat":39.290379999999999,"lon":-76.612189999999998},{"key":"716580afddf6cd0f33cf716a44cfcca22ce21eaa4c95b49ed07b6271fd6f8d5f","facility":"CBH Health, LLC","city":"Gaithersburg","region":"Maryland","country":"United States","lat":39.143439999999998,"lon":-77.201369999999997},{"key":"aed5f3a3729fadb87eb9ddf7cf97e4496c94256c79003e4950aec06f92bd9335","facility":"Pharmasite Research, Inc","city":"Pikesville","region":"Maryland","country":"United States","lat":39.374270000000003,"lon":-76.722470000000001},{"key":"3def80915b7bdc5d973f5b43fbe6e47d92c9a910c88c6ef98de29a0648309c43","facility":"University of Massachusetts Medical School","city":"North Worcester","region":"Massachusetts","country":"United States","lat":42.316760000000002,"lon":-71.817570000000003},{"key":"da66bed5e9f2c5007072da48565dcfb4c000c6aa0bc51cdf5c70ee46cf21fbda","facility":"University of Minnesota","city":"Minneapolis","region":"Minnesota","country":"United States","lat":44.979970000000002,"lon":-93.263840000000002},{"key":"cda828a419db240d879704c5ec8d0590c6dc6665b6cc951ea7d387b451349428","facility":"University of Missouri","city":"Columbia","region":"Missouri","country":"United States","lat":38.951709999999999,"lon":-92.334069999999997},{"key":"e4619be0239dcfaa6cf88391ac51a94bdeb892a639f37981575f1bfbbf8b4b7e","facility":"Midwest Research Group","city":"Saint Charles","region":"Missouri","country":"United States","lat":38.783940000000001,"lon":-90.481229999999996},{"key":"c3de2ce8933f517f3be34bd70e3809569645c3f60c38d874765d86ee599b4223","facility":"Washington University School of Medicine","city":"St Louis","region":"Missouri","country":"United States","lat":38.627270000000003,"lon":-90.197890000000001},{"key":"552a38e810ea599cab40e1a06262965439884f4f1ad26494072c517e71b41307","facility":"Alivation Research, LLC.","city":"Lincoln","region":"Nebraska","country":"United States","lat":40.799999999999997,"lon":-96.666960000000003},{"key":"4345cef85b3822f2a99a14204b9552b865c0a12a0081b0e155f454d8c0a0a130","facility":"Bio Behavioral Health","city":"Toms River","region":"New Jersey","country":"United States","lat":39.95373,"lon":-74.197919999999996},{"key":"9f6dd6c250948ab5fb811774c2613bdc33238e29b80a54c99b31bd3b33684089","facility":"New York State Psychiatric Institute","city":"New York","region":"New York","country":"United States","lat":40.714269999999999,"lon":-74.005970000000005},{"key":"e92b0749ac676724df1bafae96e4d208c7b45c522933b2dbf2bc22c00aa8ea23","facility":"The Medical Research Network, LLC","city":"New York","region":"New York","country":"United States","lat":40.714269999999999,"lon":-74.005970000000005},{"key":"bd0345ed7184630e5724c893fe997cf750f7382cdd08f6d8cfaca4e419f0098c","facility":"Insight Clinical Trials, LLC","city":"Beachwood","region":"Ohio","country":"United States","lat":41.464500000000001,"lon":-81.50873},{"key":"2f1696f8b848ef33abde31d26e5190829ce43bc6881490782f854d8bae1ad054","facility":"Neuro-Behaviroral Clinical Research, Inc.","city":"North Canton","region":"Ohio","country":"United States","lat":40.875889999999998,"lon":-81.402339999999995},{"key":"c2ab64bad8cb6e1cd94fa26091c2b7967f3576497d9b5ba77fbedf8e1cbda0b8","facility":"Rivus Wellness & Research Institute","city":"Oklahoma City","region":"Oklahoma","country":"United States","lat":35.467559999999999,"lon":-97.51643},{"key":"3d2286af2ccca60c23d4793147a69fc14dabbc3ae3f9dd6f3cb7a1caea3d8f55","facility":"Global Medical Institutes, LLC, Scranton Medical Institute","city":"Moosic","region":"Pennsylvania","country":"United States","lat":41.353409999999997,"lon":-75.738249999999994},{"key":"abde1914156fb3a015069c2985bfbe52696b55acd78e453c5b11b7dad8ea18cb","facility":"UT Health Science Center at Houston (UTHSC-H)","city":"Houston","region":"Texas","country":"United States","lat":29.763280000000002,"lon":-95.36327},{"key":"096867127180fe96e9a72bbcc7520d5592abe8032d4645482a93afa580e47078","facility":"Cedar Clinical Research","city":"Draper","region":"Utah","country":"United States","lat":40.52467,"lon":-111.86382},{"key":"b4d3e19100a06be7286fb663cf059a1979705efc30bbdaa0f7de176fb34503df","facility":"Core Clinical Research","city":"Everett","region":"Washington","country":"United States","lat":47.97898,"lon":-122.20208}],"countries":["United States"]},{"id":3453,"nct_id":"NCT06506019","title":"Neurobiological Effects of Psilocybin in Treatment Resistant Bipolar Depression: An Emotional-Processing fMRI Pilot Study","sponsor":"University Health Network, Toronto","registry_url":"https://clinicaltrials.gov/study/NCT06506019","tracker_url":"publication.php?id=3453","status":"ACTIVE_NOT_RECRUITING","status_label":"Active, not recruiting","status_verified_date":"2026-08","last_update_date":"2026-08-10","start_date":"2024-10-09","primary_completion_date":"2026-09-01","completion_date":"2027-01-01","study_type":"INTERVENTIONAL","phases":["PHASE1"],"enrollment":{"count":30,"type":"ESTIMATED"},"design":{"allocation":"NA","intervention_model":"SINGLE_GROUP","primary_purpose":"TREATMENT","masking":"NONE"},"conditions":["Bipolar Depression"],"interventions":[{"name":"Psilocybin","type":"DRUG"},{"name":"Functional MRI","type":"DEVICE"}],"substances":["psilocybin","psilocin"],"sites":[{"key":"106844c26e5555241112f8f0d56e093d03f44485cef1b730bce4ccb7c71b295f","facility":"Toronto Western Hospital - University Health Network","city":"Toronto","region":"Ontario","country":"Canada","lat":43.706429999999997,"lon":-79.39864}],"countries":["Canada"]},{"id":3561,"nct_id":"NCT06455293","title":"The Efficacy of Psilocybin Therapy for Depression in Parkinson's Disease","sponsor":"Joshua Woolley, MD, PhD","registry_url":"https://clinicaltrials.gov/study/NCT06455293","tracker_url":"publication.php?id=3561","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-05","last_update_date":"2026-08-07","start_date":"2024-08-19","primary_completion_date":"2027-06","completion_date":"2028-06","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":60,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"QUADRUPLE"},"conditions":["Parkinson Disease","Depression"],"interventions":[{"name":"Psilocybin","type":"DRUG"},{"name":"Pimavanserin","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"7f09a842484186a75c6232177464293472d56c43d4d49f24f37efcb6c9cbbbb8","facility":"University of California, San Francisco","city":"San Francisco","region":"California","country":"United States","lat":37.774929999999998,"lon":-122.41942}],"countries":["United States"]},{"id":3533,"nct_id":"NCT06835699","title":"Open Label Psilocybin Brain Stimulation and Imaging Pilot Study","sponsor":"Johns Hopkins University","registry_url":"https://clinicaltrials.gov/study/NCT06835699","tracker_url":"publication.php?id=3533","status":"COMPLETED","status_label":"Completed","status_verified_date":"2026-08","last_update_date":"2026-08-07","start_date":"2025-04-18","primary_completion_date":"2026-05-21","completion_date":"2026-05-21","study_type":"INTERVENTIONAL","phases":["PHASE1"],"enrollment":{"count":10,"type":"ACTUAL"},"design":{"allocation":"NA","intervention_model":"SINGLE_GROUP","primary_purpose":"BASIC_SCIENCE","masking":"NONE"},"conditions":["Healthy Volunteers"],"interventions":[{"name":"Psilocybin 25 mgs","type":"DRUG"},{"name":"TMS","type":"DEVICE"}],"substances":["psilocybin"],"sites":[{"key":"4c399ae21c1b15c1a76957dcb18c09f6ab07051151f994333e7109fd67ba663d","facility":"Johns Hopkins School of Medicine","city":"Baltimore","region":"Maryland","country":"United States","lat":39.290379999999999,"lon":-76.612189999999998}],"countries":["United States"]},{"id":3704,"nct_id":"NCT07406828","title":"Single Dose Psilocybin for a Post-surgical Trauma Inpatient Population for Pain, Mood, and Opioid Use Disorder","sponsor":"Trent Emerick","registry_url":"https://clinicaltrials.gov/study/NCT07406828","tracker_url":"publication.php?id=3704","status":"NOT_YET_RECRUITING","status_label":"Not yet recruiting","status_verified_date":"2026-08","last_update_date":"2026-08-06","start_date":"2027-12-31","primary_completion_date":"2029-04","completion_date":"2029-08","study_type":"INTERVENTIONAL","phases":["PHASE1"],"enrollment":{"count":70,"type":"ESTIMATED"},"design":{"allocation":"NON_RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"NONE"},"conditions":["Pain Management","Postoperative Pain"],"interventions":[{"name":"Psilocybin (Usona Institute)","type":"DRUG"},{"name":"Postoperative analgesia","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"da4eddfd2992562f2fa7a654929ec22b1272c672c077a5078fd4667df5e839c2","facility":"UPMC Presbyterian","city":"Pittsburgh","region":"Pennsylvania","country":"United States","lat":40.440620000000003,"lon":-79.995890000000003}],"countries":["United States"]},{"id":3582,"nct_id":"NCT06731621","title":"Psilocybin for Treatment-Resistant Depression in Autism: a Pilot Trial With Pre-Post Brain and Cognitive Measurement to Understand Mechanism","sponsor":"Centre for Addiction and Mental Health","registry_url":"https://clinicaltrials.gov/study/NCT06731621","tracker_url":"publication.php?id=3582","status":"ACTIVE_NOT_RECRUITING","status_label":"Active, not recruiting","status_verified_date":"2026-08","last_update_date":"2026-08-06","start_date":"2024-11-01","primary_completion_date":"2026-12","completion_date":"2026-12","study_type":"INTERVENTIONAL","phases":["PHASE1"],"enrollment":{"count":20,"type":"ESTIMATED"},"design":{"allocation":"NA","intervention_model":"SINGLE_GROUP","primary_purpose":"TREATMENT","masking":"NONE"},"conditions":["Treatment Resistant Depression","Autism Spectrum Disorder"],"interventions":[{"name":"Psilocybin","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"bf2adfb756d244974a952f7c5c58e6f72f66cbbd5ba63e61a8b987fa1820f128","facility":"Centre for Addiction and Mental Health","city":"Toronto","region":"Ontario","country":"Canada","lat":43.706429999999997,"lon":-79.39864}],"countries":["Canada"]},{"id":3507,"nct_id":"NCT06233344","title":"An Exploratory Study of Feasibility, Efficacy, and Mechanisms of Mindfulness-Assisted Psychedelic Therapy","sponsor":"University of Southern California","registry_url":"https://clinicaltrials.gov/study/NCT06233344","tracker_url":"publication.php?id=3507","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-08","last_update_date":"2026-08-06","start_date":"2025-07-30","primary_completion_date":"2027-08","completion_date":"2028-08","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":40,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"OTHER","masking":"NONE"},"conditions":["Mental Health"],"interventions":[{"name":"Psilocybin plus mindfulness training","type":"DRUG"},{"name":"Psilocybin","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"fe41ad3987d6de6fe68c69a1ba7b8083c49c8f7f3ed503bb29759b163851e03c","facility":"Univeristy of Southern California Brain and Creativity Institute","city":"Los Angeles","region":"California","country":"United States","lat":34.052230000000002,"lon":-118.24368}],"countries":["United States"]},{"id":3437,"nct_id":"NCT06001749","title":"Feasibility Phase 2 Study of Psilocybin-Assisted Therapy for Opioid-Refractory Pain in Patients With Advanced Cancer","sponsor":"Yvan Beaussant, MD, MSci","registry_url":"https://clinicaltrials.gov/study/NCT06001749","tracker_url":"publication.php?id=3437","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-08","last_update_date":"2026-08-05","start_date":"2024-09-23","primary_completion_date":"2026-10-01","completion_date":"2026-12-31","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":15,"type":"ESTIMATED"},"design":{"allocation":"NA","intervention_model":"SINGLE_GROUP","primary_purpose":"TREATMENT","masking":"NONE"},"conditions":["Opioid-Related Disorders","Pain Management","Pain Management and Care","Advanced Cancer","Advanced Cancers"],"interventions":[{"name":"Psilocybin","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"6f007287e1a63fa09fd71b03e4e4b72f285c5af84c8385a3eed252bc9a13b363","facility":"Dana-Farber Cancer Institute","city":"Boston","region":"Massachusetts","country":"United States","lat":42.358429999999998,"lon":-71.05977}],"countries":["United States"]},{"id":5846,"nct_id":"NCT07745569","title":"Precision Phenotyping of Behavioral Risk and Response to Electromagnetic and Psychedelic Therapies","sponsor":"University of New Mexico","registry_url":"https://clinicaltrials.gov/study/NCT07745569","tracker_url":"publication.php?id=5846","status":"NOT_YET_RECRUITING","status_label":"Not yet recruiting","status_verified_date":"2026-07","last_update_date":"2026-08-04","start_date":"2026-08-31","primary_completion_date":"2030-06-30","completion_date":"2030-06-30","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":150,"type":"ESTIMATED"},"design":{"allocation":"NON_RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"NONE"},"conditions":["PTSD","PTSD - Post Traumatic Stress Disorder","Major Depression","Suicidality"],"interventions":[{"name":"Transcranial Magnetic Stimulation","type":"DEVICE"},{"name":"Psilocybin (drug)","type":"DRUG"},{"name":"Neurofeedback","type":"BEHAVIORAL"}],"substances":["psilocybin"],"sites":[],"countries":[]},{"id":3565,"nct_id":"NCT07118332","title":"Psilocybin as a Treatment for Chronic Pain in Smokers","sponsor":"Yale University","registry_url":"https://clinicaltrials.gov/study/NCT07118332","tracker_url":"publication.php?id=3565","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-07","last_update_date":"2026-08-03","start_date":"2026-07-06","primary_completion_date":"2027-10-01","completion_date":"2027-12-01","study_type":"INTERVENTIONAL","phases":["EARLY_PHASE1"],"enrollment":{"count":10,"type":"ESTIMATED"},"design":{"allocation":"NA","intervention_model":"SINGLE_GROUP","primary_purpose":"HEALTH_SERVICES_RESEARCH","masking":"NONE"},"conditions":["Smokers With Chronic Pain"],"interventions":[{"name":"Psilocybin (drug)","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"1dd82fd9cc6558717200ae66d13a24d08c805492d49f67b2d8f9edc800d2c261","facility":"Department of Veterans Affairs","city":"West Haven","region":"Connecticut","country":"United States","lat":41.270650000000003,"lon":-72.947050000000004}],"countries":["United States"]},{"id":3576,"nct_id":"NCT07336238","title":"A Phase 2a Study of Group Retreat Psilocybin Therapy for Cancer-Related Anxiety and Depression","sponsor":"University of Washington","registry_url":"https://clinicaltrials.gov/study/NCT07336238","tracker_url":"publication.php?id=3576","status":"ACTIVE_NOT_RECRUITING","status_label":"Active, not recruiting","status_verified_date":"2026-07","last_update_date":"2026-07-31","start_date":"2026-05-19","primary_completion_date":"2026-12-01","completion_date":"2027-05-01","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":18,"type":"ESTIMATED"},"design":{"allocation":"NA","intervention_model":"SINGLE_GROUP","primary_purpose":"TREATMENT","masking":"NONE"},"conditions":["Anxiety","Depression","Hematopoietic and Lymphatic System Neoplasm","Metastatic Malignant Solid Neoplasm"],"interventions":[{"name":"Psychotherapy","type":"BEHAVIORAL"},{"name":"Psilocybin","type":"DRUG"},{"name":"Survey Administration","type":"OTHER"}],"substances":["psilocybin"],"sites":[{"key":"27055592446b9d587e53a6321150bf4888fc2ba23be8770451328b59a69e7dd8","facility":"Fred Hutch/University of Washington Cancer Consortium","city":"Seattle","region":"Washington","country":"United States","lat":47.606209999999997,"lon":-122.33207}],"countries":["United States"]},{"id":5761,"nct_id":"NCT07737990","title":"Psilocybin-Assisted Group Integration Psychotherapy for Treatment-Resistant Depression","sponsor":"Joshua Rosenblat","registry_url":"https://clinicaltrials.gov/study/NCT07737990","tracker_url":"publication.php?id=5761","status":"ENROLLING_BY_INVITATION","status_label":"Enrolling by invitation","status_verified_date":"2026-07","last_update_date":"2026-07-30","start_date":"2026-07-01","primary_completion_date":"2029-12-31","completion_date":"2030-06-30","study_type":"INTERVENTIONAL","phases":["NA"],"enrollment":{"count":65,"type":"ESTIMATED"},"design":{"allocation":"NA","intervention_model":"SINGLE_GROUP","primary_purpose":"TREATMENT","masking":"NONE"},"conditions":["Treatment-resistant Depression (TRD)"],"interventions":[{"name":"Group integration therapy","type":"OTHER"}],"substances":["psilocybin"],"sites":[{"key":"3590d22089fced0e188a9729567125a04d5a4db66af91f56a9d2d5c22d92597b","facility":"Toronto Western Hospital","city":"Toronto","region":"Ontario","country":"Canada","lat":43.706429999999997,"lon":-79.39864}],"countries":["Canada"]},{"id":5760,"nct_id":"NCT07737054","title":"Trauma-informed Psilocybin Assisted Psychotherapy (TiPAP) for Post-Traumatic Stress Disorder","sponsor":"Tel-Aviv Sourasky Medical Center","registry_url":"https://clinicaltrials.gov/study/NCT07737054","tracker_url":"publication.php?id=5760","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-07","last_update_date":"2026-07-30","start_date":"2025-07-22","primary_completion_date":"2026-12-01","completion_date":"2026-12-31","study_type":"INTERVENTIONAL","phases":["EARLY_PHASE1"],"enrollment":{"count":13,"type":"ESTIMATED"},"design":{"allocation":"NA","intervention_model":"SINGLE_GROUP","primary_purpose":"TREATMENT","masking":"NONE"},"conditions":["Post-Traumatic Stress Disorder, PTSD"],"interventions":[{"name":"Psilocybin (drug)","type":"DRUG"},{"name":"Trauma-Focused Psychotherapy","type":"BEHAVIORAL"}],"substances":["psilocybin"],"sites":[{"key":"a9c873ac063d6e120c29fe3a990563df65d56f36d533e4becc50b462afacd39c","facility":"Tel Aviv Sourasky Medical Center","city":"Tel Aviv","region":"","country":"Israel","lat":32.080880000000001,"lon":34.780569999999997}],"countries":["Israel"]},{"id":3647,"nct_id":"NCT06512220","title":"Imaging the Effects of Serotonin 2A Receptor Modulation on Synaptic Density in Treatment-resistant Depression (SYNVEST)","sponsor":"Centre for Addiction and Mental Health","registry_url":"https://clinicaltrials.gov/study/NCT06512220","tracker_url":"publication.php?id=3647","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-05","last_update_date":"2026-07-30","start_date":"2025-04-21","primary_completion_date":"2027-04","completion_date":"2027-09","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":12,"type":"ESTIMATED"},"design":{"allocation":"NON_RANDOMIZED","intervention_model":"SEQUENTIAL","primary_purpose":"TREATMENT","masking":"NONE"},"conditions":["Treatment Resistant Depression"],"interventions":[{"name":"Psilocybin 25 mg","type":"DRUG"},{"name":"Risperidone 1 MG","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"bf2adfb756d244974a952f7c5c58e6f72f66cbbd5ba63e61a8b987fa1820f128","facility":"Centre for Addiction and Mental Health","city":"Toronto","region":"Ontario","country":"Canada","lat":43.706429999999997,"lon":-79.39864}],"countries":["Canada"]},{"id":3591,"nct_id":"NCT06518720","title":"Treatment With Psilocybin for Chronic Neuropathic Pain and Depression (TRANSCEND): An Open-Label Clinical Trial","sponsor":"Centre for Addiction and Mental Health","registry_url":"https://clinicaltrials.gov/study/NCT06518720","tracker_url":"publication.php?id=3591","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-07","last_update_date":"2026-07-30","start_date":"2025-04-01","primary_completion_date":"2027-03","completion_date":"2027-12","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":16,"type":"ESTIMATED"},"design":{"allocation":"NA","intervention_model":"SINGLE_GROUP","primary_purpose":"TREATMENT","masking":"NONE"},"conditions":["Treatment Resistant Depression","Chronic Pain"],"interventions":[{"name":"Psilocybin 25 mg","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"bf2adfb756d244974a952f7c5c58e6f72f66cbbd5ba63e61a8b987fa1820f128","facility":"Centre for Addiction and Mental Health","city":"Toronto","region":"Ontario","country":"Canada","lat":43.706429999999997,"lon":-79.39864}],"countries":["Canada"]},{"id":3654,"nct_id":"NCT07275970","title":"An Open-Label, Phase 1 Study of the Safety Pharmacokinetic Profile, and Preliminary Efficacy, of Organic Whole Psilocybin-Containing Mushrooms in Patients Suffering From PTSD","sponsor":"Scottsdale Research Institute","registry_url":"https://clinicaltrials.gov/study/NCT07275970","tracker_url":"publication.php?id=3654","status":"ACTIVE_NOT_RECRUITING","status_label":"Active, not recruiting","status_verified_date":"2026-07","last_update_date":"2026-07-29","start_date":"2026-03-20","primary_completion_date":"2026-07-30","completion_date":"2026-10-01","study_type":"INTERVENTIONAL","phases":["PHASE1"],"enrollment":{"count":24,"type":"ESTIMATED"},"design":{"allocation":"NA","intervention_model":"SINGLE_GROUP","primary_purpose":"TREATMENT","masking":"NONE"},"conditions":["PTSD"],"interventions":[{"name":"Psychedelic","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"a702953addaa4dc3d8c52c701265782e11a96d5e3dba6aa4403c50eb6c2871a1","facility":"Scottsdale Research Institute","city":"Scottsdale","region":"Arizona","country":"United States","lat":33.509210000000003,"lon":-111.89903}],"countries":["United States"]},{"id":3542,"nct_id":"NCT05866471","title":"Activating Neuroplasticity to ENHANCE the Perception Box Expanding Effects of Psilocybin","sponsor":"University of Wisconsin, Madison","registry_url":"https://clinicaltrials.gov/study/NCT05866471","tracker_url":"publication.php?id=3542","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-07","last_update_date":"2026-07-29","start_date":"2025-01-27","primary_completion_date":"2027-11","completion_date":"2028-01","study_type":"INTERVENTIONAL","phases":["PHASE1"],"enrollment":{"count":108,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"FACTORIAL","primary_purpose":"BASIC_SCIENCE","masking":"TRIPLE"},"conditions":["Healthy","Psychedelic Experiences","Vagus Nerve Stimulation"],"interventions":[{"name":"Psilocybin","type":"DRUG"},{"name":"Transcutaneous auricular Vagus Nerve Stimulation (taVNS)","type":"DEVICE"},{"name":"Psychosocial Support Alone","type":"BEHAVIORAL"},{"name":"Sham taVNS","type":"OTHER"}],"substances":["psilocybin"],"sites":[{"key":"150ee05b89013f57afa3d4437262fc96492708dbef022aa3d4706d1b2f9b8bcd","facility":"University of Wisconsin - Madison","city":"Madison","region":"Wisconsin","country":"United States","lat":43.073050000000002,"lon":-89.401229999999998}],"countries":["United States"]},{"id":5755,"nct_id":"NCT07732166","title":"Changes in Self-awareness Induced by Psychoactive Substances: an Experimental Study With Psilocybin.","sponsor":"Pontifícia Universidade Católica do Rio de Janeiro","registry_url":"https://clinicaltrials.gov/study/NCT07732166","tracker_url":"publication.php?id=5755","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-07","last_update_date":"2026-07-28","start_date":"2026-04-01","primary_completion_date":"2027-08-01","completion_date":"2027-12-01","study_type":"INTERVENTIONAL","phases":["EARLY_PHASE1"],"enrollment":{"count":100,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"CROSSOVER","primary_purpose":"HEALTH_SERVICES_RESEARCH","masking":"TRIPLE"},"conditions":["Healthy Adults"],"interventions":[{"name":"Psilocybin (Usona Institute)","type":"DRUG"},{"name":"Niacin 100 mg","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"56dbd951047579f5e7cb6365abb06b654904e94f48585c22b28b8f01d8930412","facility":"Centro de Pesquisas Matteo Ricci","city":"Rio de Janeiro","region":"Rio de Janeiro","country":"Brazil","lat":-22.906420000000001,"lon":-43.182229999999997}],"countries":["Brazil"]},{"id":3710,"nct_id":"NCT07347405","title":"A Randomized Double-masked Dose-controlled Trial to Assess the Tolerability, Safety, Subjective Experience, and Efficacy of Repeated Administration of Three Different Doses of Psilocybin Whole Mushroom for the Treatment of Obsessive-compulsive Disorder.","sponsor":"Francisco A Moreno","registry_url":"https://clinicaltrials.gov/study/NCT07347405","tracker_url":"publication.php?id=3710","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-05","last_update_date":"2026-07-23","start_date":"2026-05-18","primary_completion_date":"2028-12-31","completion_date":"2029-01-31","study_type":"INTERVENTIONAL","phases":["PHASE1"],"enrollment":{"count":30,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"QUADRUPLE"},"conditions":["Obsessive-Compulsive Disorder"],"interventions":[{"name":"Psilocybin 10 mg","type":"DRUG"},{"name":"Psilocybin 20 mg","type":"DRUG"},{"name":"Psilocybin 30 mg","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"b7ce275dcf24ed96a64d133fef7a20f86f0b05456f00dfb40319b4e098140d69","facility":"The Clinical and Translational Sciences Research Center","city":"Tucson","region":"Arizona","country":"United States","lat":32.221739999999997,"lon":-110.92648}],"countries":["United States"]},{"id":3707,"nct_id":"NCT05301608","title":"Effects of Psilocybin on Electrophysiology and the Dynamic Content of Thought","sponsor":"Johns Hopkins University","registry_url":"https://clinicaltrials.gov/study/NCT05301608","tracker_url":"publication.php?id=3707","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-07","last_update_date":"2026-07-23","start_date":"2022-03-03","primary_completion_date":"2026-12-01","completion_date":"2027-01-01","study_type":"INTERVENTIONAL","phases":["PHASE1","PHASE2"],"enrollment":{"count":30,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"CROSSOVER","primary_purpose":"BASIC_SCIENCE","masking":"QUADRUPLE"},"conditions":["Healthy"],"interventions":[{"name":"Psilocybin","type":"DRUG"},{"name":"Placebo","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"9d7c1530695da1e0dbe5d0029c61521b74c434cedec820dcadef26feb9ead43e","facility":"Johns Hopkins Center for Psychedelic and Consciousness Research","city":"Baltimore","region":"Maryland","country":"United States","lat":39.290379999999999,"lon":-76.612189999999998}],"countries":["United States"]},{"id":3630,"nct_id":"NCT05723276","title":"Probing the Functional Magnetic Resonance Imaging Response to Psilocybin in Functional Neurological Disorder (PsiFUND)","sponsor":"King's College London","registry_url":"https://clinicaltrials.gov/study/NCT05723276","tracker_url":"publication.php?id=3630","status":"COMPLETED","status_label":"Completed","status_verified_date":"2026-07","last_update_date":"2026-07-23","start_date":"2024-02-14","primary_completion_date":"2026-04-14","completion_date":"2026-07-07","study_type":"INTERVENTIONAL","phases":["NA"],"enrollment":{"count":20,"type":"ACTUAL"},"design":{"allocation":"NA","intervention_model":"SINGLE_GROUP","primary_purpose":"BASIC_SCIENCE","masking":"NONE"},"conditions":["Functional Neurological Disorder"],"interventions":[{"name":"Psilocybin","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"8cd5c53de095e8abbdf7d2a81b2bc34a9a6968c44ae8f4eb45dc82ef2cf7b17c","facility":"South London and Maudsley NHS Foundation Trust","city":"London","region":"","country":"United Kingdom","lat":51.50853,"lon":-0.12573999999999999}],"countries":["United Kingdom"]},{"id":3615,"nct_id":"NCT06308653","title":"A Phase 3, Randomized, Double-Blind, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Psilocybin in Adults With Major Depressive Disorder (MDD)","sponsor":"Usona Institute","registry_url":"https://clinicaltrials.gov/study/NCT06308653","tracker_url":"publication.php?id=3615","status":"ACTIVE_NOT_RECRUITING","status_label":"Active, not recruiting","status_verified_date":"2026-07","last_update_date":"2026-07-23","start_date":"2024-03-13","primary_completion_date":"2026-01-05","completion_date":"2027-01-30","study_type":"INTERVENTIONAL","phases":["PHASE3"],"enrollment":{"count":238,"type":"ACTUAL"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"TRIPLE"},"conditions":["Depressive Disorder, Major"],"interventions":[{"name":"Psilocybin 25 mg","type":"DRUG"},{"name":"Inactive Placebo","type":"DRUG"},{"name":"Psilocybin 5 mg","type":"DRUG"},{"name":"Psychosocial Support","type":"BEHAVIORAL"}],"substances":["psilocybin"],"sites":[{"key":"14e7954577ce525bd2e7710b02e39fdabf72f2c8d72262f82810220f9bbc7498","facility":"University of Alabama Clinical Research Unit","city":"Birmingham","region":"Alabama","country":"United States","lat":33.520659999999999,"lon":-86.802490000000006},{"key":"134624f1b3ebc995c482aef393a9d811e84fbfdd73e9884dfc7a181efcea7a1f","facility":"Preferred Research Partners-NWA, LLC","city":"Fayetteville","region":"Arkansas","country":"United States","lat":36.062579999999997,"lon":-94.157430000000005},{"key":"36ef6d1faa16c3ec487aae6864eb7b5265c820a39cc8d48cb8f9ee8d6d813e38","facility":"Preferred Research Partners, Inc.","city":"Little Rock","region":"Arkansas","country":"United States","lat":34.746479999999998,"lon":-92.289590000000004},{"key":"b1132fa91c6c49bf3a7b5fc89a57fb89b94ff271a2081e8352dd7bd5a7ea4f1c","facility":"Kadima Neuropsychiatry Institute","city":"La Jolla","region":"California","country":"United States","lat":32.847270000000002,"lon":-117.27419999999999},{"key":"e0090c8e01843af348d108c015996af52250bb640aed2100a50bbf5478b2f43a","facility":"West LA VA Medical Center - Mental Health Department","city":"Los Angeles","region":"California","country":"United States","lat":34.052230000000002,"lon":-118.24368},{"key":"333ee8580c6de733d9a6b7d1c27943782b772607f8d8db5ad6d22a1f13cdbc38","facility":"Pacific Neuroscience Institute (PNI) at Saint John's Physician Partners","city":"Santa Monica","region":"California","country":"United States","lat":34.019489999999998,"lon":-118.49138000000001},{"key":"cd3b70cd42e414f693d2181817eaadd4560079c48ff673bea7aa12cd23f4a696","facility":"Psychedelic Science Institute","city":"Santa Monica","region":"California","country":"United States","lat":34.019489999999998,"lon":-118.49138000000001},{"key":"2fbe4fd0fc855904f5e7830f6c1af9e5e02f9eb69a12c4f076f653de81b52c55","facility":"Mountain View Clinical Research","city":"Denver","region":"Colorado","country":"United States","lat":39.739150000000002,"lon":-104.9847},{"key":"6aaffe1ee5c6e69eeb08d4ff968eff6bc874f659ee93212eeefddb37a646f777","facility":"Connecticut Mental Health Center, Yale University","city":"New Haven","region":"Connecticut","country":"United States","lat":41.308149999999998,"lon":-72.928160000000005},{"key":"dab11cb6c1feac91ad29ec450ae10d82f0c4d1351101be32a345ed9645f3e528","facility":"Clinical Neuroscience Solutions Inc.","city":"Jacksonville","region":"Florida","country":"United States","lat":30.332180000000001,"lon":-81.655649999999994},{"key":"1d86b7161c444a07e40f263de72732b54d755691bf3a60669016463f215c75dd","facility":"Innovative Clinical Research, Inc.","city":"Lauderhill","region":"Florida","country":"United States","lat":26.140360000000001,"lon":-80.213380000000001},{"key":"1238ad629d3a9b7e22f2a3b74f5e654f316fbb433b79d619fbca7571e41b3e9b","facility":"Clinical Neuroscience Solutions, Inc.","city":"Orlando","region":"Florida","country":"United States","lat":28.538340000000002,"lon":-81.379239999999996},{"key":"dddfebfd7c55fd6887c90ed4c4d9ddf35cec45fa0565c30783730eb960b19056","facility":"Emory University","city":"Atlanta","region":"Georgia","country":"United States","lat":33.749000000000002,"lon":-84.387979999999999},{"key":"37d6ce5812b7579b4de5e55e4c3cb57e1ee148c6b4602abf5d833c2e149ac515","facility":"CenExel iResearch, LLC","city":"Decatur","region":"Georgia","country":"United States","lat":33.774830000000001,"lon":-84.296310000000005},{"key":"845bec3dc316b3c2137f0d6c06c8372da8841a54f8dc62326a4964312161d387","facility":"Great Lakes Clinical Trials","city":"Chicago","region":"Illinois","country":"United States","lat":41.850029999999997,"lon":-87.650049999999993},{"key":"e28b64e754f83e37c6c04dd01732fe94b9a78655852692bd6f79cce0e822cb8d","facility":"Johns Hopkins School of Medicine, Center for Psychedelic and Consciousness Research","city":"Baltimore","region":"Maryland","country":"United States","lat":39.290379999999999,"lon":-76.612189999999998},{"key":"ee018f0ef7f8d9aa2c43156764d8851386a9cc2e57f50a485659f490014db48d","facility":"Sunstone Medical PC","city":"Rockville","region":"Maryland","country":"United States","lat":39.084000000000003,"lon":-77.152760000000001},{"key":"c3de2ce8933f517f3be34bd70e3809569645c3f60c38d874765d86ee599b4223","facility":"Washington University School of Medicine","city":"St Louis","region":"Missouri","country":"United States","lat":38.627270000000003,"lon":-90.197890000000001},{"key":"4fa1fba71596431dc1fafcac64c0506ff297f1f1a45eba4ca9b5603a69ef0512","facility":"VA Nebraska Western Iowa Health Care System","city":"Omaha","region":"Nebraska","country":"United States","lat":41.256259999999997,"lon":-95.940430000000006},{"key":"6821666350dba63b993707c9ef1bbd36cb7be5b3e36edac1be1401165a2912e1","facility":"Global Medical Institutes, LLC; Princeton Medical Institute","city":"Princeton","region":"New Jersey","country":"United States","lat":40.34872,"lon":-74.659049999999993},{"key":"558c7f9c59f7f0bcc99c2f9345254b29c79b0ad869836fb1621c4623c5996500","facility":"University of New Mexico (UNM) Interdisciplinary Substance Use and Brain Injury (ISUBI) Center","city":"Albuquerque","region":"New Mexico","country":"United States","lat":35.084490000000002,"lon":-106.65114},{"key":"45628f43bdfea032e58a89b43f8fb6c2bd63b4953aa6832c821a6edea255c9a0","facility":"NYU Clinical & Translational Science Institute","city":"New York","region":"New York","country":"United States","lat":40.714269999999999,"lon":-74.005970000000005},{"key":"6b9e755840736077e18d206704bd73d666a1c134ace71c56736b66d829529002","facility":"Bronx Veterans Research Foundation at the James J. Peters VAMC","city":"The Bronx","region":"New York","country":"United States","lat":40.849850000000004,"lon":-73.866410000000002},{"key":"7b63525882972dd6bf44fcfa835690c748540b4d1139f81fe71dd852856b83e7","facility":"AIM Trials, LLC","city":"Plano","region":"Texas","country":"United States","lat":33.019840000000002,"lon":-96.698890000000006},{"key":"37678407a2aea37d8b45c04bb4f789d0a48aefd9a52d1062eef70dd0656d3034","facility":"Clinical Trials of Texas, LLC","city":"San Antonio","region":"Texas","country":"United States","lat":29.424119999999998,"lon":-98.493629999999996},{"key":"096867127180fe96e9a72bbcc7520d5592abe8032d4645482a93afa580e47078","facility":"Cedar Clinical Research","city":"Draper","region":"Utah","country":"United States","lat":40.52467,"lon":-111.86382},{"key":"4761e7e68f171ea984a7c8e123dd21a8e90a757c6e37951311684abce81485de","facility":"Cedar Clinical Research, Inc.","city":"Murray","region":"Utah","country":"United States","lat":40.666890000000002,"lon":-111.88799},{"key":"de6dacdebeab612d78b308723aa873619b88e755a446e145e96ac60d29e18b9f","facility":"Seattle Neuropsychiatric Treatment Center","city":"Bellevue","region":"Washington","country":"United States","lat":47.610379999999999,"lon":-122.20068000000001},{"key":"6020223d1dcc5a5283db6886bb3b4b8a3172b842608688b0cbdc5b7777ff0949","facility":"VA Portland Health Care System","city":"Vancouver","region":"Washington","country":"United States","lat":45.638730000000002,"lon":-122.66149}],"countries":["United States"]},{"id":3566,"nct_id":"NCT06820723","title":"A Randomized, Double-Blind, Placebo-Controlled Mechanistic Study to Assess a Single Oral Dose of CYB003 in Participants With Major Depressive Disorder (MDD) and Moderate to Severe Anxiety","sponsor":"Ohio State University","registry_url":"https://clinicaltrials.gov/study/NCT06820723","tracker_url":"publication.php?id=3566","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-07","last_update_date":"2026-07-23","start_date":"2026-08-01","primary_completion_date":"2028-09","completion_date":"2028-11","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":40,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"OTHER","masking":"TRIPLE"},"conditions":["Depression","Anxiety","Major Depressive Disorder"],"interventions":[{"name":"CYB003","type":"DRUG"},{"name":"Placebo","type":"DRUG"}],"substances":["psilocybin","psilocin"],"sites":[{"key":"53cdbf22033ee2308c3b87787fc126f7b960b463f408d5adce7f8bc3876c2e09","facility":"The Ohio State University Department of Psychiatry","city":"Columbus","region":"Ohio","country":"United States","lat":39.961179999999999,"lon":-82.99879}],"countries":["United States"]},{"id":5731,"nct_id":"NCT07710027","title":"A Randomized, Double-Blind, Single Ascending Dose Study to Identify a Safe and Non-Psychedelic Dose of Psilocybin","sponsor":"Diamond Therapeutics Inc.","registry_url":"https://clinicaltrials.gov/study/NCT07710027","tracker_url":"publication.php?id=5731","status":"COMPLETED","status_label":"Completed","status_verified_date":"2026-07","last_update_date":"2026-07-17","start_date":"2021-10-19","primary_completion_date":"2022-03-12","completion_date":"2023-03-12","study_type":"INTERVENTIONAL","phases":["PHASE1"],"enrollment":{"count":56,"type":"ACTUAL"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"BASIC_SCIENCE","masking":"QUADRUPLE"},"conditions":["Healthy Controls"],"interventions":[{"name":"Psilocybin (low dose) or Placebo","type":"DRUG"}],"substances":["psilocybin","psilocin"],"sites":[{"key":"9dd7a5cdc662ca608b61bdc5e24508a870c1b8317b7e9fbcad9af7befe4b01a2","facility":"BioPharma Services Inc.","city":"Toronto","region":"Ontario","country":"Canada","lat":43.706429999999997,"lon":-79.39864}],"countries":["Canada"]},{"id":3691,"nct_id":"NCT06067737","title":"Outpatient Buprenorphine Induction With Psilocybin for Opioid Use Disorder: a Randomized Double-blind Trial","sponsor":"Johns Hopkins University","registry_url":"https://clinicaltrials.gov/study/NCT06067737","tracker_url":"publication.php?id=3691","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-07","last_update_date":"2026-07-17","start_date":"2024-02-08","primary_completion_date":"2028-07","completion_date":"2029-05","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":90,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"QUADRUPLE"},"conditions":["Opioid Use Disorder"],"interventions":[{"name":"Psilocybin","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"9d7c1530695da1e0dbe5d0029c61521b74c434cedec820dcadef26feb9ead43e","facility":"Johns Hopkins Center for Psychedelic and Consciousness Research","city":"Baltimore","region":"Maryland","country":"United States","lat":39.290379999999999,"lon":-76.612189999999998}],"countries":["United States"]},{"id":5722,"nct_id":"NCT07703722","title":"Effect of Psilocybin and Structured Integrated Reframing Therapy on Gut-Brain Axis Biomarkers and Depression in Trauma-Related Major Depressive Disorder: Randomized Controlled Trial","sponsor":"Khyber Medical University Peshawar","registry_url":"https://clinicaltrials.gov/study/NCT07703722","tracker_url":"publication.php?id=5722","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-07","last_update_date":"2026-07-14","start_date":"2026-04-01","primary_completion_date":"2027-10-22","completion_date":"2027-11-22","study_type":"INTERVENTIONAL","phases":["PHASE3"],"enrollment":{"count":60,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"NONE"},"conditions":["Major Depressive Disorder","Post-Traumatic Stress Disorder (PTSD)"],"interventions":[{"name":"Psilocybin","type":"DRUG"},{"name":"Structured Integrated Reframing Therapy (SIRT)","type":"BEHAVIORAL"},{"name":"Selective Serotonin Reuptake Inhibitor (SSRI)","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"e80ae31010614821a2c0251a43cb105eb5afdf4210df2d02fbca62249b4812cb","facility":"Institute of Health Science, Khyber Medical University","city":"Islamabad","region":"Capital","country":"Pakistan","lat":33.72148,"lon":73.043289999999999},{"key":"482052fef0467a4bb441cf6e5d88301072e19c45a3a032776b1d48bce47e7a68","facility":"Hayatabad Medical Complex Peshawar","city":"Peshawar","region":"KPK","country":"Pakistan","lat":34.008000000000003,"lon":71.578490000000002},{"key":"54a0606875858be17f5c6f12f6ec10397681ed8e3c5b816b0964b25c06587ac1","facility":"Khyber Medical University","city":"Peshawar","region":"KPK","country":"Pakistan","lat":34.008000000000003,"lon":71.578490000000002}],"countries":["Pakistan"]},{"id":3648,"nct_id":"NCT06464367","title":"Mechanistic Studies of Psilocybin in Headache Disorders","sponsor":"Yale University","registry_url":"https://clinicaltrials.gov/study/NCT06464367","tracker_url":"publication.php?id=3648","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-07","last_update_date":"2026-07-13","start_date":"2025-05-19","primary_completion_date":"2027-12-31","completion_date":"2027-12-31","study_type":"INTERVENTIONAL","phases":["EARLY_PHASE1"],"enrollment":{"count":50,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"OTHER","masking":"QUADRUPLE"},"conditions":["Migraine"],"interventions":[{"name":"Psilocybin","type":"DRUG"},{"name":"Placebo","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"ef06e3a474fd2949d20a68ee09bed05400191915922ddddc3e80085918c45336","facility":"VA Connecticut Healthcare System","city":"West Haven","region":"Connecticut","country":"United States","lat":41.270650000000003,"lon":-72.947050000000004}],"countries":["United States"]},{"id":3502,"nct_id":"NCT07063862","title":"PSilocybin Microdose for psYCHological and Existential Distress in PALliative Care (PSYCHED-PAL): A Multi-site Phase 3 Double-blind, Placebo-controlled, Parallel-arm Clinical Trial","sponsor":"Bruyère Health Research Institute.","registry_url":"https://clinicaltrials.gov/study/NCT07063862","tracker_url":"publication.php?id=3502","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-01","last_update_date":"2026-07-10","start_date":"2026-01-28","primary_completion_date":"2027-08","completion_date":"2027-09","study_type":"INTERVENTIONAL","phases":["PHASE3"],"enrollment":{"count":120,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"QUADRUPLE"},"conditions":["Psychological Distress"],"interventions":[{"name":"Psilocybin","type":"DRUG"},{"name":"Placebo","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"104bc03ef1be3eb283fc88bf5fce3e5ff6c85007bff327791c7a04846f88d35a","facility":"William Osler Health System","city":"Brampton","region":"Ontario","country":"Canada","lat":43.683410000000002,"lon":-79.766329999999996},{"key":"dc3875179cb830724fc5f84413b98d92146b4b6cbbf28f85a160567e32905d2c","facility":"Providence Care Hospital","city":"Kingston","region":"Ontario","country":"Canada","lat":44.229759999999999,"lon":-76.480980000000002},{"key":"6f7cb2e1921867a894d4f688041519f8adcacf7b68acf4348e2e37c6661d4cdf","facility":"St. Joseph's Healthcare","city":"London","region":"Ontario","country":"Canada","lat":42.98339,"lon":-81.233040000000003},{"key":"f934fa0d3d51d6c774793a28fc64efcf90b8e28198269a1250a0c3f99f3ed6f9","facility":"South Lake Regional Health Centre","city":"Newmarket","region":"Ontario","country":"Canada","lat":44.050109999999997,"lon":-79.466309999999993},{"key":"25666f03708722f78f57cf2a417d211304fca135b845052bac716c024043384f","facility":"Bruyere Health","city":"Ottawa","region":"Ontario","country":"Canada","lat":45.411169999999998,"lon":-75.698120000000003},{"key":"191b97d23002f5fc0aef25ec189e10d4d9cfe3306186fed0ac8629e958a94280","facility":"The Ottawa Hospital","city":"Ottawa","region":"Ontario","country":"Canada","lat":45.411169999999998,"lon":-75.698120000000003},{"key":"ef9bc15ff41fe07277a1de400fafab1b05a763305b6e78adf15926ff3f12ea42","facility":"McGill University Health Centre","city":"Montreal","region":"Quebec","country":"Canada","lat":45.508839999999999,"lon":-73.587810000000005}],"countries":["Canada"]},{"id":3467,"nct_id":"NCT04754061","title":"PSilocybin for psYCHological and Existential Distress in PALliative Care (PSYCHED-PAL): A Multi-site, Open-label, Single Arm Phase I/II Proof-of-concept, Dose-finding, and Feasibility Clinical Trial","sponsor":"Ottawa Hospital Research Institute","registry_url":"https://clinicaltrials.gov/study/NCT04754061","tracker_url":"publication.php?id=3467","status":"ACTIVE_NOT_RECRUITING","status_label":"Active, not recruiting","status_verified_date":"2026-07","last_update_date":"2026-07-10","start_date":"2024-01-08","primary_completion_date":"2026-10-01","completion_date":"2027-01-01","study_type":"INTERVENTIONAL","phases":["PHASE1","PHASE2"],"enrollment":{"count":20,"type":"ESTIMATED"},"design":{"allocation":"NA","intervention_model":"SINGLE_GROUP","primary_purpose":"TREATMENT","masking":"NONE"},"conditions":["Depression, Anxiety","Distress, Emotional"],"interventions":[{"name":"Psilocybin","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"191b97d23002f5fc0aef25ec189e10d4d9cfe3306186fed0ac8629e958a94280","facility":"The Ottawa Hospital","city":"Ottawa","region":"Ontario","country":"Canada","lat":45.411169999999998,"lon":-75.698120000000003},{"key":"49789f37aec7d28691c1a5e9cd381cbcd8b3460b042712987f08a6b62771c64a","facility":"Bruyere Continuing Care","city":"Ottawa","region":"Ontario","country":"Canada","lat":45.411169999999998,"lon":-75.698120000000003}],"countries":["Canada"]},{"id":3432,"nct_id":"NCT05265546","title":"Investigating the Mechanisms of the Effects of Psilocybin on Visual Perception and Visual Representations in the Brain","sponsor":"University of California, Berkeley","registry_url":"https://clinicaltrials.gov/study/NCT05265546","tracker_url":"publication.php?id=3432","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-07","last_update_date":"2026-07-10","start_date":"2024-03-08","primary_completion_date":"2028-12-31","completion_date":"2028-12-31","study_type":"INTERVENTIONAL","phases":["PHASE1"],"enrollment":{"count":80,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"CROSSOVER","primary_purpose":"BASIC_SCIENCE","masking":"DOUBLE"},"conditions":["Perception Disorders"],"interventions":[{"name":"Psilocybin","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"f03299e8c6bc2c4a865cc090ea047d3a962eb50dc47bdd65bf9ed339007f853b","facility":"University of California, Berkeley","city":"Berkeley","region":"California","country":"United States","lat":37.871589999999998,"lon":-122.27275}],"countries":["United States"]},{"id":5684,"nct_id":"NCT07693153","title":"The Effects of Psilocybin on Social Connectedness","sponsor":"Yale University","registry_url":"https://clinicaltrials.gov/study/NCT07693153","tracker_url":"publication.php?id=5684","status":"NOT_YET_RECRUITING","status_label":"Not yet recruiting","status_verified_date":"2026-07","last_update_date":"2026-07-09","start_date":"2026-08-31","primary_completion_date":"2031-12-15","completion_date":"2031-12-15","study_type":"INTERVENTIONAL","phases":["PHASE1"],"enrollment":{"count":51,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"OTHER","masking":"TRIPLE"},"conditions":["Loneliness","Grief"],"interventions":[{"name":"Psilocybin","type":"DRUG"},{"name":"Placebo","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"27df3ff2008239e64bf38e6c56f8f5e8652612b4aa9bff987d4ba0f94be975b1","facility":"Connecticut Mental Health Center","city":"New Haven","region":"Connecticut","country":"United States","lat":41.308149999999998,"lon":-72.928160000000005}],"countries":["United States"]},{"id":3610,"nct_id":"NCT06341426","title":"Psilocybin-Assisted Psychotherapy for Treatment-Resistant Depression: A Randomized Phase II Clinical Trial Comparing One Versus Two Psychedelic Doses of Psilocybin (PSI-1V2)","sponsor":"University Health Network, Toronto","registry_url":"https://clinicaltrials.gov/study/NCT06341426","tracker_url":"publication.php?id=3610","status":"ACTIVE_NOT_RECRUITING","status_label":"Active, not recruiting","status_verified_date":"2026-07","last_update_date":"2026-07-09","start_date":"2024-02-05","primary_completion_date":"2026-07-28","completion_date":"2026-12-28","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":92,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"QUADRUPLE"},"conditions":["Major Depressive Disorder","Depression","Treatment-Resistant Depression","Mood Disorders"],"interventions":[{"name":"Single Psychedelic Dose Psilocybin","type":"DRUG"},{"name":"Two Psychedelic Doses Psilocybin","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"3590d22089fced0e188a9729567125a04d5a4db66af91f56a9d2d5c22d92597b","facility":"Toronto Western Hospital","city":"Toronto","region":"Ontario","country":"Canada","lat":43.706429999999997,"lon":-79.39864},{"key":"2846642b890b09da9f32cb5c27a53f14767c23a4d2f66d979dc0e0c46d5d4cb3","facility":"Centre for Addiction and Mental Health (CAMH)","city":"Toronto","region":"Ontario","country":"Canada","lat":43.706429999999997,"lon":-79.39864}],"countries":["Canada"]},{"id":3537,"nct_id":"NCT06624137","title":"Computationally, Electrophysiologically, and Qualitatively Characterizing Serotonergic Psychedelics; Transdiagnostic Therapeutic and Pro-Psychotic Effects","sponsor":"Yale University","registry_url":"https://clinicaltrials.gov/study/NCT06624137","tracker_url":"publication.php?id=3537","status":"TERMINATED","status_label":"Terminated","status_verified_date":"2026-07","last_update_date":"2026-07-09","start_date":"2024-12-12","primary_completion_date":"2026-06-14","completion_date":"2026-06-14","study_type":"OBSERVATIONAL","phases":[],"enrollment":{"count":5,"type":"ACTUAL"},"design":{"allocation":"","intervention_model":"","primary_purpose":"","masking":""},"conditions":["OCD","Major Depressive Disorder (MDD)","Alcohol Use Disorder (AUD)","Healthy Volunteer","Migraine","PTSD","PTSD - Post Traumatic Stress Disorder","Addiction","Tobacco Use Disorder","Obsessive Compulsive Disorder (OCD)","Opioid Use Disorder"],"interventions":[{"name":"Serotonergic Psychedelic","type":"DRUG"},{"name":"Placebo","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"20e312916f86cde9502fe213560fb5cb84834cd4665474a7d3a3ea662605a54d","facility":"Connecticut Mental Health Center","city":"Hamden","region":"Connecticut","country":"United States","lat":41.39593,"lon":-72.896770000000004},{"key":"a17b95243bab2667321a9c9da83c8ea1ac3e43c5e4a76ea01bb2eaf6e4cac641","facility":"West Haven VA Medical Center","city":"West Haven","region":"Connecticut","country":"United States","lat":41.270650000000003,"lon":-72.947050000000004}],"countries":["United States"]},{"id":3431,"nct_id":"NCT06810310","title":"Psilocybin: Capturing Brain Mechanisms of Motivation and Neurocognition in Individuals With Opioid Use Disorder","sponsor":"University of Pennsylvania","registry_url":"https://clinicaltrials.gov/study/NCT06810310","tracker_url":"publication.php?id=3431","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-07","last_update_date":"2026-07-09","start_date":"2025-12-22","primary_completion_date":"2027-05-01","completion_date":"2027-05-01","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":24,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"BASIC_SCIENCE","masking":"QUADRUPLE"},"conditions":["Opioid Use Disorder"],"interventions":[{"name":"Psilocybin (high dose)","type":"DRUG"},{"name":"psilocybin (low dose)","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"6432b7631d0ccc20e148c4eddca2643abaa034857cab41344671f3fb747879b1","facility":"University of Pennsylvania","city":"Philadelphia","region":"Pennsylvania","country":"United States","lat":39.952379999999998,"lon":-75.163619999999995}],"countries":["United States"]},{"id":3652,"nct_id":"NCT04161066","title":"Phase I Study of the Safety and Adjunctive Effects of Psilocybin in Adults With Opioid Use Disorder Maintained on a Buprenorphine/Naloxone Formulation","sponsor":"University of Wisconsin, Madison","registry_url":"https://clinicaltrials.gov/study/NCT04161066","tracker_url":"publication.php?id=3652","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-07","last_update_date":"2026-07-07","start_date":"2021-01-13","primary_completion_date":"2026-12","completion_date":"2026-12","study_type":"INTERVENTIONAL","phases":["PHASE1"],"enrollment":{"count":10,"type":"ESTIMATED"},"design":{"allocation":"NA","intervention_model":"SINGLE_GROUP","primary_purpose":"HEALTH_SERVICES_RESEARCH","masking":"NONE"},"conditions":["Opioid Use Disorder"],"interventions":[{"name":"Psilocybin with facilitated counseling","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"0fef037c24d643378aa9f37a26412f8308ddc2ac490d10c8ef10ee242ac4bfb8","facility":"University of Wisconsin","city":"Madison","region":"Wisconsin","country":"United States","lat":43.073050000000002,"lon":-89.401229999999998}],"countries":["United States"]},{"id":3603,"nct_id":"NCT06160284","title":"Exploration of Synaptotrophic Effects of Psilocybin in Opioid Use Disorder (OUD)","sponsor":"Yale University","registry_url":"https://clinicaltrials.gov/study/NCT06160284","tracker_url":"publication.php?id=3603","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-07","last_update_date":"2026-07-07","start_date":"2025-05-28","primary_completion_date":"2027-01","completion_date":"2027-01","study_type":"INTERVENTIONAL","phases":["PHASE1"],"enrollment":{"count":12,"type":"ESTIMATED"},"design":{"allocation":"NA","intervention_model":"SINGLE_GROUP","primary_purpose":"BASIC_SCIENCE","masking":"NONE"},"conditions":["Opioid Use Disorder"],"interventions":[{"name":"Psilocybin","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"ce511e3de8dae05034afdb25043c5e28d581eecc32497eda1b36dd3837c67ae4","facility":"Yale University","city":"New Haven","region":"Connecticut","country":"United States","lat":41.308149999999998,"lon":-72.928160000000005}],"countries":["United States"]},{"id":3662,"nct_id":"NCT07638553","title":"Efficacy in Relapse Prevention: Psilocybin in Alcohol Use Disorder With Depressive Symptoms","sponsor":"Centre Hospitalier Universitaire de Nīmes","registry_url":"https://clinicaltrials.gov/study/NCT07638553","tracker_url":"publication.php?id=3662","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-06","last_update_date":"2026-07-01","start_date":"2026-06-30","primary_completion_date":"2030-06","completion_date":"2030-06","study_type":"INTERVENTIONAL","phases":["PHASE3"],"enrollment":{"count":172,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"TRIPLE"},"conditions":["Alcohol Use Disorder","Depressive Sympotoms","Psilocybin"],"interventions":[{"name":"Psilocybin (high dose)","type":"DRUG"},{"name":"Psilocybin (low dose)","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"323f6a0d326702feb35e14a7b9184860791df3488ef3495f35a0de3236897eb0","facility":"Centre Hospitalier de la Côte Basque","city":"Bayonne","region":"","country":"France","lat":43.493160000000003,"lon":-1.4730000000000001},{"key":"5ffc1075f6bec0dadbe8bc3e065b0e1b877e363dbf6627b545bf4beffff70757","facility":"CHU Besançon","city":"Besançon","region":"","country":"France","lat":47.248779999999996,"lon":6.0181500000000003},{"key":"a6fd2e2e6ed56330ba623e90ee634f2d4915008c80b207dde3ed9faf47960e8d","facility":"CHU de Bordeaux","city":"Bordeaux","region":"","country":"France","lat":44.841239999999999,"lon":-0.58045999999999998},{"key":"14ea4a2b72ea454ee54e0e0774dcd9904223f73df3e3c531e7d5f0cfa141d839","facility":"CHU Brest","city":"Brest","region":"","country":"France","lat":48.39029,"lon":-4.4862799999999998},{"key":"f89e51a603fb7d3311c5aa5e1f5fa8b931a29eab96f579366c7020edef6d63eb","facility":"CH Le Vinatier","city":"Bron","region":"","country":"France","lat":45.73865,"lon":4.91303},{"key":"979bc0acd73468b3e9e5e478d1eb8b6146cdb655e43714015ace7d5e264ec03f","facility":"CHU de Nantes","city":"Nantes","region":"","country":"France","lat":47.21725,"lon":-1.5533600000000001},{"key":"4a89439659e3f06e4c831d2ab54c7949dfe24a09c19f411896d75ff90f0f0fde","facility":"CHU de Nîmes","city":"Nîmes","region":"","country":"France","lat":43.836649999999999,"lon":4.3578799999999998},{"key":"3f02e2b16edbfc081f5b9dfd08b8a203c4b47bf73ba2fa3f66915ff73cb56a9b","facility":"CHU Saint-Etienne","city":"Saint-Priest","region":"","country":"France","lat":45.696510000000004,"lon":4.9438500000000003}],"countries":["France"]},{"id":3547,"nct_id":"NCT06902974","title":"A Phase 2, Open-Label Study Investigating the Safety and Efficacy of Psilocybin-Assisted Therapy for Sexual Assault-Related Posttraumatic Stress Disorder (PTSD)","sponsor":"Sunstone Medical","registry_url":"https://clinicaltrials.gov/study/NCT06902974","tracker_url":"publication.php?id=3547","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-06","last_update_date":"2026-07-01","start_date":"2026-05-23","primary_completion_date":"2027-11","completion_date":"2028-05","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":70,"type":"ESTIMATED"},"design":{"allocation":"NA","intervention_model":"SINGLE_GROUP","primary_purpose":"TREATMENT","masking":"NONE"},"conditions":["Post Traumatic Stress Disorder","PTSD"],"interventions":[{"name":"Psilocybin 25 mg","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"8bf6e838a381bd54a71fab76ec32329ee9e85502264bce18bfd4dce5416f5ef3","facility":"Sunstone Medical, PC","city":"Rockville","region":"Maryland","country":"United States","lat":39.084000000000003,"lon":-77.152760000000001}],"countries":["United States"]},{"id":3494,"nct_id":"NCT05452772","title":"5-HT2A Agonist Psilocybin in the Treatment of Tobacco Use Disorder","sponsor":"Johns Hopkins University","registry_url":"https://clinicaltrials.gov/study/NCT05452772","tracker_url":"publication.php?id=3494","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-06","last_update_date":"2026-06-29","start_date":"2023-11-01","primary_completion_date":"2026-12","completion_date":"2027-05","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":66,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"QUADRUPLE"},"conditions":["Tobacco Use Disorder"],"interventions":[{"name":"Psilocybin","type":"DRUG"},{"name":"Niacin","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"7ce22b002e53ab5c3978b99f32427c645bc1173311a77a8658068ba9bbf879bc","facility":"University of Alabama at Birmingham","city":"Birmingham","region":"Alabama","country":"United States","lat":33.520659999999999,"lon":-86.802490000000006},{"key":"b1b7385307b2710c76b5175c36619a7edcaff39e015a0a2e8cb2e1b125a2f6bb","facility":"Johns Hopkins University School of Medicine","city":"Baltimore","region":"Maryland","country":"United States","lat":39.290379999999999,"lon":-76.612189999999998},{"key":"bc86403d1c9f2442271abec1230ce766e06c064f627db179acfcfde14e4f85e3","facility":"New York University","city":"New York","region":"New York","country":"United States","lat":40.714269999999999,"lon":-74.005970000000005}],"countries":["United States"]},{"id":3595,"nct_id":"NCT06884514","title":"Acute Effects of MDMA Co-administration on the Response to Psilocybin in Healthy Subjects","sponsor":"University Hospital, Basel, Switzerland","registry_url":"https://clinicaltrials.gov/study/NCT06884514","tracker_url":"publication.php?id=3595","status":"COMPLETED","status_label":"Completed","status_verified_date":"2025-05","last_update_date":"2026-06-25","start_date":"2025-04-03","primary_completion_date":"2026-05-13","completion_date":"2026-05-28","study_type":"INTERVENTIONAL","phases":["PHASE1"],"enrollment":{"count":24,"type":"ACTUAL"},"design":{"allocation":"RANDOMIZED","intervention_model":"CROSSOVER","primary_purpose":"BASIC_SCIENCE","masking":"TRIPLE"},"conditions":["Healthy"],"interventions":[{"name":"Psilocybin","type":"DRUG"},{"name":"3,4-Methylenedioxymethamphetamine","type":"DRUG"},{"name":"Psilocybin placebo","type":"DRUG"},{"name":"3,4-Methylenedioxymethamphetamine placebo","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"b396510f76aa97e398e61aeedd81c7b5fcfd540d418138fc4fb60db60e0a0659","facility":"University Hospital Basel","city":"Basel","region":"","country":"Switzerland","lat":47.558390000000003,"lon":7.5732699999999999}],"countries":["Switzerland"]},{"id":3560,"nct_id":"NCT07104916","title":"A Pilot Mechanistic RCT of Psilocybin With Mindfulness-based Therapy vs Support for Posttraumatic Stress Disorder (PTSD)","sponsor":"Anthony P King","registry_url":"https://clinicaltrials.gov/study/NCT07104916","tracker_url":"publication.php?id=3560","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-06","last_update_date":"2026-06-25","start_date":"2026-07-01","primary_completion_date":"2029-09","completion_date":"2029-12","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":30,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"SINGLE"},"conditions":["Post Traumatic Stress Disorder","Depression - Major Depressive Disorder"],"interventions":[{"name":"Psilocybin + MBCT therapy","type":"COMBINATION_PRODUCT"},{"name":"Active Comparator: Psilocybin with Support Only","type":"COMBINATION_PRODUCT"}],"substances":["psilocybin"],"sites":[{"key":"dab33405eff5190f72da59b78efc1f976cb32567ca0ed993e0fa62358b51185e","facility":"The Ohio State University Medical Center","city":"Columbus","region":"Ohio","country":"United States","lat":39.961179999999999,"lon":-82.99879}],"countries":["United States"]},{"id":3650,"nct_id":"NCT07048743","title":"Psilocybin-assisted Existential, Attachment and Relational (PEARL) Therapy for Caregivers of Patients With Advanced Cancer: A Phase II Open-Label Trial","sponsor":"University Health Network, Toronto","registry_url":"https://clinicaltrials.gov/study/NCT07048743","tracker_url":"publication.php?id=3650","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-06","last_update_date":"2026-06-23","start_date":"2025-07-16","primary_completion_date":"2027-12-02","completion_date":"2027-12-02","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":15,"type":"ESTIMATED"},"design":{"allocation":"NA","intervention_model":"SINGLE_GROUP","primary_purpose":"SUPPORTIVE_CARE","masking":"NONE"},"conditions":["Caregiver Distress"],"interventions":[{"name":"Psilocybin","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"c2b8ac7cbe1dfe7dfd4a496dfe7196accedd01cd287918d4f9a3f24cacfa9649","facility":"Toronto General Hospital","city":"Toronto","region":"Ontario","country":"Canada","lat":43.706429999999997,"lon":-79.39864}],"countries":["Canada"]},{"id":3637,"nct_id":"NCT06724289","title":"Psilocybin-Assisted Therapy for Prolonged Grief","sponsor":"University of Virginia","registry_url":"https://clinicaltrials.gov/study/NCT06724289","tracker_url":"publication.php?id=3637","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-06","last_update_date":"2026-06-23","start_date":"2026-03-24","primary_completion_date":"2027-08","completion_date":"2027-08","study_type":"INTERVENTIONAL","phases":["EARLY_PHASE1"],"enrollment":{"count":12,"type":"ESTIMATED"},"design":{"allocation":"NA","intervention_model":"SINGLE_GROUP","primary_purpose":"TREATMENT","masking":"NONE"},"conditions":["Prolonged Grief Disorder"],"interventions":[{"name":"Psilocybin 25 mg","type":"DRUG"},{"name":"Functional Magnetic Resonance Imaging (fMRI)","type":"DIAGNOSTIC_TEST"}],"substances":["psilocybin"],"sites":[{"key":"7d95aada95625af597e7f99db1d1499ad1edcc4815ba129bc332e93fab4f316e","facility":"University of Virginia","city":"Charlottesville","region":"Virginia","country":"United States","lat":38.029310000000002,"lon":-78.476680000000002}],"countries":["United States"]},{"id":3471,"nct_id":"NCT06407635","title":"Psilocybin for PTSD With or Without Psychotherapy: A Pilot Study of Safety and Efficacy","sponsor":"Johns Hopkins University","registry_url":"https://clinicaltrials.gov/study/NCT06407635","tracker_url":"publication.php?id=3471","status":"ACTIVE_NOT_RECRUITING","status_label":"Active, not recruiting","status_verified_date":"2026-06","last_update_date":"2026-06-22","start_date":"2024-06-07","primary_completion_date":"2026-03-09","completion_date":"2027-05","study_type":"INTERVENTIONAL","phases":["PHASE1"],"enrollment":{"count":20,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"NONE"},"conditions":["Post Traumatic Stress Disorder"],"interventions":[{"name":"Psilocybin","type":"DRUG"},{"name":"Trauma-focused psychotherapy","type":"OTHER"},{"name":"Standard psychological support","type":"OTHER"}],"substances":["psilocybin"],"sites":[{"key":"9d7c1530695da1e0dbe5d0029c61521b74c434cedec820dcadef26feb9ead43e","facility":"Johns Hopkins Center for Psychedelic and Consciousness Research","city":"Baltimore","region":"Maryland","country":"United States","lat":39.290379999999999,"lon":-76.612189999999998}],"countries":["United States"]},{"id":3460,"nct_id":"NCT06416085","title":"Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) Therapy for Patients With Advanced Cancer: A Phase II Open-Label Trial","sponsor":"University Health Network, Toronto","registry_url":"https://clinicaltrials.gov/study/NCT06416085","tracker_url":"publication.php?id=3460","status":"ACTIVE_NOT_RECRUITING","status_label":"Active, not recruiting","status_verified_date":"2026-06","last_update_date":"2026-06-22","start_date":"2024-06-06","primary_completion_date":"2026-12-15","completion_date":"2026-12-15","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":15,"type":"ESTIMATED"},"design":{"allocation":"NA","intervention_model":"SINGLE_GROUP","primary_purpose":"SUPPORTIVE_CARE","masking":"NONE"},"conditions":["Advanced Cancer","Stage IV Solid Tumor Cancer","Stage IV Sarcoma of Bone","Stage IV Lymphoma","Stage IV Melanoma","Endocrine Cancer"],"interventions":[{"name":"Psilocybin","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"3104f6716f75e5b945ffa549ff984557ea0e6967b3dba8f4b49a8f03caf190bf","facility":"Princess Margaret Cancer Centre","city":"Toronto","region":"Ontario","country":"Canada","lat":43.706429999999997,"lon":-79.39864}],"countries":["Canada"]},{"id":3589,"nct_id":"NCT07079852","title":"The Acute Effects of Psilocybin on Cognition, Memory, and Brain Function","sponsor":"Manoj Doss","registry_url":"https://clinicaltrials.gov/study/NCT07079852","tracker_url":"publication.php?id=3589","status":"NOT_YET_RECRUITING","status_label":"Not yet recruiting","status_verified_date":"2026-06","last_update_date":"2026-06-15","start_date":"2026-09","primary_completion_date":"2028-08","completion_date":"2028-08","study_type":"INTERVENTIONAL","phases":["PHASE1","PHASE2"],"enrollment":{"count":48,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"CROSSOVER","primary_purpose":"BASIC_SCIENCE","masking":"QUADRUPLE"},"conditions":["Healthy"],"interventions":[{"name":"Placebo","type":"DRUG"},{"name":"Psilocybin 15mg","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"bfd791b360bb10aa29e67bf9e59fc1b2f04b81de0d1e71a0170094e14bdf29df","facility":"The University of Texas at Austin Dell Medical School","city":"Austin","region":"Texas","country":"United States","lat":30.267150000000001,"lon":-97.74306}],"countries":["United States"]},{"id":3702,"nct_id":"NCT05698511","title":"Multivariate Neural and Physiological Correlates of Psychedelic Sub-states: a Within-subjects, Healthy Volunteer Study With Experience-sampling","sponsor":"Robin Carhart-Harris, PhD, MA","registry_url":"https://clinicaltrials.gov/study/NCT05698511","tracker_url":"publication.php?id=3702","status":"ACTIVE_NOT_RECRUITING","status_label":"Active, not recruiting","status_verified_date":"2026-03","last_update_date":"2026-06-05","start_date":"2023-07-31","primary_completion_date":"2026-01-30","completion_date":"2027-01-30","study_type":"INTERVENTIONAL","phases":["PHASE1"],"enrollment":{"count":12,"type":"ESTIMATED"},"design":{"allocation":"NA","intervention_model":"SINGLE_GROUP","primary_purpose":"BASIC_SCIENCE","masking":"NONE"},"conditions":["Psychedelic Experiences","Neuroimaging","Healthy Volunteers"],"interventions":[{"name":"Psilocybin","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"7f09a842484186a75c6232177464293472d56c43d4d49f24f37efcb6c9cbbbb8","facility":"University of California, San Francisco","city":"San Francisco","region":"California","country":"United States","lat":37.774929999999998,"lon":-122.41942}],"countries":["United States"]},{"id":3664,"nct_id":"NCT05370911","title":"Effects of Repeated Dosing of Psilocybin on Obsessive-Compulsive Disorder: A Randomized, Waitlist-Controlled Study","sponsor":"Yale University","registry_url":"https://clinicaltrials.gov/study/NCT05370911","tracker_url":"publication.php?id=3664","status":"ACTIVE_NOT_RECRUITING","status_label":"Active, not recruiting","status_verified_date":"2026-06","last_update_date":"2026-06-04","start_date":"2023-07-20","primary_completion_date":"2026-02-17","completion_date":"2027-02","study_type":"INTERVENTIONAL","phases":["PHASE1"],"enrollment":{"count":28,"type":"ACTUAL"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"SINGLE"},"conditions":["Obsessive-Compulsive Disorder"],"interventions":[{"name":"Psilocybin","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"4662514f893f3efe4da6f3a3a4ba0f9edfcd2d0e99897470f8dae3ff6d2f70fd","facility":"Enact Research Collaborative (40 Temple St, 4th Floor)","city":"New Haven","region":"Connecticut","country":"United States","lat":41.308149999999998,"lon":-72.928160000000005},{"key":"6c4e35a8a1d85d417c6c566904ebcd1766b91b815d9762c5e984afa8b2885908","facility":"Yale Program for Psychedelic Research","city":"New Haven","region":"Connecticut","country":"United States","lat":41.308149999999998,"lon":-72.928160000000005}],"countries":["United States"]},{"id":3483,"nct_id":"NCT06626139","title":"2 x 2 Factorial, Double-blind, Randomized Trial of 'Set and Setting': a Translational Study in Healthy Volunteers","sponsor":"Robin Carhart-Harris, PhD, MA","registry_url":"https://clinicaltrials.gov/study/NCT06626139","tracker_url":"publication.php?id=3483","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-06","last_update_date":"2026-06-04","start_date":"2024-10-20","primary_completion_date":"2027-11-30","completion_date":"2028-11-30","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":120,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"FACTORIAL","primary_purpose":"BASIC_SCIENCE","masking":"DOUBLE"},"conditions":["Healthy Participants With Lower-than-average Mental Well-being"],"interventions":[{"name":"Psilocybin","type":"DRUG"},{"name":"Context 1","type":"BEHAVIORAL"},{"name":"Context 2","type":"BEHAVIORAL"},{"name":"Placebo","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"198d5bb2b7293acb85f77709d851433288e2bd94aaa3b81634c72028f5024289","facility":"UCSF Mission Bay","city":"San Francisco","region":"California","country":"United States","lat":37.774929999999998,"lon":-122.41942}],"countries":["United States"]},{"id":3661,"nct_id":"NCT06230757","title":"Effects of Psilocybin With Psychological Support on Anhedonia in Treatment-resistant Depression: a Randomized Controlled Pilot Trial","sponsor":"University of Colorado, Denver","registry_url":"https://clinicaltrials.gov/study/NCT06230757","tracker_url":"publication.php?id=3661","status":"COMPLETED","status_label":"Completed","status_verified_date":"2026-05","last_update_date":"2026-05-22","start_date":"2024-07-08","primary_completion_date":"2026-05-08","completion_date":"2026-05-08","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":20,"type":"ACTUAL"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"QUADRUPLE"},"conditions":["Major Depressive Disorder","Anhedonia","Treatment Resistant Depression"],"interventions":[{"name":"Psilocybin 25mg","type":"DRUG"},{"name":"Placebo (active placebo)","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"0473ab642c74b3812c946daf78fe3c51c20132227d55cd3b18f186955bf391f2","facility":"University of Colorado Anschutz Medical Campus","city":"Aurora","region":"Colorado","country":"United States","lat":39.729430000000001,"lon":-104.83192}],"countries":["United States"]},{"id":3614,"nct_id":"NCT07506395","title":"Group Psilocybin-Assisted Therapy for Post-Traumatic Stress Disorder","sponsor":"University of New Mexico","registry_url":"https://clinicaltrials.gov/study/NCT07506395","tracker_url":"publication.php?id=3614","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-05","last_update_date":"2026-05-22","start_date":"2026-05-01","primary_completion_date":"2027-05-01","completion_date":"2028-05-01","study_type":"INTERVENTIONAL","phases":["PHASE1"],"enrollment":{"count":36,"type":"ESTIMATED"},"design":{"allocation":"NA","intervention_model":"SINGLE_GROUP","primary_purpose":"TREATMENT","masking":"NONE"},"conditions":["PTSD"],"interventions":[{"name":"Psilocybin","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"1a9055771782109a22253dda7644c3735bc7758f34ad52e7af1cb4208b995f4b","facility":"Interdisciplinary Substance Use and Brain Injury (ISUBI)","city":"Albuquerque","region":"New Mexico","country":"United States","lat":35.084490000000002,"lon":-106.65114}],"countries":["United States"]},{"id":3636,"nct_id":"NCT07582120","title":"A Pilot Mechanistic Study of Psilocybin-Assisted Therapy as a Treatment for Depression","sponsor":"Washington University School of Medicine","registry_url":"https://clinicaltrials.gov/study/NCT07582120","tracker_url":"publication.php?id=3636","status":"NOT_YET_RECRUITING","status_label":"Not yet recruiting","status_verified_date":"2026-05","last_update_date":"2026-05-20","start_date":"2026-06","primary_completion_date":"2031-06","completion_date":"2031-12","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":50,"type":"ESTIMATED"},"design":{"allocation":"NA","intervention_model":"SINGLE_GROUP","primary_purpose":"BASIC_SCIENCE","masking":"NONE"},"conditions":["Depression"],"interventions":[{"name":"Psilocybin (Usona Institute)","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"c3de2ce8933f517f3be34bd70e3809569645c3f60c38d874765d86ee599b4223","facility":"Washington University School of Medicine","city":"St Louis","region":"Missouri","country":"United States","lat":38.627270000000003,"lon":-90.197890000000001}],"countries":["United States"]},{"id":5844,"nct_id":"NCT05227612","title":"Psilocybin-assisted Cognitive Behavioral Therapy for Depression","sponsor":"University of California, Los Angeles","registry_url":"https://clinicaltrials.gov/study/NCT05227612","tracker_url":"publication.php?id=5844","status":"COMPLETED","status_label":"Completed","status_verified_date":"2025-12","last_update_date":"2026-05-19","start_date":"2023-06-27","primary_completion_date":"2025-09-12","completion_date":"2025-09-12","study_type":"INTERVENTIONAL","phases":["PHASE1"],"enrollment":{"count":16,"type":"ACTUAL"},"design":{"allocation":"NA","intervention_model":"SINGLE_GROUP","primary_purpose":"TREATMENT","masking":"NONE"},"conditions":["Major Depressive Disorder"],"interventions":[{"name":"Psilocybin","type":"DRUG"},{"name":"Cognitive behavioral therapy","type":"BEHAVIORAL"}],"substances":["psilocybin"],"sites":[{"key":"d6737ae6c1d4e88b0250366ac1706c0eb50510292a7547d4474ad9750824e06e","facility":"UCLA Semel Institute","city":"Los Angeles","region":"California","country":"United States","lat":34.052230000000002,"lon":-118.24368}],"countries":["United States"]},{"id":3580,"nct_id":"NCT02037126","title":"Psilocybin-facilitated Treatment for Cocaine Use","sponsor":"University of Alabama at Birmingham","registry_url":"https://clinicaltrials.gov/study/NCT02037126","tracker_url":"publication.php?id=3580","status":"COMPLETED","status_label":"Completed","status_verified_date":"2026-02","last_update_date":"2026-05-18","start_date":"2015-05","primary_completion_date":"2024-05","completion_date":"2024-05","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":40,"type":"ACTUAL"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"QUADRUPLE"},"conditions":["Cocaine-Related Disorders"],"interventions":[{"name":"Psilocybin","type":"DRUG"},{"name":"Diphenhydramine","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"39238c4b9e015bf29cc6e59ed247b7046f1b27b521fdf451030d1ab29482f72d","facility":"UAB Outpatient Clinical Research Unit","city":"Birmingham","region":"Alabama","country":"United States","lat":33.520659999999999,"lon":-86.802490000000006}],"countries":["United States"]},{"id":3606,"nct_id":"NCT07216404","title":"Exploring the Safety, Acceptability, and Efficacy of Psilocybin Among Non-Small Cell Lung Cancer Patients With Major Depressive Disorder: A Proof-of-Concept Trial (DREAM LUNG STUDY)","sponsor":"Alan Davis","registry_url":"https://clinicaltrials.gov/study/NCT07216404","tracker_url":"publication.php?id=3606","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-05","last_update_date":"2026-05-14","start_date":"2026-01-01","primary_completion_date":"2027-10-31","completion_date":"2027-10-31","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":10,"type":"ESTIMATED"},"design":{"allocation":"NA","intervention_model":"SINGLE_GROUP","primary_purpose":"SUPPORTIVE_CARE","masking":"NONE"},"conditions":["Lung Non-Small Cell Carcinoma","Unipolar Depression"],"interventions":[{"name":"Biospecimen Collection","type":"PROCEDURE"},{"name":"Counseling","type":"OTHER"},{"name":"Interview","type":"OTHER"},{"name":"Psilocybin","type":"DRUG"},{"name":"Survey Administration","type":"OTHER"}],"substances":["psilocybin"],"sites":[{"key":"d57ba16f21b5e5513a5f85825fdee40ef908d80b41bdf65f0b98dc075445577b","facility":"Ohio State University Comprehensive Cancer Center","city":"Columbus","region":"Ohio","country":"United States","lat":39.961179999999999,"lon":-82.99879}],"countries":["United States"]},{"id":3593,"nct_id":"NCT06992999","title":"Psilocybin for Treatment of Obsessive Compulsive Disorder","sponsor":"Francisco A Moreno","registry_url":"https://clinicaltrials.gov/study/NCT06992999","tracker_url":"publication.php?id=3593","status":"NOT_YET_RECRUITING","status_label":"Not yet recruiting","status_verified_date":"2026-05","last_update_date":"2026-05-12","start_date":"2026-09-08","primary_completion_date":"2028-12","completion_date":"2028-12","study_type":"INTERVENTIONAL","phases":["PHASE1","PHASE2"],"enrollment":{"count":20,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"TRIPLE"},"conditions":["Obsessive - Compulsive Disorder"],"interventions":[{"name":"Low Dose Psilocybin","type":"DRUG"},{"name":"High Dose Psilocybin","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"6185aa05c828ffdfd70299b8b961de62ec98b322b02bb5db160c13829b0a3b78","facility":"University of Arizona-Tucson","city":"Tucson","region":"Arizona","country":"United States","lat":32.221739999999997,"lon":-110.92648}],"countries":["United States"]},{"id":3527,"nct_id":"NCT05322954","title":"Safety and Feasibility of Psilocybin in Methamphetamine Use Disorder in a Community-Based Sample","sponsor":"University of Wisconsin, Madison","registry_url":"https://clinicaltrials.gov/study/NCT05322954","tracker_url":"publication.php?id=3527","status":"TERMINATED","status_label":"Terminated","status_verified_date":"2026-05","last_update_date":"2026-05-12","start_date":"2023-03-03","primary_completion_date":"2024-03-07","completion_date":"2024-03-07","study_type":"INTERVENTIONAL","phases":["PHASE1"],"enrollment":{"count":5,"type":"ACTUAL"},"design":{"allocation":"NA","intervention_model":"SINGLE_GROUP","primary_purpose":"HEALTH_SERVICES_RESEARCH","masking":"NONE"},"conditions":["Methamphetamine Use Disorder","Substance-Related Disorders","Chemically-Induced Disorders","Substance Use Disorders","Stimulant-Use Disorder"],"interventions":[{"name":"Psilocybin","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"0fef037c24d643378aa9f37a26412f8308ddc2ac490d10c8ef10ee242ac4bfb8","facility":"University of Wisconsin","city":"Madison","region":"Wisconsin","country":"United States","lat":43.073050000000002,"lon":-89.401229999999998}],"countries":["United States"]},{"id":3570,"nct_id":"NCT06782724","title":"The Safety and Efficacy of Psilocybin Therapy Compared to Low-dose Control in Reducing Depressive Symptoms in Patients With COPD, ALS, MS, or APD.","sponsor":"University Medical Center Groningen","registry_url":"https://clinicaltrials.gov/study/NCT06782724","tracker_url":"publication.php?id=3570","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-04","last_update_date":"2026-05-08","start_date":"2025-07-01","primary_completion_date":"2027-01-01","completion_date":"2028-01-01","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":108,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"SUPPORTIVE_CARE","masking":"QUADRUPLE"},"conditions":["COPD (Chronic Obstructive Pulmonary Disease)","ALS (Amyotrophic Lateral Sclerosis)","MS (Multiple Sclerosis)","Major Depressive Disorder (MDD)","Atypical Parkinson Disease"],"interventions":[{"name":"Psilocybin therapy","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"815dca1c51560a2771c70b436758dad26e0e7113577a98422d68f884f890d354","facility":"National Institute of Mental Health","city":"Prague","region":"","country":"Czechia","lat":50.088039999999999,"lon":14.42076},{"key":"34a79f541cea47ad7b374bfde6da99960b2120ed088ec92eaa3df41e96eb7390","facility":"Bispebjerg Hospital","city":"Copenhagen","region":"","country":"Denmark","lat":55.675939999999997,"lon":12.565530000000001},{"key":"27d7b4df35cb1e0b4d4349418e100597b52afe044578477ac7a1e36059b373ba","facility":"University Medical Center Groningen","city":"Groningen","region":"Provincie Groningen","country":"Netherlands","lat":53.219169999999998,"lon":6.5666700000000002},{"key":"0aaa8840c6965661f46de84dc613d0842e14dbd41f5597c5ec01c47dcbaabd26","facility":"Champalimaud Foundation","city":"Lisbon","region":"","country":"Portugal","lat":38.725090000000002,"lon":-9.1498000000000008}],"countries":["Czechia","Denmark","Netherlands","Portugal"]},{"id":3496,"nct_id":"NCT05710237","title":"Does Psilocybin Require Psychedelic Effects to Treat Depression? A 4-Week, Double-Blind, Proof-of-Concept Randomized Controlled Trial","sponsor":"Centre for Addiction and Mental Health","registry_url":"https://clinicaltrials.gov/study/NCT05710237","tracker_url":"publication.php?id=3496","status":"COMPLETED","status_label":"Completed","status_verified_date":"2026-05","last_update_date":"2026-05-07","start_date":"2023-07-01","primary_completion_date":"2026-04-14","completion_date":"2026-04-14","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":41,"type":"ACTUAL"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"QUADRUPLE"},"conditions":["Treatment-resistant Depression"],"interventions":[{"name":"Psilocybin 25 mg","type":"DRUG"},{"name":"Risperidone 1 MG","type":"DRUG"},{"name":"Placebo","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"bf2adfb756d244974a952f7c5c58e6f72f66cbbd5ba63e61a8b987fa1820f128","facility":"Centre for Addiction and Mental Health","city":"Toronto","region":"Ontario","country":"Canada","lat":43.706429999999997,"lon":-79.39864}],"countries":["Canada"]},{"id":3620,"nct_id":"NCT05947383","title":"A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of up to Two Doses of Psilocybin for the Treatment of Major Depressive Disorder in Adults With Cancer","sponsor":"Sunstone Medical","registry_url":"https://clinicaltrials.gov/study/NCT05947383","tracker_url":"publication.php?id=3620","status":"ACTIVE_NOT_RECRUITING","status_label":"Active, not recruiting","status_verified_date":"2026-05","last_update_date":"2026-05-06","start_date":"2023-10-23","primary_completion_date":"2027-04-30","completion_date":"2027-11-01","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":56,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"SINGLE_GROUP","primary_purpose":"TREATMENT","masking":"QUADRUPLE"},"conditions":["Cancer","Major Depressive Disorder"],"interventions":[{"name":"Psilocybin","type":"DRUG"},{"name":"Placebo","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"8bf6e838a381bd54a71fab76ec32329ee9e85502264bce18bfd4dce5416f5ef3","facility":"Sunstone Medical, PC","city":"Rockville","region":"Maryland","country":"United States","lat":39.084000000000003,"lon":-77.152760000000001}],"countries":["United States"]},{"id":3613,"nct_id":"NCT06303739","title":"Induction Protocol for Psilocybin-Assisted Therapy in Treatment-Resistant Depression (TRD): A Pilot Study","sponsor":"University of North Carolina, Chapel Hill","registry_url":"https://clinicaltrials.gov/study/NCT06303739","tracker_url":"publication.php?id=3613","status":"ACTIVE_NOT_RECRUITING","status_label":"Active, not recruiting","status_verified_date":"2026-05","last_update_date":"2026-05-06","start_date":"2024-04-19","primary_completion_date":"2026-04-09","completion_date":"2027-03-26","study_type":"INTERVENTIONAL","phases":["PHASE3"],"enrollment":{"count":20,"type":"ACTUAL"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"SINGLE"},"conditions":["Refractory Depression","Treatment Resistant Depression"],"interventions":[{"name":"psilocybin","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"d01e30cccc9c6ab8dac4908e28126c4f365239b13b07ded6735ea9cc343d434d","facility":"UNC Chapel Hill Medical Center","city":"Chapel Hill","region":"North Carolina","country":"United States","lat":35.913200000000003,"lon":-79.055840000000003}],"countries":["United States"]},{"id":3536,"nct_id":"NCT07479550","title":"A Phase 2 Randomized Study Examining the Safety, Feasibility, and Effectiveness of Masking Psilocybin Therapy With General Anesthesia in Major Depressive Disorder","sponsor":"Stanford University","registry_url":"https://clinicaltrials.gov/study/NCT07479550","tracker_url":"publication.php?id=3536","status":"NOT_YET_RECRUITING","status_label":"Not yet recruiting","status_verified_date":"2026-04","last_update_date":"2026-05-06","start_date":"2026-07","primary_completion_date":"2027-07","completion_date":"2027-08","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":10,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"CROSSOVER","primary_purpose":"TREATMENT","masking":"DOUBLE"},"conditions":["Major Depression"],"interventions":[{"name":"Psilocybin (Usona Institute)","type":"DRUG"},{"name":"Propofol","type":"DRUG"},{"name":"Placebo","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"50c13e63ee1fe4325b40dc6b409f9002d59ae4e7e4879bf350dcad72bc996f6d","facility":"Stanford University","city":"Stanford","region":"California","country":"United States","lat":37.424109999999999,"lon":-122.16607999999999}],"countries":["United States"]},{"id":3577,"nct_id":"NCT04353921","title":"A One-Year Observational Follow-up Study of Participants With Major Depressive Disorder Following a Randomized, Double-Blind Single-Dose of Psilocybin or Niacin-Control","sponsor":"Usona Institute","registry_url":"https://clinicaltrials.gov/study/NCT04353921","tracker_url":"publication.php?id=3577","status":"TERMINATED","status_label":"Terminated","status_verified_date":"2026-04","last_update_date":"2026-05-04","start_date":"2020-06-30","primary_completion_date":"2022-10-18","completion_date":"2022-10-18","study_type":"OBSERVATIONAL","phases":[],"enrollment":{"count":26,"type":"ACTUAL"},"design":{"allocation":"","intervention_model":"","primary_purpose":"","masking":""},"conditions":["Major Depressive Disorder"],"interventions":[{"name":"No intervention will be administered as part of this study.","type":"OTHER"}],"substances":["psilocybin"],"sites":[{"key":"025fc70936d18468a795a0604c0b4bc08e27cb12d5e5b43e1127d0c30c53c200","facility":"Innovative Clinical Research, Inc. (formerly Segal Trials)","city":"Lauderhill","region":"Florida","country":"United States","lat":26.140360000000001,"lon":-80.213380000000001}],"countries":["United States"]},{"id":3559,"nct_id":"NCT07565909","title":"A Phase 2 Sequential Dose-Finding Study of Preparation for Group Retreat Psilocybin Therapy for Healthcare Clinicians With Loss of Meaning in Their Work and Symptoms of Depression","sponsor":"University of Washington","registry_url":"https://clinicaltrials.gov/study/NCT07565909","tracker_url":"publication.php?id=3559","status":"NOT_YET_RECRUITING","status_label":"Not yet recruiting","status_verified_date":"2026-04","last_update_date":"2026-05-04","start_date":"2026-06","primary_completion_date":"2027-12","completion_date":"2028-07","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":72,"type":"ESTIMATED"},"design":{"allocation":"NA","intervention_model":"SEQUENTIAL","primary_purpose":"TREATMENT","masking":"NONE"},"conditions":["Depression","Anxiety"],"interventions":[{"name":"Psilocybin","type":"DRUG"}],"substances":["psilocybin"],"sites":[],"countries":[]},{"id":3516,"nct_id":"NCT07566104","title":"Group Psilocybin-assisted Cognitive Behavioral Therapy for Major Depressive Disorder","sponsor":"University of California, Los Angeles","registry_url":"https://clinicaltrials.gov/study/NCT07566104","tracker_url":"publication.php?id=3516","status":"NOT_YET_RECRUITING","status_label":"Not yet recruiting","status_verified_date":"2026-04","last_update_date":"2026-05-04","start_date":"2027-01","primary_completion_date":"2028-12","completion_date":"2028-12","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":30,"type":"ESTIMATED"},"design":{"allocation":"NA","intervention_model":"SINGLE_GROUP","primary_purpose":"TREATMENT","masking":"NONE"},"conditions":["Depression - Major Depressive Disorder","Psilocybin","Cognitive Behavioral Therapy"],"interventions":[{"name":"Psilocybin (drug)","type":"DRUG"},{"name":"Group Cognitive Behavioral Therapy","type":"BEHAVIORAL"}],"substances":["psilocybin"],"sites":[{"key":"d6737ae6c1d4e88b0250366ac1706c0eb50510292a7547d4474ad9750824e06e","facility":"UCLA Semel Institute","city":"Los Angeles","region":"California","country":"United States","lat":34.052230000000002,"lon":-118.24368}],"countries":["United States"]},{"id":3509,"nct_id":"NCT05883540","title":"Lysergic Acid Diethylamide (LSD) in Palliative Care: a Randomised, Double-blind, Active-placebo Controlled Phase II Study (LPC-Study)","sponsor":"University Hospital, Basel, Switzerland","registry_url":"https://clinicaltrials.gov/study/NCT05883540","tracker_url":"publication.php?id=3509","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-04","last_update_date":"2026-04-29","start_date":"2024-06-09","primary_completion_date":"2027-09","completion_date":"2028-05","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":60,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"SUPPORTIVE_CARE","masking":"QUADRUPLE"},"conditions":["Palliative Care","Pain","Anxiety","Depression","Demoralization","Psychological Distress","Quality of Life","Caregiver Burden","Fear of Death","Existential Distress"],"interventions":[{"name":"Lysergic Acid Diethylamide Tartrate","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"b28ad4c1ff8ff143bf7c2827ef2d114686d3c82f734dbd59191da6544cce398b","facility":"University Hospital Basel, Division of Clinical Pharmacology and Toxicology","city":"Basel","region":"","country":"Switzerland","lat":47.558390000000003,"lon":7.5732699999999999},{"key":"2609712e4f7c93509e6b3bbd8713f3242d8e8886b7480458304bd6280a3610bb","facility":"University Hospital Geneva, Palliative medicine department","city":"Collonge-Bellerive","region":"","country":"Switzerland","lat":46.250610000000002,"lon":6.20174},{"key":"f23fcd3a56bf1387f2f4eb3ab67dce163cae1cad5a551f60baa5d5c5a6da894b","facility":"Spital Uster AG, Division of Internal Medicine","city":"Uster","region":"","country":"Switzerland","lat":47.34713,"lon":8.7209099999999999},{"key":"90de5e97b9c55b0ae303eb535137dc52bdcbaab9be856fa3b3812a38fcbc8990","facility":"University Hospital Zurich, Clinic for Radio-Oncology, Competence Centre Palliative Care","city":"Zurich","region":"","country":"Switzerland","lat":47.366669999999999,"lon":8.5500000000000007}],"countries":["Switzerland"]},{"id":3474,"nct_id":"NCT05351541","title":"A Double-blind, Randomized Trial Examining the Preliminary Efficacy of Psilocybin Therapy for People With Chronic Low Back Pain","sponsor":"Joshua Woolley, MD, PhD","registry_url":"https://clinicaltrials.gov/study/NCT05351541","tracker_url":"publication.php?id=3474","status":"ACTIVE_NOT_RECRUITING","status_label":"Active, not recruiting","status_verified_date":"2026-04","last_update_date":"2026-04-29","start_date":"2023-12-01","primary_completion_date":"2026-07","completion_date":"2026-09","study_type":"INTERVENTIONAL","phases":["PHASE1","PHASE2"],"enrollment":{"count":30,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"QUADRUPLE"},"conditions":["Chronic Low-back Pain"],"interventions":[{"name":"Psilocybin therapy with Zolpidem and Modafinil","type":"DRUG"},{"name":"Psilocybin therapy with Zolpidem","type":"DRUG"},{"name":"Psilocybin therapy with Modafinil","type":"DRUG"},{"name":"Psilocybin therapy with Placebo","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"4e446ae220965839316b16732aaafbe4ddf148f28c168186b043252417bda1e0","facility":"University of California San Francisco","city":"San Francisco","region":"California","country":"United States","lat":37.774929999999998,"lon":-122.41942}],"countries":["United States"]},{"id":3658,"nct_id":"NCT04982796","title":"Psilocybin-Enhanced Psychotherapy for Methamphetamine Use Disorder","sponsor":"Portland VA Research Foundation, Inc","registry_url":"https://clinicaltrials.gov/study/NCT04982796","tracker_url":"publication.php?id=3658","status":"ACTIVE_NOT_RECRUITING","status_label":"Active, not recruiting","status_verified_date":"2026-04","last_update_date":"2026-04-22","start_date":"2022-07-07","primary_completion_date":"2026-12-31","completion_date":"2026-12-31","study_type":"INTERVENTIONAL","phases":["PHASE1","PHASE2"],"enrollment":{"count":30,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"SINGLE"},"conditions":["Amphetamine-Related Disorders"],"interventions":[{"name":"Psilocybin","type":"DRUG"},{"name":"Treatment-as-usual","type":"BEHAVIORAL"}],"substances":["psilocybin"],"sites":[{"key":"c4162229ed6f67b102ed1a6e733b6496859b57b83054c37e22f1710b8c9ce433","facility":"Portland VA Health Care System","city":"Vancouver","region":"Washington","country":"United States","lat":45.638730000000002,"lon":-122.66149}],"countries":["United States"]},{"id":3596,"nct_id":"NCT03866174","title":"A Randomized, Double-Blind Study of Single-Dose Psilocybin for Major Depressive Disorder (MDD)","sponsor":"Usona Institute","registry_url":"https://clinicaltrials.gov/study/NCT03866174","tracker_url":"publication.php?id=3596","status":"COMPLETED","status_label":"Completed","status_verified_date":"2026-03","last_update_date":"2026-04-22","start_date":"2020-01-23","primary_completion_date":"2022-06-28","completion_date":"2022-06-28","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":347,"type":"ACTUAL"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"TRIPLE"},"conditions":["Depressive Disorder, Major"],"interventions":[{"name":"Psilocybin","type":"DRUG"},{"name":"Niacin","type":"DRUG"},{"name":"Set and Setting (SaS) Protocol","type":"OTHER"}],"substances":["psilocybin"],"sites":[{"key":"7f09a842484186a75c6232177464293472d56c43d4d49f24f37efcb6c9cbbbb8","facility":"University of California, San Francisco","city":"San Francisco","region":"California","country":"United States","lat":37.774929999999998,"lon":-122.41942},{"key":"ce5773649410208756c8f157ae6af094b53dc7a89423f78b2c8c86f9f332def8","facility":"Pacific Neuroscience Institute","city":"Santa Monica","region":"California","country":"United States","lat":34.019489999999998,"lon":-118.49138000000001},{"key":"ce511e3de8dae05034afdb25043c5e28d581eecc32497eda1b36dd3837c67ae4","facility":"Yale University","city":"New Haven","region":"Connecticut","country":"United States","lat":41.308149999999998,"lon":-72.928160000000005},{"key":"a5489b7d1d0b138d5597a0dd410270ad86c9c871bb9c486d957b24f6ec0dee05","facility":"Segal Trials","city":"Lauderhill","region":"Florida","country":"United States","lat":26.140360000000001,"lon":-80.213380000000001},{"key":"dddfebfd7c55fd6887c90ed4c4d9ddf35cec45fa0565c30783730eb960b19056","facility":"Emory University","city":"Atlanta","region":"Georgia","country":"United States","lat":33.749000000000002,"lon":-84.387979999999999},{"key":"845bec3dc316b3c2137f0d6c06c8372da8841a54f8dc62326a4964312161d387","facility":"Great Lakes Clinical Trials","city":"Chicago","region":"Illinois","country":"United States","lat":41.850029999999997,"lon":-87.650049999999993},{"key":"be5d63bf40aada157fda0af485fadeddd7eac0c079ecab26a1612289fb4c7fdb","facility":"Johns Hopkins University","city":"Baltimore","region":"Maryland","country":"United States","lat":39.290379999999999,"lon":-76.612189999999998},{"key":"ade48b4a9a79751c77c933de17f5be45d01a947eb4f6d0c0ae3d9779c9e993cc","facility":"Hassman Research Institute","city":"Berlin","region":"New Jersey","country":"United States","lat":39.791229999999999,"lon":-74.929050000000004},{"key":"4190340e2c4a95cd68e889c7c9dbfa57587443bfb24f2b6116c85564833f04c2","facility":"New York University School of Medicine","city":"New York","region":"New York","country":"United States","lat":40.714269999999999,"lon":-74.005970000000005},{"key":"096867127180fe96e9a72bbcc7520d5592abe8032d4645482a93afa580e47078","facility":"Cedar Clinical Research","city":"Draper","region":"Utah","country":"United States","lat":40.52467,"lon":-111.86382},{"key":"150ee05b89013f57afa3d4437262fc96492708dbef022aa3d4706d1b2f9b8bcd","facility":"University of Wisconsin - Madison","city":"Madison","region":"Wisconsin","country":"United States","lat":43.073050000000002,"lon":-89.401229999999998}],"countries":["United States"]},{"id":3567,"nct_id":"NCT07373535","title":"Toward Patient-Tailored Care for Treatment-Resistant Depression: A Pilot Patient-Preference Clinical Trial of Music and Mindfulness in Psilocybin-Assisted Psychotherapy","sponsor":"Kyle Greenway","registry_url":"https://clinicaltrials.gov/study/NCT07373535","tracker_url":"publication.php?id=3567","status":"NOT_YET_RECRUITING","status_label":"Not yet recruiting","status_verified_date":"2026-04","last_update_date":"2026-04-22","start_date":"2026-05","primary_completion_date":"2028-07","completion_date":"2028-12","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":16,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"CROSSOVER","primary_purpose":"TREATMENT","masking":"NONE"},"conditions":["Treatment-Resistant Major Depressive Disorder"],"interventions":[{"name":"Psilocybin 25mg","type":"DRUG"},{"name":"Music-centered psilocybin-assisted therapy","type":"OTHER"},{"name":"Mindfulness-centered psilocybin-assisted therapy","type":"OTHER"}],"substances":["psilocybin"],"sites":[{"key":"176e9ccf5caf25b2aaa9d97e556d0fa794ccf156c4dbf22575b8a382ba3a6aed","facility":"Jewish General Hospital","city":"Montreal","region":"Quebec","country":"Canada","lat":45.508839999999999,"lon":-73.587810000000005}],"countries":["Canada"]},{"id":3578,"nct_id":"NCT06319378","title":"CAPSI - Cancer Related Major Depression Treated With a Single Dose of Psilocybin: A Multicenter Randomized Placebo Controlled Double Blind Clinical Trial","sponsor":"Section for Affective Disorders; Northern Stockholm Psychiatry","registry_url":"https://clinicaltrials.gov/study/NCT06319378","tracker_url":"publication.php?id=3578","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-04","last_update_date":"2026-04-13","start_date":"2024-04-19","primary_completion_date":"2026-12","completion_date":"2026-12","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":100,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"QUADRUPLE"},"conditions":["MDD"],"interventions":[{"name":"psilocybin 25 mg sod","type":"DRUG"},{"name":"psilocybin 1 mg sod","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"5f5211b90f32857d4a2b3783ed0a8d299123b97980aecac0dc9fd0a8439396d7","facility":"region Västra Götaland","city":"Gothenburg","region":"Göteborg","country":"Sweden","lat":57.707160000000002,"lon":11.96679},{"key":"56f6973050dae2540f6877689b3512d938f70ee52e4bd51ebc6542c3a6adaa89","facility":"Norra Stockholms Psykiatri","city":"Stockholm","region":"Stockholm County","country":"Sweden","lat":59.32938,"lon":18.068709999999999},{"key":"384faadacad1af176bc642c675eb5c7bdc2ad01c26ea770b0702143798b59dfa","facility":"Psykiatriska Kliniken, Akademiska Sjukhuset","city":"Uppsala","region":"Uppsala County","country":"Sweden","lat":59.858820000000001,"lon":17.63889},{"key":"046953804b0a225af99cd7bd152e5969b25e38978f43961e75862c8ef2f53fc5","facility":"Örebro sjukhus","city":"Örebro","region":"Örebro County","country":"Sweden","lat":59.274120000000003,"lon":15.2066}],"countries":["Sweden"]},{"id":3656,"nct_id":"NCT06102434","title":"Safety Profile of 25 mg Psilocybin in Individuals With Cocaine Use Disorder","sponsor":"University of California, Los Angeles","registry_url":"https://clinicaltrials.gov/study/NCT06102434","tracker_url":"publication.php?id=3656","status":"SUSPENDED","status_label":"Suspended","status_verified_date":"2026-04","last_update_date":"2026-04-07","start_date":"2029-02-01","primary_completion_date":"2029-05","completion_date":"2029-06","study_type":"INTERVENTIONAL","phases":["EARLY_PHASE1"],"enrollment":{"count":10,"type":"ESTIMATED"},"design":{"allocation":"NA","intervention_model":"SINGLE_GROUP","primary_purpose":"TREATMENT","masking":"NONE"},"conditions":["Cocaine Use Disorder"],"interventions":[{"name":"Psilocybin","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"721cc70d44836b7fa9283632bc238d3076c232982cd2852343243f358edfbe43","facility":"University of California, Los Angeles","city":"Los Angeles","region":"California","country":"United States","lat":34.052230000000002,"lon":-118.24368}],"countries":["United States"]},{"id":3670,"nct_id":"NCT06180759","title":"Acute Analgesic Effects of DMT on Experimentally Induced Acute Nociceptive Pain, Hyperalgesia and Allodynia in Healthy Participants","sponsor":"University Hospital, Basel, Switzerland","registry_url":"https://clinicaltrials.gov/study/NCT06180759","tracker_url":"publication.php?id=3670","status":"COMPLETED","status_label":"Completed","status_verified_date":"2025-01","last_update_date":"2026-04-02","start_date":"2025-01-23","primary_completion_date":"2025-09-29","completion_date":"2025-11-06","study_type":"INTERVENTIONAL","phases":["PHASE1"],"enrollment":{"count":17,"type":"ACTUAL"},"design":{"allocation":"RANDOMIZED","intervention_model":"CROSSOVER","primary_purpose":"BASIC_SCIENCE","masking":"TRIPLE"},"conditions":["Healthy"],"interventions":[{"name":"Intravenous infusion of DMT","type":"DRUG"},{"name":"Intravenous infusion of ketamine","type":"DRUG"},{"name":"Intravenous infusion of placebo","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"3bd85f8d9169f9145f6dadbdc3b3147879111bb22b7030edc0ce62cf2445458e","facility":"Clinical Pharmacology & Toxicology, University Hospital Basel","city":"Basel","region":"Basel","country":"Switzerland","lat":47.558390000000003,"lon":7.5732699999999999}],"countries":["Switzerland"]},{"id":3663,"nct_id":"NCT06072898","title":"Engaging Mood Brain Circuits With Psilocybin: a Randomized Neuroimaging Trial in Depression","sponsor":"Sunnybrook Health Sciences Centre","registry_url":"https://clinicaltrials.gov/study/NCT06072898","tracker_url":"publication.php?id=3663","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-03","last_update_date":"2026-03-30","start_date":"2025-05-28","primary_completion_date":"2028-05","completion_date":"2029-05","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":50,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"CROSSOVER","primary_purpose":"BASIC_SCIENCE","masking":"QUADRUPLE"},"conditions":["Depressive Disorder","Major Depressive Disorder"],"interventions":[{"name":"Psilocybin","type":"DRUG"},{"name":"Microcrystalline cellulose","type":"OTHER"},{"name":"Supportive psychotherapy","type":"BEHAVIORAL"}],"substances":["psilocybin"],"sites":[{"key":"d8875f7f4d4e3f36b2235d0201354748ba8de08e94380e3b3cb5c9f3cfca0d9e","facility":"Sunnybrook Health Sciences Centre","city":"Toronto","region":"Ontario","country":"Canada","lat":43.706429999999997,"lon":-79.39864}],"countries":["Canada"]},{"id":3478,"nct_id":"NCT07499583","title":"Psilocybin Assisted Psychotherapy for Treatment Resistant Depression and Co-occurring Substance Use Disorder","sponsor":"Indiana University","registry_url":"https://clinicaltrials.gov/study/NCT07499583","tracker_url":"publication.php?id=3478","status":"NOT_YET_RECRUITING","status_label":"Not yet recruiting","status_verified_date":"2026-03","last_update_date":"2026-03-30","start_date":"2026-08-01","primary_completion_date":"2031-01-01","completion_date":"2031-02-28","study_type":"INTERVENTIONAL","phases":["PHASE1","PHASE2"],"enrollment":{"count":50,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"QUADRUPLE"},"conditions":["Treatment Resistant Depression","Substance Use Disorders"],"interventions":[{"name":"Psilocybin","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"5d4ed4b3f6bae7820b0119284aa91b928890b70232a51d746a42e7bc415455f1","facility":"Goodman Hall, Dept of Psychiatry, Indiana University","city":"Indianapolis","region":"Indiana","country":"United States","lat":39.768380000000001,"lon":-86.15804},{"key":"260f0d35c8c3f36f16deaf88e7bddbffd9e05e866f4ee5850ef906d177f62a36","facility":"The Stark Neuroscience Building (Goodman Hall)","city":"Indianapolis","region":"Indiana","country":"United States","lat":39.768380000000001,"lon":-86.15804}],"countries":["United States"]},{"id":3696,"nct_id":"NCT06898606","title":"Psilocybe Cubensis Mushrooms With or Without Fluoxetine for Refractory Depression","sponsor":"Federal University of Latin American Integration","registry_url":"https://clinicaltrials.gov/study/NCT06898606","tracker_url":"publication.php?id=3696","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-03","last_update_date":"2026-03-27","start_date":"2024-09-05","primary_completion_date":"2026-08-20","completion_date":"2026-11-20","study_type":"INTERVENTIONAL","phases":["PHASE1","PHASE2"],"enrollment":{"count":24,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"TRIPLE"},"conditions":["Depressive Disorder"],"interventions":[{"name":"Psilocybin and Psilocyn","type":"DRUG"},{"name":"Placebo","type":"DRUG"},{"name":"Psychotherapy-assisted session","type":"BEHAVIORAL"},{"name":"Fluoxetine","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"0baab4fede4fc6054da41261b4cd831dfa37af046f4a5adc5c2912ab388dff0e","facility":"Federal University of Latin American Integration","city":"Foz do Iguaçu","region":"Paraná","country":"Brazil","lat":-25.547779999999999,"lon":-54.588059999999999}],"countries":["Brazil"]},{"id":3456,"nct_id":"NCT05416229","title":"The QUANTUM Trip Trial - Psilocybin-assisted Therapy for Reducing Alcohol Intake in Patients With Alcohol Use Disorder: A Randomized, Double-blinded, Placebo-controlled Clinical Trial.","sponsor":"Anders Fink-Jensen, MD, DMSci","registry_url":"https://clinicaltrials.gov/study/NCT05416229","tracker_url":"publication.php?id=3456","status":"COMPLETED","status_label":"Completed","status_verified_date":"2026-03","last_update_date":"2026-03-24","start_date":"2023-09-01","primary_completion_date":"2025-12-22","completion_date":"2025-12-22","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":60,"type":"ACTUAL"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"QUADRUPLE"},"conditions":["Alcohol Use Disorder"],"interventions":[{"name":"Psilocybin","type":"DRUG"},{"name":"Maltodextrin","type":"DRUG"}],"substances":["psilocybin","psilocin"],"sites":[{"key":"89e2d67761ad37e19e964873766cfa07d5443f9dabbd7226a4f9fcb320860b0c","facility":"Psychiatric Center Copenhagen, Frederiksberg Hospital","city":"Frederiksberg","region":"","country":"Denmark","lat":55.679380000000002,"lon":12.53463}],"countries":["Denmark"]},{"id":3447,"nct_id":"NCT07490353","title":"Elucidating the Relevance of the Psychedelic Experience to Psilocybin's Anti-Anhedonic Effects: A Randomized, Open-Label, Cross-Over Functional Magnetic Resonance Imaging Trial","sponsor":"Medical University of Vienna","registry_url":"https://clinicaltrials.gov/study/NCT07490353","tracker_url":"publication.php?id=3447","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-03","last_update_date":"2026-03-24","start_date":"2025-11-01","primary_completion_date":"2028-05-31","completion_date":"2028-05-31","study_type":"INTERVENTIONAL","phases":["PHASE1"],"enrollment":{"count":85,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"CROSSOVER","primary_purpose":"TREATMENT","masking":"NONE"},"conditions":["Depression - Major Depressive Disorder","Anhedonia"],"interventions":[{"name":"Psilocybin (Usona Institute)","type":"DRUG"},{"name":"Risperidone 1 MG","type":"DRUG"},{"name":"MRI","type":"DIAGNOSTIC_TEST"}],"substances":["psilocybin"],"sites":[{"key":"e1f0adb91f843c24eebaa1127eb64810250131187c9a0be296d3c4b271f3acb7","facility":"Medical University of Vienna, Department of Psychiatry and Psychotherapy, Division of General Psychiatry","city":"Vienna","region":"State of Vienna","country":"Austria","lat":48.208489999999998,"lon":16.37208}],"countries":["Austria"]},{"id":3657,"nct_id":"NCT07484906","title":"Precision Phenotyping of Behavioral Risk and Response to Electromagnetic and Psychedelic Therapies","sponsor":"University of New Mexico","registry_url":"https://clinicaltrials.gov/study/NCT07484906","tracker_url":"publication.php?id=3657","status":"WITHDRAWN","status_label":"Withdrawn","status_verified_date":"2026-03","last_update_date":"2026-03-20","start_date":"2026-05-01","primary_completion_date":"2029-08-31","completion_date":"2029-08-31","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":0,"type":"ACTUAL"},"design":{"allocation":"NON_RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"NONE"},"conditions":["Suicidal Ideation"],"interventions":[{"name":"fMRI Neurofeedback","type":"BEHAVIORAL"},{"name":"Accelerated theta burst stimulation","type":"DEVICE"},{"name":"Psilocybin assisted therapy","type":"DRUG"}],"substances":["psilocybin"],"sites":[],"countries":[]},{"id":3643,"nct_id":"NCT06660381","title":"Pilot Study of Psilocybin-assisted Treatment for Cannabis Use Disorder","sponsor":"Johns Hopkins University","registry_url":"https://clinicaltrials.gov/study/NCT06660381","tracker_url":"publication.php?id=3643","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-03","last_update_date":"2026-03-18","start_date":"2024-11-08","primary_completion_date":"2026-11","completion_date":"2026-12","study_type":"INTERVENTIONAL","phases":["PHASE1"],"enrollment":{"count":12,"type":"ESTIMATED"},"design":{"allocation":"NA","intervention_model":"SINGLE_GROUP","primary_purpose":"TREATMENT","masking":"NONE"},"conditions":["Cannabis Use Disorder"],"interventions":[{"name":"Psilocybin","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"9d7c1530695da1e0dbe5d0029c61521b74c434cedec820dcadef26feb9ead43e","facility":"Johns Hopkins Center for Psychedelic and Consciousness Research","city":"Baltimore","region":"Maryland","country":"United States","lat":39.290379999999999,"lon":-76.612189999999998}],"countries":["United States"]},{"id":3641,"nct_id":"NCT06818994","title":"Safety and Efficacy of Psilocybin-assisted Psychotherapy for Demoralization Syndrome in Patients Diagnosed With Advanced Stage Cancer: a Pilot Study","sponsor":"Gustavo Vazquez","registry_url":"https://clinicaltrials.gov/study/NCT06818994","tracker_url":"publication.php?id=3641","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-03","last_update_date":"2026-03-18","start_date":"2026-04-01","primary_completion_date":"2027-06-01","completion_date":"2027-06-01","study_type":"INTERVENTIONAL","phases":["PHASE1"],"enrollment":{"count":15,"type":"ESTIMATED"},"design":{"allocation":"NA","intervention_model":"SINGLE_GROUP","primary_purpose":"TREATMENT","masking":"NONE"},"conditions":["Demoralization","Safety"],"interventions":[{"name":"Psilocybin-assisted Psychotherapy","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"73be9e73a15b0a509c30e07498262eb93d5497d1e464edc1a0207267273a032a","facility":"Queen's University","city":"Kingston","region":"Ontario","country":"Canada","lat":44.229759999999999,"lon":-76.480980000000002}],"countries":["Canada"]},{"id":3493,"nct_id":"NCT04620759","title":"Psilocybin Treatment of Major Depressive Disorder With Co-occurring Alcohol Use Disorder","sponsor":"Johns Hopkins University","registry_url":"https://clinicaltrials.gov/study/NCT04620759","tracker_url":"publication.php?id=3493","status":"ACTIVE_NOT_RECRUITING","status_label":"Active, not recruiting","status_verified_date":"2026-03","last_update_date":"2026-03-13","start_date":"2021-04-14","primary_completion_date":"2026-03-02","completion_date":"2027-03-30","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":90,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"QUADRUPLE"},"conditions":["Major Depressive Disorder","Alcohol Use Disorder"],"interventions":[{"name":"Psilocybin","type":"DRUG"},{"name":"Placebo","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"9d7c1530695da1e0dbe5d0029c61521b74c434cedec820dcadef26feb9ead43e","facility":"Johns Hopkins Center for Psychedelic and Consciousness Research","city":"Baltimore","region":"Maryland","country":"United States","lat":39.290379999999999,"lon":-76.612189999999998}],"countries":["United States"]},{"id":3599,"nct_id":"NCT05227742","title":"Exploratory Study of the Effects of Low-Dose Psilocybin on Sensory Processing, Neurophysiological Arousal, and Emotional Health","sponsor":"University of Alabama at Birmingham","registry_url":"https://clinicaltrials.gov/study/NCT05227742","tracker_url":"publication.php?id=3599","status":"WITHDRAWN","status_label":"Withdrawn","status_verified_date":"2026-03","last_update_date":"2026-03-11","start_date":"2023-08-15","primary_completion_date":"2026-03","completion_date":"2026-03","study_type":"INTERVENTIONAL","phases":["EARLY_PHASE1"],"enrollment":{"count":0,"type":"ACTUAL"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"QUADRUPLE"},"conditions":["Demoralization"],"interventions":[{"name":"Psilocybin","type":"DRUG"},{"name":"Placebo","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"7ce22b002e53ab5c3978b99f32427c645bc1173311a77a8658068ba9bbf879bc","facility":"University of Alabama at Birmingham","city":"Birmingham","region":"Alabama","country":"United States","lat":33.520659999999999,"lon":-86.802490000000006}],"countries":["United States"]},{"id":3517,"nct_id":"NCT05068791","title":"Psilocybin-facilitated Treatment for Chronic Pain","sponsor":"University of Alabama at Birmingham","registry_url":"https://clinicaltrials.gov/study/NCT05068791","tracker_url":"publication.php?id=3517","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-03","last_update_date":"2026-03-11","start_date":"2023-11-01","primary_completion_date":"2026-12-31","completion_date":"2026-12-31","study_type":"INTERVENTIONAL","phases":["EARLY_PHASE1"],"enrollment":{"count":30,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"QUADRUPLE"},"conditions":["Fibromyalgia, Primary"],"interventions":[{"name":"Psilocybin","type":"DRUG"},{"name":"Dextromethorphan","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"57b51432bd54eead1665bf308d75c58452112099cecfea39a38a9a4ae8d6e95d","facility":"UAB Beacon Tower","city":"Birmingham","region":"Alabama","country":"United States","lat":33.520659999999999,"lon":-86.802490000000006}],"countries":["United States"]},{"id":3473,"nct_id":"NCT06442423","title":"Safety, Feasibility, and Tolerability of Psilocybin Treatment for Individuals With Functional Impairment Related to Mood, Anxiety, Trauma and/or Addiction Symptoms: An Open-label Proof-of-concept Study","sponsor":"Yale University","registry_url":"https://clinicaltrials.gov/study/NCT06442423","tracker_url":"publication.php?id=3473","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-03","last_update_date":"2026-03-11","start_date":"2024-10-17","primary_completion_date":"2027-12","completion_date":"2027-12","study_type":"INTERVENTIONAL","phases":["PHASE1"],"enrollment":{"count":50,"type":"ESTIMATED"},"design":{"allocation":"NA","intervention_model":"SINGLE_GROUP","primary_purpose":"TREATMENT","masking":"NONE"},"conditions":["Transdiagnostic","Depression - Major Depressive Disorder","Anxiety","PTSD Symptoms","PTSD","Substance Use","Substance Use Disorder (SUD)","OCD"],"interventions":[{"name":"Psilocybin","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"53cb5faca3c60ecf068797736403edeb0302d95d0a85337b9536bbc345ef7916","facility":"Connecticut Mental Health Center - Yale School of Medicine","city":"New Haven","region":"Connecticut","country":"United States","lat":41.308149999999998,"lon":-72.928160000000005}],"countries":["United States"]},{"id":3598,"nct_id":"NCT06760533","title":"Pilot Proof of Concept Study Evaluating the Potential Psilocybin Assisted Psychotherapy (PAP) as a Therapeutic Tool for Patients Suffering From Severe Irritable Bowel Syndrome.","sponsor":"NYU Langone Health","registry_url":"https://clinicaltrials.gov/study/NCT06760533","tracker_url":"publication.php?id=3598","status":"NOT_YET_RECRUITING","status_label":"Not yet recruiting","status_verified_date":"2026-03","last_update_date":"2026-03-05","start_date":"2026-08","primary_completion_date":"2026-12","completion_date":"2026-12","study_type":"INTERVENTIONAL","phases":["EARLY_PHASE1"],"enrollment":{"count":10,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"TRIPLE"},"conditions":["IBS - Irritable Bowel Syndrome"],"interventions":[{"name":"Psilocybin 25 mg","type":"DRUG"},{"name":"Psychotherapy Treatment Session","type":"BEHAVIORAL"},{"name":"Niacin 100 mg","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"f013c15d8112693910d9bf055f39dc54c2a9c3749b21ac7dacc4c09c7de423df","facility":"NYU Langone Health","city":"New York","region":"New York","country":"United States","lat":40.714269999999999,"lon":-74.005970000000005}],"countries":["United States"]},{"id":3497,"nct_id":"NCT05554094","title":"Examining the Safety and Clinical Efficacy of Psilocybin Therapy for Veterans With PTSD: An Open-Label Proof-of-Concept Trial","sponsor":"Ohio State University","registry_url":"https://clinicaltrials.gov/study/NCT05554094","tracker_url":"publication.php?id=3497","status":"ACTIVE_NOT_RECRUITING","status_label":"Active, not recruiting","status_verified_date":"2025-10","last_update_date":"2026-03-04","start_date":"2023-01-01","primary_completion_date":"2025-12-31","completion_date":"2026-07-31","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":15,"type":"ESTIMATED"},"design":{"allocation":"NA","intervention_model":"SINGLE_GROUP","primary_purpose":"TREATMENT","masking":"NONE"},"conditions":["PTSD","Stress Disorders, Traumatic","Stress Disorders, Post-Traumatic","Trauma and Stressor Related Disorders","Mental Disorder"],"interventions":[{"name":"Psilocybin","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"281c2eb56c8da95ba692a4789013f5bedb7069494aeb666eb410ca73d4c419da","facility":"Ohio State University Department of Psychiatry and Behavioral Health at the Davis Medical Research Center","city":"Columbus","region":"Ohio","country":"United States","lat":39.961179999999999,"lon":-82.99879}],"countries":["United States"]},{"id":3616,"nct_id":"NCT07072728","title":"A Phase 2b Double-blind, Randomized, Low-dose Comparator-controlled Clinical Trial to Assess the Efficacy and Safety of NPX-5 in Psilocybin-assisted Psychotherapy for the Treatment of Adjustment Disorder Associated With Cancer.","sponsor":"Psyence Australia Pty Ltd","registry_url":"https://clinicaltrials.gov/study/NCT07072728","tracker_url":"publication.php?id=3616","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-02","last_update_date":"2026-03-03","start_date":"2025-10-01","primary_completion_date":"2026-12-30","completion_date":"2027-07-30","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":87,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"SEQUENTIAL","primary_purpose":"TREATMENT","masking":"QUADRUPLE"},"conditions":["Adjustment Disorder","Adjustment Disorder With Anxious Mood","Cancer","Cancer Cachexia","Cancer of Endometrium","Cancer of Kidney","Cancer of Prostate","Cancer of the Breast","Cancer of Stomach","Cancer Melanoma Skin","Cancer Pancreas"],"interventions":[{"name":"Psilocybin therapy","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"60b561826ea1087d0a6075e09763aebb8728c09f0183a3d029f1558c69e69bd3","facility":"Mind Medicine Australia Clinic","city":"Abbotsford","region":"Victoria","country":"Australia","lat":-37.799999999999997,"lon":145},{"key":"bc24127b43b0f70565a09f33f689e5c1c9ef6f31ba136c7650ba0fd99b8289cb","facility":"Paratus Clinical Research Melbourne","city":"Northcote","region":"Victoria","country":"Australia","lat":-37.766669999999998,"lon":145},{"key":"adfbd3436ba3de0148122053ef79072e74006b058256ba9b8f2d0a035013fd6b","facility":"Empax Centre","city":"Leederville","region":"Western Australia","country":"Australia","lat":-31.93628,"lon":115.8419}],"countries":["Australia"]},{"id":3458,"nct_id":"NCT06399263","title":"Study of Psilocybin for Anorexia in Young Adults","sponsor":"Marissa Raymond-Flesch, MD, MPH","registry_url":"https://clinicaltrials.gov/study/NCT06399263","tracker_url":"publication.php?id=3458","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-01","last_update_date":"2026-03-03","start_date":"2024-11-18","primary_completion_date":"2029-11","completion_date":"2029-11","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":40,"type":"ESTIMATED"},"design":{"allocation":"NA","intervention_model":"SINGLE_GROUP","primary_purpose":"TREATMENT","masking":"NONE"},"conditions":["Anorexia Nervosa"],"interventions":[{"name":"Psilocybin","type":"DRUG"},{"name":"Preparation and Integration Sessions","type":"BEHAVIORAL"}],"substances":["psilocybin"],"sites":[{"key":"7f09a842484186a75c6232177464293472d56c43d4d49f24f37efcb6c9cbbbb8","facility":"University of California, San Francisco","city":"San Francisco","region":"California","country":"United States","lat":37.774929999999998,"lon":-122.41942}],"countries":["United States"]},{"id":3439,"nct_id":"NCT07433452","title":"The Effects of Psilocybin in Healthy Volunteers: Psychological, Biochemical and Electrophysiological Biomarkers.","sponsor":"Gabriella Gobbi","registry_url":"https://clinicaltrials.gov/study/NCT07433452","tracker_url":"publication.php?id=3439","status":"NOT_YET_RECRUITING","status_label":"Not yet recruiting","status_verified_date":"2026-02","last_update_date":"2026-02-25","start_date":"2026-09-01","primary_completion_date":"2028-09-01","completion_date":"2029-09-01","study_type":"INTERVENTIONAL","phases":["PHASE1"],"enrollment":{"count":50,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"TRIPLE"},"conditions":["Healthy Participants","Placebo - Control","Psilocybin"],"interventions":[{"name":"Psilocybin (drug)","type":"DRUG"},{"name":"Placebo","type":"DRUG"}],"substances":["psilocybin","psilocin"],"sites":[],"countries":[]},{"id":3675,"nct_id":"NCT06005662","title":"Inpatient Buprenorphine Induction With Psilocybin for Opioid Use Disorder: a Randomized Double-blind Trial","sponsor":"Johns Hopkins University","registry_url":"https://clinicaltrials.gov/study/NCT06005662","tracker_url":"publication.php?id=3675","status":"WITHDRAWN","status_label":"Withdrawn","status_verified_date":"2026-02","last_update_date":"2026-02-23","start_date":"2027-04","primary_completion_date":"2028-07","completion_date":"2028-07","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":0,"type":"ACTUAL"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"QUADRUPLE"},"conditions":["Opioid Use Disorder"],"interventions":[{"name":"Psilocybin","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"be5d63bf40aada157fda0af485fadeddd7eac0c079ecab26a1612289fb4c7fdb","facility":"Johns Hopkins University","city":"Baltimore","region":"Maryland","country":"United States","lat":39.290379999999999,"lon":-76.612189999999998}],"countries":["United States"]},{"id":3551,"nct_id":"NCT06772753","title":"Investigation of Psychedelic Effects in Psychoactive Substances","sponsor":"Johns Hopkins University","registry_url":"https://clinicaltrials.gov/study/NCT06772753","tracker_url":"publication.php?id=3551","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-02","last_update_date":"2026-02-23","start_date":"2025-02-05","primary_completion_date":"2027-06","completion_date":"2027-12","study_type":"INTERVENTIONAL","phases":["PHASE1"],"enrollment":{"count":50,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"BASIC_SCIENCE","masking":"TRIPLE"},"conditions":["Psychedelic Effects in Healthy Volunteers"],"interventions":[{"name":"Placebo","type":"DRUG"},{"name":"Psilocybin","type":"DRUG"},{"name":"Ketamine","type":"DRUG"},{"name":"Dextromethorphan (DXM)","type":"DRUG"},{"name":"Dimethyltryptamine (DMT)","type":"DRUG"},{"name":"Methylenedioxymethamphetamine (MDMA)","type":"DRUG"},{"name":"Tetrahydrocannabinol (THC)","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"9d7c1530695da1e0dbe5d0029c61521b74c434cedec820dcadef26feb9ead43e","facility":"Johns Hopkins Center for Psychedelic and Consciousness Research","city":"Baltimore","region":"Maryland","country":"United States","lat":39.290379999999999,"lon":-76.612189999999998}],"countries":["United States"]},{"id":3520,"nct_id":"NCT04950608","title":"Pilot Study of Psilocybin-Assisted Therapy for Demoralization in Patients Receiving Hospice Care - PATH Study","sponsor":"Yvan Beaussant, MD, MSci","registry_url":"https://clinicaltrials.gov/study/NCT04950608","tracker_url":"publication.php?id=3520","status":"COMPLETED","status_label":"Completed","status_verified_date":"2026-01","last_update_date":"2026-02-17","start_date":"2022-03-09","primary_completion_date":"2024-07-27","completion_date":"2025-12-31","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":15,"type":"ACTUAL"},"design":{"allocation":"NA","intervention_model":"SINGLE_GROUP","primary_purpose":"TREATMENT","masking":"NONE"},"conditions":["Hospice","Psilocybin","Demoralization","Terminal Illness","Cancer-related Problem/Condition","Psychotherapy","Terminal Cancer","Cancer Terminal"],"interventions":[{"name":"Psilocybin","type":"DRUG"},{"name":"Psychotherapy","type":"BEHAVIORAL"}],"substances":["psilocybin"],"sites":[{"key":"206ee54b8eec5bd83c44ff9bdf50d3c675f8537d8c74f1be1ba471dae964c101","facility":"Care Dimensions","city":"Danvers","region":"Massachusetts","country":"United States","lat":42.575090000000003,"lon":-70.930049999999994}],"countries":["United States"]},{"id":3541,"nct_id":"NCT07050368","title":"A Phase 1 Translational Study to Assess Brain Activity Using Functional Magnetic Resonance Imaging (fMRI) and to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Doses of MLS101 (Psilocybin) in Healthy Volunteers","sponsor":"MycoMedica Life Sciences PBC","registry_url":"https://clinicaltrials.gov/study/NCT07050368","tracker_url":"publication.php?id=3541","status":"COMPLETED","status_label":"Completed","status_verified_date":"2026-02","last_update_date":"2026-02-13","start_date":"2025-07-28","primary_completion_date":"2026-01-13","completion_date":"2026-01-13","study_type":"INTERVENTIONAL","phases":["PHASE1"],"enrollment":{"count":20,"type":"ACTUAL"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"SINGLE"},"conditions":["Healthy Volunteer"],"interventions":[{"name":"Psilocybin","type":"DRUG"},{"name":"Placebo","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"acb92468b8bdb8e495997bdcc5a1aab1cb194abab89bbb8f698d935f8a4f86a9","facility":"Hammersmith Medicines Research (HMR)","city":"London","region":"","country":"United Kingdom","lat":51.50853,"lon":-0.12573999999999999}],"countries":["United Kingdom"]},{"id":3425,"nct_id":"NCT07053917","title":"Psychedelic Healing: Adjunct Therapy Harnessing Opened Malleability","sponsor":"Johns Hopkins University","registry_url":"https://clinicaltrials.gov/study/NCT07053917","tracker_url":"publication.php?id=3425","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-02","last_update_date":"2026-02-13","start_date":"2026-02-09","primary_completion_date":"2027-02","completion_date":"2027-03","study_type":"INTERVENTIONAL","phases":["PHASE1"],"enrollment":{"count":20,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"NONE"},"conditions":["Stroke","Chronic Stroke","Intracerebral Haemorrhage","Intracerebral Haemorrhage (ICH)","Intracerebral Hemorrhage Basal Ganglia","Ischemic Stroke","Ischemic Stroke and Hemorrhagic Stroke","Hemiparesis After Stroke","Hemiplegia Following Ischemic Stroke","Hemiplegia and Hemiparesis","Hemiplegia and/or Hemiparesis Following Stroke","Middle Cerebral Artery Stroke"],"interventions":[{"name":"Psilocybin (Usona Institute)","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"10c44137a9b4880068299ddcb07a1eb31ce3cb82a82abd191c04b907f1430cba","facility":"Johns Hopkins","city":"Baltimore","region":"Maryland","country":"United States","lat":39.290379999999999,"lon":-76.612189999999998}],"countries":["United States"]},{"id":3624,"nct_id":"NCT07405606","title":"Psilocybin-assisted Therapy for Comorbid Major Depressive Disorder and Alcohol Use Disorder: A Pilot Randomized Clinical Trial","sponsor":"Centre for Addiction and Mental Health","registry_url":"https://clinicaltrials.gov/study/NCT07405606","tracker_url":"publication.php?id=3624","status":"NOT_YET_RECRUITING","status_label":"Not yet recruiting","status_verified_date":"2026-01","last_update_date":"2026-02-12","start_date":"2026-03","primary_completion_date":"2028-03","completion_date":"2028-06","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":30,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"QUADRUPLE"},"conditions":["Major Depressive Disorder (MDD)","Alcohol Use Disorder (AUD)"],"interventions":[{"name":"Psilocybin 25 mg","type":"DRUG"},{"name":"Placebo","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"bf2adfb756d244974a952f7c5c58e6f72f66cbbd5ba63e61a8b987fa1820f128","facility":"Centre for Addiction and Mental Health","city":"Toronto","region":"Ontario","country":"Canada","lat":43.706429999999997,"lon":-79.39864}],"countries":["Canada"]},{"id":3514,"nct_id":"NCT07281352","title":"Psilocybin-Assisted Cognitive Behavioral Therapy for Depression","sponsor":"University of California, Los Angeles","registry_url":"https://clinicaltrials.gov/study/NCT07281352","tracker_url":"publication.php?id=3514","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2025-12","last_update_date":"2026-02-12","start_date":"2026-01-05","primary_completion_date":"2027-11-30","completion_date":"2027-11-30","study_type":"INTERVENTIONAL","phases":["PHASE1","PHASE2"],"enrollment":{"count":50,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"SINGLE"},"conditions":["Major Depressive Diorder"],"interventions":[{"name":"Psilocybin (drug)","type":"DRUG"},{"name":"cognitive behavioral therapy","type":"BEHAVIORAL"},{"name":"Minimal supportive therapy","type":"BEHAVIORAL"}],"substances":["psilocybin"],"sites":[{"key":"d6737ae6c1d4e88b0250366ac1706c0eb50510292a7547d4474ad9750824e06e","facility":"UCLA Semel Institute","city":"Los Angeles","region":"California","country":"United States","lat":34.052230000000002,"lon":-118.24368}],"countries":["United States"]},{"id":3690,"nct_id":"NCT07079930","title":"Safety and Psychological Effects of Psilocybin and D-Serine Formulation in Healthy Volunteers","sponsor":"Hadassah Medical Organization","registry_url":"https://clinicaltrials.gov/study/NCT07079930","tracker_url":"publication.php?id=3690","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2025-07","last_update_date":"2026-02-05","start_date":"2025-12-11","primary_completion_date":"2026-11","completion_date":"2027-02","study_type":"INTERVENTIONAL","phases":["PHASE1"],"enrollment":{"count":10,"type":"ESTIMATED"},"design":{"allocation":"NON_RANDOMIZED","intervention_model":"SEQUENTIAL","primary_purpose":"TREATMENT","masking":"NONE"},"conditions":["Healthy Volunteers"],"interventions":[{"name":"Psilocybin and D-Serine","type":"DRUG"},{"name":"Physical Examination","type":"DIAGNOSTIC_TEST"},{"name":"Vital signs","type":"DIAGNOSTIC_TEST"},{"name":"ECG test","type":"DIAGNOSTIC_TEST"},{"name":"Comprehensive Blood Panel","type":"DIAGNOSTIC_TEST"},{"name":"Complete Blood Count","type":"DIAGNOSTIC_TEST"},{"name":"Urinalysis","type":"DIAGNOSTIC_TEST"},{"name":"Urine Toxicology Screen","type":"DIAGNOSTIC_TEST"},{"name":"A pregnancy Urine test","type":"DIAGNOSTIC_TEST"},{"name":"Electroencephalogram","type":"DIAGNOSTIC_TEST"},{"name":"Plasma Amino Acid Levels","type":"DIAGNOSTIC_TEST"},{"name":"Plasma Inflammation Markers","type":"DIAGNOSTIC_TEST"},{"name":"Plasma Brain-Derived Neurotrophic Facto","type":"DIAGNOSTIC_TEST"},{"name":"Mini International Neuropsychiatric Interview","type":"OTHER"},{"name":"Family Psychiatric History Assessment","type":"OTHER"},{"name":"Beck Depression Inventory","type":"OTHER"},{"name":"State-Trait Anxiety Inventory","type":"OTHER"},{"name":"Profile of Mood States","type":"BEHAVIORAL"},{"name":"Subjective Units of Distress Scale","type":"BEHAVIORAL"},{"name":"Five-Dimensional Altered States of Consciousness questionnaire","type":"OTHER"},{"name":"Integration","type":"BEHAVIORAL"}],"substances":["psilocybin"],"sites":[{"key":"429fe69d07db5cabcda31c9415fb3b7bade24763ccdfea22c895d8c381fdd472","facility":"Hadassah Medical Organization, Jerusalem, Israel","city":"Jerusalem","region":"","country":"Israel","lat":31.76904,"lon":35.216329999999999}],"countries":["Israel"]},{"id":3550,"nct_id":"NCT06206265","title":"A Phase 2a, Open-label, Pilot Study to Assess the Safety and Efficacy of Oral Psilocybin (TRP-8802) Administration in Concert With Psychotherapy Among Adult Patients With Irritable Bowel Syndrome: A Randomized Delayed Treatment Control Design","sponsor":"TRYP Therapeutics","registry_url":"https://clinicaltrials.gov/study/NCT06206265","tracker_url":"publication.php?id=3550","status":"ACTIVE_NOT_RECRUITING","status_label":"Active, not recruiting","status_verified_date":"2026-02","last_update_date":"2026-02-05","start_date":"2024-01-17","primary_completion_date":"2026-03-01","completion_date":"2026-03-01","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":14,"type":"ACTUAL"},"design":{"allocation":"RANDOMIZED","intervention_model":"SEQUENTIAL","primary_purpose":"TREATMENT","masking":"NONE"},"conditions":["Irritable Bowel Syndrome"],"interventions":[{"name":"TRYP-0082","type":"DRUG"},{"name":"Psychotherapy","type":"BEHAVIORAL"}],"substances":["psilocybin"],"sites":[{"key":"ea40aea40039489b09eb593dd7ca752f9e392333d283c9e911f6668d71b89b42","facility":"Massachusetts General Hospital","city":"Boston","region":"Massachusetts","country":"United States","lat":42.358429999999998,"lon":-71.05977}],"countries":["United States"]},{"id":3486,"nct_id":"NCT07391332","title":"Psilocybin AsSisted pSychotherapy for the treatmENt of Gambling disordER: a Pilot Study","sponsor":"Nantes University Hospital","registry_url":"https://clinicaltrials.gov/study/NCT07391332","tracker_url":"publication.php?id=3486","status":"NOT_YET_RECRUITING","status_label":"Not yet recruiting","status_verified_date":"2026-01","last_update_date":"2026-02-05","start_date":"2026-04-01","primary_completion_date":"2029-01-01","completion_date":"2029-01-01","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":30,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"DOUBLE"},"conditions":["Gambling Disorder"],"interventions":[{"name":"Psychotherapy assisted by high-dose psilocybin (25mg or 40mg where appropriate)","type":"DRUG"},{"name":"Psychotherapy assisted by low-dose psilocybin (1 mg)","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"97ab6774326b85ebb62ea5871bc0b94c44c9454e26b8d744944779b684f9004d","facility":"Nantes University Hospital","city":"Nantes","region":"","country":"France","lat":47.21725,"lon":-1.5533600000000001}],"countries":["France"]},{"id":3673,"nct_id":"NCT06796062","title":"A Phase 2 Trial of Psilocybin as an Adjunctive Treatment for OUD Patients Who Continue to Use Illicit Opioids Despite Adherence to Methadone Treatment","sponsor":"NYU Langone Health","registry_url":"https://clinicaltrials.gov/study/NCT06796062","tracker_url":"publication.php?id=3673","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2025-12","last_update_date":"2026-01-23","start_date":"2025-12-17","primary_completion_date":"2029-02","completion_date":"2029-02","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":480,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"DOUBLE"},"conditions":["Opioid Use Disorder"],"interventions":[{"name":"Psilocybin","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"2efd177beb9722b60d05070a66389e71ae259668c4178f5411487061f62efb7c","facility":"Duke City Recovery Toolbox","city":"Albuquerque","region":"New Mexico","country":"United States","lat":35.084490000000002,"lon":-106.65114},{"key":"8fccc71c53b40f7dc5e28040c7be06eae1a4b7bb5a7209d9aca29d9c5f6643d0","facility":"University of New Mexico","city":"Albuquerque","region":"New Mexico","country":"United States","lat":35.084490000000002,"lon":-106.65114},{"key":"cb49fa24dfbf8e250086b9d17c0538ca82fa2466c8dd249c6067d4280ab1f354","facility":"StartCare","city":"Brooklyn","region":"New York","country":"United States","lat":40.650100000000002,"lon":-73.949579999999997},{"key":"f013c15d8112693910d9bf055f39dc54c2a9c3749b21ac7dacc4c09c7de423df","facility":"NYU Langone Health","city":"New York","region":"New York","country":"United States","lat":40.714269999999999,"lon":-74.005970000000005},{"key":"cbc94afe933fcad9921964a6f0b6402d02a73d8e689068a95ac7f922a80f8c1f","facility":"VIP Community Services, Inc","city":"The Bronx","region":"New York","country":"United States","lat":40.849850000000004,"lon":-73.866410000000002}],"countries":["United States"]},{"id":3703,"nct_id":"NCT06888128","title":"The STARLIGHT Protocol: State-Funded Trial Assessing Recovery and Long-Term Impact of Guided Psilocybin for Healing Trauma","sponsor":"Baylor College of Medicine","registry_url":"https://clinicaltrials.gov/study/NCT06888128","tracker_url":"publication.php?id=3703","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-01","last_update_date":"2026-01-22","start_date":"2025-01-30","primary_completion_date":"2026-12-15","completion_date":"2026-12-15","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":15,"type":"ESTIMATED"},"design":{"allocation":"NA","intervention_model":"SINGLE_GROUP","primary_purpose":"TREATMENT","masking":"NONE"},"conditions":["PTSD"],"interventions":[{"name":"Psilocybin 15mg","type":"DRUG"},{"name":"Psilocybin 25mg","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"e9371a41662463aee2a73b489b08fd54498561d5f98b540ab6947525b5b46514","facility":"Baylor College of Medicine","city":"Houston","region":"Texas","country":"United States","lat":29.763280000000002,"lon":-95.36327}],"countries":["United States"]},{"id":3645,"nct_id":"NCT05224336","title":"Behavioral and Neural Mechanisms Supporting Psilocybin-assisted Therapy for Phantom Limb Pain","sponsor":"University of California, San Diego","registry_url":"https://clinicaltrials.gov/study/NCT05224336","tracker_url":"publication.php?id=3645","status":"COMPLETED","status_label":"Completed","status_verified_date":"2026-01","last_update_date":"2026-01-09","start_date":"2022-10-03","primary_completion_date":"2024-03-07","completion_date":"2024-03-07","study_type":"INTERVENTIONAL","phases":["PHASE1"],"enrollment":{"count":10,"type":"ACTUAL"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"TRIPLE"},"conditions":["Phantom Limb Pain"],"interventions":[{"name":"Psilocybin","type":"DRUG"},{"name":"Placebo Niacin","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"99eb38b713e3399c654ea67c21623804abe68f3e3b585ac71a2500aeee975686","facility":"University of California, San Diego","city":"San Diego","region":"California","country":"United States","lat":32.715710000000001,"lon":-117.16472}],"countries":["United States"]},{"id":3464,"nct_id":"NCT05259943","title":"Microdosing Psychedelics to Improve Mood","sponsor":"Rotem Petranker","registry_url":"https://clinicaltrials.gov/study/NCT05259943","tracker_url":"publication.php?id=3464","status":"COMPLETED","status_label":"Completed","status_verified_date":"2025-12","last_update_date":"2025-12-30","start_date":"2023-07-15","primary_completion_date":"2024-12-21","completion_date":"2025-02-01","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":39,"type":"ACTUAL"},"design":{"allocation":"RANDOMIZED","intervention_model":"CROSSOVER","primary_purpose":"TREATMENT","masking":"TRIPLE"},"conditions":["Major Depressive Disorder"],"interventions":[{"name":"Psilocybin first","type":"DRUG"},{"name":"Placebo first","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"6c0ef8e5236bcabb35a2af5615a610385af1e769f0b6c1dd1a8182e395efb066","facility":"Psych Research","city":"Toronto","region":"Ontario","country":"Canada","lat":43.706429999999997,"lon":-79.39864}],"countries":["Canada"]},{"id":3701,"nct_id":"NCT05220410","title":"The Safety and Efficacy of Psilocybin in Patients With Treatment-resistant Depression and Chronic Suicidal Ideation","sponsor":"Sheppard Pratt Health System","registry_url":"https://clinicaltrials.gov/study/NCT05220410","tracker_url":"publication.php?id=3701","status":"COMPLETED","status_label":"Completed","status_verified_date":"2025-07","last_update_date":"2025-12-24","start_date":"2022-03-28","primary_completion_date":"2025-05-12","completion_date":"2025-05-12","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":20,"type":"ACTUAL"},"design":{"allocation":"NA","intervention_model":"SINGLE_GROUP","primary_purpose":"TREATMENT","masking":"NONE"},"conditions":["Treatment Resistant Depression","Suicidal Ideation"],"interventions":[{"name":"Psilocybin","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"bc376e1e0a696ea23f74184c3639e3209c4cf2754b05d49dcebccf226428bc05","facility":"Sheppard Pratt Health System","city":"Baltimore","region":"Maryland","country":"United States","lat":39.290379999999999,"lon":-76.612189999999998}],"countries":["United States"]},{"id":3506,"nct_id":"NCT05399498","title":"An Open Label Study of Single-Dose Psilocybin for Major Depressive Disorder With Co-occurring Borderline Personality Disorder","sponsor":"University of Chicago","registry_url":"https://clinicaltrials.gov/study/NCT05399498","tracker_url":"publication.php?id=3506","status":"COMPLETED","status_label":"Completed","status_verified_date":"2025-12","last_update_date":"2025-12-23","start_date":"2023-11-01","primary_completion_date":"2025-12-01","completion_date":"2025-12-01","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":9,"type":"ACTUAL"},"design":{"allocation":"NA","intervention_model":"SINGLE_GROUP","primary_purpose":"TREATMENT","masking":"NONE"},"conditions":["Borderline Personality Disorder","Major Depressive Disorder"],"interventions":[{"name":"Psilocybin","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"485cbb329a25d951a977ec15ee6793be07aa56a676a1928d2423d057bc2c5e59","facility":"University of Chicago","city":"Chicago","region":"Illinois","country":"United States","lat":41.850029999999997,"lon":-87.650049999999993}],"countries":["United States"]},{"id":3585,"nct_id":"NCT07296328","title":"Effects of Psilocybin on Speech Fluency, Struggle, and Brain Activity in People Who Stutter","sponsor":"NYU Langone Health","registry_url":"https://clinicaltrials.gov/study/NCT07296328","tracker_url":"publication.php?id=3585","status":"NOT_YET_RECRUITING","status_label":"Not yet recruiting","status_verified_date":"2025-12","last_update_date":"2025-12-22","start_date":"2026-01-15","primary_completion_date":"2027-04-01","completion_date":"2027-04-01","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":25,"type":"ESTIMATED"},"design":{"allocation":"NA","intervention_model":"SINGLE_GROUP","primary_purpose":"TREATMENT","masking":"NONE"},"conditions":["Stuttering"],"interventions":[{"name":"Psilocybin","type":"DRUG"},{"name":"Speech therapy","type":"BEHAVIORAL"}],"substances":["psilocybin"],"sites":[{"key":"f013c15d8112693910d9bf055f39dc54c2a9c3749b21ac7dacc4c09c7de423df","facility":"NYU Langone Health","city":"New York","region":"New York","country":"United States","lat":40.714269999999999,"lon":-74.005970000000005}],"countries":["United States"]},{"id":3625,"nct_id":"NCT06798636","title":"Investigating the Effects of a Psychedelic-augmented Mental Imagery-based Intervention for Young People With Self-harm Behaviour: an Experimental Medicine Study","sponsor":"Imperial College London","registry_url":"https://clinicaltrials.gov/study/NCT06798636","tracker_url":"publication.php?id=3625","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2025-11","last_update_date":"2025-12-05","start_date":"2025-10-01","primary_completion_date":"2026-08-31","completion_date":"2026-10-31","study_type":"INTERVENTIONAL","phases":["EARLY_PHASE1"],"enrollment":{"count":30,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"OTHER","masking":"TRIPLE"},"conditions":["Self Harm"],"interventions":[{"name":"Psilocybin 5 mg with cognitive behavioural therapy intervention","type":"DRUG"},{"name":"Placebo with cognitive behavioural therapy intervention","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"bd9ef7ba5708708e271ac4223cd8f759659fe972f273d761152a6c0134e8622e","facility":"Imperial College London","city":"London","region":"","country":"United Kingdom","lat":51.50853,"lon":-0.12573999999999999}],"countries":["United Kingdom"]},{"id":3692,"nct_id":"NCT05585229","title":"Standardized Natural Psilocybin-assisted Psychotherapy for Tapering of Opioid Medication in Patients With Chronic Pain: an Open-label Feasibility Study","sponsor":"University of British Columbia","registry_url":"https://clinicaltrials.gov/study/NCT05585229","tracker_url":"publication.php?id=3692","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2025-11","last_update_date":"2025-12-04","start_date":"2025-10-27","primary_completion_date":"2026-08-31","completion_date":"2026-08-31","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":10,"type":"ESTIMATED"},"design":{"allocation":"NA","intervention_model":"SINGLE_GROUP","primary_purpose":"TREATMENT","masking":"NONE"},"conditions":["Opioid Dependence","Chronic Pain"],"interventions":[{"name":"Psilocybin-assisted Psychotherapy","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"ea083ab2fc2ae83a35a58fe8386ef0b69ef14561d64fefb0069b5be4bb994b97","facility":"University of British Columbia - Okanagan Campus","city":"Kelowna","region":"British Columbia","country":"Canada","lat":49.883069999999996,"lon":-119.48568}],"countries":["Canada"]},{"id":3513,"nct_id":"NCT05398484","title":"A Phase 2b, Randomized, Double-blind, Placebo-controlled, Multi-center Study of the Effects of Psilocybin-assisted Psychotherapy on Psychiatric and Existential Distress in Advanced Cancer","sponsor":"NYU Langone Health","registry_url":"https://clinicaltrials.gov/study/NCT05398484","tracker_url":"publication.php?id=3513","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2025-12","last_update_date":"2025-12-04","start_date":"2023-05-24","primary_completion_date":"2027-01-01","completion_date":"2027-01-01","study_type":"INTERVENTIONAL","phases":["PHASE2","PHASE3"],"enrollment":{"count":200,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"DOUBLE"},"conditions":["Advanced Cancer"],"interventions":[{"name":"Psilocybin 25 mgs","type":"DRUG"},{"name":"Niacin 100mg","type":"DRUG"},{"name":"Psychotherapy","type":"BEHAVIORAL"}],"substances":["psilocybin"],"sites":[{"key":"7af9ac6392b1552d76cfb9c7864f12f879094bf439d72053786dd890245b723b","facility":"University of Colorado Anschutz Medical campus (CU AMC)","city":"Aurora","region":"Colorado","country":"United States","lat":39.729430000000001,"lon":-104.83192},{"key":"f013c15d8112693910d9bf055f39dc54c2a9c3749b21ac7dacc4c09c7de423df","facility":"NYU Langone Health","city":"New York","region":"New York","country":"United States","lat":40.714269999999999,"lon":-74.005970000000005}],"countries":["United States"]},{"id":3444,"nct_id":"NCT06405607","title":"Psilocybin vs Ketamine for Alcohol Use Disorder","sponsor":"University of Iowa","registry_url":"https://clinicaltrials.gov/study/NCT06405607","tracker_url":"publication.php?id=3444","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2025-11","last_update_date":"2025-11-28","start_date":"2025-06-12","primary_completion_date":"2028-04","completion_date":"2028-04","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":80,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"DOUBLE"},"conditions":["Alcohol Use Disorder","Alcohol Dependence","Alcohol Abuse"],"interventions":[{"name":"Psilocybin","type":"DRUG"},{"name":"Ketamine","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"96f2bd88eed1d3818ed1f1051b3996f8f528fdb49be756ea1e8244ba9e93f7ba","facility":"University of Iowa Health Care","city":"Iowa City","region":"Iowa","country":"United States","lat":41.66113,"lon":-91.530169999999998}],"countries":["United States"]},{"id":3698,"nct_id":"NCT06815653","title":"Digital Intervention for Psychedelic Preparation (DIPP): A Randomised Controlled Feasibility Trial Comparing Meditation and Music-Based Programs in Healthy Volunteers.","sponsor":"University College, London","registry_url":"https://clinicaltrials.gov/study/NCT06815653","tracker_url":"publication.php?id=3698","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2025-02","last_update_date":"2025-11-26","start_date":"2025-03-01","primary_completion_date":"2026-03","completion_date":"2026-12","study_type":"INTERVENTIONAL","phases":["PHASE1"],"enrollment":{"count":40,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"OTHER","masking":"SINGLE"},"conditions":["Healthy"],"interventions":[{"name":"Psilocybin 25mg","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"6ca657d87e4528cc481a8c1baf8515a664bf591f795d28d79266623762f21568","facility":"University College London","city":"London","region":"","country":"United Kingdom","lat":51.50853,"lon":-0.12573999999999999}],"countries":["United Kingdom"]},{"id":3681,"nct_id":"NCT06132178","title":"Assessing the Safety, Tolerability, and Efficacy of Psilocybin Therapy Followed by Accelerated Intermittent Theta Burst (aiTBS) Repetitive Transcranial Magnetic Stimulation (rTMS) for Treatment-Resistant Major Depressive Disorder","sponsor":"University of Texas at Austin","registry_url":"https://clinicaltrials.gov/study/NCT06132178","tracker_url":"publication.php?id=3681","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2025-11","last_update_date":"2025-11-26","start_date":"2025-01-10","primary_completion_date":"2029-12-31","completion_date":"2030-12-31","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":100,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"FACTORIAL","primary_purpose":"TREATMENT","masking":"TRIPLE"},"conditions":["Treatment Resistant Depression","MDD","Major Depressive Disorder","Recurrent Depression","Depression"],"interventions":[{"name":"Psilocybin","type":"DRUG"},{"name":"Accelerated intermittent theta burst (aiTBS) rTMS treatment","type":"DEVICE"},{"name":"Low-dose psilocybin","type":"DRUG"},{"name":"Sham Accelerated intermittent theta burst (aiTBS) rTMS treatment","type":"DEVICE"}],"substances":["psilocybin"],"sites":[{"key":"15784c018ae70fcfb16f6b7f984cc9132fb865e356d99c82ce788fa1bede4b39","facility":"Health Discovery Building (HDB), 1601 Trinity St., Bldg B., Z0600","city":"Austin","region":"Texas","country":"United States","lat":30.267150000000001,"lon":-97.74306}],"countries":["United States"]},{"id":3700,"nct_id":"NCT05403086","title":"Pragmatic Trial of Psilocybin Therapy in Palliative Care (PT2PC): A Multicenter Triple-blind Phase 2 Randomized Controlled Trial of Psilocybin Therapy for Demoralized Adults Near the End of Life","sponsor":"Charles S. Grob, M.D.","registry_url":"https://clinicaltrials.gov/study/NCT05403086","tracker_url":"publication.php?id=3700","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2025-11","last_update_date":"2025-11-25","start_date":"2025-01-19","primary_completion_date":"2026-12-31","completion_date":"2027-12-31","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":100,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"QUADRUPLE"},"conditions":["Demoralization"],"interventions":[{"name":"Psilocybin","type":"DRUG"},{"name":"Ketamine","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"0ad263eeae1a75dac732ec21553e04d77ca0a990e5577d37801aa0cdfc72ee7c","facility":"Marin Cancer Care","city":"Greenbrae","region":"California","country":"United States","lat":37.948540000000001,"lon":-122.5247},{"key":"721cc70d44836b7fa9283632bc238d3076c232982cd2852343243f358edfbe43","facility":"University of California, Los Angeles","city":"Los Angeles","region":"California","country":"United States","lat":34.052230000000002,"lon":-118.24368},{"key":"332dc40567d170a508105ad5d90cc0c3fa47296c7aa99226e6588e8748f592ae","facility":"University of San Francisco","city":"San Francisco","region":"California","country":"United States","lat":37.774929999999998,"lon":-122.41942},{"key":"38d8694ffd1fa8f9e8c095acaf21b7bd718da3dd6a2d2a4642a6dce4e7784baa","facility":"Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center","city":"Torrance","region":"California","country":"United States","lat":33.835850000000001,"lon":-118.34063},{"key":"52db1aeead88bb42011a4764f5c07cbf6c76496768465bd5c4fcd8e25775a003","facility":"Sunstone Therapies","city":"Rockville","region":"Maryland","country":"United States","lat":39.084000000000003,"lon":-77.152760000000001}],"countries":["United States"]},{"id":3665,"nct_id":"NCT06081179","title":"Does Serotonin System Stimulation Increase Pro-social Behavior? - A Comparative Pharmacological Neuroscientific Study in Healthy Humans","sponsor":"University of Zurich","registry_url":"https://clinicaltrials.gov/study/NCT06081179","tracker_url":"publication.php?id=3665","status":"COMPLETED","status_label":"Completed","status_verified_date":"2025-11","last_update_date":"2025-11-19","start_date":"2023-10-24","primary_completion_date":"2025-09-22","completion_date":"2025-09-22","study_type":"INTERVENTIONAL","phases":["PHASE1"],"enrollment":{"count":122,"type":"ACTUAL"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"BASIC_SCIENCE","masking":"DOUBLE"},"conditions":["Healthy"],"interventions":[{"name":"Psilocybin","type":"DRUG"},{"name":"3,4 Methylenedioxymethamphetamine","type":"DRUG"},{"name":"Methylphenidate","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"963ff36be3d4be959779a50db385d5b17dd29d729076a98c276ec54e5bf5cfdd","facility":"Psychiatrische Universitätsklinik Zürich","city":"Zurich","region":"Canton of Zurich","country":"Switzerland","lat":47.366669999999999,"lon":8.5500000000000007}],"countries":["Switzerland"]},{"id":3548,"nct_id":"NCT07183748","title":"A Double-blind, Phase II Feasibility Study to Assess the Safety and Efficacy of Psilocybin Microdosing Combined With Psychotherapy in Treatment-resistant Depression","sponsor":"Beersheva Mental Health Center","registry_url":"https://clinicaltrials.gov/study/NCT07183748","tracker_url":"publication.php?id=3548","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2025-08","last_update_date":"2025-11-19","start_date":"2025-12-01","primary_completion_date":"2027-06-01","completion_date":"2028-06-01","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":20,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"CROSSOVER","primary_purpose":"TREATMENT","masking":"TRIPLE"},"conditions":["Treatment Resistant Depression"],"interventions":[{"name":"Psilocybin (drug)","type":"DRUG"},{"name":"Placebo","type":"OTHER"}],"substances":["psilocybin"],"sites":[{"key":"f6e857b260b7429beba395444fac2f816d9d86eb9ae717988e7a361b734fead7","facility":"Mental Health Center Beer Sheva","city":"Beersheba","region":"","country":"Israel","lat":31.251809999999999,"lon":34.7913}],"countries":["Israel"]},{"id":3454,"nct_id":"NCT04882839","title":"Open Label, Phase 2 Study for Evaluating the Feasibility, Safety and Efficacy of Psychotherapy Assisted Psilocybin for Treatment of Severe Obsessive Compulsive Disorder (OCD) in Drug and/or Psychotherapy Resistant Patients.","sponsor":"Beersheva Mental Health Center","registry_url":"https://clinicaltrials.gov/study/NCT04882839","tracker_url":"publication.php?id=3454","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2025-02","last_update_date":"2025-11-19","start_date":"2024-11-25","primary_completion_date":"2026-06-01","completion_date":"2027-06-01","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":15,"type":"ESTIMATED"},"design":{"allocation":"NA","intervention_model":"SINGLE_GROUP","primary_purpose":"TREATMENT","masking":"NONE"},"conditions":["Obsessive-compulsive Disorder"],"interventions":[{"name":"psychotherapy assisted psilocybin","type":"COMBINATION_PRODUCT"}],"substances":["psilocybin","psilocin"],"sites":[{"key":"5b227dd2e6263d32525d87b3fb390db797275e595c1806af406b57648ac86736","facility":"Beer Sheva Mental Health Center","city":"Beersheba","region":"","country":"Israel","lat":31.251809999999999,"lon":34.7913}],"countries":["Israel"]},{"id":3443,"nct_id":"NCT05421065","title":"Psilocybin-Assisted vs Ketamine-Assisted Psychotherapy for Alcohol Use Disorder","sponsor":"Peggy C Nopoulos","registry_url":"https://clinicaltrials.gov/study/NCT05421065","tracker_url":"publication.php?id=3443","status":"ACTIVE_NOT_RECRUITING","status_label":"Active, not recruiting","status_verified_date":"2025-11","last_update_date":"2025-11-17","start_date":"2024-02-02","primary_completion_date":"2025-08-30","completion_date":"2026-09","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":20,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"BASIC_SCIENCE","masking":"NONE"},"conditions":["Alcohol Use Disorder"],"interventions":[{"name":"Psilocybin","type":"DRUG"},{"name":"Ketamine","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"097d4730cb01f99d9d2fa793ee390c7860c40b2cbc6537289fd39fa1de4c2ebc","facility":"University of Iowa","city":"Iowa City","region":"Iowa","country":"United States","lat":41.66113,"lon":-91.530169999999998}],"countries":["United States"]},{"id":3510,"nct_id":"NCT03554174","title":"Psilocybin - Induced Neuroplasticity in the Treatment of Major Depressive Disorder","sponsor":"Yale University","registry_url":"https://clinicaltrials.gov/study/NCT03554174","tracker_url":"publication.php?id=3510","status":"ACTIVE_NOT_RECRUITING","status_label":"Active, not recruiting","status_verified_date":"2025-11","last_update_date":"2025-11-05","start_date":"2018-02-27","primary_completion_date":"2021-07-08","completion_date":"2026-09","study_type":"INTERVENTIONAL","phases":["PHASE1"],"enrollment":{"count":18,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"CROSSOVER","primary_purpose":"TREATMENT","masking":"DOUBLE"},"conditions":["Major Depressive Disorder"],"interventions":[{"name":"Low Dose Psilocybin","type":"DRUG"},{"name":"Placebo","type":"DRUG"},{"name":"Medium Dose Psilocybin","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"97fa1d69e8603abe5a3ef3a9d6071788707797dc09d271650fc5589a2d7cd901","facility":"VA Connecticut Healthcare System, West Haven Campus","city":"West Haven","region":"Connecticut","country":"United States","lat":41.270650000000003,"lon":-72.947050000000004}],"countries":["United States"]},{"id":3489,"nct_id":"NCT05847686","title":"A Phase 1/2 Study of a Group Model of Psilocybin-Assisted Therapy for Cancer-Related Anxiety in Patients With Metastatic Cancer","sponsor":"University of Washington","registry_url":"https://clinicaltrials.gov/study/NCT05847686","tracker_url":"publication.php?id=3489","status":"COMPLETED","status_label":"Completed","status_verified_date":"2025-10","last_update_date":"2025-11-05","start_date":"2023-06-27","primary_completion_date":"2024-04-08","completion_date":"2024-10-17","study_type":"INTERVENTIONAL","phases":["PHASE1","PHASE2"],"enrollment":{"count":55,"type":"ACTUAL"},"design":{"allocation":"NA","intervention_model":"SINGLE_GROUP","primary_purpose":"TREATMENT","masking":"NONE"},"conditions":["Hematopoietic and Lymphatic System Neoplasm","Metastatic Malignant Solid Neoplasm"],"interventions":[{"name":"Counseling","type":"OTHER"},{"name":"Psilocybin","type":"DRUG"},{"name":"Questionnaire Administration","type":"OTHER"}],"substances":["psilocybin"],"sites":[{"key":"27055592446b9d587e53a6321150bf4888fc2ba23be8770451328b59a69e7dd8","facility":"Fred Hutch/University of Washington Cancer Consortium","city":"Seattle","region":"Washington","country":"United States","lat":47.606209999999997,"lon":-122.33207}],"countries":["United States"]},{"id":3503,"nct_id":"NCT04501653","title":"Precision Functional Brain Mapping to Understand the Mechanisms of Psilocybin","sponsor":"Washington University School of Medicine","registry_url":"https://clinicaltrials.gov/study/NCT04501653","tracker_url":"publication.php?id=3503","status":"COMPLETED","status_label":"Completed","status_verified_date":"2024-10","last_update_date":"2025-10-31","start_date":"2021-06-01","primary_completion_date":"2023-03-19","completion_date":"2023-03-19","study_type":"INTERVENTIONAL","phases":["EARLY_PHASE1"],"enrollment":{"count":11,"type":"ACTUAL"},"design":{"allocation":"RANDOMIZED","intervention_model":"CROSSOVER","primary_purpose":"BASIC_SCIENCE","masking":"SINGLE"},"conditions":["Psilocybin"],"interventions":[{"name":"Psilocybin","type":"DRUG"},{"name":"Methylphenidate","type":"DRUG"}],"substances":["psilocybin","psilocin"],"sites":[{"key":"02631a4a6a3dbc51fd551af9bdf1e4a90d67561f5bc211248aa42c89119b55bc","facility":"Washington University","city":"St Louis","region":"Missouri","country":"United States","lat":38.627270000000003,"lon":-90.197890000000001}],"countries":["United States"]},{"id":3597,"nct_id":"NCT06786325","title":"A Wellcome Leap for the Opioid Crisis: Can the 5HT2A Agonist Psilocybin Improve Brain, Behavioral, and Clinical Outcomes in Opioid Use Disorder (OUD)?","sponsor":"Anna Rose Childress, Ph.D.","registry_url":"https://clinicaltrials.gov/study/NCT06786325","tracker_url":"publication.php?id=3597","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2025-10","last_update_date":"2025-10-29","start_date":"2025-10-07","primary_completion_date":"2027-06","completion_date":"2027-10","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":36,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"TRIPLE"},"conditions":["Opioid Use Disorder"],"interventions":[{"name":"Psilocybin","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"6432b7631d0ccc20e148c4eddca2643abaa034857cab41344671f3fb747879b1","facility":"University of Pennsylvania","city":"Philadelphia","region":"Pennsylvania","country":"United States","lat":39.952379999999998,"lon":-75.163619999999995}],"countries":["United States"]},{"id":3688,"nct_id":"NCT06367738","title":"Investigating the Persisting Effects of a Single Dose of Psilocybin on Structural Plasticity in Healthy Older Adults","sponsor":"University of California, Berkeley","registry_url":"https://clinicaltrials.gov/study/NCT06367738","tracker_url":"publication.php?id=3688","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2025-10","last_update_date":"2025-10-21","start_date":"2025-11","primary_completion_date":"2026-12-30","completion_date":"2027-12-30","study_type":"INTERVENTIONAL","phases":["PHASE1"],"enrollment":{"count":40,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"SINGLE_GROUP","primary_purpose":"BASIC_SCIENCE","masking":"TRIPLE"},"conditions":["Aging"],"interventions":[{"name":"Psilocybin","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"f03299e8c6bc2c4a865cc090ea047d3a962eb50dc47bdd65bf9ed339007f853b","facility":"University of California, Berkeley","city":"Berkeley","region":"California","country":"United States","lat":37.871589999999998,"lon":-122.27275}],"countries":["United States"]},{"id":3640,"nct_id":"NCT06644170","title":"A Phase 1 Study of a Second Psilocybin Group Retreat for Partial Responders With Anxiety Associated With Metastatic Cancer","sponsor":"University of Washington","registry_url":"https://clinicaltrials.gov/study/NCT06644170","tracker_url":"publication.php?id=3640","status":"COMPLETED","status_label":"Completed","status_verified_date":"2025-10","last_update_date":"2025-10-14","start_date":"2024-11-19","primary_completion_date":"2025-09-30","completion_date":"2025-09-30","study_type":"INTERVENTIONAL","phases":["PHASE1"],"enrollment":{"count":15,"type":"ACTUAL"},"design":{"allocation":"NA","intervention_model":"SINGLE_GROUP","primary_purpose":"TREATMENT","masking":"NONE"},"conditions":["Hematopoietic and Lymphatic System Neoplasm","Metastatic Malignant Solid Neoplasm"],"interventions":[{"name":"Behavioral Intervention","type":"BEHAVIORAL"},{"name":"Group Therapy","type":"BEHAVIORAL"},{"name":"Psilocybin","type":"DRUG"},{"name":"Questionnaire Administration","type":"OTHER"}],"substances":["psilocybin"],"sites":[{"key":"27055592446b9d587e53a6321150bf4888fc2ba23be8770451328b59a69e7dd8","facility":"Fred Hutch/University of Washington Cancer Consortium","city":"Seattle","region":"Washington","country":"United States","lat":47.606209999999997,"lon":-122.33207}],"countries":["United States"]},{"id":3668,"nct_id":"NCT06899594","title":"A Pilot Study in North Louisiana to Assess the Tolerability of Psilocybin as Well as Its Capacity to Promote Abstinence From Methamphetamine","sponsor":"Kevin Murnane","registry_url":"https://clinicaltrials.gov/study/NCT06899594","tracker_url":"publication.php?id=3668","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2025-03","last_update_date":"2025-10-07","start_date":"2025-04-04","primary_completion_date":"2027-03","completion_date":"2027-03","study_type":"INTERVENTIONAL","phases":["EARLY_PHASE1"],"enrollment":{"count":20,"type":"ESTIMATED"},"design":{"allocation":"NA","intervention_model":"SINGLE_GROUP","primary_purpose":"TREATMENT","masking":"NONE"},"conditions":["Methamphetamine Use Disorder"],"interventions":[{"name":"Psilocybin 25 mg","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"80808de48757f3ab86bdc23356fb96e401f106b134925f19370a66e24bdd35b1","facility":"LSU Health Shreveport","city":"Shreveport","region":"Louisiana","country":"United States","lat":32.525149999999996,"lon":-93.75018}],"countries":["United States"]},{"id":3677,"nct_id":"NCT07164287","title":"Retrospective Observational Study of Intensity Effects in Psychedelic-assisted Treatment","sponsor":"University Hospital, Geneva","registry_url":"https://clinicaltrials.gov/study/NCT07164287","tracker_url":"publication.php?id=3677","status":"ACTIVE_NOT_RECRUITING","status_label":"Active, not recruiting","status_verified_date":"2025-09","last_update_date":"2025-10-02","start_date":"2020-06-01","primary_completion_date":"2025-04-30","completion_date":"2025-09-30","study_type":"OBSERVATIONAL","phases":[],"enrollment":{"count":376,"type":"ESTIMATED"},"design":{"allocation":"","intervention_model":"","primary_purpose":"","masking":""},"conditions":["Major Depressive Disorder (MDD)","Anxiety Disorders","Substance Use Disorder (SUD)","PTSD - Post Traumatic Stress Disorder"],"interventions":[{"name":"Lysergic Acid Diethylamide (LSD) or psilocybin","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"17373296f16c3a4efdaa8068b534d498ee273ea3e341911c48b8927bb2cf1330","facility":"Geneva University Hospital","city":"Geneva","region":"","country":"Switzerland","lat":46.202219999999997,"lon":6.1456900000000001}],"countries":["Switzerland"]},{"id":3588,"nct_id":"NCT07189988","title":"Observational Pilot Study to Explore the Social and Health Impacts of a New Model of Care in Oregon: Psilocybin Services on Alcoholism","sponsor":"Healing Advocacy Fund","registry_url":"https://clinicaltrials.gov/study/NCT07189988","tracker_url":"publication.php?id=3588","status":"ACTIVE_NOT_RECRUITING","status_label":"Active, not recruiting","status_verified_date":"2025-09","last_update_date":"2025-09-24","start_date":"2025-03-05","primary_completion_date":"2026-06-10","completion_date":"2026-08-05","study_type":"OBSERVATIONAL","phases":[],"enrollment":{"count":20,"type":"ACTUAL"},"design":{"allocation":"","intervention_model":"","primary_purpose":"","masking":""},"conditions":["Alcohol Use Disorder"],"interventions":[{"name":"psilocybin","type":"OTHER"}],"substances":["psilocybin"],"sites":[{"key":"2e5a211e4aae826703cd0d478a5304735037ed9f6e5d1fffb9064c5fa43504bb","facility":"Innertrek Patient Service Center","city":"Portland","region":"Oregon","country":"United States","lat":45.523449999999997,"lon":-122.67621}],"countries":["United States"]},{"id":3435,"nct_id":"NCT06368492","title":"The Impact of Psilocybin on Pain in Fibromyalgia Patients: a Multicentre Trial.","sponsor":"Maastricht University","registry_url":"https://clinicaltrials.gov/study/NCT06368492","tracker_url":"publication.php?id=3435","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2025-09","last_update_date":"2025-09-15","start_date":"2024-05-03","primary_completion_date":"2025-12","completion_date":"2025-12","study_type":"INTERVENTIONAL","phases":["NA"],"enrollment":{"count":35,"type":"ESTIMATED"},"design":{"allocation":"NA","intervention_model":"SINGLE_GROUP","primary_purpose":"TREATMENT","masking":"NONE"},"conditions":["Fibromyalgia"],"interventions":[{"name":"Psilocybin","type":"DRUG"},{"name":"Hypnosis script","type":"BEHAVIORAL"}],"substances":["psilocybin"],"sites":[{"key":"f26bee6a0a45781053d5dfa012f97c3db3997369bce9de3db4cd4cc54b57daa6","facility":"Maastricht University","city":"Maastricht","region":"Limburg","country":"Netherlands","lat":50.848329999999997,"lon":5.6888899999999998},{"key":"53531a82330e40fa414108ebaefe85390bc30ce9a2da6c9a7d1d8128d9c6c3a2","facility":"Leiden University Medical Center","city":"Leiden","region":"South Holland","country":"Netherlands","lat":52.158329999999999,"lon":4.4930599999999998}],"countries":["Netherlands"]},{"id":3699,"nct_id":"NCT07164755","title":"Measurement of Serum Cytokine Levels in Samples Collected as Part of a Clinical Trial of Psilocybin for Treatment-resistant Depression.","sponsor":"King's College London","registry_url":"https://clinicaltrials.gov/study/NCT07164755","tracker_url":"publication.php?id=3699","status":"ACTIVE_NOT_RECRUITING","status_label":"Active, not recruiting","status_verified_date":"2025-09","last_update_date":"2025-09-10","start_date":"2021-06-21","primary_completion_date":"2026-09","completion_date":"2026-09","study_type":"OBSERVATIONAL","phases":[],"enrollment":{"count":46,"type":"ACTUAL"},"design":{"allocation":"","intervention_model":"","primary_purpose":"","masking":""},"conditions":["Depression - Major Depressive Disorder"],"interventions":[],"substances":["psilocybin"],"sites":[{"key":"84d3b2e5a3a8521c2be63f3b94f0d00d44e1ecaff45bb8e80b74fbc4dd66bb3c","facility":"King's College London Institute of Psychiatry, Psychology and Neuroscience","city":"London","region":"","country":"United Kingdom","lat":51.50853,"lon":-0.12573999999999999}],"countries":["United Kingdom"]},{"id":3571,"nct_id":"NCT06746441","title":"Effect of Psilocybin Only and Psilocybin Assisted Cognitive Behavioral Therapy in the Management of Major Depressive Disorder and Associated Metabolic, Immune, Inflammatory, Neuroplasticity and Electrical Activity Markers: a Randomized Controlled Trial","sponsor":"Khyber Medical University Peshawar","registry_url":"https://clinicaltrials.gov/study/NCT06746441","tracker_url":"publication.php?id=3571","status":"COMPLETED","status_label":"Completed","status_verified_date":"2025-08","last_update_date":"2025-09-02","start_date":"2024-12-01","primary_completion_date":"2025-06-01","completion_date":"2025-07-30","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":60,"type":"ACTUAL"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"SINGLE"},"conditions":["Major Depressive Disorder"],"interventions":[{"name":"Psilocybin","type":"DRUG"},{"name":"Cognitive Behavioral Therapy (CBT)","type":"BEHAVIORAL"}],"substances":["psilocybin","psilocin"],"sites":[{"key":"c7d0f9ad38775ee389ffdd32d7a11b15a481184b7eb272189d6f8312f3074323","facility":"Lady Reading Hospital, Pakistan","city":"Peshawar","region":"Khyber Pakhtunkhwa","country":"Pakistan","lat":34.008000000000003,"lon":71.578490000000002}],"countries":["Pakistan"]},{"id":3622,"nct_id":"NCT06647056","title":"Evaluation of the Effect of a Single Dose of Psilocybin on Neural Correlates of Cognitive Control in Patients With Psychogenic Nonepileptic Seizures","sponsor":"Centre Hospitalier Universitaire de Nīmes","registry_url":"https://clinicaltrials.gov/study/NCT06647056","tracker_url":"publication.php?id=3622","status":"COMPLETED","status_label":"Completed","status_verified_date":"2025-08","last_update_date":"2025-08-21","start_date":"2024-12-19","primary_completion_date":"2025-01-03","completion_date":"2025-05-22","study_type":"INTERVENTIONAL","phases":["NA"],"enrollment":{"count":4,"type":"ACTUAL"},"design":{"allocation":"NA","intervention_model":"SINGLE_GROUP","primary_purpose":"TREATMENT","masking":"NONE"},"conditions":["Psychogenic Nonepileptic Seizures","Psilocybin"],"interventions":[{"name":"Psilocybin","type":"DRUG"},{"name":"MRI","type":"OTHER"}],"substances":["psilocybin"],"sites":[{"key":"6c7782ed88077aba01acca89cafaa29ef044132bd5e6ac7264c2f146705cf434","facility":"CHU de Nîmes, Hôpital Universitaire Carémeau","city":"Nîmes","region":"","country":"France","lat":43.836649999999999,"lon":4.3578799999999998}],"countries":["France"]},{"id":3557,"nct_id":"NCT06650800","title":"Effect of Psilocybin on the Positive Valence System in Treatment-resistant Depression: a Pilot Clinical Neuroimaging Study","sponsor":"Centre Hospitalier Universitaire de Nīmes","registry_url":"https://clinicaltrials.gov/study/NCT06650800","tracker_url":"publication.php?id=3557","status":"COMPLETED","status_label":"Completed","status_verified_date":"2025-08","last_update_date":"2025-08-20","start_date":"2024-11-19","primary_completion_date":"2025-03-26","completion_date":"2025-06-26","study_type":"INTERVENTIONAL","phases":["NA"],"enrollment":{"count":10,"type":"ACTUAL"},"design":{"allocation":"NA","intervention_model":"SINGLE_GROUP","primary_purpose":"OTHER","masking":"NONE"},"conditions":["Depressive Disorder","Depressive Disorder, Treatment-Resistant","Hallucinogens","Reinforcement, Psychology"],"interventions":[{"name":"Psilocybin","type":"DRUG"},{"name":"MRI","type":"OTHER"}],"substances":["psilocybin","psilocin"],"sites":[{"key":"6c7782ed88077aba01acca89cafaa29ef044132bd5e6ac7264c2f146705cf434","facility":"CHU de Nîmes, Hôpital Universitaire Carémeau","city":"Nîmes","region":"","country":"France","lat":43.836649999999999,"lon":4.3578799999999998}],"countries":["France"]},{"id":3505,"nct_id":"NCT05305105","title":"Effects of Psilocybin in Post-Treatment Lyme Disease","sponsor":"Johns Hopkins University","registry_url":"https://clinicaltrials.gov/study/NCT05305105","tracker_url":"publication.php?id=3505","status":"COMPLETED","status_label":"Completed","status_verified_date":"2025-08","last_update_date":"2025-08-20","start_date":"2022-07-01","primary_completion_date":"2024-10-26","completion_date":"2025-04-07","study_type":"INTERVENTIONAL","phases":["PHASE1"],"enrollment":{"count":20,"type":"ACTUAL"},"design":{"allocation":"NA","intervention_model":"SINGLE_GROUP","primary_purpose":"TREATMENT","masking":"NONE"},"conditions":["Post-Treatment Lyme Disease","Chronic Lyme Disease","Lyme Disease, Chronic"],"interventions":[{"name":"Psilocybin","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"c99816974f0fb391132ed7769c5eb4ada168032749e3008faafa7d34aaedf88d","facility":"Behavioral Pharmacology Research Unit","city":"Baltimore","region":"Maryland","country":"United States","lat":39.290379999999999,"lon":-76.612189999999998}],"countries":["United States"]},{"id":3466,"nct_id":"NCT05733546","title":"A Phase II, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of COMP360 in Participants With Recurrent Major Depressive Disorder","sponsor":"COMPASS Pathways","registry_url":"https://clinicaltrials.gov/study/NCT05733546","tracker_url":"publication.php?id=3466","status":"ACTIVE_NOT_RECRUITING","status_label":"Active, not recruiting","status_verified_date":"2025-08","last_update_date":"2025-08-19","start_date":"2023-01-30","primary_completion_date":"2025-09","completion_date":"2025-09","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":102,"type":"ACTUAL"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"QUADRUPLE"},"conditions":["Major Depressive Disorder"],"interventions":[{"name":"Psilocybin","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"b1132fa91c6c49bf3a7b5fc89a57fb89b94ff271a2081e8352dd7bd5a7ea4f1c","facility":"Kadima Neuropsychiatry Institute","city":"La Jolla","region":"California","country":"United States","lat":32.847270000000002,"lon":-117.27419999999999},{"key":"8c60b612e34dd2ffc6608ca0a06d7e3d5b026f9298fdb849106297822e4ca75d","facility":"Clinical Neuroscience Solutions Inc","city":"Jacksonville","region":"Florida","country":"United States","lat":30.332180000000001,"lon":-81.655649999999994},{"key":"52db1aeead88bb42011a4764f5c07cbf6c76496768465bd5c4fcd8e25775a003","facility":"Sunstone Therapies","city":"Rockville","region":"Maryland","country":"United States","lat":39.084000000000003,"lon":-77.152760000000001},{"key":"5094cd778f2393158194a4acd2f61f98cd406b23d443dab41e2f4a1fa2124035","facility":"Elixia MA, LLC","city":"Springfield","region":"Massachusetts","country":"United States","lat":42.101480000000002,"lon":-72.58981},{"key":"1245c616ad9a5aafc72a46e45a4f8a7944fc567e32ee983414fa2a90dff5b99f","facility":"Aims Trial","city":"Plano","region":"Texas","country":"United States","lat":33.019840000000002,"lon":-96.698890000000006}],"countries":["United States"]},{"id":3424,"nct_id":"NCT05651126","title":"Modulation of Serotonin Pathways Using Psilocybin in Adults With and Without Autism Spectrum Disorder (ASD)","sponsor":"King's College London","registry_url":"https://clinicaltrials.gov/study/NCT05651126","tracker_url":"publication.php?id=3424","status":"COMPLETED","status_label":"Completed","status_verified_date":"2024-03","last_update_date":"2025-07-28","start_date":"2022-12-12","primary_completion_date":"2024-08-23","completion_date":"2024-08-23","study_type":"INTERVENTIONAL","phases":["NA"],"enrollment":{"count":67,"type":"ACTUAL"},"design":{"allocation":"RANDOMIZED","intervention_model":"CROSSOVER","primary_purpose":"BASIC_SCIENCE","masking":"DOUBLE"},"conditions":["Autism Spectrum Disorder"],"interventions":[{"name":"Psilocybin 5 mg","type":"DRUG"},{"name":"Psilocybin 2 mg","type":"DRUG"},{"name":"Placebo","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"a2a4ed472d0c860a706d8a130661a9baa3742799c37bd96f2f64a1cdd0866b66","facility":"King's College London","city":"London","region":"","country":"United Kingdom","lat":51.50853,"lon":-0.12573999999999999}],"countries":["United Kingdom"]},{"id":3633,"nct_id":"NCT05506982","title":"The Safety, Feasibility, and Acceptability of Psilocybin Combined With Multidisciplinary Palliative Care in Demoralized Cancer Survivors With Chronic Pain (P-PC)","sponsor":"Emory University","registry_url":"https://clinicaltrials.gov/study/NCT05506982","tracker_url":"publication.php?id=3633","status":"COMPLETED","status_label":"Completed","status_verified_date":"2025-07","last_update_date":"2025-07-23","start_date":"2022-11-01","primary_completion_date":"2024-04-25","completion_date":"2025-01-24","study_type":"INTERVENTIONAL","phases":["PHASE1"],"enrollment":{"count":11,"type":"ACTUAL"},"design":{"allocation":"NA","intervention_model":"SINGLE_GROUP","primary_purpose":"SUPPORTIVE_CARE","masking":"NONE"},"conditions":["Hematopoietic and Lymphoid Cell Neoplasm","Malignant Solid Neoplasm"],"interventions":[{"name":"Psilocybin","type":"DRUG"},{"name":"Psychotherapy","type":"BEHAVIORAL"},{"name":"Quality-of-Life Assessment","type":"OTHER"},{"name":"Questionnaire Administration","type":"OTHER"}],"substances":["psilocybin"],"sites":[{"key":"18db5edcbdce2ce9d52632dc7fd86a8c0ad5c72075ddcbaef8ccbc091276d0ba","facility":"Emory University/Winship Cancer Institute","city":"Atlanta","region":"Georgia","country":"United States","lat":33.749000000000002,"lon":-84.387979999999999},{"key":"40311bdce25b868fa367c6b593e5197383e808ec7d37f412f45ff21e464e2ef8","facility":"Brain Health Center at Executive Park","city":"Atlanta","region":"Georgia","country":"United States","lat":33.749000000000002,"lon":-84.387979999999999}],"countries":["United States"]},{"id":3682,"nct_id":"NCT04424225","title":"Visual Surround Suppression and Perceptual Expectation Under Psilocybin","sponsor":"University of Minnesota","registry_url":"https://clinicaltrials.gov/study/NCT04424225","tracker_url":"publication.php?id=3682","status":"TERMINATED","status_label":"Terminated","status_verified_date":"2025-06","last_update_date":"2025-06-27","start_date":"2021-08-30","primary_completion_date":"2023-09-01","completion_date":"2023-09-01","study_type":"INTERVENTIONAL","phases":["PHASE1"],"enrollment":{"count":10,"type":"ACTUAL"},"design":{"allocation":"RANDOMIZED","intervention_model":"CROSSOVER","primary_purpose":"BASIC_SCIENCE","masking":"TRIPLE"},"conditions":["Perception Disturbance","Visual Suppression","Psychedelic Experiences"],"interventions":[{"name":"Psilocybin","type":"DRUG"},{"name":"Niacin","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"da66bed5e9f2c5007072da48565dcfb4c000c6aa0bc51cdf5c70ee46cf21fbda","facility":"University of Minnesota","city":"Minneapolis","region":"Minnesota","country":"United States","lat":44.979970000000002,"lon":-93.263840000000002}],"countries":["United States"]},{"id":3482,"nct_id":"NCT05312151","title":"The Safety and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder","sponsor":"COMPASS Pathways","registry_url":"https://clinicaltrials.gov/study/NCT05312151","tracker_url":"publication.php?id=3482","status":"COMPLETED","status_label":"Completed","status_verified_date":"2025-05","last_update_date":"2025-06-13","start_date":"2022-06-10","primary_completion_date":"2024-02-12","completion_date":"2024-02-12","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":22,"type":"ACTUAL"},"design":{"allocation":"NA","intervention_model":"SINGLE_GROUP","primary_purpose":"TREATMENT","masking":"NONE"},"conditions":["Post Traumatic Stress Disorder"],"interventions":[{"name":"Psilocybin","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"52db1aeead88bb42011a4764f5c07cbf6c76496768465bd5c4fcd8e25775a003","facility":"Sunstone Therapies","city":"Rockville","region":"Maryland","country":"United States","lat":39.084000000000003,"lon":-77.152760000000001},{"key":"6332cc00e1ef6b028ce5b2931bc428fb44a6e2eca82b5135ec346b7ceedf62ae","facility":"Icahn School of Medicine at Mount Sinai","city":"New York","region":"New York","country":"United States","lat":40.714269999999999,"lon":-74.005970000000005},{"key":"190dd76ab65ad7b28570cf2992585e62e7281887f8f4acc4cc7ee1b0ebcb7c7e","facility":"Kings College London, Institute of Psychiatry, Psychology and Neurology","city":"London","region":"","country":"United Kingdom","lat":51.50853,"lon":-0.12573999999999999}],"countries":["United States","United Kingdom"]},{"id":3611,"nct_id":"NCT06643637","title":"A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Doses of MLS101 (Psilocybin) in Healthy Participants","sponsor":"MycoMedica Life Sciences PBC","registry_url":"https://clinicaltrials.gov/study/NCT06643637","tracker_url":"publication.php?id=3611","status":"COMPLETED","status_label":"Completed","status_verified_date":"2025-06","last_update_date":"2025-06-12","start_date":"2024-11-08","primary_completion_date":"2025-03-12","completion_date":"2025-03-12","study_type":"INTERVENTIONAL","phases":["PHASE1"],"enrollment":{"count":16,"type":"ACTUAL"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"QUADRUPLE"},"conditions":["Healthy Volunteers"],"interventions":[{"name":"Psilocybin","type":"DRUG"},{"name":"Placebo","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"a09e8186ba91aa1702e842c7ad40903a2cbce5c4b72a9493394ca5b209d4e052","facility":"CMAX Clinical Research","city":"Adelaide","region":"South Australia","country":"Australia","lat":-34.928660000000001,"lon":138.59863000000001}],"countries":["Australia"]},{"id":3617,"nct_id":"NCT05317689","title":"Comparison of the Effects of PEX20 (Oral Psilocin), PEX30 (Sublingual Psilocin), and PEX10 (Oral Psilocybin) in Healthy Adults","sponsor":"University of California, San Francisco","registry_url":"https://clinicaltrials.gov/study/NCT05317689","tracker_url":"publication.php?id=3617","status":"ACTIVE_NOT_RECRUITING","status_label":"Active, not recruiting","status_verified_date":"2024-09","last_update_date":"2025-06-10","start_date":"2022-05-26","primary_completion_date":"2025-01-16","completion_date":"2025-07","study_type":"INTERVENTIONAL","phases":["PHASE1"],"enrollment":{"count":20,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"CROSSOVER","primary_purpose":"OTHER","masking":"TRIPLE"},"conditions":["Healthy"],"interventions":[{"name":"Psilocin","type":"DRUG"},{"name":"Psilocybin","type":"DRUG"},{"name":"Sublingual Psilocin","type":"DRUG"}],"substances":["psilocybin","psilocin"],"sites":[{"key":"7f09a842484186a75c6232177464293472d56c43d4d49f24f37efcb6c9cbbbb8","facility":"University of California, San Francisco","city":"San Francisco","region":"California","country":"United States","lat":37.774929999999998,"lon":-122.41942}],"countries":["United States"]},{"id":3601,"nct_id":"NCT06919640","title":"Psilocybin With Intracranial Neural Sensing","sponsor":"Joshua Woolley, MD, PhD","registry_url":"https://clinicaltrials.gov/study/NCT06919640","tracker_url":"publication.php?id=3601","status":"ENROLLING_BY_INVITATION","status_label":"Enrolling by invitation","status_verified_date":"2025-04","last_update_date":"2025-06-06","start_date":"2025-06-01","primary_completion_date":"2028-04-30","completion_date":"2028-04-30","study_type":"INTERVENTIONAL","phases":["PHASE1"],"enrollment":{"count":20,"type":"ESTIMATED"},"design":{"allocation":"NA","intervention_model":"SINGLE_GROUP","primary_purpose":"OTHER","masking":"NONE"},"conditions":["Chronic Pain"],"interventions":[{"name":"Psilocybin","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"7f09a842484186a75c6232177464293472d56c43d4d49f24f37efcb6c9cbbbb8","facility":"University of California, San Francisco","city":"San Francisco","region":"California","country":"United States","lat":37.774929999999998,"lon":-122.41942}],"countries":["United States"]},{"id":3672,"nct_id":"NCT06372197","title":"Low-Income Group Psilocybin Assisted Therapy for Depression: A Feasibility Study","sponsor":"Matthew Hicks","registry_url":"https://clinicaltrials.gov/study/NCT06372197","tracker_url":"publication.php?id=3672","status":"COMPLETED","status_label":"Completed","status_verified_date":"2025-06","last_update_date":"2025-06-05","start_date":"2024-08-01","primary_completion_date":"2025-05-14","completion_date":"2025-05-14","study_type":"INTERVENTIONAL","phases":["NA"],"enrollment":{"count":20,"type":"ACTUAL"},"design":{"allocation":"NON_RANDOMIZED","intervention_model":"SINGLE_GROUP","primary_purpose":"TREATMENT","masking":"NONE"},"conditions":["Depression"],"interventions":[{"name":"Psilocybin","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"3f8d5218d2ffc6ea8473ce2d358bca1e459782dafccddcfd64ae7296c5336987","facility":"National University of Natural Medicine","city":"Portland","region":"Oregon","country":"United States","lat":45.523449999999997,"lon":-122.67621}],"countries":["United States"]},{"id":3480,"nct_id":"NCT06560658","title":"Optimizing Microdosing and Meditation","sponsor":"National University of Natural Medicine","registry_url":"https://clinicaltrials.gov/study/NCT06560658","tracker_url":"publication.php?id=3480","status":"WITHDRAWN","status_label":"Withdrawn","status_verified_date":"2025-06","last_update_date":"2025-06-05","start_date":"2024-10-01","primary_completion_date":"2025-10-01","completion_date":"2025-11-01","study_type":"INTERVENTIONAL","phases":["NA"],"enrollment":{"count":0,"type":"ACTUAL"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"PREVENTION","masking":"NONE"},"conditions":["Meditation","Microdosing"],"interventions":[{"name":"Psilocybin","type":"DRUG"},{"name":"Meditation","type":"BEHAVIORAL"}],"substances":["psilocybin"],"sites":[{"key":"3f8d5218d2ffc6ea8473ce2d358bca1e459782dafccddcfd64ae7296c5336987","facility":"National University of Natural Medicine","city":"Portland","region":"Oregon","country":"United States","lat":45.523449999999997,"lon":-122.67621}],"countries":["United States"]},{"id":3708,"nct_id":"NCT06796361","title":"Role of the Serotonin 2A Receptor in Psilocybin-induced Altered States of Consciousness (PDR-Study)","sponsor":"University Hospital, Basel, Switzerland","registry_url":"https://clinicaltrials.gov/study/NCT06796361","tracker_url":"publication.php?id=3708","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2025-05","last_update_date":"2025-05-28","start_date":"2025-04-21","primary_completion_date":"2026-08","completion_date":"2026-08","study_type":"INTERVENTIONAL","phases":["PHASE1"],"enrollment":{"count":16,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"CROSSOVER","primary_purpose":"BASIC_SCIENCE","masking":"TRIPLE"},"conditions":["Healthy"],"interventions":[{"name":"Ketanserin 40mg plus Psilocybin 40mg","type":"DRUG"},{"name":"40mg Psilocybin","type":"DRUG"},{"name":"20mg Psilocybin","type":"DRUG"},{"name":"10mg Psilocybin","type":"DRUG"},{"name":"5mg Psilocybin","type":"DRUG"},{"name":"Placebo","type":"OTHER"}],"substances":["psilocybin","psilocin"],"sites":[{"key":"ebda5e93566d65c5a0d08874906c8e63c9d620a77b25a4867b0465a3d920d8ef","facility":"Clinical Trial Unit","city":"Basel","region":"Canton of Basel-City","country":"Switzerland","lat":47.558390000000003,"lon":7.5732699999999999}],"countries":["Switzerland"]},{"id":3655,"nct_id":"NCT01943994","title":"Psilocybin-facilitated Smoking Cessation Treatment: A Pilot Study","sponsor":"Johns Hopkins University","registry_url":"https://clinicaltrials.gov/study/NCT01943994","tracker_url":"publication.php?id=3655","status":"COMPLETED","status_label":"Completed","status_verified_date":"2025-05","last_update_date":"2025-05-25","start_date":"2008-09","primary_completion_date":"2023-05-01","completion_date":"2023-11-14","study_type":"INTERVENTIONAL","phases":["NA"],"enrollment":{"count":82,"type":"ACTUAL"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"NONE"},"conditions":["Nicotine Dependence"],"interventions":[{"name":"Psilocybin-assisted treatment","type":"DRUG"},{"name":"Nicotine Replacement Therapy (NRT)","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"c99816974f0fb391132ed7769c5eb4ada168032749e3008faafa7d34aaedf88d","facility":"Behavioral Pharmacology Research Unit","city":"Baltimore","region":"Maryland","country":"United States","lat":39.290379999999999,"lon":-76.612189999999998},{"key":"f728406bf268c1157eadcec1c17036ddef288c0c8a17b0883ee337abaeaac4bc","facility":"Neuroimaging Research Branch, NIDA-IRP","city":"Baltimore","region":"Maryland","country":"United States","lat":39.290379999999999,"lon":-76.612189999999998}],"countries":["United States"]},{"id":3427,"nct_id":"NCT05592379","title":"Consciousness and Psilocybin Effects on Well-Being (The CoPE Study): Pilot Phase","sponsor":"University of Wisconsin, Madison","registry_url":"https://clinicaltrials.gov/study/NCT05592379","tracker_url":"publication.php?id=3427","status":"COMPLETED","status_label":"Completed","status_verified_date":"2025-05","last_update_date":"2025-05-16","start_date":"2023-11-07","primary_completion_date":"2025-02-19","completion_date":"2025-02-19","study_type":"INTERVENTIONAL","phases":["PHASE1"],"enrollment":{"count":6,"type":"ACTUAL"},"design":{"allocation":"NON_RANDOMIZED","intervention_model":"SEQUENTIAL","primary_purpose":"BASIC_SCIENCE","masking":"SINGLE"},"conditions":["Healthy","Psychedelic Experiences","Sleep"],"interventions":[{"name":"Psilocybin","type":"DRUG"},{"name":"Clonidine","type":"DRUG"},{"name":"Saline","type":"OTHER"}],"substances":["psilocybin"],"sites":[{"key":"dfd44dbf58c7269a3dc9de0e69126ca81c5af72da9ff806f80dc2a90ae2be7f0","facility":"University of Wisconsin Hospital and Clinics","city":"Madison","region":"Wisconsin","country":"United States","lat":43.073050000000002,"lon":-89.401229999999998}],"countries":["United States"]},{"id":3694,"nct_id":"NCT06592833","title":"Investigating the Role of Serotonin in the Mechanism of Action of Psilocybin in Patients With Major Depressive Disorder","sponsor":"Icahn School of Medicine at Mount Sinai","registry_url":"https://clinicaltrials.gov/study/NCT06592833","tracker_url":"publication.php?id=3694","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2025-05","last_update_date":"2025-05-14","start_date":"2025-02-25","primary_completion_date":"2028-03-01","completion_date":"2028-03-01","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":60,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"QUADRUPLE"},"conditions":["Major Depressive Disorder"],"interventions":[{"name":"Psilocybin","type":"DRUG"},{"name":"Pimavanserin","type":"DRUG"},{"name":"Placebo","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"e61b82022d59d1b6f216840fa8e11fe15a6e63ddf70a4fefdcdd7e0f971a1974","facility":"Icahn School of Medicine at Mount Sinai, Center for Psychedelic Therapy Research","city":"New York","region":"New York","country":"United States","lat":40.714269999999999,"lon":-74.005970000000005}],"countries":["United States"]},{"id":3465,"nct_id":"NCT05128162","title":"A Phase 2a, Open-label, Pilot Study to Assess the Safety and Efficacy of Psilocybin Administration in Concert With Psychotherapy Among Adult Patients With Fibromyalgia","sponsor":"Kevin Boehnke","registry_url":"https://clinicaltrials.gov/study/NCT05128162","tracker_url":"publication.php?id=3465","status":"COMPLETED","status_label":"Completed","status_verified_date":"2025-03","last_update_date":"2025-04-16","start_date":"2023-09-27","primary_completion_date":"2024-06-12","completion_date":"2024-06-12","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":17,"type":"ACTUAL"},"design":{"allocation":"NA","intervention_model":"SINGLE_GROUP","primary_purpose":"TREATMENT","masking":"NONE"},"conditions":["Fibromyalgia"],"interventions":[{"name":"Psilocybin","type":"DRUG"},{"name":"Psychotherapy","type":"BEHAVIORAL"}],"substances":["psilocybin"],"sites":[{"key":"38277cc33e9b01c0912117b90ec217a624b83ded19092f8b50f1fc25417f8e3f","facility":"Chronic Pain and Fatigue Research Center","city":"Ann Arbor","region":"Michigan","country":"United States","lat":42.277560000000001,"lon":-83.740880000000004}],"countries":["United States"]},{"id":3612,"nct_id":"NCT05570708","title":"The Role of Personal Experience for the Therapeutic Attitude in the Context of Substance-assisted Therapy Training","sponsor":"Felix Mueller","registry_url":"https://clinicaltrials.gov/study/NCT05570708","tracker_url":"publication.php?id=3612","status":"ENROLLING_BY_INVITATION","status_label":"Enrolling by invitation","status_verified_date":"2025-04","last_update_date":"2025-04-14","start_date":"2022-10-25","primary_completion_date":"2029-06-01","completion_date":"2029-06-01","study_type":"INTERVENTIONAL","phases":["NA"],"enrollment":{"count":48,"type":"ESTIMATED"},"design":{"allocation":"NA","intervention_model":"SINGLE_GROUP","primary_purpose":"OTHER","masking":"NONE"},"conditions":["Personal Experience of Substance-assisted Therapy Using Psilocybin, MDMA, and LSD"],"interventions":[{"name":"MDMA, LSD, psilocybin","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"b396510f76aa97e398e61aeedd81c7b5fcfd540d418138fc4fb60db60e0a0659","facility":"University Hospital Basel","city":"Basel","region":"","country":"Switzerland","lat":47.558390000000003,"lon":7.5732699999999999}],"countries":["Switzerland"]},{"id":3646,"nct_id":"NCT05695495","title":"Acute Dose-dependent Effects of DMT-bolus Applications in Healthy Subjects: A Placebo-controlled Cross-over Study (DMT BDR-Study).","sponsor":"University Hospital, Basel, Switzerland","registry_url":"https://clinicaltrials.gov/study/NCT05695495","tracker_url":"publication.php?id=3646","status":"COMPLETED","status_label":"Completed","status_verified_date":"2025-04","last_update_date":"2025-04-11","start_date":"2024-06-12","primary_completion_date":"2025-02-02","completion_date":"2025-03-04","study_type":"INTERVENTIONAL","phases":["PHASE1"],"enrollment":{"count":36,"type":"ACTUAL"},"design":{"allocation":"RANDOMIZED","intervention_model":"CROSSOVER","primary_purpose":"BASIC_SCIENCE","masking":"TRIPLE"},"conditions":["Healthy"],"interventions":[{"name":"N,N-Dimethyltryptamine (5mg)","type":"DRUG"},{"name":"N,N-Dimethyltryptamine (10mg)","type":"DRUG"},{"name":"N,N-Dimethyltryptamine (15mg)","type":"DRUG"},{"name":"N,N-Dimethyltryptamine (20mg)","type":"DRUG"},{"name":"N,N-Dimethyltryptamine (25mg)","type":"DRUG"},{"name":"Placebo (saline)","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"3bd85f8d9169f9145f6dadbdc3b3147879111bb22b7030edc0ce62cf2445458e","facility":"Clinical Pharmacology & Toxicology, University Hospital Basel","city":"Basel","region":"","country":"Switzerland","lat":47.558390000000003,"lon":7.5732699999999999}],"countries":["Switzerland"]},{"id":3446,"nct_id":"NCT05581797","title":"Psilocybin-assisted Interpersonal Therapy for Depression","sponsor":"University of Otago","registry_url":"https://clinicaltrials.gov/study/NCT05581797","tracker_url":"publication.php?id=3446","status":"COMPLETED","status_label":"Completed","status_verified_date":"2024-04","last_update_date":"2025-04-09","start_date":"2023-03-15","primary_completion_date":"2024-05-06","completion_date":"2024-06-04","study_type":"INTERVENTIONAL","phases":["NA"],"enrollment":{"count":5,"type":"ACTUAL"},"design":{"allocation":"NA","intervention_model":"SINGLE_GROUP","primary_purpose":"TREATMENT","masking":"NONE"},"conditions":["Depressive Disorder, Treatment-Resistant"],"interventions":[{"name":"Psilocybin-assisted psychotherapy","type":"OTHER"}],"substances":["psilocybin"],"sites":[{"key":"403cf26dc1cd086ac357e6e0704cef6be00b732058ea333f56c4183c0c6738b6","facility":"University of Otago","city":"Christchurch","region":"","country":"New Zealand","lat":-43.533329999999999,"lon":172.63333}],"countries":["New Zealand"]},{"id":3635,"nct_id":"NCT06731335","title":"Psilocybin for Enhanced Analgesia in Chronic nEuropathic PAIN","sponsor":"Unity Health Toronto","registry_url":"https://clinicaltrials.gov/study/NCT06731335","tracker_url":"publication.php?id=3635","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2025-03","last_update_date":"2025-03-30","start_date":"2025-03-05","primary_completion_date":"2026-08","completion_date":"2026-12","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":30,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"TRIPLE"},"conditions":["Chronic Neuropathic Pain","Pain Management"],"interventions":[{"name":"Psilocybin","type":"DRUG"},{"name":"Active Placebo","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"de943dc53921b98b85839676ebd9bd35ab84bed7e937ec479cae02f2f56e5fd9","facility":"St. Michael's Hospital. Unity Health Toronto","city":"Toronto","region":"Ontario","country":"Canada","lat":43.706429999999997,"lon":-79.39864}],"countries":["Canada"]},{"id":3586,"nct_id":"NCT06899334","title":"Direct Comparison of Altered States of Consciousness Induced by LSD, Psilocybin, and DMT in a Randomized, Placebo-controlled, Cross-over Trial in Healthy Participants (LPD-Study)","sponsor":"University Hospital, Basel, Switzerland","registry_url":"https://clinicaltrials.gov/study/NCT06899334","tracker_url":"publication.php?id=3586","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2025-03","last_update_date":"2025-03-27","start_date":"2025-04-01","primary_completion_date":"2026-08-01","completion_date":"2026-08-01","study_type":"INTERVENTIONAL","phases":["PHASE1"],"enrollment":{"count":24,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"CROSSOVER","primary_purpose":"BASIC_SCIENCE","masking":"TRIPLE"},"conditions":["Healthy"],"interventions":[{"name":"LSD","type":"DRUG"},{"name":"Psilocybin","type":"DRUG"},{"name":"DMT","type":"DRUG"},{"name":"Placebo","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"ac63a9b87b0d17c174df6cd33e9b23cdf05c23cc85c8cd317f6c08206a61f3ac","facility":"University Hospital","city":"Basel","region":"","country":"Switzerland","lat":47.558390000000003,"lon":7.5732699999999999}],"countries":["Switzerland"]},{"id":3476,"nct_id":"NCT06252506","title":"Molecular Imaging Study of Harmine/DMT: a Basic Research Approach","sponsor":"Insel Gruppe AG, University Hospital Bern","registry_url":"https://clinicaltrials.gov/study/NCT06252506","tracker_url":"publication.php?id=3476","status":"COMPLETED","status_label":"Completed","status_verified_date":"2025-03","last_update_date":"2025-03-19","start_date":"2024-01-22","primary_completion_date":"2025-02-17","completion_date":"2025-03-05","study_type":"INTERVENTIONAL","phases":["PHASE1"],"enrollment":{"count":17,"type":"ACTUAL"},"design":{"allocation":"RANDOMIZED","intervention_model":"CROSSOVER","primary_purpose":"BASIC_SCIENCE","masking":"SINGLE"},"conditions":["Neuropharmacological Investigation of Ayahuasca Constituents DMT and Harmine"],"interventions":[{"name":"N,N-dimethyltryptamine (DMT) + harmine","type":"DRUG"},{"name":"Placebo","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"715908c4979cbcb23bee4bb972336ab1530b5731718f5dd77546b6021989aad2","facility":"Department of Nuclear Medicine, Bern University Hospital","city":"Bern","region":"","country":"Switzerland","lat":46.948090000000001,"lon":7.4474400000000003},{"key":"b2f80bbc21f8f731c71b9ae4cd9db0e64fd8e3bd14ac7dbf1065c5b86be66a11","facility":"Psychiatric University Hospital Zurich","city":"Zurich","region":"","country":"Switzerland","lat":47.366669999999999,"lon":8.5500000000000007}],"countries":["Switzerland"]},{"id":3457,"nct_id":"NCT06235411","title":"Psilocybin in Alcohol Use Disorder With Comorbid Depression","sponsor":"Centre Hospitalier Universitaire de Nīmes","registry_url":"https://clinicaltrials.gov/study/NCT06235411","tracker_url":"publication.php?id=3457","status":"COMPLETED","status_label":"Completed","status_verified_date":"2025-03","last_update_date":"2025-03-19","start_date":"2024-02-05","primary_completion_date":"2024-11-19","completion_date":"2025-01-09","study_type":"INTERVENTIONAL","phases":["NA"],"enrollment":{"count":30,"type":"ACTUAL"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"QUADRUPLE"},"conditions":["Alcohol-Related Disorders","Depressive Disorder","Addiction"],"interventions":[{"name":"Psilocybin therapy","type":"DRUG"},{"name":"Inactive Psilocybin therapy","type":"DRUG"},{"name":"Electroencephalogram","type":"OTHER"},{"name":"Blood samples for the analysis of immune and inflammatory profiles","type":"OTHER"},{"name":"stool samples","type":"OTHER"},{"name":"MRI functional and cerebral","type":"OTHER"}],"substances":["psilocybin"],"sites":[{"key":"4fd62086c4d69458b7c2814650e353d5cc7313e840825f60e22f1fe59e5ab9b1","facility":"CHU","city":"Nîmes","region":"Nîmes","country":"France","lat":43.836649999999999,"lon":4.3578799999999998}],"countries":["France"]},{"id":3530,"nct_id":"NCT05163496","title":"A Randomized, Placebo-controlled Trial of Psychedelic-assisted Psychotherapy With Single Dose Psilocybin for Frontline Clinicians Experiencing COVID-related Symptoms of Depression and Burnout","sponsor":"University of Washington","registry_url":"https://clinicaltrials.gov/study/NCT05163496","tracker_url":"publication.php?id=3530","status":"COMPLETED","status_label":"Completed","status_verified_date":"2025-03","last_update_date":"2025-03-18","start_date":"2022-03-03","primary_completion_date":"2023-12-30","completion_date":"2024-06-30","study_type":"INTERVENTIONAL","phases":["PHASE3"],"enrollment":{"count":30,"type":"ACTUAL"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"TRIPLE"},"conditions":["Burnout, Caregiver","Burnout, Professional","COVID-19","Depression","Post Traumatic Stress Disorder","Moral Injury"],"interventions":[{"name":"Psilocybin (Usona Institute)","type":"DRUG"},{"name":"Active placebo","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"285f505708621e1f0fc9c6266c0110f7a1a84d0c2b08e83438836c81413008ad","facility":"University of Washington","city":"Seattle","region":"Washington","country":"United States","lat":47.606209999999997,"lon":-122.33207}],"countries":["United States"]},{"id":3649,"nct_id":"NCT00302744","title":"Effects of Psilocybin in Advanced-Stage Cancer Patients With Anxiety","sponsor":"Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center","registry_url":"https://clinicaltrials.gov/study/NCT00302744","tracker_url":"publication.php?id=3649","status":"COMPLETED","status_label":"Completed","status_verified_date":"2025-03","last_update_date":"2025-03-13","start_date":"2004-04","primary_completion_date":"2008-12","completion_date":"2008-12","study_type":"INTERVENTIONAL","phases":["PHASE1","PHASE2"],"enrollment":{"count":12,"type":"ACTUAL"},"design":{"allocation":"RANDOMIZED","intervention_model":"SINGLE_GROUP","primary_purpose":"TREATMENT","masking":"QUADRUPLE"},"conditions":["Anxiety"],"interventions":[{"name":"Psilocybin (drug)","type":"DRUG"},{"name":"Niacin","type":"OTHER"},{"name":"MRI","type":"DIAGNOSTIC_TEST"}],"substances":["psilocybin"],"sites":[{"key":"91c08ea7e8178d877e37065524d657f71f7f45eb4588c8396bf5ed6845e64c72","facility":"Harbor-UCLA Medical Center","city":"Torrance","region":"California","country":"United States","lat":33.835850000000001,"lon":-118.34063}],"countries":["United States"]},{"id":3666,"nct_id":"NCT05523401","title":"Acute Effects of 2C-B Compared With MDMA and Psilocybin in Healthy Subjects","sponsor":"University Hospital, Basel, Switzerland","registry_url":"https://clinicaltrials.gov/study/NCT05523401","tracker_url":"publication.php?id=3666","status":"COMPLETED","status_label":"Completed","status_verified_date":"2025-02","last_update_date":"2025-03-05","start_date":"2023-08-16","primary_completion_date":"2024-10-20","completion_date":"2024-11-05","study_type":"INTERVENTIONAL","phases":["PHASE1"],"enrollment":{"count":24,"type":"ACTUAL"},"design":{"allocation":"RANDOMIZED","intervention_model":"CROSSOVER","primary_purpose":"BASIC_SCIENCE","masking":"TRIPLE"},"conditions":["Healthy"],"interventions":[{"name":"4-bromo-2,5-dimethoxyphenethylamine (10 mg)","type":"DRUG"},{"name":"4-bromo-2,5-dimethoxyphenethylamine (20 mg)","type":"DRUG"},{"name":"4-bromo-2,5-dimethoxyphenethylamine (30 mg)","type":"DRUG"},{"name":"3,4-methylenedioxymethamphetamine","type":"DRUG"},{"name":"Psilocybin","type":"DRUG"},{"name":"Placebo","type":"OTHER"}],"substances":["psilocybin","psilocin"],"sites":[{"key":"b396510f76aa97e398e61aeedd81c7b5fcfd540d418138fc4fb60db60e0a0659","facility":"University Hospital Basel","city":"Basel","region":"","country":"Switzerland","lat":47.558390000000003,"lon":7.5732699999999999}],"countries":["Switzerland"]},{"id":3679,"nct_id":"NCT04670081","title":"A Phase II Randomized, Double-blind, Active Placebo-controlled Parallel Group Trial to Examine the Efficacy and Safety of Psilocybin in Treatment-resistant Major Depression","sponsor":"Central Institute of Mental Health, Mannheim","registry_url":"https://clinicaltrials.gov/study/NCT04670081","tracker_url":"publication.php?id=3679","status":"COMPLETED","status_label":"Completed","status_verified_date":"2025-01","last_update_date":"2025-01-20","start_date":"2021-06-10","primary_completion_date":"2024-02-27","completion_date":"2024-12-11","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":144,"type":"ACTUAL"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"TRIPLE"},"conditions":["Treatment-resistant Depression"],"interventions":[{"name":"Psilocybin","type":"DRUG"},{"name":"Nicotinamide","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"ca2d4ec9703fe3f5f146e1bd00eb9f0e2994b62836d9dfa60c94b7c30be1bf37","facility":"Charité Berlin, Campus Mitte, Department of Psychiatry and Psychotherapy","city":"Berlin","region":"","country":"Germany","lat":52.524369999999998,"lon":13.41053},{"key":"1c79f25f1e0ee6d8df07a3e5e4b5a843a34080ae32902e2e0c01f99d02b07a16","facility":"Central Institute of Mental Health (CIMH)","city":"Mannheim","region":"","country":"Germany","lat":49.489100000000001,"lon":8.4669399999999992}],"countries":["Germany"]},{"id":3627,"nct_id":"NCT03289949","title":"The Neurobiological Effect of 5-HT2AR Modulation","sponsor":"Gitte Moos Knudsen","registry_url":"https://clinicaltrials.gov/study/NCT03289949","tracker_url":"publication.php?id=3627","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2024-12","last_update_date":"2024-12-16","start_date":"2017-03-03","primary_completion_date":"2030-06-01","completion_date":"2030-06-01","study_type":"INTERVENTIONAL","phases":["PHASE1"],"enrollment":{"count":200,"type":"ESTIMATED"},"design":{"allocation":"NON_RANDOMIZED","intervention_model":"SEQUENTIAL","primary_purpose":"BASIC_SCIENCE","masking":"SINGLE"},"conditions":["Basic Science"],"interventions":[{"name":"Psilocybine","type":"DRUG"},{"name":"Ketanserin","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"194d419533160aa241e58316c109a3778e280f27677956060dac8d0bfae574c6","facility":"Neurobiology Research Unit, Rigshospitalet","city":"Copenhagen","region":"","country":"Denmark","lat":55.675939999999997,"lon":12.565530000000001}],"countries":["Denmark"]},{"id":3689,"nct_id":"NCT05481736","title":"Efficacy and Safety of COMP360 Psilocybin Therapy in Anorexia Nervosa: a Proof-of-concept Study","sponsor":"COMPASS Pathways","registry_url":"https://clinicaltrials.gov/study/NCT05481736","tracker_url":"publication.php?id=3689","status":"COMPLETED","status_label":"Completed","status_verified_date":"2024-12","last_update_date":"2024-12-04","start_date":"2022-10-12","primary_completion_date":"2024-11-18","completion_date":"2024-11-18","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":32,"type":"ACTUAL"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"QUADRUPLE"},"conditions":["Anorexia Nervosa"],"interventions":[{"name":"Psilocybin","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"b62c29cd779fd43501f426fef3293a64089108a0e7e17ae13b4044a87d256c81","facility":"Altman Clinical and Translational Research Institute","city":"San Diego","region":"California","country":"United States","lat":32.715710000000001,"lon":-117.16472},{"key":"bc376e1e0a696ea23f74184c3639e3209c4cf2754b05d49dcebccf226428bc05","facility":"Sheppard Pratt Health System","city":"Baltimore","region":"Maryland","country":"United States","lat":39.290379999999999,"lon":-76.612189999999998},{"key":"44dff036ba0c252b89f384cafd7b6afe7f6dbbde33d112b5813eb8a58984f3ba","facility":"Dell Medical School","city":"Austin","region":"Texas","country":"United States","lat":30.267150000000001,"lon":-97.74306},{"key":"1936d05fa8ae325b9934cffa0a0c3f08afa8e902d6fe3597cf7ffaec91b70308","facility":"Tallaght University Hospital","city":"Dublin","region":"","country":"Ireland","lat":53.333060000000003,"lon":-6.2488900000000003},{"key":"190dd76ab65ad7b28570cf2992585e62e7281887f8f4acc4cc7ee1b0ebcb7c7e","facility":"Kings College London, Institute of Psychiatry, Psychology and Neurology","city":"London","region":"","country":"United Kingdom","lat":51.50853,"lon":-0.12573999999999999}],"countries":["United States","Ireland","United Kingdom"]},{"id":3488,"nct_id":"NCT03356483","title":"Psilocybin Treatment in Obsessive-Compulsive Disorder: a Preliminary Efficacy Study and Exploratory Investigation of Neural Correlates.","sponsor":"Yale University","registry_url":"https://clinicaltrials.gov/study/NCT03356483","tracker_url":"publication.php?id=3488","status":"COMPLETED","status_label":"Completed","status_verified_date":"2024-11","last_update_date":"2024-11-20","start_date":"2018-11-13","primary_completion_date":"2024-07-25","completion_date":"2024-07-25","study_type":"INTERVENTIONAL","phases":["PHASE1"],"enrollment":{"count":31,"type":"ACTUAL"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"QUADRUPLE"},"conditions":["Obsessive-Compulsive Disorder"],"interventions":[{"name":"Psilocybin (0.25mg/kg)","type":"DRUG"},{"name":"Niacin (250mg)","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"27df3ff2008239e64bf38e6c56f8f5e8652612b4aa9bff987d4ba0f94be975b1","facility":"Connecticut Mental Health Center","city":"New Haven","region":"Connecticut","country":"United States","lat":41.308149999999998,"lon":-72.928160000000005}],"countries":["United States"]},{"id":3512,"nct_id":"NCT05035927","title":"A Phase 2a Safety and Feasibility Study Evaluating Psilocybin (TRP-8802) Administration in Concert With Psychotherapy in the Treatment of Binge Eating Disorder","sponsor":"TRYP Therapeutics","registry_url":"https://clinicaltrials.gov/study/NCT05035927","tracker_url":"publication.php?id=3512","status":"COMPLETED","status_label":"Completed","status_verified_date":"2024-11","last_update_date":"2024-11-19","start_date":"2022-03-16","primary_completion_date":"2024-03-07","completion_date":"2024-06-07","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":5,"type":"ACTUAL"},"design":{"allocation":"NA","intervention_model":"SINGLE_GROUP","primary_purpose":"TREATMENT","masking":"NONE"},"conditions":["Binge Eating Disorder"],"interventions":[{"name":"TRYP-0082","type":"DRUG"},{"name":"Psychotherapy","type":"BEHAVIORAL"}],"substances":["psilocybin"],"sites":[{"key":"5770cc81f9352293b4571ef32e9013b2ee451488e071dd9fa0c99aebe3a521cb","facility":"University of Florida","city":"Gainesville","region":"Florida","country":"United States","lat":29.651630000000001,"lon":-82.324830000000006}],"countries":["United States"]},{"id":3430,"nct_id":"NCT05557643","title":"PAPR: Psilocybin-assisted Psychotherapy + Mindfulness-Based Stress Reduction (MBSR) for Front-line Healthcare Provider COVID-19 Related Burnout","sponsor":"University of Utah","registry_url":"https://clinicaltrials.gov/study/NCT05557643","tracker_url":"publication.php?id=3430","status":"COMPLETED","status_label":"Completed","status_verified_date":"2024-11","last_update_date":"2024-11-12","start_date":"2023-01-02","primary_completion_date":"2024-09-20","completion_date":"2024-09-20","study_type":"INTERVENTIONAL","phases":["PHASE1"],"enrollment":{"count":24,"type":"ACTUAL"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"SINGLE"},"conditions":["Depression","Burnout, Professional"],"interventions":[{"name":"Psilocybin","type":"DRUG"},{"name":"Mindfulness-Based Stress Reduction (MBSR)","type":"BEHAVIORAL"}],"substances":["psilocybin"],"sites":[{"key":"0c0bb514818072629295ef417bfbdcf56e7ac0531b9beee0971543a5f874732e","facility":"Huntsman Mental Health Institute","city":"Salt Lake City","region":"Utah","country":"United States","lat":40.760779999999997,"lon":-111.89105000000001}],"countries":["United States"]},{"id":3669,"nct_id":"NCT06258031","title":"PsilOCD: Evaluating the Effects of the 5-HT2A Agonist Psilocybin on the Neurocognitive and Clinical Correlates of Compulsivity (A Pharmacological-Challenge Feasibility Study)","sponsor":"Imperial College London","registry_url":"https://clinicaltrials.gov/study/NCT06258031","tracker_url":"publication.php?id=3669","status":"COMPLETED","status_label":"Completed","status_verified_date":"2024-11","last_update_date":"2024-11-06","start_date":"2022-10-28","primary_completion_date":"2024-06-28","completion_date":"2024-07-24","study_type":"INTERVENTIONAL","phases":["PHASE1"],"enrollment":{"count":19,"type":"ACTUAL"},"design":{"allocation":"NA","intervention_model":"SINGLE_GROUP","primary_purpose":"OTHER","masking":"NONE"},"conditions":["Obsessive-Compulsive Disorder"],"interventions":[{"name":"Psilocybin (COMP360)","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"cd53ff909631c02493009d6fa3e945541560209fce31bf8b65855864408557b7","facility":"CIPPRes Clinic","city":"London","region":"","country":"United Kingdom","lat":51.50853,"lon":-0.12573999999999999}],"countries":["United Kingdom"]},{"id":3584,"nct_id":"NCT06666010","title":"A Registered Clinical Trial of PEX010-Assisted Therapy for Stimulant Use Disorder: A Safety, Feasibility and Efficacy Study","sponsor":"Filament Health Corp.","registry_url":"https://clinicaltrials.gov/study/NCT06666010","tracker_url":"publication.php?id=3584","status":"NOT_YET_RECRUITING","status_label":"Not yet recruiting","status_verified_date":"2024-10","last_update_date":"2024-10-30","start_date":"2025-01","primary_completion_date":"2028-01","completion_date":"2028-07","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":86,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"QUADRUPLE"},"conditions":["Stimulant Use Disorder"],"interventions":[{"name":"PEX010-Assisted Therapy","type":"DRUG"},{"name":"PEX010(01)","type":"DRUG"}],"substances":["psilocybin"],"sites":[],"countries":[]},{"id":3644,"nct_id":"NCT03429075","title":"Psilocybin vs Escitalopram for Major Depressive Disorder: Comparative Mechanisms","sponsor":"Imperial College London","registry_url":"https://clinicaltrials.gov/study/NCT03429075","tracker_url":"publication.php?id=3644","status":"COMPLETED","status_label":"Completed","status_verified_date":"2024-08","last_update_date":"2024-10-24","start_date":"2019-01-07","primary_completion_date":"2020-04-17","completion_date":"2020-10-17","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":59,"type":"ACTUAL"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"DOUBLE"},"conditions":["Depressive Disorder, Major"],"interventions":[{"name":"Psilocybin + Placebo","type":"DRUG"},{"name":"Psilocybin + Escitalopram","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"92f7e0cc003e9611ea48c068566e59f517929115533a6bed42bf34a1e382a8a8","facility":"Imperial College Hammersmith campus","city":"London","region":"","country":"United Kingdom","lat":51.50853,"lon":-0.12573999999999999}],"countries":["United Kingdom"]},{"id":3469,"nct_id":"NCT06326606","title":"A Phase 1 Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MLS101 (psilocybin) in Healthy Participants","sponsor":"MycoMedica Life Sciences PBC","registry_url":"https://clinicaltrials.gov/study/NCT06326606","tracker_url":"publication.php?id=3469","status":"COMPLETED","status_label":"Completed","status_verified_date":"2024-10","last_update_date":"2024-10-09","start_date":"2024-03-27","primary_completion_date":"2024-07-08","completion_date":"2024-07-08","study_type":"INTERVENTIONAL","phases":["PHASE1"],"enrollment":{"count":24,"type":"ACTUAL"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"QUADRUPLE"},"conditions":["Healthy Volunteers"],"interventions":[{"name":"Psilocybin","type":"DRUG"},{"name":"Placebo","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"dd2376bcaedbd8ec29b41fc08e574f0f48cfcd642bdbaf4b61cdc470ebcda7cc","facility":"CMAX Clinical Research Pty Ltd","city":"Adelaide","region":"South Australia","country":"Australia","lat":-34.928660000000001,"lon":138.59863000000001}],"countries":["Australia"]},{"id":3546,"nct_id":"NCT06529939","title":"The Effects of Psilocybin on Shared Experience in Film Processing","sponsor":"Western University, Canada","registry_url":"https://clinicaltrials.gov/study/NCT06529939","tracker_url":"publication.php?id=3546","status":"UNKNOWN","status_label":"Unknown status","status_verified_date":"2024-07","last_update_date":"2024-09-27","start_date":"2024-11","primary_completion_date":"2025-09","completion_date":"2025-09","study_type":"INTERVENTIONAL","phases":["NA"],"enrollment":{"count":30,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"BASIC_SCIENCE","masking":"NONE"},"conditions":["Disorders of Consciousness","Psychedelic Experiences"],"interventions":[{"name":"Psilocybin","type":"DRUG"},{"name":"Placebo","type":"OTHER"}],"substances":["psilocybin"],"sites":[],"countries":[]},{"id":3592,"nct_id":"NCT05065294","title":"An Open-Label Pilot Study Examining the Feasibility, Safety, and Effectiveness of Psilocybin Therapy for Depression in Bipolar II Disorder","sponsor":"University of California, San Francisco","registry_url":"https://clinicaltrials.gov/study/NCT05065294","tracker_url":"publication.php?id=3592","status":"ACTIVE_NOT_RECRUITING","status_label":"Active, not recruiting","status_verified_date":"2024-09","last_update_date":"2024-09-25","start_date":"2022-01-28","primary_completion_date":"2024-08-01","completion_date":"2025-07","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":14,"type":"ESTIMATED"},"design":{"allocation":"NA","intervention_model":"SINGLE_GROUP","primary_purpose":"OTHER","masking":"NONE"},"conditions":["Bipolar II Disorder"],"interventions":[{"name":"Psilocybin therapy","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"7f09a842484186a75c6232177464293472d56c43d4d49f24f37efcb6c9cbbbb8","facility":"University of California, San Francisco","city":"San Francisco","region":"California","country":"United States","lat":37.774929999999998,"lon":-122.41942}],"countries":["United States"]},{"id":3528,"nct_id":"NCT06378229","title":"Psilocybin-assisted Psychotherapy in the Treatment of Patients Hospitalized for Treatment-resistant Depression: an Open-label Feasibility Study with an Experiential and Systemic Focus","sponsor":"University Hospital, Ghent","registry_url":"https://clinicaltrials.gov/study/NCT06378229","tracker_url":"publication.php?id=3528","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2024-09","last_update_date":"2024-09-19","start_date":"2024-05-21","primary_completion_date":"2026-03","completion_date":"2026-12-31","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":100,"type":"ESTIMATED"},"design":{"allocation":"NA","intervention_model":"SINGLE_GROUP","primary_purpose":"TREATMENT","masking":"NONE"},"conditions":["Treatment Resistant Depression"],"interventions":[{"name":"Psilocybin","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"de5de4cd4a64693d58b4d482b491ab2adbd6db4602a86d03c76d0c7dfa1737de","facility":"Ghent University Hospital","city":"Ghent","region":"Oost-Vlaanderen","country":"Belgium","lat":51.049999999999997,"lon":3.7166700000000001}],"countries":["Belgium"]},{"id":5843,"nct_id":"NCT03300947","title":"Psilocybin for Treatment of Obsessive Compulsive Disorder","sponsor":"University of Arizona","registry_url":"https://clinicaltrials.gov/study/NCT03300947","tracker_url":"publication.php?id=5843","status":"COMPLETED","status_label":"Completed","status_verified_date":"2024-08","last_update_date":"2024-08-30","start_date":"2019-01-02","primary_completion_date":"2023-10-30","completion_date":"2023-12-30","study_type":"INTERVENTIONAL","phases":["PHASE1"],"enrollment":{"count":15,"type":"ACTUAL"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"QUADRUPLE"},"conditions":["Obsessive-compulsive Disorder (OCD)"],"interventions":[{"name":"Psilocybin 100 mcg/kg","type":"DRUG"},{"name":"Psilocybin 300 mcg/kg","type":"DRUG"},{"name":"Lorazepam 1 mg","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"5b68ee01102e7545497cccc1eed4861724cfdb4157ff64793fb872b22d1007f6","facility":"University of Arizona","city":"Tucson","region":"Arizona","country":"United States","lat":32.221739999999997,"lon":-110.92648}],"countries":["United States"]},{"id":3428,"nct_id":"NCT05646303","title":"A 24-Week, Multicentre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Clinical Trial to Evaluate Efficacy and Safety of Psilocybin-Assisted Psychotherapy in Adults With Alcohol Use Disorder (AUD)","sponsor":"Clairvoyant Therapeutics","registry_url":"https://clinicaltrials.gov/study/NCT05646303","tracker_url":"publication.php?id=3428","status":"UNKNOWN","status_label":"Unknown status","status_verified_date":"2023-09","last_update_date":"2024-08-15","start_date":"2022-05-02","primary_completion_date":"2024-08-31","completion_date":"2024-12-31","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":128,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"QUADRUPLE"},"conditions":["Alcohol Use Disorder"],"interventions":[{"name":"Psilocybin","type":"DRUG"},{"name":"Placebo","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"7921922108da606383f02d461f4df4e14db71c279c22c13f6e0098569e6fc045","facility":"Sabi Mind","city":"Calgary","region":"Alberta","country":"Canada","lat":51.050109999999997,"lon":-114.08529},{"key":"b6145ff487ffb39fe26ce240998c399fbf6f9a455da2b4bd7a6baefc497639eb","facility":"Okanagan Clinical Trials","city":"Kelowna","region":"British Columbia","country":"Canada","lat":49.883069999999996,"lon":-119.48568},{"key":"f382a179650c2df27e8a44e5fbd93e67557feb21753716040410f9b7f60eb029","facility":"Centre for Neurology Studies","city":"Surrey","region":"British Columbia","country":"Canada","lat":49.106349999999999,"lon":-122.82509},{"key":"67a68181704a60b202e5bd17a9943b90ad9f4f4bae50a883bcee9366ae6b07ab","facility":"University of British Columbia, Department of Psychiatry, BRAIN Lab","city":"Vancouver","region":"British Columbia","country":"Canada","lat":49.249659999999999,"lon":-123.11933999999999},{"key":"48228a6e53745d2e5d9ebb9d9e380833b371fa7e760c88385827be732372c4f7","facility":"Centricity Research","city":"Halifax","region":"Nova Scotia","country":"Canada","lat":44.642690000000002,"lon":-63.576880000000003},{"key":"51a9a92a0508b764f9a4517d8d60933b3ee3ba0964375b23c07f442f64b82278","facility":"MacAnxiety Research Centre","city":"Hamilton","region":"Ontario","country":"Canada","lat":43.250109999999999,"lon":-79.849630000000005},{"key":"e6f14c804d63d788a9de79fa6c9092129f515985d376c7b8cc0020b9e61c1729","facility":"Department of Psychiatry, Queen's University","city":"Kingston","region":"Ontario","country":"Canada","lat":44.229759999999999,"lon":-76.480980000000002},{"key":"bf2adfb756d244974a952f7c5c58e6f72f66cbbd5ba63e61a8b987fa1820f128","facility":"Centre for Addiction and Mental Health","city":"Toronto","region":"Ontario","country":"Canada","lat":43.706429999999997,"lon":-79.39864},{"key":"d06e48f11f12f9cf06e95d71a691ebf90c8fe98aefa9008cd221096d6eabb8b9","facility":"Research Center Oxidi Oy / Addiktum Oy","city":"Helsinki","region":"","country":"Finland","lat":60.169519999999999,"lon":24.935449999999999},{"key":"a967236f529970e305e31c0bb38c4df0951a3d9fa9defea114930d40bbcb3df8","facility":"A-Klinikka","city":"Kouvola","region":"","country":"Finland","lat":60.866669999999999,"lon":26.699999999999999},{"key":"097f01f888974a19c581a1a4a48207f44890c9eb5fc62fd738265f1e44166755","facility":"Mentacare Oy","city":"Oulu","region":"","country":"Finland","lat":65.012360000000001,"lon":25.468160000000001},{"key":"2b75d8f2d0990670d7c5884774f83a08cea77ea8701cbb5acf36b7aa6d726817","facility":"Addiktum Oy","city":"Turku","region":"","country":"Finland","lat":60.451479999999997,"lon":22.268689999999999}],"countries":["Canada","Finland"]},{"id":3609,"nct_id":"NCT04433858","title":"An Open Label Study of the Safety and Efficacy of Psilocybin in Participants With Treatment-Resistant Depression (P-TRD)","sponsor":"Sheppard Pratt Health System","registry_url":"https://clinicaltrials.gov/study/NCT04433858","tracker_url":"publication.php?id=3609","status":"ACTIVE_NOT_RECRUITING","status_label":"Active, not recruiting","status_verified_date":"2024-08","last_update_date":"2024-08-09","start_date":"2021-03-01","primary_completion_date":"2025-06-01","completion_date":"2026-05-01","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":27,"type":"ACTUAL"},"design":{"allocation":"NA","intervention_model":"SINGLE_GROUP","primary_purpose":"TREATMENT","masking":"NONE"},"conditions":["Treatment Resistant Depression"],"interventions":[{"name":"Psilocybin","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"ec5ea7fe39f9d8b779c8f5306f31a5e6e2852baac72dfa28060b9c9d1d8cf5c5","facility":"VA Palo Alto Healthcare System/Stanford Medicine","city":"Palo Alto","region":"California","country":"United States","lat":37.441879999999998,"lon":-122.14302000000001},{"key":"bc376e1e0a696ea23f74184c3639e3209c4cf2754b05d49dcebccf226428bc05","facility":"Sheppard Pratt Health System","city":"Baltimore","region":"Maryland","country":"United States","lat":39.290379999999999,"lon":-76.612189999999998}],"countries":["United States"]},{"id":3438,"nct_id":"NCT06160232","title":"Psilocybin-Assisted Therapy for Severe Alcohol Use Disorder: Feasibility, Clinical Efficacy & (Neuro)Cognitive Mechanisms","sponsor":"Brugmann University Hospital","registry_url":"https://clinicaltrials.gov/study/NCT06160232","tracker_url":"publication.php?id=3438","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2024-08","last_update_date":"2024-08-07","start_date":"2024-02-15","primary_completion_date":"2025-12-15","completion_date":"2026-06-15","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":62,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"QUADRUPLE"},"conditions":["Severe Alcohol Use Disorder"],"interventions":[{"name":"Psilocybin (high dose)","type":"DRUG"},{"name":"Active placebo (low dose of psilocybin)","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"dafa3859e760931a703dbfafba7ca9060f6a965b188b8bd05bfcdce5b2f5f81d","facility":"Brugmann University Hospital","city":"Brussels","region":"","country":"Belgium","lat":50.850450000000002,"lon":4.3487799999999996}],"countries":["Belgium"]},{"id":3450,"nct_id":"NCT05675800","title":"Psilocybin for the Treatment of Major Depressive Disorder","sponsor":"Washington University School of Medicine","registry_url":"https://clinicaltrials.gov/study/NCT05675800","tracker_url":"publication.php?id=3450","status":"WITHDRAWN","status_label":"Withdrawn","status_verified_date":"2024-07","last_update_date":"2024-07-25","start_date":"2024-01-01","primary_completion_date":"2025-01-01","completion_date":"2025-03-31","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":0,"type":"ACTUAL"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"NONE"},"conditions":["Major Depressive Disorder"],"interventions":[{"name":"Psilocybin","type":"DRUG"}],"substances":["psilocybin"],"sites":[],"countries":[]},{"id":3638,"nct_id":"NCT04718792","title":"Psilocybin for Treatment of Alcohol Use Disorder: a Feasibility Study","sponsor":"Anders Fink-Jensen, MD, DMSci","registry_url":"https://clinicaltrials.gov/study/NCT04718792","tracker_url":"publication.php?id=3638","status":"UNKNOWN","status_label":"Unknown status","status_verified_date":"2024-07","last_update_date":"2024-07-12","start_date":"2023-02-09","primary_completion_date":"2024-07-21","completion_date":"2024-07-21","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":10,"type":"ACTUAL"},"design":{"allocation":"NA","intervention_model":"SINGLE_GROUP","primary_purpose":"TREATMENT","masking":"NONE"},"conditions":["Alcohol Use Disorder (AUD)"],"interventions":[{"name":"Psilocybin","type":"DRUG"}],"substances":["psilocybin","psilocin"],"sites":[{"key":"480677b0a56d457be4a4efa8940d8eceb5f184eb3c10619dc4359584550e04e3","facility":"Psychiatric Center Copenhagen","city":"Copenhagen","region":"Frederiksberg","country":"Denmark","lat":55.675939999999997,"lon":12.565530000000001}],"countries":["Denmark"]},{"id":3535,"nct_id":"NCT06471959","title":"Assessing the Feasibility of a Custom Psychedelic-assisted Group Program on Mental and Physical Health in First Responders","sponsor":"Empower Research Inc","registry_url":"https://clinicaltrials.gov/study/NCT06471959","tracker_url":"publication.php?id=3535","status":"UNKNOWN","status_label":"Unknown status","status_verified_date":"2024-06","last_update_date":"2024-06-24","start_date":"2025-01-01","primary_completion_date":"2025-07-01","completion_date":"2025-09-01","study_type":"INTERVENTIONAL","phases":["PHASE1","PHASE2"],"enrollment":{"count":32,"type":"ESTIMATED"},"design":{"allocation":"NA","intervention_model":"SEQUENTIAL","primary_purpose":"TREATMENT","masking":"NONE"},"conditions":["Psilocybin","Psychotherapy, Group"],"interventions":[{"name":"Psilocybin","type":"DRUG"}],"substances":["psilocybin","psilocin"],"sites":[{"key":"f382a179650c2df27e8a44e5fbd93e67557feb21753716040410f9b7f60eb029","facility":"Centre for Neurology Studies","city":"Surrey","region":"British Columbia","country":"Canada","lat":49.106349999999999,"lon":-122.82509}],"countries":["Canada"]},{"id":3545,"nct_id":"NCT02243813","title":"Effects of Psilocybin-facilitated Experience on the Psychology and Effectiveness of Professional Leaders in Religion","sponsor":"Johns Hopkins University","registry_url":"https://clinicaltrials.gov/study/NCT02243813","tracker_url":"publication.php?id=3545","status":"COMPLETED","status_label":"Completed","status_verified_date":"2024-06","last_update_date":"2024-06-18","start_date":"2015-03","primary_completion_date":"2024-05-31","completion_date":"2024-05-31","study_type":"INTERVENTIONAL","phases":["PHASE1"],"enrollment":{"count":24,"type":"ACTUAL"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"BASIC_SCIENCE","masking":"NONE"},"conditions":["Healthy"],"interventions":[{"name":"Psilocybin","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"6732f25d9e7c5ee9eed300cdd40165c9c1b7f0ca5cc99960985a65e7da08f98b","facility":"Behavioral Biology Research Center, Johns Hopkins Bayview","city":"Baltimore","region":"Maryland","country":"United States","lat":39.290379999999999,"lon":-76.612189999999998}],"countries":["United States"]},{"id":3462,"nct_id":"NCT04505189","title":"Psilocybin as a Treatment for Anorexia Nervosa: A Pilot Study","sponsor":"Imperial College London","registry_url":"https://clinicaltrials.gov/study/NCT04505189","tracker_url":"publication.php?id=3462","status":"COMPLETED","status_label":"Completed","status_verified_date":"2024-06","last_update_date":"2024-06-17","start_date":"2021-05-28","primary_completion_date":"2023-12-11","completion_date":"2024-06-12","study_type":"INTERVENTIONAL","phases":["PHASE1","PHASE2"],"enrollment":{"count":21,"type":"ACTUAL"},"design":{"allocation":"NA","intervention_model":"SINGLE_GROUP","primary_purpose":"TREATMENT","masking":"NONE"},"conditions":["Anorexia Nervosa"],"interventions":[{"name":"Psilocybin","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"92f7e0cc003e9611ea48c068566e59f517929115533a6bed42bf34a1e382a8a8","facility":"Imperial College Hammersmith campus","city":"London","region":"","country":"United Kingdom","lat":51.50853,"lon":-0.12573999999999999}],"countries":["United Kingdom"]},{"id":3445,"nct_id":"NCT06444243","title":"A Multi-centre, Double-blinded, Placebo-controlled, Randomised, Phase II Clinical Trial for Psilocybin-assisted Therapy for Alcohol Use Disorder","sponsor":"University of Sydney","registry_url":"https://clinicaltrials.gov/study/NCT06444243","tracker_url":"publication.php?id=3445","status":"UNKNOWN","status_label":"Unknown status","status_verified_date":"2024-06","last_update_date":"2024-06-10","start_date":"2024-09","primary_completion_date":"2025-07","completion_date":"2025-12","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":90,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"OTHER","masking":"DOUBLE"},"conditions":["Alcohol Use Disorder","Alcohol Dependence","Depression","Anxiety"],"interventions":[{"name":"Psilocybin","type":"DRUG"},{"name":"Niacin","type":"DRUG"}],"substances":["psilocybin"],"sites":[],"countries":[]},{"id":3534,"nct_id":"NCT05832255","title":"An Open-Label Investigation of the Effects of Sub-Perceptual Repeat Dosing of Psilocybin on the Behavioural and Cognitive Symptoms of Fragile X Syndrome in Adult Patients","sponsor":"Nova Mentis Life Science Corp","registry_url":"https://clinicaltrials.gov/study/NCT05832255","tracker_url":"publication.php?id=3534","status":"SUSPENDED","status_label":"Suspended","status_verified_date":"2024-05","last_update_date":"2024-05-08","start_date":"2023-03-28","primary_completion_date":"2024-05","completion_date":"2024-05","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":10,"type":"ESTIMATED"},"design":{"allocation":"NA","intervention_model":"SINGLE_GROUP","primary_purpose":"TREATMENT","masking":"NONE"},"conditions":["Fragile X Syndrome","Behavior","Cognitive Dysfunction"],"interventions":[{"name":"Psilocybin, 1.5 mg","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"ab3cd7771782c6f43e2834a6cc70a3c0c8ea89ffdaffe63af517b64058c9c50f","facility":"KGK Science Inc.","city":"London","region":"Ontario","country":"Canada","lat":42.98339,"lon":-81.233040000000003}],"countries":["Canada"]},{"id":3632,"nct_id":"NCT05995769","title":"Mechanisms Supporting Psilocybin-assisted Psychotherapy for Alcohol Use Disorder: A Randomized, Controlled Clinical Trial","sponsor":"University of Calgary","registry_url":"https://clinicaltrials.gov/study/NCT05995769","tracker_url":"publication.php?id=3632","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2023-08","last_update_date":"2024-05-07","start_date":"2024-03-20","primary_completion_date":"2027-10-01","completion_date":"2027-10-01","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":128,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"QUADRUPLE"},"conditions":["Alcohol Use Disorder","Alcoholism"],"interventions":[{"name":"Psilocybin","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"43d6a4c1bec6b0da7fbcdcf29f22e29eb9ee146f88b69aa1d4bc718a46bed666","facility":"University of Calgary","city":"Calgary","region":"Alberta","country":"Canada","lat":51.050109999999997,"lon":-114.08529}],"countries":["Canada"]},{"id":3564,"nct_id":"NCT05384678","title":"Acute Dose-dependent Effects of DMT in Healthy Subjects: A Placebo-controlled Cross-over Study","sponsor":"University Hospital, Basel, Switzerland","registry_url":"https://clinicaltrials.gov/study/NCT05384678","tracker_url":"publication.php?id=3564","status":"COMPLETED","status_label":"Completed","status_verified_date":"2024-04","last_update_date":"2024-04-25","start_date":"2022-11-15","primary_completion_date":"2024-03-08","completion_date":"2024-03-13","study_type":"INTERVENTIONAL","phases":["PHASE1"],"enrollment":{"count":24,"type":"ACTUAL"},"design":{"allocation":"RANDOMIZED","intervention_model":"CROSSOVER","primary_purpose":"BASIC_SCIENCE","masking":"TRIPLE"},"conditions":["Healthy"],"interventions":[{"name":"N,N-Dimethyltryptamine (54 mg)","type":"DRUG"},{"name":"N,N-Dimethyltryptamine (108 mg)","type":"DRUG"},{"name":"N,N-Dimethyltryptamine (162 mg)","type":"DRUG"},{"name":"N,N-Dimethyltryptamine (216 mg)","type":"DRUG"},{"name":"Placebo","type":"DRUG"},{"name":"N,N-Dimethyltryptamine (108 mg) + dose titration","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"233b6ae11780c805724450c320e419d5b4e212f235659d5a9581ded7c6d5ea19","facility":"Universtity Hospital Basel","city":"Basel","region":"","country":"Switzerland","lat":47.558390000000003,"lon":7.5732699999999999}],"countries":["Switzerland"]},{"id":3434,"nct_id":"NCT04630964","title":"The Effect of Psilocybin on MDD Symptom Severity and Synaptic Density - A Single Dose Randomized, Double Blind, Placebo- Controlled Phase 2 Positron Emission Tomography Study","sponsor":"Section for Affective Disorders; Northern Stockholm Psychiatry","registry_url":"https://clinicaltrials.gov/study/NCT04630964","tracker_url":"publication.php?id=3434","status":"COMPLETED","status_label":"Completed","status_verified_date":"2024-04","last_update_date":"2024-04-19","start_date":"2021-01-01","primary_completion_date":"2023-04-19","completion_date":"2024-04-18","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":35,"type":"ACTUAL"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"QUADRUPLE"},"conditions":["Major Depressive Disorder","Depression"],"interventions":[{"name":"Psilocybin","type":"DRUG"},{"name":"Niacin","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"08ca08bcbae798f4e6b61831eefcfb8b407b6ae9119e1caf821ef346cd1389e6","facility":"Northern Stockholm Spychiatry Clinic","city":"Stockholm","region":"","country":"Sweden","lat":59.32938,"lon":18.068709999999999}],"countries":["Sweden"]},{"id":3697,"nct_id":"NCT04522804","title":"A Pilot Study of Psilocybin Enhanced Group Psychotherapy in Patients With Cancer","sponsor":"University of Utah","registry_url":"https://clinicaltrials.gov/study/NCT04522804","tracker_url":"publication.php?id=3697","status":"COMPLETED","status_label":"Completed","status_verified_date":"2024-03","last_update_date":"2024-03-20","start_date":"2021-10-04","primary_completion_date":"2022-06-11","completion_date":"2022-12-16","study_type":"INTERVENTIONAL","phases":["EARLY_PHASE1"],"enrollment":{"count":12,"type":"ACTUAL"},"design":{"allocation":"NA","intervention_model":"SINGLE_GROUP","primary_purpose":"TREATMENT","masking":"NONE"},"conditions":["Cancer"],"interventions":[{"name":"Psilocybin","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"be135dd6d3f7f605d0d633fc0bf5a818d78aa1bf95594c214d6c72a5b15b1206","facility":"Huntsman Cancer Institute","city":"Salt Lake City","region":"Utah","country":"United States","lat":40.760779999999997,"lon":-111.89105000000001}],"countries":["United States"]},{"id":3498,"nct_id":"NCT04218539","title":"Repeat Dosing of Psilocybin in Headache Disorders","sponsor":"Yale University","registry_url":"https://clinicaltrials.gov/study/NCT04218539","tracker_url":"publication.php?id=3498","status":"COMPLETED","status_label":"Completed","status_verified_date":"2024-02","last_update_date":"2024-02-09","start_date":"2021-08-10","primary_completion_date":"2023-11-05","completion_date":"2023-11-05","study_type":"INTERVENTIONAL","phases":["PHASE1"],"enrollment":{"count":18,"type":"ACTUAL"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"QUADRUPLE"},"conditions":["Migraine Headache"],"interventions":[{"name":"Psilocybin","type":"DRUG"},{"name":"Placebo","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"ef06e3a474fd2949d20a68ee09bed05400191915922ddddc3e80085918c45336","facility":"VA Connecticut Healthcare System","city":"West Haven","region":"Connecticut","country":"United States","lat":41.270650000000003,"lon":-72.947050000000004}],"countries":["United States"]},{"id":3518,"nct_id":"NCT05242029","title":"A Randomized, Double-Blind Study of Psilocybin for Opioid Use Disorder in Patients on Methadone Maintenance With Ongoing Opioid Use","sponsor":"Johns Hopkins University","registry_url":"https://clinicaltrials.gov/study/NCT05242029","tracker_url":"publication.php?id=3518","status":"WITHDRAWN","status_label":"Withdrawn","status_verified_date":"2024-01","last_update_date":"2024-02-02","start_date":"2023-12","primary_completion_date":"2024-02","completion_date":"2024-12","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":0,"type":"ACTUAL"},"design":{"allocation":"RANDOMIZED","intervention_model":"CROSSOVER","primary_purpose":"TREATMENT","masking":"QUADRUPLE"},"conditions":["Opioid Use Disorder"],"interventions":[{"name":"Placebo","type":"DRUG"},{"name":"Psilocybin","type":"DRUG"}],"substances":["psilocybin"],"sites":[],"countries":[]},{"id":3706,"nct_id":"NCT04227756","title":"Comparative Acute Effects of LSD, Psilocybin and Mescaline in a Random-Order Placebo-Controlled Cross-Over Study in Healthy Subjects","sponsor":"University Hospital, Basel, Switzerland","registry_url":"https://clinicaltrials.gov/study/NCT04227756","tracker_url":"publication.php?id=3706","status":"COMPLETED","status_label":"Completed","status_verified_date":"2024-01","last_update_date":"2024-01-24","start_date":"2020-05-19","primary_completion_date":"2022-09-02","completion_date":"2022-09-02","study_type":"INTERVENTIONAL","phases":["PHASE1"],"enrollment":{"count":32,"type":"ACTUAL"},"design":{"allocation":"RANDOMIZED","intervention_model":"CROSSOVER","primary_purpose":"BASIC_SCIENCE","masking":"QUADRUPLE"},"conditions":["Healthy"],"interventions":[{"name":"LSD","type":"DRUG"},{"name":"Psilocybin","type":"DRUG"},{"name":"Mescaline","type":"DRUG"},{"name":"Placebo","type":"OTHER"}],"substances":["psilocybin"],"sites":[{"key":"bc118043aa3f26bbd3206be4e9c03a0fb0cffd4b4da900e4718d4e5764570ea5","facility":"University Hospital Basel, Clinical Trial Unit","city":"Basel","region":"Canton of Basel-City","country":"Switzerland","lat":47.558390000000003,"lon":7.5732699999999999}],"countries":["Switzerland"]},{"id":3492,"nct_id":"NCT05381974","title":"The Effects of Psilocybin on Self-Focus and Self-Related Processing in Treatment Resistant MDD","sponsor":"Massachusetts General Hospital","registry_url":"https://clinicaltrials.gov/study/NCT05381974","tracker_url":"publication.php?id=3492","status":"WITHDRAWN","status_label":"Withdrawn","status_verified_date":"2024-01","last_update_date":"2024-01-24","start_date":"2022-09-15","primary_completion_date":"2023-06-01","completion_date":"2023-06-01","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":0,"type":"ACTUAL"},"design":{"allocation":"NA","intervention_model":"SINGLE_GROUP","primary_purpose":"BASIC_SCIENCE","masking":"NONE"},"conditions":["Treatment-Resistant Major Depressive Disorder"],"interventions":[{"name":"Psilocybin","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"ae85e9f90db4bd1845b2a9817e008d4a625ffc046123c8a22344695349c7e230","facility":"Athinoula A. Martinos Center for Biomedical Imaging","city":"Charlestown","region":"Massachusetts","country":"United States","lat":42.377870000000001,"lon":-71.061999999999998}],"countries":["United States"]},{"id":3499,"nct_id":"NCT05548075","title":"Psilocybin in Patients With Fibromyalgia: EEG-measured Brain Biomarkers of Action","sponsor":"Imperial College London","registry_url":"https://clinicaltrials.gov/study/NCT05548075","tracker_url":"publication.php?id=3499","status":"UNKNOWN","status_label":"Unknown status","status_verified_date":"2024-01","last_update_date":"2024-01-19","start_date":"2022-08-15","primary_completion_date":"2024-01-10","completion_date":"2024-07-30","study_type":"OBSERVATIONAL","phases":[],"enrollment":{"count":20,"type":"ESTIMATED"},"design":{"allocation":"","intervention_model":"","primary_purpose":"","masking":""},"conditions":["Fibromyalgia"],"interventions":[{"name":"Psilocybin","type":"DRUG"},{"name":"Therapeutic support","type":"BEHAVIORAL"}],"substances":["psilocybin"],"sites":[{"key":"bd9ef7ba5708708e271ac4223cd8f759659fe972f273d761152a6c0134e8622e","facility":"Imperial College London","city":"London","region":"","country":"United Kingdom","lat":51.50853,"lon":-0.12573999999999999}],"countries":["United Kingdom"]},{"id":3623,"nct_id":"NCT05562973","title":"Safety and Tolerability of Psilocybin in Post-Traumatic Stress Disorder","sponsor":"Johns Hopkins University","registry_url":"https://clinicaltrials.gov/study/NCT05562973","tracker_url":"publication.php?id=3623","status":"WITHDRAWN","status_label":"Withdrawn","status_verified_date":"2024-01","last_update_date":"2024-01-05","start_date":"2025-01","primary_completion_date":"2025-12","completion_date":"2025-12","study_type":"INTERVENTIONAL","phases":["PHASE1"],"enrollment":{"count":0,"type":"ACTUAL"},"design":{"allocation":"NON_RANDOMIZED","intervention_model":"SEQUENTIAL","primary_purpose":"TREATMENT","masking":"NONE"},"conditions":["Post-Traumatic Stress Disorder"],"interventions":[{"name":"Psilocybin","type":"DRUG"}],"substances":["psilocybin"],"sites":[],"countries":[]},{"id":3572,"nct_id":"NCT00979693","title":"Psilocybin-assisted Psychotherapy in the Management of Anxiety Associated With Stage IV Melanoma.","sponsor":"Multidisciplinary Association for Psychedelic Studies","registry_url":"https://clinicaltrials.gov/study/NCT00979693","tracker_url":"publication.php?id=3572","status":"WITHDRAWN","status_label":"Withdrawn","status_verified_date":"2023-12","last_update_date":"2023-12-26","start_date":"2012-01","primary_completion_date":"2013-04","completion_date":"2013-06","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":0,"type":"ACTUAL"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"QUADRUPLE"},"conditions":["Anxiety","Stage IV Melanoma"],"interventions":[{"name":"psilocybin","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"4326182cc3c941409c93d0ef63691280ed9c41889de2f55922782d475630190d","facility":"Mount Sinai Comprehensive Cancer Center","city":"Miami Beach","region":"Florida","country":"United States","lat":25.790649999999999,"lon":-80.130049999999997}],"countries":["United States"]},{"id":3549,"nct_id":"NCT02981173","title":"Safety and Efficacy of Psilocybin for the Treatment of Headache Disorders","sponsor":"Yale University","registry_url":"https://clinicaltrials.gov/study/NCT02981173","tracker_url":"publication.php?id=3549","status":"COMPLETED","status_label":"Completed","status_verified_date":"2023-12","last_update_date":"2023-12-15","start_date":"2016-12-05","primary_completion_date":"2022-06-30","completion_date":"2022-10-21","study_type":"INTERVENTIONAL","phases":["PHASE1"],"enrollment":{"count":25,"type":"ACTUAL"},"design":{"allocation":"RANDOMIZED","intervention_model":"CROSSOVER","primary_purpose":"TREATMENT","masking":"TRIPLE"},"conditions":["Cluster Headache"],"interventions":[{"name":"0.143 mg/kg Psilocybin or 10 mg Psilocybin","type":"DRUG"},{"name":"0.0143 mg/kg Psilocybin or 1 mg Psilocybin","type":"DRUG"},{"name":"Placebo","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"ef06e3a474fd2949d20a68ee09bed05400191915922ddddc3e80085918c45336","facility":"VA Connecticut Healthcare System","city":"West Haven","region":"Connecticut","country":"United States","lat":41.270650000000003,"lon":-72.947050000000004}],"countries":["United States"]},{"id":3629,"nct_id":"NCT06141876","title":"A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of Psilocybin-Assisted Psychotherapy in Treating Severe Depression Among Adults With Post-Traumatic Stress Disorder (PTSD).","sponsor":"Apex Labs Ltd.","registry_url":"https://clinicaltrials.gov/study/NCT06141876","tracker_url":"publication.php?id=3629","status":"UNKNOWN","status_label":"Unknown status","status_verified_date":"2023-11","last_update_date":"2023-11-29","start_date":"2023-12-15","primary_completion_date":"2025-06-15","completion_date":"2025-06-15","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":160,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"QUADRUPLE"},"conditions":["Post-traumatic Stress Disorder","Depression"],"interventions":[{"name":"APEX-002-A02","type":"DRUG"},{"name":"Placebo","type":"OTHER"}],"substances":["psilocybin"],"sites":[],"countries":[]},{"id":3680,"nct_id":"NCT04739865","title":"The Safety and Efficacy Of Psilocybin as an Adjunctive Therapy in Participants With Treatment Resistant Depression","sponsor":"COMPASS Pathways","registry_url":"https://clinicaltrials.gov/study/NCT04739865","tracker_url":"publication.php?id=3680","status":"COMPLETED","status_label":"Completed","status_verified_date":"2023-11","last_update_date":"2023-11-09","start_date":"2020-08-10","primary_completion_date":"2021-10-14","completion_date":"2021-10-14","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":19,"type":"ACTUAL"},"design":{"allocation":"NA","intervention_model":"SINGLE_GROUP","primary_purpose":"TREATMENT","masking":"NONE"},"conditions":["Treatment Resistant Depression"],"interventions":[{"name":"Psilocybin","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"b1132fa91c6c49bf3a7b5fc89a57fb89b94ff271a2081e8352dd7bd5a7ea4f1c","facility":"Kadima Neuropsychiatry Institute","city":"La Jolla","region":"California","country":"United States","lat":32.847270000000002,"lon":-117.27419999999999},{"key":"27288850d009a8b31ead8ba5cf86982457592df2fa39c3adaf10d04517cf8a5c","facility":"Sheaf House, Tallaght Hospital","city":"Dublin","region":"","country":"Ireland","lat":53.333060000000003,"lon":-6.2488900000000003}],"countries":["United States","Ireland"]},{"id":3619,"nct_id":"NCT03806985","title":"Safety and Efficacy of Psilocybin for the Treatment of Headache Disorders: Sub-Study II","sponsor":"Yale University","registry_url":"https://clinicaltrials.gov/study/NCT03806985","tracker_url":"publication.php?id=3619","status":"TERMINATED","status_label":"Terminated","status_verified_date":"2023-10","last_update_date":"2023-10-12","start_date":"2019-03-28","primary_completion_date":"2023-06-27","completion_date":"2023-06-27","study_type":"INTERVENTIONAL","phases":["PHASE1"],"enrollment":{"count":12,"type":"ACTUAL"},"design":{"allocation":"RANDOMIZED","intervention_model":"CROSSOVER","primary_purpose":"TREATMENT","masking":"DOUBLE"},"conditions":["Post-Traumatic Headache"],"interventions":[{"name":"Placebo oral capsule","type":"DRUG"},{"name":"Low Dose Psilocybin","type":"DRUG"},{"name":"High Dose Psilocybin","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"ef06e3a474fd2949d20a68ee09bed05400191915922ddddc3e80085918c45336","facility":"VA Connecticut Healthcare System","city":"West Haven","region":"Connecticut","country":"United States","lat":41.270650000000003,"lon":-72.947050000000004}],"countries":["United States"]},{"id":3569,"nct_id":"NCT03341689","title":"Safety and Efficacy of Psilocybin for the Treatment of Headache Disorders: Sub-Study I","sponsor":"Yale University","registry_url":"https://clinicaltrials.gov/study/NCT03341689","tracker_url":"publication.php?id=3569","status":"COMPLETED","status_label":"Completed","status_verified_date":"2023-10","last_update_date":"2023-10-12","start_date":"2017-11-01","primary_completion_date":"2021-04-30","completion_date":"2021-10-31","study_type":"INTERVENTIONAL","phases":["PHASE1"],"enrollment":{"count":14,"type":"ACTUAL"},"design":{"allocation":"RANDOMIZED","intervention_model":"CROSSOVER","primary_purpose":"TREATMENT","masking":"DOUBLE"},"conditions":["Migraine Headache"],"interventions":[{"name":"High Dose Psilocybin","type":"DRUG"},{"name":"Low Dose Psilocybin","type":"DRUG"},{"name":"Placebo","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"97fa1d69e8603abe5a3ef3a9d6071788707797dc09d271650fc5589a2d7cd901","facility":"VA Connecticut Healthcare System, West Haven Campus","city":"West Haven","region":"Connecticut","country":"United States","lat":41.270650000000003,"lon":-72.947050000000004}],"countries":["United States"]},{"id":3667,"nct_id":"NCT01534494","title":"Effects and Therapeutic Potential of Psilocybin in Alcohol Dependence","sponsor":"University of New Mexico","registry_url":"https://clinicaltrials.gov/study/NCT01534494","tracker_url":"publication.php?id=3667","status":"COMPLETED","status_label":"Completed","status_verified_date":"2023-09","last_update_date":"2023-09-26","start_date":"2012-01","primary_completion_date":"2013-09","completion_date":"2014-03","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":10,"type":"ACTUAL"},"design":{"allocation":"NA","intervention_model":"SINGLE_GROUP","primary_purpose":"TREATMENT","masking":"NONE"},"conditions":["Alcohol Dependence"],"interventions":[{"name":"Psilocybin","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"d761fe5f7a78138ff98cd1bb8712803a88c9a303339158053d3bf4cc3260d670","facility":"University of New Mexico Health Sciences Center","city":"Albuquerque","region":"New Mexico","country":"United States","lat":35.084490000000002,"lon":-106.65114}],"countries":["United States"]},{"id":3605,"nct_id":"NCT05780216","title":"Mindfulness and Psychedelics: A Combined Neurophenomenological and Pharmacological Approach to the Characterization of Mindfulness States in Experienced Meditators","sponsor":"Milan Scheidegger","registry_url":"https://clinicaltrials.gov/study/NCT05780216","tracker_url":"publication.php?id=3605","status":"COMPLETED","status_label":"Completed","status_verified_date":"2023-09","last_update_date":"2023-09-21","start_date":"2023-02-20","primary_completion_date":"2023-08-05","completion_date":"2023-09-15","study_type":"INTERVENTIONAL","phases":["EARLY_PHASE1"],"enrollment":{"count":40,"type":"ACTUAL"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"BASIC_SCIENCE","masking":"QUADRUPLE"},"conditions":["Healthy Participants"],"interventions":[{"name":"DMT + harmine","type":"DRUG"},{"name":"Placebo","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"b2f80bbc21f8f731c71b9ae4cd9db0e64fd8e3bd14ac7dbf1065c5b86be66a11","facility":"Psychiatric University Hospital Zurich","city":"Zurich","region":"","country":"Switzerland","lat":47.366669999999999,"lon":8.5500000000000007}],"countries":["Switzerland"]},{"id":3573,"nct_id":"NCT04141501","title":"Phase II, Randomized, Double Blind, Placebo Controlled, Parallel Group, Single Center Study of Psilocybin Efficacy and Mechanism in Alcohol Use Disorder","sponsor":"University of Zurich","registry_url":"https://clinicaltrials.gov/study/NCT04141501","tracker_url":"publication.php?id=3573","status":"COMPLETED","status_label":"Completed","status_verified_date":"2023-09","last_update_date":"2023-09-21","start_date":"2020-06-08","primary_completion_date":"2023-03-14","completion_date":"2023-09-14","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":37,"type":"ACTUAL"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"TRIPLE"},"conditions":["Alcohol Use Disorder"],"interventions":[{"name":"Psilocybin","type":"DRUG"},{"name":"Placebo oral capsule","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"963ff36be3d4be959779a50db385d5b17dd29d729076a98c276ec54e5bf5cfdd","facility":"Psychiatrische Universitätsklinik Zürich","city":"Zurich","region":"","country":"Switzerland","lat":47.366669999999999,"lon":8.5500000000000007}],"countries":["Switzerland"]},{"id":3543,"nct_id":"NCT06035900","title":"Phase 1, Open-Label, One-Treatment, Single-Dose, One-Period, Pharmacokinetic Study of Psilocin 4 mg as Its Mucic Acid Salt (L-130) Form, in Healthy Subjects Under Fasted Conditions","sponsor":"Lobe Sciences Ltd.","registry_url":"https://clinicaltrials.gov/study/NCT06035900","tracker_url":"publication.php?id=3543","status":"COMPLETED","status_label":"Completed","status_verified_date":"2023-09","last_update_date":"2023-09-13","start_date":"2023-06-21","primary_completion_date":"2023-07-30","completion_date":"2023-07-30","study_type":"INTERVENTIONAL","phases":["PHASE1"],"enrollment":{"count":10,"type":"ACTUAL"},"design":{"allocation":"NA","intervention_model":"SINGLE_GROUP","primary_purpose":"BASIC_SCIENCE","masking":"NONE"},"conditions":["Side Effect of Drug"],"interventions":[{"name":"Psilocin","type":"DRUG"}],"substances":["psilocybin","psilocin"],"sites":[{"key":"372b3cad1815f00ae861323f9482b2ae015f778ad15ef5ae35dd9e54c31af368","facility":"Pharmaceutical Research Unit","city":"Amman","region":"","country":"Jordan","lat":31.955220000000001,"lon":35.945030000000003}],"countries":["Jordan"]},{"id":3618,"nct_id":"NCT05478278","title":"A Phase 1, Two-Part Study in Healthy Volunteers to Evaluate The Effect of Psilocybin on Cardiac Repolarization and The Effect of Food on Psilocybin Pharmacokinetics","sponsor":"Usona Institute","registry_url":"https://clinicaltrials.gov/study/NCT05478278","tracker_url":"publication.php?id=3618","status":"COMPLETED","status_label":"Completed","status_verified_date":"2023-08","last_update_date":"2023-08-15","start_date":"2022-06-22","primary_completion_date":"2023-08-09","completion_date":"2023-08-09","study_type":"INTERVENTIONAL","phases":["PHASE1"],"enrollment":{"count":60,"type":"ACTUAL"},"design":{"allocation":"RANDOMIZED","intervention_model":"CROSSOVER","primary_purpose":"TREATMENT","masking":"TRIPLE"},"conditions":["QTc Interval","Pharmacokinetics"],"interventions":[{"name":"Psilocybin","type":"DRUG"},{"name":"Moxifloxacin","type":"DRUG"},{"name":"Micro-Crystalline Cellulose","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"c1ae66a93c93e2e1e5f32a14c0f481e169db396e25ea7da6058e79087f8bffe5","facility":"Altasciences Clinical Kansas, Inc","city":"Overland Park","region":"Kansas","country":"United States","lat":38.982230000000001,"lon":-94.670789999999997}],"countries":["United States"]},{"id":3519,"nct_id":"NCT05029466","title":"The Efficacy and Tolerability of Psilocybin in Participants With Treatment-Resistant Depression: a Phase 2, Randomized Feasibility Study","sponsor":"Brain and Cognition Discovery Foundation","registry_url":"https://clinicaltrials.gov/study/NCT05029466","tracker_url":"publication.php?id=3519","status":"COMPLETED","status_label":"Completed","status_verified_date":"2023-07","last_update_date":"2023-07-27","start_date":"2021-11-19","primary_completion_date":"2023-07-22","completion_date":"2023-07-22","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":30,"type":"ACTUAL"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"NONE"},"conditions":["Treatment Resistant Depression"],"interventions":[{"name":"Psilocybin","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"25aca439e042e37bcb80c657bd30517c9daccd35fcab6328ee61c917337dfdd8","facility":"Canadian Rapid Treatment Centre of Excellence (CRTCE)","city":"Mississauga","region":"Ontario","country":"Canada","lat":43.578899999999997,"lon":-79.658299999999997}],"countries":["Canada"]},{"id":3470,"nct_id":"NCT05958758","title":"An Open Label Pragmatic Feasibility Study on a Resilience Focused Community of Practice Program With Psilocybin-assisted Therapy (PaT) for End-of-Life Patients.","sponsor":"The Roots to Thrive Society for Psychedelic Therapy","registry_url":"https://clinicaltrials.gov/study/NCT05958758","tracker_url":"publication.php?id=3470","status":"UNKNOWN","status_label":"Unknown status","status_verified_date":"2023-07","last_update_date":"2023-07-25","start_date":"2023-09-01","primary_completion_date":"2025-04-30","completion_date":"2025-10-31","study_type":"INTERVENTIONAL","phases":["EARLY_PHASE1"],"enrollment":{"count":64,"type":"ESTIMATED"},"design":{"allocation":"NA","intervention_model":"SINGLE_GROUP","primary_purpose":"TREATMENT","masking":"NONE"},"conditions":["End of Life"],"interventions":[{"name":"Psilocybin-assisted therapy within a community of practice model (group administered)","type":"DRUG"}],"substances":["psilocybin"],"sites":[],"countries":[]},{"id":3449,"nct_id":"NCT05594667","title":"Evaluating the Effect of Length of Time on Selective Serotonin Reuptake Inhibitors (SSRIs) on the Response to Psilocybin-assisted Therapy in Individuals With Mild-moderate Major Depressive Disorder (MDD)","sponsor":"Cybin Therapeutics Inc.","registry_url":"https://clinicaltrials.gov/study/NCT05594667","tracker_url":"publication.php?id=3449","status":"WITHDRAWN","status_label":"Withdrawn","status_verified_date":"2023-07","last_update_date":"2023-07-06","start_date":"2023-01-01","primary_completion_date":"2023-03-14","completion_date":"2023-03-14","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":0,"type":"ACTUAL"},"design":{"allocation":"NA","intervention_model":"SINGLE_GROUP","primary_purpose":"TREATMENT","masking":"NONE"},"conditions":["Depression","Major Depressive Disorder","Mild Depression","Moderate Depression","Depressive Disorder"],"interventions":[{"name":"Psilocybin","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"a548c29a91f00e104ef28ac8ad761250fc7cefa257637d971bae85c1e19fc9fc","facility":"Centre for Neurology Studies x Upstream","city":"Abbotsford British Columbia","region":"British Columbia","country":"Canada","lat":49.057980000000001,"lon":-122.25257000000001}],"countries":["Canada"]},{"id":3538,"nct_id":"NCT05243329","title":"Investigating the Therapeutic Effects of Psilocybin in Treatment-Resistant Post-Traumatic Stress Disorder","sponsor":"Halucenex Life Sciences Inc.","registry_url":"https://clinicaltrials.gov/study/NCT05243329","tracker_url":"publication.php?id=3538","status":"UNKNOWN","status_label":"Unknown status","status_verified_date":"2023-06","last_update_date":"2023-06-29","start_date":"2022-10-03","primary_completion_date":"2023-10-30","completion_date":"2023-12-30","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":20,"type":"ESTIMATED"},"design":{"allocation":"NA","intervention_model":"SINGLE_GROUP","primary_purpose":"HEALTH_SERVICES_RESEARCH","masking":"NONE"},"conditions":["Treatment Resistant Disorders","Post Traumatic Stress Disorder"],"interventions":[{"name":"Psilocybin","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"d7257b7fd44162d83dfa116702665c090a51c6ae85a769c73bad67cf2d2ceb74","facility":"Halucenex Life Sciences Inc.","city":"Windsor","region":"Nova Scotia","country":"Canada","lat":44.983449999999998,"lon":-64.132040000000003}],"countries":["Canada"]},{"id":3475,"nct_id":"NCT05876481","title":"Evaluation of the Acceptability, Safety, Feasibility, and Efficacy of Psilocybin-assisted Psychotherapy (PaP) for the Treatment of Post-traumatic Stress Disorder (PTSD) in Military Veterans","sponsor":"Combat Stress","registry_url":"https://clinicaltrials.gov/study/NCT05876481","tracker_url":"publication.php?id=3475","status":"UNKNOWN","status_label":"Unknown status","status_verified_date":"2023-05","last_update_date":"2023-05-25","start_date":"2023-06","primary_completion_date":"2025-07","completion_date":"2025-08","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":8,"type":"ESTIMATED"},"design":{"allocation":"NA","intervention_model":"SINGLE_GROUP","primary_purpose":"TREATMENT","masking":"NONE"},"conditions":["PTSD"],"interventions":[{"name":"Psilocybin","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"9b630a2a90cc4073ef88d0ddbb37bf0acd68f69db35ab18518826ea459738714","facility":"Combat Stress","city":"Leatherhead","region":"Surrey","country":"United Kingdom","lat":51.296520000000001,"lon":-0.33379999999999999}],"countries":["United Kingdom"]},{"id":3683,"nct_id":"NCT04842045","title":"Recall of Experience and Conscious Awareness in Psilocybin Treatment of Depression (The RECAP Study): Pilot Phase in Healthy Adult Volunteers","sponsor":"University of Wisconsin, Madison","registry_url":"https://clinicaltrials.gov/study/NCT04842045","tracker_url":"publication.php?id=3683","status":"COMPLETED","status_label":"Completed","status_verified_date":"2023-05","last_update_date":"2023-05-19","start_date":"2021-05-21","primary_completion_date":"2022-11-17","completion_date":"2022-11-17","study_type":"INTERVENTIONAL","phases":["PHASE1"],"enrollment":{"count":8,"type":"ACTUAL"},"design":{"allocation":"NA","intervention_model":"SINGLE_GROUP","primary_purpose":"TREATMENT","masking":"NONE"},"conditions":["Psychedelic Experiences","Amnesia"],"interventions":[{"name":"Psilocybin and Midazolam","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"47a84d20902561e3e1fff1f955d9e2b25ff749b49e7a043201a36eaa8d67beee","facility":"UWHealth, 600 Highland Avenue","city":"Madison","region":"Wisconsin","country":"United States","lat":43.073050000000002,"lon":-89.401229999999998}],"countries":["United States"]},{"id":3634,"nct_id":"NCT05467761","title":"A Phase 1 Study Comparing the Pharmacokinetics and Safety of Intravenous and Oral Psilocybin","sponsor":"University of Wisconsin, Madison","registry_url":"https://clinicaltrials.gov/study/NCT05467761","tracker_url":"publication.php?id=3634","status":"WITHDRAWN","status_label":"Withdrawn","status_verified_date":"2023-05","last_update_date":"2023-05-15","start_date":"2023-06","primary_completion_date":"2024-03","completion_date":"2024-03","study_type":"INTERVENTIONAL","phases":["PHASE1"],"enrollment":{"count":0,"type":"ACTUAL"},"design":{"allocation":"NA","intervention_model":"SINGLE_GROUP","primary_purpose":"BASIC_SCIENCE","masking":"NONE"},"conditions":["Healthy"],"interventions":[{"name":"Oral Psilocybin","type":"DRUG"},{"name":"IV Psilocybin","type":"DRUG"}],"substances":["psilocybin","psilocin"],"sites":[{"key":"0fef037c24d643378aa9f37a26412f8308ddc2ac490d10c8ef10ee242ac4bfb8","facility":"University of Wisconsin","city":"Madison","region":"Wisconsin","country":"United States","lat":43.073050000000002,"lon":-89.401229999999998}],"countries":["United States"]},{"id":3463,"nct_id":"NCT04052568","title":"Effects of Psilocybin in Anorexia Nervosa","sponsor":"Johns Hopkins University","registry_url":"https://clinicaltrials.gov/study/NCT04052568","tracker_url":"publication.php?id=3463","status":"COMPLETED","status_label":"Completed","status_verified_date":"2023-05","last_update_date":"2023-05-06","start_date":"2019-08-26","primary_completion_date":"2022-01-05","completion_date":"2023-04-20","study_type":"INTERVENTIONAL","phases":["PHASE1"],"enrollment":{"count":22,"type":"ACTUAL"},"design":{"allocation":"NA","intervention_model":"SINGLE_GROUP","primary_purpose":"TREATMENT","masking":"NONE"},"conditions":["Anorexia Nervosa"],"interventions":[{"name":"Psilocybin","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"c99816974f0fb391132ed7769c5eb4ada168032749e3008faafa7d34aaedf88d","facility":"Behavioral Pharmacology Research Unit","city":"Baltimore","region":"Maryland","country":"United States","lat":39.290379999999999,"lon":-76.612189999999998}],"countries":["United States"]},{"id":3563,"nct_id":"NCT03775200","title":"The Safety and Efficacy of Psilocybin in Participants With Treatment Resistant Depression","sponsor":"COMPASS Pathways","registry_url":"https://clinicaltrials.gov/study/NCT03775200","tracker_url":"publication.php?id=3563","status":"COMPLETED","status_label":"Completed","status_verified_date":"2023-04","last_update_date":"2023-04-24","start_date":"2019-03-01","primary_completion_date":"2021-07-30","completion_date":"2021-09-27","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":233,"type":"ACTUAL"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"QUADRUPLE"},"conditions":["Treatment Resistant Depression"],"interventions":[{"name":"Psilocybin","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"b1132fa91c6c49bf3a7b5fc89a57fb89b94ff271a2081e8352dd7bd5a7ea4f1c","facility":"Kadima Neuropsychiatry Institute","city":"La Jolla","region":"California","country":"United States","lat":32.847270000000002,"lon":-117.27419999999999},{"key":"b902b2ed0312cb2a3cc5ba1cbae37f314afc33004604dfd9c9cef9895f4cf659","facility":"Altman Clinical and Translational Research Institute, University of California","city":"San Diego","region":"California","country":"United States","lat":32.715710000000001,"lon":-117.16472},{"key":"98e89c02051d49d5ecbaeeb42b54b85d2011fdba360a21f7bb381022221609db","facility":"Stanford Department of Psychiatry","city":"Stanford","region":"California","country":"United States","lat":37.424109999999999,"lon":-122.16607999999999},{"key":"4a761e46fb0059d7f502f97e7ff683ed2ef7e77e5bb9c131a2f074aa39eba6a4","facility":"Mood and Anxiety Disorders Program Emory University School of Medicine","city":"Atlanta","region":"Georgia","country":"United States","lat":33.749000000000002,"lon":-84.387979999999999},{"key":"f364e291f7f50ffe0211133728e04e54d4b08d8bbf7f1e2e84acca880af73791","facility":"Ray Worthy Psychiatry LLC","city":"New Orleans","region":"Louisiana","country":"United States","lat":29.954650000000001,"lon":-90.075069999999997},{"key":"bc376e1e0a696ea23f74184c3639e3209c4cf2754b05d49dcebccf226428bc05","facility":"Sheppard Pratt Health System","city":"Baltimore","region":"Maryland","country":"United States","lat":39.290379999999999,"lon":-76.612189999999998},{"key":"9f6dd6c250948ab5fb811774c2613bdc33238e29b80a54c99b31bd3b33684089","facility":"New York State Psychiatric Institute","city":"New York","region":"New York","country":"United States","lat":40.714269999999999,"lon":-74.005970000000005},{"key":"bc6f21f5dce4d260a52c1cf80e4684418e2cef5172a8a249513f0bd649090cc4","facility":"UT Center of Excellence on Mood Disorders, University of Texas Health Science Center","city":"Houston","region":"Texas","country":"United States","lat":29.763280000000002,"lon":-95.36327},{"key":"4518bb99925a2afc34b082750c6bbd85e5a2401e5aedd715ecf330439d7becd3","facility":"Canadian Rapid Treatment Centre of Excellence","city":"Mississauga","region":"Ontario","country":"Canada","lat":43.578899999999997,"lon":-79.658299999999997},{"key":"bf2adfb756d244974a952f7c5c58e6f72f66cbbd5ba63e61a8b987fa1820f128","facility":"Centre for Addiction and Mental Health","city":"Toronto","region":"Ontario","country":"Canada","lat":43.706429999999997,"lon":-79.39864},{"key":"fcbe4ef7ab96b23d49f2236d5eef4a63ae4ba8b1ef6fda33e2d4ecdfcd59a37c","facility":"National Institute of Mental Health Czech Republic","city":"Klecany","region":"","country":"Czechia","lat":50.175989999999999,"lon":14.411479999999999},{"key":"4325121d3f92a59587a95d740aec742f926476ae029c126cfb5dca75235c060c","facility":"Enhed for Psykiatrisk Forskning, Psykiatrien i Aalborg","city":"Aalborg","region":"","country":"Denmark","lat":57.048000000000002,"lon":9.9186999999999994},{"key":"acb48d7ccc1915a74261eb4d19980566f9e91227b002d29827c3b573468fca20","facility":"Charité - Universitätsmedizin Berlin, Department of Psychiatry and Psychotherapy, Campus Benjamin Franklin","city":"Berlin","region":"","country":"Germany","lat":52.524369999999998,"lon":13.41053},{"key":"1936d05fa8ae325b9934cffa0a0c3f08afa8e902d6fe3597cf7ffaec91b70308","facility":"Tallaght University Hospital","city":"Dublin","region":"","country":"Ireland","lat":53.333060000000003,"lon":-6.2488900000000003},{"key":"4676f983baba50649c69d87e10227647f558552da403e1c02eb74db43f5954ef","facility":"Groningen University Medical Centre","city":"Groningen","region":"","country":"Netherlands","lat":53.219169999999998,"lon":6.5666700000000002},{"key":"e3f0197997fa9570956493b45ec7d746c6d8470a0084194ccfaca38d381335d5","facility":"Leiden University Medical Centre","city":"Leiden","region":"","country":"Netherlands","lat":52.158329999999999,"lon":4.4930599999999998},{"key":"8739aa2791a55723dbde929d6b1781e8da3c89797ac9f3c5cdcebc53f0be213d","facility":"Utrecht University Medical Centre","city":"Utrecht","region":"","country":"Netherlands","lat":52.090829999999997,"lon":5.1222200000000004},{"key":"0825127fed75b48491c482e72ff85f37b6d6a30ff270fa31a00aa738dfdab8b5","facility":"Unidade de Neuropsiquiatria, Centro Clinico Champalimaud","city":"Lisbon","region":"","country":"Portugal","lat":38.725090000000002,"lon":-9.1498000000000008},{"key":"8f7b027dc17f2a210264a5079ecaf11ec7851ea8acc52e06427fe3f08b1d2d69","facility":"Hospital de Dia Numancia","city":"Barcelona","region":"","country":"Spain","lat":41.38879,"lon":2.1589900000000002},{"key":"591cc23da3dbb467891a35aca8c18e00a3a00b36e679e2bc3a5c63f9cf912dff","facility":"Institute Hospital del Mar of Medical Research (IMIM)","city":"Barcelona","region":"","country":"Spain","lat":41.38879,"lon":2.1589900000000002},{"key":"4cb30a0cc2db1ef7bb013544a9f7756b74181b28b02d444b55518e6a7c5edd95","facility":"Clinical Research and Imaging Centre","city":"Bristol","region":"Avon","country":"United Kingdom","lat":51.45523,"lon":-2.5966499999999999},{"key":"ca5a318b9a8ab497d31d6e617a67f5536afaff42907d21d3392ac8c92cf5b910","facility":"Wolfson Research Centre, Campus for Ageing and Vitality","city":"Newcastle upon Tyne","region":"Tyne and Wear","country":"United Kingdom","lat":54.973280000000003,"lon":-1.6139600000000001},{"key":"2af6f49013d0328846d4ce8ee776c303f013ff687e95fd27fa857af0c681008b","facility":"St. Pancras Clinical Research","city":"London","region":"","country":"United Kingdom","lat":51.50853,"lon":-0.12573999999999999},{"key":"190dd76ab65ad7b28570cf2992585e62e7281887f8f4acc4cc7ee1b0ebcb7c7e","facility":"Kings College London, Institute of Psychiatry, Psychology and Neurology","city":"London","region":"","country":"United Kingdom","lat":51.50853,"lon":-0.12573999999999999},{"key":"49c938f65ac4e8234198d3d31829a1e4505a68760ed1739762448f71dbb85a8c","facility":"Greater Manchester Mental Health Foundation Trust","city":"Manchester","region":"","country":"United Kingdom","lat":53.48095,"lon":-2.2374299999999998}],"countries":["United States","Canada","Czechia","Denmark","Germany","Ireland","Netherlands","Portugal","Spain","United Kingdom"]},{"id":3468,"nct_id":"NCT04849013","title":"Role of the Serotonin 5-HT2A Receptor in Mescaline-induced Altered States of Consciousness","sponsor":"University Hospital, Basel, Switzerland","registry_url":"https://clinicaltrials.gov/study/NCT04849013","tracker_url":"publication.php?id=3468","status":"COMPLETED","status_label":"Completed","status_verified_date":"2023-03","last_update_date":"2023-03-29","start_date":"2021-08-11","primary_completion_date":"2023-03-27","completion_date":"2023-03-27","study_type":"INTERVENTIONAL","phases":["PHASE1"],"enrollment":{"count":16,"type":"ACTUAL"},"design":{"allocation":"RANDOMIZED","intervention_model":"CROSSOVER","primary_purpose":"BASIC_SCIENCE","masking":"QUADRUPLE"},"conditions":["Healthy"],"interventions":[{"name":"Placebo","type":"DRUG"},{"name":"Mescaline 100mg","type":"DRUG"},{"name":"Mescaline 200mg","type":"DRUG"},{"name":"Mescaline 400mg","type":"DRUG"},{"name":"Mescaline 800mg","type":"DRUG"},{"name":"Mescaline 800mg + Ketanserin 40mg","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"bc118043aa3f26bbd3206be4e9c03a0fb0cffd4b4da900e4718d4e5764570ea5","facility":"University Hospital Basel, Clinical Trial Unit","city":"Basel","region":"Canton of Basel-City","country":"Switzerland","lat":47.558390000000003,"lon":7.5732699999999999}],"countries":["Switzerland"]},{"id":3433,"nct_id":"NCT05252598","title":"Mood and Cognitive Effects of Low Doses of Psilocybin Observed in Healthy Subjects (\"MELO\"): A Blinded, Placebo-Controlled, Dose-Finding Study","sponsor":"Optimi Health Corporation","registry_url":"https://clinicaltrials.gov/study/NCT05252598","tracker_url":"publication.php?id=3433","status":"WITHDRAWN","status_label":"Withdrawn","status_verified_date":"2023-03","last_update_date":"2023-03-20","start_date":"2023-01","primary_completion_date":"2023-08","completion_date":"2023-12","study_type":"INTERVENTIONAL","phases":["EARLY_PHASE1"],"enrollment":{"count":0,"type":"ACTUAL"},"design":{"allocation":"RANDOMIZED","intervention_model":"SINGLE_GROUP","primary_purpose":"TREATMENT","masking":"QUADRUPLE"},"conditions":["Mood Disturbance","Mood Change","Sleep Disturbance","Drug Effect","Psychedelic Experiences","Health, Subjective","Psilocin Toxicity","Psilocybin Toxicity","Psilocybin Causing Adverse Effects in Therapeutic Use","Anxiety"],"interventions":[{"name":"Psilocybin","type":"DRUG"},{"name":"Inonotus Obliquus Whole Extract","type":"DRUG"}],"substances":["psilocybin","psilocin"],"sites":[],"countries":[]},{"id":3524,"nct_id":"NCT04656301","title":"Safety and Efficacy of Psilocybin for Body Dysmorphic Disorder","sponsor":"New York State Psychiatric Institute","registry_url":"https://clinicaltrials.gov/study/NCT04656301","tracker_url":"publication.php?id=3524","status":"COMPLETED","status_label":"Completed","status_verified_date":"2023-02","last_update_date":"2023-03-13","start_date":"2021-02-26","primary_completion_date":"2022-11-02","completion_date":"2022-11-02","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":12,"type":"ACTUAL"},"design":{"allocation":"NA","intervention_model":"SINGLE_GROUP","primary_purpose":"TREATMENT","masking":"NONE"},"conditions":["Body Dysmorphic Disorders"],"interventions":[{"name":"Psilocybin","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"abe2a0347c9a44ae241f4c2ee5f16cf0ec3542f9eaaaf340b9331c306c8d45ee","facility":"New York State Psychiatric Institute, 1051 Riverside Drive","city":"New York","region":"New York","country":"United States","lat":40.714269999999999,"lon":-74.005970000000005}],"countries":["United States"]},{"id":3695,"nct_id":"NCT05601648","title":"SV2A Marker of Synaptogenesis in a Clinical Trial of Psilocybin for Depression","sponsor":"Washington University School of Medicine","registry_url":"https://clinicaltrials.gov/study/NCT05601648","tracker_url":"publication.php?id=3695","status":"WITHDRAWN","status_label":"Withdrawn","status_verified_date":"2023-01","last_update_date":"2023-01-30","start_date":"2023-07-01","primary_completion_date":"2025-01-01","completion_date":"2025-07-01","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":0,"type":"ACTUAL"},"design":{"allocation":"NA","intervention_model":"SINGLE_GROUP","primary_purpose":"TREATMENT","masking":"NONE"},"conditions":["Major Depressive Disorder","Anhedonia"],"interventions":[{"name":"Psilocybin","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"c3de2ce8933f517f3be34bd70e3809569645c3f60c38d874765d86ee599b4223","facility":"Washington University School of Medicine","city":"St Louis","region":"Missouri","country":"United States","lat":38.627270000000003,"lon":-90.197890000000001}],"countries":["United States"]},{"id":3568,"nct_id":"NCT04410913","title":"Pilot Trial of Visual Healing®, a Nature-themed Virtual Immersive Experience, to Optimize Set and Setting in Psilocybin-assisted Therapy for Alcohol Use Disorder","sponsor":"Keith Heinzerling","registry_url":"https://clinicaltrials.gov/study/NCT04410913","tracker_url":"publication.php?id=3568","status":"ACTIVE_NOT_RECRUITING","status_label":"Active, not recruiting","status_verified_date":"2023-01","last_update_date":"2023-01-17","start_date":"2021-02-18","primary_completion_date":"2023-02","completion_date":"2023-02","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":20,"type":"ACTUAL"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"NONE"},"conditions":["Alcohol Use Disorder"],"interventions":[{"name":"Psilocybin plus Visual Healing Set and Setting","type":"DRUG"},{"name":"Psilocybin plus Standard Set and Setting","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"16d9ba9702f70f239da1a221cfefc364c6d5b87b4d0db3a5b080e4cd80046ae8","facility":"Pacific Treatment & Research in Psychedelics","city":"Santa Monica","region":"California","country":"United States","lat":34.019489999999998,"lon":-118.49138000000001}],"countries":["United States"]},{"id":3639,"nct_id":"NCT05042466","title":"NW Trauma Therapies, Chronic Illness of Chronic Depression, PTSD, MS, HIV, and SARS-CoV-2, Long Haulers Syndrome. Treatment of Unregulaaible Trauma by the Treatment of Enhanced Micro Dosing the Levels of 0.15, Thru 0.33, With a Maintenance Dose of 1 Gram Per Month for Neural Pathway Increase of Non Synthesized Psilocybin, Using the Actual Plant to Regulate the Highjacked Nervous System.","sponsor":"NWTraumatherapies","registry_url":"https://clinicaltrials.gov/study/NCT05042466","tracker_url":"publication.php?id=3639","status":"UNKNOWN","status_label":"Unknown status","status_verified_date":"2022-11","last_update_date":"2022-11-16","start_date":"2023-09-03","primary_completion_date":"2025-08-30","completion_date":"2025-10-03","study_type":"INTERVENTIONAL","phases":["PHASE1"],"enrollment":{"count":30,"type":"ESTIMATED"},"design":{"allocation":"NON_RANDOMIZED","intervention_model":"SINGLE_GROUP","primary_purpose":"TREATMENT","masking":"TRIPLE"},"conditions":["Trauma, Nervous System"],"interventions":[{"name":"Trauma","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"187f9016fa20748a1f0b5436017e547660508fd4ed996a1485b5172a8705a463","facility":"Ross Allison NPI #1437519899 Administrator Of Study","city":"Bozeman","region":"Montana","country":"United States","lat":45.679650000000002,"lon":-111.03856}],"countries":["United States"]},{"id":3442,"nct_id":"NCT02061293","title":"A Double-Blind Trial of Psilocybin-Assisted Treatment of Alcohol Dependence","sponsor":"NYU Langone Health","registry_url":"https://clinicaltrials.gov/study/NCT02061293","tracker_url":"publication.php?id=3442","status":"COMPLETED","status_label":"Completed","status_verified_date":"2022-10","last_update_date":"2022-11-08","start_date":"2014-06","primary_completion_date":"2021-07-30","completion_date":"2021-07-30","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":95,"type":"ACTUAL"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"QUADRUPLE"},"conditions":["Alcohol Dependence"],"interventions":[{"name":"Psilocybin","type":"DRUG"},{"name":"Diphenhydramine","type":"DRUG"},{"name":"Motivational Enhancement and Taking Action (META)","type":"BEHAVIORAL"}],"substances":["psilocybin"],"sites":[{"key":"d761fe5f7a78138ff98cd1bb8712803a88c9a303339158053d3bf4cc3260d670","facility":"University of New Mexico Health Sciences Center","city":"Albuquerque","region":"New Mexico","country":"United States","lat":35.084490000000002,"lon":-106.65114},{"key":"2715c70c5a3cf61074816c8f4c0e3981b0c63530ec8157146313a3c8963e5794","facility":"Clinical and Translational Science Institute, NYU Langone Medical Center","city":"New York","region":"New York","country":"United States","lat":40.714269999999999,"lon":-74.005970000000005}],"countries":["United States"]},{"id":3461,"nct_id":"NCT04433845","title":"The Safety and Efficacy of Psilocybin in Participants With Type 2 Bipolar Disorder (BP-II) Depression.","sponsor":"Sheppard Pratt Health System","registry_url":"https://clinicaltrials.gov/study/NCT04433845","tracker_url":"publication.php?id=3461","status":"UNKNOWN","status_label":"Unknown status","status_verified_date":"2022-10","last_update_date":"2022-10-25","start_date":"2021-03-01","primary_completion_date":"2023-01-15","completion_date":"2023-04-15","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":15,"type":"ACTUAL"},"design":{"allocation":"NA","intervention_model":"SINGLE_GROUP","primary_purpose":"TREATMENT","masking":"NONE"},"conditions":["Treatment Resistant Depression"],"interventions":[{"name":"Psilocybin","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"9676aa62be8612c7fce92ed8df2903ba93533215f56626938a83ac502dae0874","facility":"Sheppard Pratt","city":"Baltimore","region":"Maryland","country":"United States","lat":39.290379999999999,"lon":-76.612189999999998}],"countries":["United States"]},{"id":3685,"nct_id":"NCT04905121","title":"An Exploratory Open-Label, Phase 1b, Ascending Dose Study to Evaluate the Effects of Oral 3-[2-(Dimethylamino)Ethyl]-1h-indol-4-yl Dihydrogen Phosphate (Psilocybin, BPL-PSILO) on Cognition in Patients With Chronic Short-Lasting Unilateral Neuralgiform Headache Attacks (SUNHA)","sponsor":"Beckley Psytech Limited","registry_url":"https://clinicaltrials.gov/study/NCT04905121","tracker_url":"publication.php?id=3685","status":"TERMINATED","status_label":"Terminated","status_verified_date":"2022-10","last_update_date":"2022-10-12","start_date":"2021-08-11","primary_completion_date":"2022-04-22","completion_date":"2022-04-22","study_type":"INTERVENTIONAL","phases":["PHASE1"],"enrollment":{"count":4,"type":"ACTUAL"},"design":{"allocation":"NA","intervention_model":"SINGLE_GROUP","primary_purpose":"TREATMENT","masking":"NONE"},"conditions":["Short Lasting Unilateral Neuralgiform Headache Attacks"],"interventions":[{"name":"Psilocybin","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"a2a4ed472d0c860a706d8a130661a9baa3742799c37bd96f2f64a1cdd0866b66","facility":"King's College London","city":"London","region":"","country":"United Kingdom","lat":51.50853,"lon":-0.12573999999999999}],"countries":["United Kingdom"]},{"id":3477,"nct_id":"NCT04519957","title":"Multicentre Study To Assess Safety And Efficacy Of Psilocybin In Patients With Treatment-Resistant Depression Following Completion Of COMP 001 And COMP 003 Trials (P-TRD LTFU)","sponsor":"COMPASS Pathways","registry_url":"https://clinicaltrials.gov/study/NCT04519957","tracker_url":"publication.php?id=3477","status":"COMPLETED","status_label":"Completed","status_verified_date":"2022-09","last_update_date":"2022-09-22","start_date":"2020-07-20","primary_completion_date":"2022-08-11","completion_date":"2022-08-11","study_type":"OBSERVATIONAL","phases":[],"enrollment":{"count":66,"type":"ACTUAL"},"design":{"allocation":"","intervention_model":"","primary_purpose":"","masking":""},"conditions":["Treatment Resistant Depression"],"interventions":[],"substances":["psilocybin"],"sites":[{"key":"b1132fa91c6c49bf3a7b5fc89a57fb89b94ff271a2081e8352dd7bd5a7ea4f1c","facility":"Kadima Neuropsychiatry Institute","city":"La Jolla","region":"California","country":"United States","lat":32.847270000000002,"lon":-117.27419999999999},{"key":"b902b2ed0312cb2a3cc5ba1cbae37f314afc33004604dfd9c9cef9895f4cf659","facility":"Altman Clinical and Translational Research Institute, University of California","city":"San Diego","region":"California","country":"United States","lat":32.715710000000001,"lon":-117.16472},{"key":"4a761e46fb0059d7f502f97e7ff683ed2ef7e77e5bb9c131a2f074aa39eba6a4","facility":"Mood and Anxiety Disorders Program Emory University School of Medicine","city":"Atlanta","region":"Georgia","country":"United States","lat":33.749000000000002,"lon":-84.387979999999999},{"key":"bc6f21f5dce4d260a52c1cf80e4684418e2cef5172a8a249513f0bd649090cc4","facility":"UT Center of Excellence on Mood Disorders, University of Texas Health Science Center","city":"Houston","region":"Texas","country":"United States","lat":29.763280000000002,"lon":-95.36327},{"key":"fcbe4ef7ab96b23d49f2236d5eef4a63ae4ba8b1ef6fda33e2d4ecdfcd59a37c","facility":"National Institute of Mental Health Czech Republic","city":"Klecany","region":"","country":"Czechia","lat":50.175989999999999,"lon":14.411479999999999},{"key":"27288850d009a8b31ead8ba5cf86982457592df2fa39c3adaf10d04517cf8a5c","facility":"Sheaf House, Tallaght Hospital","city":"Dublin","region":"","country":"Ireland","lat":53.333060000000003,"lon":-6.2488900000000003},{"key":"4676f983baba50649c69d87e10227647f558552da403e1c02eb74db43f5954ef","facility":"Groningen University Medical Centre","city":"Groningen","region":"","country":"Netherlands","lat":53.219169999999998,"lon":6.5666700000000002},{"key":"190dd76ab65ad7b28570cf2992585e62e7281887f8f4acc4cc7ee1b0ebcb7c7e","facility":"Kings College London, Institute of Psychiatry, Psychology and Neurology","city":"London","region":"","country":"United Kingdom","lat":51.50853,"lon":-0.12573999999999999}],"countries":["United States","Czechia","Ireland","Netherlands","United Kingdom"]},{"id":3554,"nct_id":"NCT04280055","title":"Prophylactic Effects of Psilocybin on Chronic Cluster Headache: an Open-label Clinical Trial and Neuroimaging Study","sponsor":"Gitte Moos Knudsen","registry_url":"https://clinicaltrials.gov/study/NCT04280055","tracker_url":"publication.php?id=3554","status":"TERMINATED","status_label":"Terminated","status_verified_date":"2022-08","last_update_date":"2022-08-10","start_date":"2020-01-21","primary_completion_date":"2020-11-01","completion_date":"2022-06-01","study_type":"INTERVENTIONAL","phases":["PHASE1","PHASE2"],"enrollment":{"count":10,"type":"ACTUAL"},"design":{"allocation":"NA","intervention_model":"SINGLE_GROUP","primary_purpose":"TREATMENT","masking":"NONE"},"conditions":["Cluster Headache"],"interventions":[{"name":"Psilocybin","type":"DRUG"}],"substances":["psilocybin","psilocin"],"sites":[{"key":"194d419533160aa241e58316c109a3778e280f27677956060dac8d0bfae574c6","facility":"Neurobiology Research Unit, Rigshospitalet","city":"Copenhagen","region":"","country":"Denmark","lat":55.675939999999997,"lon":12.565530000000001}],"countries":["Denmark"]},{"id":3594,"nct_id":"NCT04661514","title":"Evaluation of Psilocybin in Anorexia Nervosa: Safety and Efficacy","sponsor":"University of California, San Diego","registry_url":"https://clinicaltrials.gov/study/NCT04661514","tracker_url":"publication.php?id=3594","status":"COMPLETED","status_label":"Completed","status_verified_date":"2022-07","last_update_date":"2022-07-25","start_date":"2021-05-01","primary_completion_date":"2022-03-10","completion_date":"2022-06-10","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":16,"type":"ACTUAL"},"design":{"allocation":"NA","intervention_model":"SINGLE_GROUP","primary_purpose":"TREATMENT","masking":"NONE"},"conditions":["Anorexia Nervosa"],"interventions":[{"name":"Psilocybin","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"36cbadd08074d94fbe0a5b1b81e0701fcbda7798b24d5e8d9d9005fb9eb81047","facility":"Altman Clinical and Translational Research Institute","city":"La Jolla","region":"California","country":"United States","lat":32.847270000000002,"lon":-117.27419999999999}],"countries":["United States"]},{"id":3653,"nct_id":"NCT04989972","title":"Randomized Double Blind Placebo Controlled Assessing the Efficacy of Micro-dosed Psilocybin in Reducing Anxiety and or Depression Levels in Adults","sponsor":"Wake Network, Inc.","registry_url":"https://clinicaltrials.gov/study/NCT04989972","tracker_url":"publication.php?id=3653","status":"WITHDRAWN","status_label":"Withdrawn","status_verified_date":"2021-06","last_update_date":"2022-06-30","start_date":"2022-09-15","primary_completion_date":"2023-06-20","completion_date":"2023-08-31","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":0,"type":"ACTUAL"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"DOUBLE"},"conditions":["Anxiety and Depression"],"interventions":[{"name":"PSIL428","type":"DRUG"},{"name":"Oyster mushroom","type":"DIETARY_SUPPLEMENT"}],"substances":["psilocybin"],"sites":[{"key":"67679966468a2018f1bdb6a74e7e4ef191ee055a3a28ed6d73618e92950f9177","facility":"FMS Department of Psychiatry","city":"Kingston","region":"","country":"Jamaica","lat":17.997019999999999,"lon":-76.793580000000006}],"countries":["Jamaica"]},{"id":3676,"nct_id":"NCT05383313","title":"Psilocybin Versus Ketamine - Fast Acting Antidepressant Strategies in Treatment-resistant Depression","sponsor":"National Institute of Mental Health, Czech Republic","registry_url":"https://clinicaltrials.gov/study/NCT05383313","tracker_url":"publication.php?id=3676","status":"UNKNOWN","status_label":"Unknown status","status_verified_date":"2021-09","last_update_date":"2022-05-20","start_date":"2021-05-01","primary_completion_date":"2025-04-30","completion_date":"2025-04-30","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":60,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"HEALTH_SERVICES_RESEARCH","masking":"QUADRUPLE"},"conditions":["Treatment Resistant Depression"],"interventions":[{"name":"Psilocybin","type":"DRUG"},{"name":"Ketamine Hydrochloride","type":"DRUG"},{"name":"Midazolam Ph. Eur 9.0","type":"DRUG"}],"substances":["psilocybin","psilocin"],"sites":[{"key":"d389d3900cc088a27974b2b5e13fc6f9ec37fc5b84a0948484673de1d44e47a5","facility":"National Institute of Mental Health","city":"Klecany","region":"","country":"Czechia","lat":50.175989999999999,"lon":14.411479999999999}],"countries":["Czechia"]},{"id":3659,"nct_id":"NCT03715127","title":"Phase II, Randomized, Double Blind, Placebo Controlled, Parallel Group, Single Center Study of Psilocybin Efficacy in Major Depression","sponsor":"University of Zurich","registry_url":"https://clinicaltrials.gov/study/NCT03715127","tracker_url":"publication.php?id=3659","status":"COMPLETED","status_label":"Completed","status_verified_date":"2022-04","last_update_date":"2022-04-29","start_date":"2019-03-11","primary_completion_date":"2021-10-12","completion_date":"2022-04-12","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":55,"type":"ACTUAL"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"QUADRUPLE"},"conditions":["Depressive Disorder, Major"],"interventions":[{"name":"Psilocybine oral capsule","type":"DRUG"},{"name":"Placebo oral capsule","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"963ff36be3d4be959779a50db385d5b17dd29d729076a98c276ec54e5bf5cfdd","facility":"Psychiatrische Universitätsklinik Zürich","city":"Zurich","region":"","country":"Switzerland","lat":47.366669999999999,"lon":8.5500000000000007}],"countries":["Switzerland"]},{"id":3508,"nct_id":"NCT02421263","title":"A Randomized Controlled Trial of the Effects of Psilocybin-Facilitated Experience on the Psychology and Effectiveness of Professional Leaders in Religion","sponsor":"NYU Langone Health","registry_url":"https://clinicaltrials.gov/study/NCT02421263","tracker_url":"publication.php?id=3508","status":"COMPLETED","status_label":"Completed","status_verified_date":"2022-02","last_update_date":"2022-02-14","start_date":"2015-04","primary_completion_date":"2020-06-05","completion_date":"2020-06-05","study_type":"INTERVENTIONAL","phases":["PHASE1"],"enrollment":{"count":12,"type":"ACTUAL"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"HEALTH_SERVICES_RESEARCH","masking":"NONE"},"conditions":["Religious or Spiritual Problem"],"interventions":[{"name":"Psilocybin","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"d1d8d084525b2d3486bf0c2b7d493ab1c682a967c30c20c77a945624472cd2ab","facility":"NYU Langone Medical Center/Tisch Hospital","city":"New York","region":"New York","country":"United States","lat":40.714269999999999,"lon":-74.005970000000005}],"countries":["United States"]},{"id":3526,"nct_id":"NCT03153579","title":"LSD Treatment in Persons Suffering From Anxiety Symptoms in Severe Somatic Diseases or in Psychiatric Anxiety Disorders: a Randomized, Double-blind, Placebo-controlled Phase II Study","sponsor":"University Hospital, Basel, Switzerland","registry_url":"https://clinicaltrials.gov/study/NCT03153579","tracker_url":"publication.php?id=3526","status":"COMPLETED","status_label":"Completed","status_verified_date":"2021-12","last_update_date":"2021-12-22","start_date":"2017-06-23","primary_completion_date":"2021-12-15","completion_date":"2021-12-15","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":46,"type":"ACTUAL"},"design":{"allocation":"RANDOMIZED","intervention_model":"CROSSOVER","primary_purpose":"TREATMENT","masking":"QUADRUPLE"},"conditions":["Patients","Anxiety Disorders"],"interventions":[{"name":"LSD","type":"DRUG"},{"name":"Placebo","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"b396510f76aa97e398e61aeedd81c7b5fcfd540d418138fc4fb60db60e0a0659","facility":"University Hospital Basel","city":"Basel","region":"Canton of Basel-City","country":"Switzerland","lat":47.558390000000003,"lon":7.5732699999999999},{"key":"8f4b75aaf233d6bdd457e79d183df0aeecff4606794e577db9ad0470e8f822bd","facility":"Private Practice P.Gasser","city":"Solothurn","region":"Canton of Solothurn","country":"Switzerland","lat":47.207909999999998,"lon":7.53714}],"countries":["Switzerland"]},{"id":3671,"nct_id":"NCT05160220","title":"Double-blind Placebo-controlled Naturalistic Study of Microdosing With Psilocybin: Effects on Brain Activity, Behavior, Cognition, Creativity, and Mental Health","sponsor":"National Council of Scientific and Technical Research, Argentina","registry_url":"https://clinicaltrials.gov/study/NCT05160220","tracker_url":"publication.php?id=3671","status":"COMPLETED","status_label":"Completed","status_verified_date":"2021-12","last_update_date":"2021-12-16","start_date":"2021-01-20","primary_completion_date":"2021-06-30","completion_date":"2021-10-01","study_type":"INTERVENTIONAL","phases":["NA"],"enrollment":{"count":34,"type":"ACTUAL"},"design":{"allocation":"RANDOMIZED","intervention_model":"SINGLE_GROUP","primary_purpose":"BASIC_SCIENCE","masking":"DOUBLE"},"conditions":["Cognitive Change","Creativity","Mood Change","Sleep"],"interventions":[{"name":"Psilocybin","type":"DRUG"},{"name":"Placebo","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"45122612fb949f8500264d93f224a0323fcb7b1201661dbaff6914df06fb22b6","facility":"Instituto de Fisica de Buenos Aires (IFIBA)","city":"Buenos Aires","region":"","country":"Argentina","lat":-34.613149999999997,"lon":-58.377229999999997}],"countries":["Argentina"]},{"id":3500,"nct_id":"NCT03181529","title":"Effects of Psilocybin in Major Depressive Disorder","sponsor":"Johns Hopkins University","registry_url":"https://clinicaltrials.gov/study/NCT03181529","tracker_url":"publication.php?id=3500","status":"COMPLETED","status_label":"Completed","status_verified_date":"2021-11","last_update_date":"2021-12-15","start_date":"2017-08-10","primary_completion_date":"2020-12-02","completion_date":"2020-12-02","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":27,"type":"ACTUAL"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"SINGLE"},"conditions":["Major Depressive Disorder"],"interventions":[{"name":"Psilocybin","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"86fc9804485a03c3ff76195ce0de591aa8df52a325e697383b84e2beae895656","facility":"Behavioral Pharmacology Research Unit, Johns Hopkins Bayview Medical Center","city":"Baltimore","region":"Maryland","country":"United States","lat":39.290379999999999,"lon":-76.612189999999998}],"countries":["United States"]},{"id":3459,"nct_id":"NCT04593563","title":"The Safety and Efficacy of Psilocybin in Cancer Patients With Major Depressive Disorder","sponsor":"Maryland Oncology Hematology, PA","registry_url":"https://clinicaltrials.gov/study/NCT04593563","tracker_url":"publication.php?id=3459","status":"UNKNOWN","status_label":"Unknown status","status_verified_date":"2021-10","last_update_date":"2021-10-15","start_date":"2020-09-01","primary_completion_date":"2022-10","completion_date":"2023-10","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":30,"type":"ACTUAL"},"design":{"allocation":"NA","intervention_model":"SINGLE_GROUP","primary_purpose":"TREATMENT","masking":"NONE"},"conditions":["Major Depressive Disorder"],"interventions":[{"name":"Psilocybin","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"6efaf5397268b87a303da006e78044c4e6a5b482459e0d1e7b74ca9c58ce0e0b","facility":"Maryland Oncology Hematology PA","city":"Rockville","region":"Maryland","country":"United States","lat":39.084000000000003,"lon":-77.152760000000001}],"countries":["United States"]},{"id":3487,"nct_id":"NCT03853577","title":"Characterization of Altered Waking States of Consciousness in Healthy Humans","sponsor":"University of Zurich","registry_url":"https://clinicaltrials.gov/study/NCT03853577","tracker_url":"publication.php?id=3487","status":"COMPLETED","status_label":"Completed","status_verified_date":"2020-04","last_update_date":"2021-04-29","start_date":"2020-07-08","primary_completion_date":"2021-04-25","completion_date":"2021-04-25","study_type":"INTERVENTIONAL","phases":["NA"],"enrollment":{"count":25,"type":"ACTUAL"},"design":{"allocation":"RANDOMIZED","intervention_model":"CROSSOVER","primary_purpose":"BASIC_SCIENCE","masking":"QUADRUPLE"},"conditions":["Altered Waking States of Consciousness in Healthy Humans"],"interventions":[{"name":"TMS/EEG","type":"OTHER"}],"substances":["psilocybin"],"sites":[{"key":"963ff36be3d4be959779a50db385d5b17dd29d729076a98c276ec54e5bf5cfdd","facility":"Psychiatrische Universitätsklinik Zürich","city":"Zurich","region":"","country":"Switzerland","lat":47.366669999999999,"lon":8.5500000000000007}],"countries":["Switzerland"]},{"id":3441,"nct_id":"NCT03604744","title":"Direct Comparison of Altered States of Consciousness Induced by LSD and Psilocybin in a Random-order Placebo-controlled Cross-over Study in Healthy Subjects","sponsor":"University Hospital, Basel, Switzerland","registry_url":"https://clinicaltrials.gov/study/NCT03604744","tracker_url":"publication.php?id=3441","status":"COMPLETED","status_label":"Completed","status_verified_date":"2021-04","last_update_date":"2021-04-27","start_date":"2019-03-27","primary_completion_date":"2021-04-10","completion_date":"2021-04-15","study_type":"INTERVENTIONAL","phases":["EARLY_PHASE1"],"enrollment":{"count":28,"type":"ACTUAL"},"design":{"allocation":"RANDOMIZED","intervention_model":"CROSSOVER","primary_purpose":"BASIC_SCIENCE","masking":"QUADRUPLE"},"conditions":["Healthy"],"interventions":[{"name":"LSD","type":"DRUG"},{"name":"Psilocybin","type":"DRUG"}],"substances":["psilocybin","psilocin"],"sites":[{"key":"3bd85f8d9169f9145f6dadbdc3b3147879111bb22b7030edc0ce62cf2445458e","facility":"Clinical Pharmacology & Toxicology, University Hospital Basel","city":"Basel","region":"","country":"Switzerland","lat":47.558390000000003,"lon":7.5732699999999999}],"countries":["Switzerland"]},{"id":3556,"nct_id":"NCT02950467","title":"Psilocybin-assisted Group Therapy for Demoralization in Long-term AIDS Survivors","sponsor":"Joshua Woolley","registry_url":"https://clinicaltrials.gov/study/NCT02950467","tracker_url":"publication.php?id=3556","status":"COMPLETED","status_label":"Completed","status_verified_date":"2020-12","last_update_date":"2021-01-07","start_date":"2018-01-05","primary_completion_date":"2019-12-31","completion_date":"2019-12-31","study_type":"INTERVENTIONAL","phases":["PHASE1"],"enrollment":{"count":30,"type":"ACTUAL"},"design":{"allocation":"NA","intervention_model":"SINGLE_GROUP","primary_purpose":"TREATMENT","masking":"NONE"},"conditions":["Distress","Depression","Grief"],"interventions":[{"name":"Psilocybin","type":"DRUG"},{"name":"Modified brief Supportive Expressive Group Therapy","type":"BEHAVIORAL"}],"substances":["psilocybin"],"sites":[{"key":"7f09a842484186a75c6232177464293472d56c43d4d49f24f37efcb6c9cbbbb8","facility":"University of California, San Francisco","city":"San Francisco","region":"California","country":"United States","lat":37.774929999999998,"lon":-122.41942}],"countries":["United States"]},{"id":3491,"nct_id":"NCT03912974","title":"Effects of Serotonin Transporter Inhibition on the Subjective Response to Psilocybin in Healthy Subjects","sponsor":"University Hospital, Basel, Switzerland","registry_url":"https://clinicaltrials.gov/study/NCT03912974","tracker_url":"publication.php?id=3491","status":"COMPLETED","status_label":"Completed","status_verified_date":"2020-11","last_update_date":"2020-12-01","start_date":"2019-07-04","primary_completion_date":"2020-11-26","completion_date":"2020-11-26","study_type":"INTERVENTIONAL","phases":["PHASE1"],"enrollment":{"count":27,"type":"ACTUAL"},"design":{"allocation":"RANDOMIZED","intervention_model":"CROSSOVER","primary_purpose":"BASIC_SCIENCE","masking":"TRIPLE"},"conditions":["Healthy"],"interventions":[{"name":"Escitalopram","type":"DRUG"},{"name":"Placebo oral capsule","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"bc118043aa3f26bbd3206be4e9c03a0fb0cffd4b4da900e4718d4e5764570ea5","facility":"University Hospital Basel, Clinical Trial Unit","city":"Basel","region":"Canton of Basel-City","country":"Switzerland","lat":47.558390000000003,"lon":7.5732699999999999}],"countries":["Switzerland"]},{"id":3448,"nct_id":"NCT03736980","title":"Beyond the Self and Back: Neuropharmacological Mechanisms Underlying the Dissolution of the Self","sponsor":"University of Zurich","registry_url":"https://clinicaltrials.gov/study/NCT03736980","tracker_url":"publication.php?id=3448","status":"COMPLETED","status_label":"Completed","status_verified_date":"2020-11","last_update_date":"2020-11-04","start_date":"2013-10-01","primary_completion_date":"2018-12-31","completion_date":"2018-12-31","study_type":"INTERVENTIONAL","phases":["NA"],"enrollment":{"count":140,"type":"ACTUAL"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"BASIC_SCIENCE","masking":"DOUBLE"},"conditions":["Healthy"],"interventions":[{"name":"Placebo","type":"DRUG"},{"name":"Psilocybine","type":"DRUG"}],"substances":["psilocybin"],"sites":[],"countries":[]},{"id":3429,"nct_id":"NCT00957359","title":"Effects of Psilocybin on Anxiety and Psychosocial Distress in Cancer Patients","sponsor":"NYU Langone Health","registry_url":"https://clinicaltrials.gov/study/NCT00957359","tracker_url":"publication.php?id=3429","status":"COMPLETED","status_label":"Completed","status_verified_date":"2020-09","last_update_date":"2020-10-20","start_date":"2009-02","primary_completion_date":"2018-09-06","completion_date":"2018-09-06","study_type":"INTERVENTIONAL","phases":["EARLY_PHASE1"],"enrollment":{"count":29,"type":"ACTUAL"},"design":{"allocation":"RANDOMIZED","intervention_model":"CROSSOVER","primary_purpose":"TREATMENT","masking":"QUADRUPLE"},"conditions":["Cancer"],"interventions":[{"name":"Psilocybin","type":"DRUG"},{"name":"Niacin","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"78b406395b11d45e5de52f1bd4997ed2ba1a3a3edbf561ff0ce4bc7bc43bb19f","facility":"NYU College of Dentistry Bluestone Center for Clinical Research","city":"New York","region":"New York","country":"United States","lat":40.714269999999999,"lon":-74.005970000000005}],"countries":["United States"]},{"id":3451,"nct_id":"NCT02163707","title":"Pharmacokinetics of Psilocybin in Normal Adult Volunteers","sponsor":"University of Wisconsin, Madison","registry_url":"https://clinicaltrials.gov/study/NCT02163707","tracker_url":"publication.php?id=3451","status":"COMPLETED","status_label":"Completed","status_verified_date":"2020-04","last_update_date":"2020-04-15","start_date":"2014-06","primary_completion_date":"2015-12","completion_date":"2015-12","study_type":"INTERVENTIONAL","phases":["PHASE1"],"enrollment":{"count":12,"type":"ACTUAL"},"design":{"allocation":"NON_RANDOMIZED","intervention_model":"SINGLE_GROUP","primary_purpose":"TREATMENT","masking":"NONE"},"conditions":["Healthy"],"interventions":[{"name":"Psilocybin","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"6aef8b3e098d088faf66b099ff25db39f20cd48e8cf64e636833f68681dcc663","facility":"University of Wisconsin, School of Pharmacy","city":"Madison","region":"Wisconsin","country":"United States","lat":43.073050000000002,"lon":-89.401229999999998}],"countries":["United States"]},{"id":3579,"nct_id":"NCT02145091","title":"Effects of Psilocybin on Behavior, Psychology and Brain Function in Long-term Meditators","sponsor":"Johns Hopkins University","registry_url":"https://clinicaltrials.gov/study/NCT02145091","tracker_url":"publication.php?id=3579","status":"COMPLETED","status_label":"Completed","status_verified_date":"2019-12","last_update_date":"2019-12-30","start_date":"2014-05","primary_completion_date":"2019-12-26","completion_date":"2019-12-26","study_type":"INTERVENTIONAL","phases":["PHASE1"],"enrollment":{"count":40,"type":"ACTUAL"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"BASIC_SCIENCE","masking":"DOUBLE"},"conditions":["Healthy"],"interventions":[{"name":"Moderately-high dose of psilocybin","type":"DRUG"},{"name":"Moderately-low dose of psilocybin","type":"DRUG"},{"name":"Very-low dose of psilocybin","type":"DRUG"},{"name":"Placebo","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"86fc9804485a03c3ff76195ce0de591aa8df52a325e697383b84e2beae895656","facility":"Behavioral Pharmacology Research Unit, Johns Hopkins Bayview Medical Center","city":"Baltimore","region":"Maryland","country":"United States","lat":39.290379999999999,"lon":-76.612189999999998}],"countries":["United States"]},{"id":3504,"nct_id":"NCT02971605","title":"Measurement of Persisting Changes in Emotional Brain Functioning Produced by Psilocybin","sponsor":"Johns Hopkins University","registry_url":"https://clinicaltrials.gov/study/NCT02971605","tracker_url":"publication.php?id=3504","status":"COMPLETED","status_label":"Completed","status_verified_date":"2019-08","last_update_date":"2019-09-10","start_date":"2017-07-01","primary_completion_date":"2018-08-21","completion_date":"2018-08-21","study_type":"INTERVENTIONAL","phases":["PHASE1","PHASE2"],"enrollment":{"count":13,"type":"ACTUAL"},"design":{"allocation":"NA","intervention_model":"SINGLE_GROUP","primary_purpose":"BASIC_SCIENCE","masking":"NONE"},"conditions":["Healthy"],"interventions":[{"name":"Psilocybin","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"86fc9804485a03c3ff76195ce0de591aa8df52a325e697383b84e2beae895656","facility":"Behavioral Pharmacology Research Unit, Johns Hopkins Bayview Medical Center","city":"Baltimore","region":"Maryland","country":"United States","lat":39.290379999999999,"lon":-76.612189999999998}],"countries":["United States"]},{"id":3583,"nct_id":"NCT03661125","title":"A Randomised, Balanced, Double-blind Two-way Crossover Design Study to Evaluate the Effects of SRC Kinase Inhibitor, Saracatinib, on Brain Activity Associated With Visual Processing in Patients With Parkinson's Disease Psychosis.","sponsor":"King's College London","registry_url":"https://clinicaltrials.gov/study/NCT03661125","tracker_url":"publication.php?id=3583","status":"UNKNOWN","status_label":"Unknown status","status_verified_date":"2018-08","last_update_date":"2019-08-13","start_date":"2019-04-11","primary_completion_date":"2021-09-01","completion_date":"2021-09-01","study_type":"INTERVENTIONAL","phases":["EARLY_PHASE1"],"enrollment":{"count":30,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"CROSSOVER","primary_purpose":"BASIC_SCIENCE","masking":"TRIPLE"},"conditions":["Parkinson Disease Psychosis"],"interventions":[{"name":"Saracatinib","type":"DRUG"},{"name":"Placebo Oral Tablet","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"07a8178170a30179f640b9c70731e1d415c7038aab9705b99f55e89c1cc1fb21","facility":"Mitul Mehta","city":"London","region":"Camberwell","country":"United Kingdom","lat":51.50853,"lon":-0.12573999999999999}],"countries":["United Kingdom"]},{"id":3553,"nct_id":"NCT00465595","title":"Psychopharmacology of Psilocybin in Cancer Patients","sponsor":"Johns Hopkins University","registry_url":"https://clinicaltrials.gov/study/NCT00465595","tracker_url":"publication.php?id=3553","status":"COMPLETED","status_label":"Completed","status_verified_date":"2018-06","last_update_date":"2018-07-19","start_date":"2007-04","primary_completion_date":"2014-12","completion_date":"2016-12","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":56,"type":"ACTUAL"},"design":{"allocation":"RANDOMIZED","intervention_model":"CROSSOVER","primary_purpose":"SUPPORTIVE_CARE","masking":"QUADRUPLE"},"conditions":["Depressive Symptoms","Anxiety","Cancer"],"interventions":[{"name":"psilocybin","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"8a9fa87413d480bac878c14fd3780e61a2c0f2573c87aa67b3913724f16cc960","facility":"Behavioral Pharmacology Research Unit, Johns Hopkins Bayview Campus","city":"Baltimore","region":"Maryland","country":"United States","lat":39.290379999999999,"lon":-76.612189999999998}],"countries":["United States"]},{"id":3631,"nct_id":"NCT03380442","title":"Psilocybin and Depression - Assessing the Long-term Effects of a Single Administration of Psilocybin on the Psychiatric Symptoms and Brain Activity of Patients With Severe Depression","sponsor":"University of Helsinki","registry_url":"https://clinicaltrials.gov/study/NCT03380442","tracker_url":"publication.php?id=3631","status":"UNKNOWN","status_label":"Unknown status","status_verified_date":"2017-12","last_update_date":"2017-12-21","start_date":"2018-09","primary_completion_date":"2020-01","completion_date":"2021-09","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":60,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"BASIC_SCIENCE","masking":"QUADRUPLE"},"conditions":["Severe Depression"],"interventions":[{"name":"Psilocybin","type":"DRUG"},{"name":"Ketamine (Ketalar)","type":"DRUG"}],"substances":["psilocybin"],"sites":[],"countries":[]},{"id":3628,"nct_id":"NCT00802282","title":"Effects of Psilocybin and Spiritual Practice on Persisting Changes in Attitudes and Behavior","sponsor":"Johns Hopkins University","registry_url":"https://clinicaltrials.gov/study/NCT00802282","tracker_url":"publication.php?id=3628","status":"COMPLETED","status_label":"Completed","status_verified_date":"2016-02","last_update_date":"2016-02-24","start_date":"2009-08","primary_completion_date":"2014-02","completion_date":"2014-05","study_type":"INTERVENTIONAL","phases":["PHASE1"],"enrollment":{"count":75,"type":"ACTUAL"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"BASIC_SCIENCE","masking":"QUADRUPLE"},"conditions":["Healthy"],"interventions":[{"name":"psilocybin","type":"DRUG"},{"name":"Intensity of support for spiritual practice","type":"BEHAVIORAL"},{"name":"Number of sessions","type":"BEHAVIORAL"}],"substances":["psilocybin"],"sites":[{"key":"86fc9804485a03c3ff76195ce0de591aa8df52a325e697383b84e2beae895656","facility":"Behavioral Pharmacology Research Unit, Johns Hopkins Bayview Medical Center","city":"Baltimore","region":"Maryland","country":"United States","lat":39.290379999999999,"lon":-76.612189999999998}],"countries":["United States"]},{"id":3484,"nct_id":"NCT01988311","title":"Pilot Study: Effects of Psilocybin on Behavior, Psychology and Brain Function in Long-term Meditators","sponsor":"Johns Hopkins University","registry_url":"https://clinicaltrials.gov/study/NCT01988311","tracker_url":"publication.php?id=3484","status":"COMPLETED","status_label":"Completed","status_verified_date":"2014-05","last_update_date":"2014-05-20","start_date":"2013-05","primary_completion_date":"2014-01","completion_date":"2014-05","study_type":"INTERVENTIONAL","phases":["PHASE1"],"enrollment":{"count":10,"type":"ESTIMATED"},"design":{"allocation":"NON_RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"BASIC_SCIENCE","masking":"NONE"},"conditions":["Psilocybin","Hallucinogens","Pharmacologic Actions","Central Nervous System Agents","Therapeutic Uses","Psychotropic Drugs"],"interventions":[{"name":"psilocybin","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"86fc9804485a03c3ff76195ce0de591aa8df52a325e697383b84e2beae895656","facility":"Behavioral Pharmacology Research Unit, Johns Hopkins Bayview Medical Center","city":"Baltimore","region":"Maryland","country":"United States","lat":39.290379999999999,"lon":-76.612189999999998}],"countries":["United States"]}],"facets":{"countries":{"United States":182,"Canada":41,"Switzerland":21,"United Kingdom":18,"France":7,"Denmark":7,"Netherlands":6,"Czechia":5,"Ireland":5,"Sweden":4,"Israel":4,"Germany":3,"Australia":3,"Spain":2,"Brazil":2,"Pakistan":2,"Portugal":2,"Belgium":2,"Poland":1,"Austria":1,"New Zealand":1,"Finland":1,"Jordan":1,"Jamaica":1,"Argentina":1},"sponsors":{"Johns Hopkins University":31,"Yale University":16,"University Hospital, Basel, Switzerland":13,"COMPASS Pathways":9,"University of Wisconsin, Madison":9,"NYU Langone Health":9,"Centre for Addiction and Mental Health":8,"University Health Network, Toronto":5,"University of Calgary":5,"King's College London":5,"University of Washington":5,"Imperial College London":5,"University of Zurich":5,"MycoMedica Life Sciences PBC":4,"Joshua Woolley, MD, PhD":4,"University of New Mexico":4,"Usona Institute":4,"Centre Hospitalier Universitaire de Nīmes":4,"Washington University School of Medicine":4,"University of California, Los Angeles":4,"M.D. Anderson Cancer Center":3,"University of Colorado, Denver":3,"University of California, San Diego":3,"University of Alabama at Birmingham":3,"Sheppard Pratt Health System":3,"Unity Health Toronto":2,"University of British Columbia":2,"Emory University":2,"University of Minnesota":2,"Charles Raison":2,"Yvan Beaussant, MD, MSci":2,"Francisco A Moreno":2,"Ohio State University":2,"Khyber Medical University Peshawar":2,"University of California, Berkeley":2,"Sunstone Medical":2,"Robin Carhart-Harris, PhD, MA":2,"Section for Affective Disorders; Northern Stockholm Psychiatry":2,"Anders Fink-Jensen, MD, DMSci":2,"TRYP Therapeutics":2,"Beersheva Mental Health Center":2,"University of California, San Francisco":2,"Gitte Moos Knudsen":2,"University of Utah":2,"Brown University":1,"National Institute on Aging (NIA)":1,"Brigham and Women's Hospital":1,"Oregon Health and Science University":1,"Peter Hendricks":1,"Centre Hospitalier St Anne":1,"Lakshmi N Yatham":1,"Jennifer Mitchell":1,"McMaster University":1,"ARQ National Psychotrauma Centre":1,"University of Nebraska":1,"Region Skane":1,"VA Office of Research and Development":1,"Rachel Yehuda":1,"Sharmin Ghaznavi":1,"Nathan Brashares Sackett":1,"The University of Texas Health Science Center, Houston":1,"Roswell Park Cancer Institute":1,"Claudio N Soares":1,"Nicky Mehtani, MD, MPH":1,"James J. Peters Veterans Affairs Medical Center":1,"Trent Emerick":1,"University of Southern California":1,"Joshua Rosenblat":1,"Tel-Aviv Sourasky Medical Center":1,"Scottsdale Research Institute":1,"Pontifícia Universidade Católica do Rio de Janeiro":1,"Diamond Therapeutics Inc.":1,"Bruyère Health Research Institute.":1,"Ottawa Hospital Research Institute":1,"University of Pennsylvania":1,"Anthony P King":1,"University of Virginia":1,"Manoj Doss":1,"Alan Davis":1,"University Medical Center Groningen":1,"University of North Carolina, Chapel Hill":1,"Stanford University":1,"Portland VA Research Foundation, Inc":1,"Kyle Greenway":1,"Sunnybrook Health Sciences Centre":1,"Indiana University":1,"Federal University of Latin American Integration":1,"Medical University of Vienna":1,"Gustavo Vazquez":1,"Psyence Australia Pty Ltd":1,"Marissa Raymond-Flesch, MD, MPH":1,"Gabriella Gobbi":1,"Hadassah Medical Organization":1,"Nantes University Hospital":1,"Baylor College of Medicine":1,"Rotem Petranker":1,"University of Chicago":1,"University of Iowa":1,"University College, London":1,"University of Texas at Austin":1,"Charles S. Grob, M.D.":1,"Peggy C Nopoulos":1,"Anna Rose Childress, Ph.D.":1,"Kevin Murnane":1,"University Hospital, Geneva":1,"Healing Advocacy Fund":1,"Maastricht University":1,"Matthew Hicks":1,"National University of Natural Medicine":1,"Icahn School of Medicine at Mount Sinai":1,"Kevin Boehnke":1,"Felix Mueller":1,"University of Otago":1,"Insel Gruppe AG, University Hospital Bern":1,"Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center":1,"Central Institute of Mental Health, Mannheim":1,"Filament Health Corp.":1,"Western University, Canada":1,"University Hospital, Ghent":1,"University of Arizona":1,"Clairvoyant Therapeutics":1,"Brugmann University Hospital":1,"Empower Research Inc":1,"University of Sydney":1,"Nova Mentis Life Science Corp":1,"Massachusetts General Hospital":1,"Multidisciplinary Association for Psychedelic Studies":1,"Apex Labs Ltd.":1,"Milan Scheidegger":1,"Lobe Sciences Ltd.":1,"Brain and Cognition Discovery Foundation":1,"The Roots to Thrive Society for Psychedelic Therapy":1,"Cybin Therapeutics Inc.":1,"Halucenex Life Sciences Inc.":1,"Combat Stress":1,"Optimi Health Corporation":1,"New York State Psychiatric Institute":1,"Keith Heinzerling":1,"NWTraumatherapies":1,"Beckley Psytech Limited":1,"Wake Network, Inc.":1,"National Institute of Mental Health, Czech Republic":1,"National Council of Scientific and Technical Research, Argentina":1,"Maryland Oncology Hematology, PA":1,"Joshua Woolley":1,"University of Helsinki":1},"phases":{"PHASE2":157,"PHASE1":112,"EARLY_PHASE1":24,"NA":16,"PHASE3":12},"conditions":{"Healthy":26,"Depression":23,"Major Depressive Disorder":23,"Treatment Resistant Depression":20,"PTSD":13,"Alcohol Use Disorder":13,"Anxiety":13,"Psilocybin":12,"Psychedelic Experiences":9,"Opioid Use Disorder":9,"Post Traumatic Stress Disorder":7,"Depression - Major Depressive Disorder":7,"Obsessive-Compulsive Disorder":6,"Advanced Cancer":6,"Demoralization":6,"Anorexia Nervosa":6,"Cancer":6,"Healthy Volunteers":5,"Depressive Disorder":5,"PTSD - Post Traumatic Stress Disorder":4,"Methamphetamine Use Disorder":4,"Anhedonia":4,"Psychological Distress":4,"Alcohol Use Disorder (AUD)":4,"Hematopoietic and Lymphatic System Neoplasm":4,"Depressive Disorder, Major":4,"Major Depressive Disorder (MDD)":4,"Alcohol Dependence":4,"Depressive Symptoms":3,"Suicidal Ideation":3,"Healthy Volunteer":3,"Stage IV Melanoma":3,"Major Depression":3,"Pain Management":3,"Metastatic Malignant Solid Neoplasm":3,"Chronic Pain":3,"Fibromyalgia":3,"PTSD Symptoms":2,"Nicotine Dependence":2,"Borderline Personality Disorder":2,"Treatment-resistant Depression (TRD)":2,"Stage IV Solid Tumor Cancer":2,"Stage IV Sarcoma of Bone":2,"Stage IV Lymphoma":2,"Endocrine Cancer":2,"Psychedelic Effects in Healthy Volunteers":2,"Depression, Anxiety":2,"Chronic Low-back Pain":2,"Parkinson Disease":2,"Existential Distress":2,"Treatment-Resistant Depression":2,"Aging":2,"Bipolar II Disorder":2,"Suicidality":2,"Malignant Solid Neoplasm":2,"Autism Spectrum Disorder":2,"Migraine":2,"Grief":2,"OCD":2,"Addiction":2,"Tobacco Use Disorder":2,"Substance Use Disorders":2,"Treatment-resistant Depression":2,"Treatment-Resistant Major Depressive Disorder":2,"MDD":2,"Substance Use Disorder (SUD)":2,"Healthy Participants":2,"Anxiety Disorders":2,"Depressive Disorder, Treatment-Resistant":2,"Hallucinogens":2,"Sleep":2,"Burnout, Professional":2,"Migraine Headache":2,"Cluster Headache":2,"Mood Change":2,"Phase I":1,"Alzheimer's Disease":1,"Chronic PTSD":1,"PTSD, Post Traumatic Stress Disorder":1,"Amnestic Mild Cognitive Impairment":1,"Neuropathy":1,"Mood (Psychological Function)":1,"Well Being":1,"Mood":1,"Well-Being, Psychological":1,"Parkinson's Disease (PD)":1,"Psychedelic Microdosing Effects on Mood, Cognition, Subjective Well-being and MRI":1,"Chronic Pelvic Pain":1,"Borderline Personality Pathology":1,"Emotion Dysregulation":1,"Older Adults (65-85 Years)":1,"Music Intervention":1,"Emotional Blunting":1,"Bipolar II Depression":1,"Premenstrual Dysphoric Disorder ( PMDD)":1,"PMDD":1,"Psilocybin-Assisted Psychotherapy":1,"Persisting Symptoms After Concussion":1,"Anhedonia in Healthy Volunteers":1,"Older Adults (50-90 Years)":1,"Post Traumatic Stress Disorder PTSD":1,"Intimate Partner Violence (IPV)":1,"Alzheimer Disease":1,"Mild Cognitive Impairment":1,"Posttraumatic Stress Disorder":1,"Breast Cancer":1,"Ovarian Cancer":1,"Investigating the Importance of the Subjective Psychedelic Experience":1,"Burnout":1,"Burnout, Healthcare Workers":1,"Cannabis Use Disorder, Moderate":1,"Cannabis Use Disorder, Severe":1,"Posttraumatic Stress Disorder (PTSD)":1,"Chronic Low Back Pain (CLBP)":1,"Physical Therapy":1,"Pancreas Cancer":1,"Biliary Tract Cancer":1,"Gastrointestinal Cancer":1,"Longevity":1,"Biomarkers of Aging":1,"Psychological Stress":1,"Depression, Bipolar":1,"Generalized Anxiety Disorder (GAD)":1,"Human Immunodeficiency Virus (HIV)":1,"Amyotrophic Lateral Sclerosis":1,"Spinal Cord Injury":1,"Veteran":1,"Bipolar Depression":1,"Postoperative Pain":1,"Mental Health":1,"Opioid-Related Disorders":1,"Pain Management and Care":1,"Advanced Cancers":1,"Smokers With Chronic Pain":1,"Post-Traumatic Stress Disorder, PTSD":1,"Vagus Nerve Stimulation":1,"Healthy Adults":1,"Functional Neurological Disorder":1,"Healthy Controls":1,"Post-Traumatic Stress Disorder (PTSD)":1,"Distress, Emotional":1,"Perception Disorders":1,"Loneliness":1,"Mood Disorders":1,"Obsessive Compulsive Disorder (OCD)":1,"Depressive Sympotoms":1,"Caregiver Distress":1,"Prolonged Grief Disorder":1,"Neuroimaging":1,"Healthy Participants With Lower-than-average Mental Well-being":1,"Cocaine-Related Disorders":1,"Lung Non-Small Cell Carcinoma":1,"Unipolar Depression":1,"Obsessive - Compulsive Disorder":1,"Substance-Related Disorders":1,"Chemically-Induced Disorders":1,"Stimulant-Use Disorder":1,"COPD (Chronic Obstructive Pulmonary Disease)":1,"ALS (Amyotrophic Lateral Sclerosis)":1,"MS (Multiple Sclerosis)":1,"Atypical Parkinson Disease":1,"Refractory Depression":1,"Cognitive Behavioral Therapy":1,"Palliative Care":1,"Pain":1,"Quality of Life":1,"Caregiver Burden":1,"Fear of Death":1,"Amphetamine-Related Disorders":1,"Cocaine Use Disorder":1,"Cannabis Use Disorder":1,"Safety":1,"Fibromyalgia, Primary":1,"Transdiagnostic":1,"Substance Use":1,"IBS - Irritable Bowel Syndrome":1,"Stress Disorders, Traumatic":1,"Stress Disorders, Post-Traumatic":1,"Trauma and Stressor Related Disorders":1,"Mental Disorder":1,"Adjustment Disorder":1,"Adjustment Disorder With Anxious Mood":1,"Cancer Cachexia":1,"Cancer of Endometrium":1,"Cancer of Kidney":1,"Cancer of Prostate":1,"Cancer of the Breast":1,"Cancer of Stomach":1,"Cancer Melanoma Skin":1,"Cancer Pancreas":1,"Placebo - Control":1,"Hospice":1,"Terminal Illness":1,"Cancer-related Problem/Condition":1,"Psychotherapy":1,"Terminal Cancer":1,"Cancer Terminal":1,"Stroke":1,"Chronic Stroke":1,"Intracerebral Haemorrhage":1,"Intracerebral Haemorrhage (ICH)":1,"Intracerebral Hemorrhage Basal Ganglia":1,"Ischemic Stroke":1,"Ischemic Stroke and Hemorrhagic Stroke":1,"Hemiparesis After Stroke":1,"Hemiplegia Following Ischemic Stroke":1,"Hemiplegia and Hemiparesis":1,"Hemiplegia and/or Hemiparesis Following Stroke":1,"Middle Cerebral Artery Stroke":1,"Major Depressive Diorder":1,"Irritable Bowel Syndrome":1,"Gambling Disorder":1,"Phantom Limb Pain":1,"Stuttering":1,"Self Harm":1,"Opioid Dependence":1,"Alcohol Abuse":1,"Recurrent Depression":1,"Obsessive-compulsive Disorder":1,"Psychogenic Nonepileptic Seizures":1,"Reinforcement, Psychology":1,"Post-Treatment Lyme Disease":1,"Chronic Lyme Disease":1,"Lyme Disease, Chronic":1,"Hematopoietic and Lymphoid Cell Neoplasm":1,"Perception Disturbance":1,"Visual Suppression":1,"Meditation":1,"Microdosing":1,"Personal Experience of Substance-assisted Therapy Using Psilocybin, MDMA, and LSD":1,"Chronic Neuropathic Pain":1,"Neuropharmacological Investigation of Ayahuasca Constituents DMT and Harmine":1,"Alcohol-Related Disorders":1,"Burnout, Caregiver":1,"COVID-19":1,"Moral Injury":1,"Basic Science":1,"Binge Eating Disorder":1,"Stimulant Use Disorder":1,"Disorders of Consciousness":1,"Obsessive-compulsive Disorder (OCD)":1,"Severe Alcohol Use Disorder":1,"Psychotherapy, Group":1,"Fragile X Syndrome":1,"Behavior":1,"Cognitive Dysfunction":1,"Alcoholism":1,"Post-Traumatic Stress Disorder":1,"Post-traumatic Stress Disorder":1,"Post-Traumatic Headache":1,"Side Effect of Drug":1,"QTc Interval":1,"Pharmacokinetics":1,"End of Life":1,"Mild Depression":1,"Moderate Depression":1,"Treatment Resistant Disorders":1,"Amnesia":1,"Mood Disturbance":1,"Sleep Disturbance":1,"Drug Effect":1,"Health, Subjective":1,"Psilocin Toxicity":1,"Psilocybin Toxicity":1,"Psilocybin Causing Adverse Effects in Therapeutic Use":1,"Body Dysmorphic Disorders":1,"Trauma, Nervous System":1,"Short Lasting Unilateral Neuralgiform Headache Attacks":1,"Anxiety and Depression":1,"Religious or Spiritual Problem":1,"Patients":1,"Cognitive Change":1,"Creativity":1,"Altered Waking States of Consciousness in Healthy Humans":1,"Distress":1,"Parkinson Disease Psychosis":1,"Severe Depression":1,"Pharmacologic Actions":1,"Central Nervous System Agents":1,"Therapeutic Uses":1,"Psychotropic Drugs":1},"statuses":{"RECRUITING":103,"COMPLETED":97,"ACTIVE_NOT_RECRUITING":33,"NOT_YET_RECRUITING":33,"UNKNOWN":16,"WITHDRAWN":14,"TERMINATED":7,"ENROLLING_BY_INVITATION":3,"SUSPENDED":2}},"years":{"2004":1,"2007":1,"2008":1,"2009":2,"2012":2,"2013":2,"2014":3,"2015":3,"2016":1,"2017":5,"2018":4,"2019":9,"2020":10,"2021":25,"2022":24,"2023":40,"2024":49,"2025":52,"2026":68,"2027":5,"2029":1},"statuses":{"Recruiting":103,"Completed":97,"Active, not recruiting":33,"Not yet recruiting":33,"Unknown status":16,"Withdrawn":14,"Terminated":7,"Enrolling by invitation":3,"Suspended":2},"conditions":{"Healthy":26,"Depression":23,"Major Depressive Disorder":23,"Treatment Resistant Depression":20,"PTSD":13,"Alcohol Use Disorder":13,"Anxiety":13,"Psilocybin":12,"Psychedelic Experiences":9,"Opioid Use Disorder":9,"Post Traumatic Stress Disorder":7,"Depression - Major Depressive Disorder":7,"Obsessive-Compulsive Disorder":6,"Advanced Cancer":6,"Demoralization":6,"Anorexia Nervosa":6,"Cancer":6,"Healthy Volunteers":5,"Depressive Disorder":5,"PTSD - Post Traumatic Stress Disorder":4,"Methamphetamine Use Disorder":4,"Anhedonia":4,"Psychological Distress":4,"Alcohol Use Disorder (AUD)":4,"Hematopoietic and Lymphatic System Neoplasm":4,"Depressive Disorder, Major":4,"Major Depressive Disorder (MDD)":4,"Alcohol Dependence":4,"Depressive Symptoms":3,"Suicidal Ideation":3,"Healthy Volunteer":3,"Stage IV Melanoma":3,"Major Depression":3,"Pain Management":3,"Metastatic Malignant Solid Neoplasm":3,"Chronic Pain":3,"Fibromyalgia":3,"PTSD Symptoms":2,"Nicotine Dependence":2,"Borderline Personality Disorder":2,"Treatment-resistant Depression (TRD)":2,"Stage IV Solid Tumor Cancer":2,"Stage IV Sarcoma of Bone":2,"Stage IV Lymphoma":2,"Endocrine Cancer":2,"Psychedelic Effects in Healthy Volunteers":2,"Depression, Anxiety":2,"Chronic Low-back Pain":2,"Parkinson Disease":2,"Existential Distress":2,"Treatment-Resistant Depression":2,"Aging":2,"Bipolar II Disorder":2,"Suicidality":2,"Malignant Solid Neoplasm":2,"Autism Spectrum Disorder":2,"Migraine":2,"Grief":2,"OCD":2,"Addiction":2,"Tobacco Use Disorder":2,"Substance Use Disorders":2,"Treatment-resistant Depression":2,"Treatment-Resistant Major Depressive Disorder":2,"MDD":2,"Substance Use Disorder (SUD)":2,"Healthy Participants":2,"Anxiety Disorders":2,"Depressive Disorder, Treatment-Resistant":2,"Hallucinogens":2,"Sleep":2,"Burnout, Professional":2,"Migraine Headache":2,"Cluster Headache":2,"Mood Change":2,"Phase I":1,"Alzheimer's Disease":1,"Chronic PTSD":1,"PTSD, Post Traumatic Stress Disorder":1,"Amnestic Mild Cognitive Impairment":1,"Neuropathy":1,"Mood (Psychological Function)":1,"Well Being":1,"Mood":1,"Well-Being, Psychological":1,"Parkinson's Disease (PD)":1,"Psychedelic Microdosing Effects on Mood, Cognition, Subjective Well-being and MRI":1,"Chronic Pelvic Pain":1,"Borderline Personality Pathology":1,"Emotion Dysregulation":1,"Older Adults (65-85 Years)":1,"Music Intervention":1,"Emotional Blunting":1,"Bipolar II Depression":1,"Premenstrual Dysphoric Disorder ( PMDD)":1,"PMDD":1,"Psilocybin-Assisted Psychotherapy":1,"Persisting Symptoms After Concussion":1,"Anhedonia in Healthy Volunteers":1,"Older Adults (50-90 Years)":1,"Post Traumatic Stress Disorder PTSD":1,"Intimate Partner Violence (IPV)":1,"Alzheimer Disease":1,"Mild Cognitive Impairment":1,"Posttraumatic Stress Disorder":1,"Breast Cancer":1,"Ovarian Cancer":1,"Investigating the Importance of the Subjective Psychedelic Experience":1,"Burnout":1,"Burnout, Healthcare Workers":1,"Cannabis Use Disorder, Moderate":1,"Cannabis Use Disorder, Severe":1,"Posttraumatic Stress Disorder (PTSD)":1,"Chronic Low Back Pain (CLBP)":1,"Physical Therapy":1,"Pancreas Cancer":1,"Biliary Tract Cancer":1,"Gastrointestinal Cancer":1,"Longevity":1,"Biomarkers of Aging":1,"Psychological Stress":1,"Depression, Bipolar":1,"Generalized Anxiety Disorder (GAD)":1,"Human Immunodeficiency Virus (HIV)":1,"Amyotrophic Lateral Sclerosis":1,"Spinal Cord Injury":1,"Veteran":1,"Bipolar Depression":1,"Postoperative Pain":1,"Mental Health":1,"Opioid-Related Disorders":1,"Pain Management and Care":1,"Advanced Cancers":1,"Smokers With Chronic Pain":1,"Post-Traumatic Stress Disorder, PTSD":1,"Vagus Nerve Stimulation":1,"Healthy Adults":1,"Functional Neurological Disorder":1,"Healthy Controls":1,"Post-Traumatic Stress Disorder (PTSD)":1,"Distress, Emotional":1,"Perception Disorders":1,"Loneliness":1,"Mood Disorders":1,"Obsessive Compulsive Disorder (OCD)":1,"Depressive Sympotoms":1,"Caregiver Distress":1,"Prolonged Grief Disorder":1,"Neuroimaging":1,"Healthy Participants With Lower-than-average Mental Well-being":1,"Cocaine-Related Disorders":1,"Lung Non-Small Cell Carcinoma":1,"Unipolar Depression":1,"Obsessive - Compulsive Disorder":1,"Substance-Related Disorders":1,"Chemically-Induced Disorders":1,"Stimulant-Use Disorder":1,"COPD (Chronic Obstructive Pulmonary Disease)":1,"ALS (Amyotrophic Lateral Sclerosis)":1,"MS (Multiple Sclerosis)":1,"Atypical Parkinson Disease":1,"Refractory Depression":1,"Cognitive Behavioral Therapy":1,"Palliative Care":1,"Pain":1,"Quality of Life":1,"Caregiver Burden":1,"Fear of Death":1,"Amphetamine-Related Disorders":1,"Cocaine Use Disorder":1,"Cannabis Use Disorder":1,"Safety":1,"Fibromyalgia, Primary":1,"Transdiagnostic":1,"Substance Use":1,"IBS - Irritable Bowel Syndrome":1,"Stress Disorders, Traumatic":1,"Stress Disorders, Post-Traumatic":1,"Trauma and Stressor Related Disorders":1,"Mental Disorder":1,"Adjustment Disorder":1,"Adjustment Disorder With Anxious Mood":1,"Cancer Cachexia":1,"Cancer of Endometrium":1,"Cancer of Kidney":1,"Cancer of Prostate":1,"Cancer of the Breast":1,"Cancer of Stomach":1,"Cancer Melanoma Skin":1,"Cancer Pancreas":1,"Placebo - Control":1,"Hospice":1,"Terminal Illness":1,"Cancer-related Problem/Condition":1,"Psychotherapy":1,"Terminal Cancer":1,"Cancer Terminal":1,"Stroke":1,"Chronic Stroke":1,"Intracerebral Haemorrhage":1,"Intracerebral Haemorrhage (ICH)":1,"Intracerebral Hemorrhage Basal Ganglia":1,"Ischemic Stroke":1,"Ischemic Stroke and Hemorrhagic Stroke":1,"Hemiparesis After Stroke":1,"Hemiplegia Following Ischemic Stroke":1,"Hemiplegia and Hemiparesis":1,"Hemiplegia and/or Hemiparesis Following Stroke":1,"Middle Cerebral Artery Stroke":1,"Major Depressive Diorder":1,"Irritable Bowel Syndrome":1,"Gambling Disorder":1,"Phantom Limb Pain":1,"Stuttering":1,"Self Harm":1,"Opioid Dependence":1,"Alcohol Abuse":1,"Recurrent Depression":1,"Obsessive-compulsive Disorder":1,"Psychogenic Nonepileptic Seizures":1,"Reinforcement, Psychology":1,"Post-Treatment Lyme Disease":1,"Chronic Lyme Disease":1,"Lyme Disease, Chronic":1,"Hematopoietic and Lymphoid Cell Neoplasm":1,"Perception Disturbance":1,"Visual Suppression":1,"Meditation":1,"Microdosing":1,"Personal Experience of Substance-assisted Therapy Using Psilocybin, MDMA, and LSD":1,"Chronic Neuropathic Pain":1,"Neuropharmacological Investigation of Ayahuasca Constituents DMT and Harmine":1,"Alcohol-Related Disorders":1,"Burnout, Caregiver":1,"COVID-19":1,"Moral Injury":1,"Basic Science":1,"Binge Eating Disorder":1,"Stimulant Use Disorder":1,"Disorders of Consciousness":1,"Obsessive-compulsive Disorder (OCD)":1,"Severe Alcohol Use Disorder":1,"Psychotherapy, Group":1,"Fragile X Syndrome":1,"Behavior":1,"Cognitive Dysfunction":1,"Alcoholism":1,"Post-Traumatic Stress Disorder":1,"Post-traumatic Stress Disorder":1,"Post-Traumatic Headache":1,"Side Effect of Drug":1,"QTc Interval":1,"Pharmacokinetics":1,"End of Life":1,"Mild Depression":1,"Moderate Depression":1,"Treatment Resistant Disorders":1,"Amnesia":1,"Mood Disturbance":1,"Sleep Disturbance":1,"Drug Effect":1,"Health, Subjective":1,"Psilocin Toxicity":1,"Psilocybin Toxicity":1,"Psilocybin Causing Adverse Effects in Therapeutic Use":1,"Body Dysmorphic Disorders":1,"Trauma, Nervous System":1,"Short Lasting Unilateral Neuralgiform Headache Attacks":1,"Anxiety and Depression":1,"Religious or Spiritual Problem":1,"Patients":1,"Cognitive Change":1,"Creativity":1,"Altered Waking States of Consciousness in Healthy Humans":1,"Distress":1,"Parkinson Disease Psychosis":1,"Severe Depression":1,"Pharmacologic Actions":1,"Central Nervous System Agents":1,"Therapeutic Uses":1,"Psychotropic Drugs":1},"sites":[{"key":"989968603bde40ea62cec15821beab8b75357cd99d372a1c9c6f3bbeebc55d37","facility":"Brown University School of Public Health","city":"Providence","region":"Rhode Island","country":"United States","lat":41.823990000000002,"lon":-71.41283},{"key":"28a3d9c38002b595ae213eb3bb81b2024aaf1d5bdcc3b9fd3ac81fe627252323","facility":"National Institute of Aging, Clinical Research Unit","city":"Baltimore","region":"Maryland","country":"United States","lat":39.290379999999999,"lon":-76.612189999999998},{"key":"f8718ebbb2d22b3721ee7415ff50f53592161a61926e613b38dcc6395cbf5438","facility":"St. Michael's Hospital, Unity Health Toronto","city":"Toronto","region":"Ontario","country":"Canada","lat":43.706429999999997,"lon":-79.39864},{"key":"ddc0834a1890df449d67ca69d92e76e6f1b5160403493ab29dfc1c2e1aed69c6","facility":"FL","city":"Miami","region":"Florida","country":"United States","lat":25.774270000000001,"lon":-80.193659999999994},{"key":"4b235d9fa455f60193f31a0d89a5dee284e9661ca9046ed4a1e57536aca09d6f","facility":"FL","city":"Orlando","region":"Florida","country":"United States","lat":28.538340000000002,"lon":-81.379239999999996},{"key":"a3f3b33aa62b155795dadc7cd5bdf343b9f66b44bc44a2ad0d5ee5fa338c2557","facility":"IL","city":"Chicago","region":"Illinois","country":"United States","lat":41.850029999999997,"lon":-87.650049999999993},{"key":"dbbb51357e4d710396c355b1f980917dd53615a81be8d319622d67aba5bb4e0e","facility":"MN","city":"Eden Prairie","region":"Minnesota","country":"United States","lat":44.854689999999998,"lon":-93.470789999999994},{"key":"c3798f7e7cf15a4eef1a10f53d46184aaf3eec07c5a23828e9e7a968feadf7db","facility":"NE","city":"Lincoln","region":"Nebraska","country":"United States","lat":40.799999999999997,"lon":-96.666960000000003},{"key":"1d793527c906ffb5c84860c6577d23027344e23eb25b29e2b74f8a07d64f5514","facility":"NV","city":"Las Vegas","region":"Nevada","country":"United States","lat":36.174970000000002,"lon":-115.13722},{"key":"6214ddb8e0d6a9b9b5b4cd7c9be7f1b1f04d1f4f17ff5715a68f589a0d3c671a","facility":"NY","city":"New York","region":"New York","country":"United States","lat":40.714269999999999,"lon":-74.005970000000005},{"key":"593189837e8532b432a369deaaa9a95dd6d9069e9ee0f7d4f302734d14cb430e","facility":"BC","city":"North Vancouver","region":"British Columbia","country":"Canada","lat":49.316360000000003,"lon":-123.06934},{"key":"bf2adfb756d244974a952f7c5c58e6f72f66cbbd5ba63e61a8b987fa1820f128","facility":"Centre for Addiction and Mental Health","city":"Toronto","region":"Ontario","country":"Canada","lat":43.706429999999997,"lon":-79.39864},{"key":"3a46b1d6e7fd8e6d4ac3522c52ea258b11d52f64ed81a85f442fdb36db5182f6","facility":"MD Anderson Cancer Center","city":"Houston","region":"Texas","country":"United States","lat":29.763280000000002,"lon":-95.36327},{"key":"9d7c1530695da1e0dbe5d0029c61521b74c434cedec820dcadef26feb9ead43e","facility":"Johns Hopkins Center for Psychedelic and Consciousness Research","city":"Baltimore","region":"Maryland","country":"United States","lat":39.290379999999999,"lon":-76.612189999999998},{"key":"8d12e2a0185c4db904e4654a720cc76843665c984d8a6666af2af6398451abcf","facility":"Emory University Hospital","city":"Atlanta","region":"Georgia","country":"United States","lat":33.749000000000002,"lon":-84.387979999999999},{"key":"0fef037c24d643378aa9f37a26412f8308ddc2ac490d10c8ef10ee242ac4bfb8","facility":"University of Wisconsin","city":"Madison","region":"Wisconsin","country":"United States","lat":43.073050000000002,"lon":-89.401229999999998},{"key":"ce511e3de8dae05034afdb25043c5e28d581eecc32497eda1b36dd3837c67ae4","facility":"Yale University","city":"New Haven","region":"Connecticut","country":"United States","lat":41.308149999999998,"lon":-72.928160000000005},{"key":"2a5127e58b092bb500853eb27d6f1063d5c783b90322382c367deb6192edd0bc","facility":"Olin Neuropsychiatry Research Center","city":"Hartford","region":"Connecticut","country":"United States","lat":41.763710000000003,"lon":-72.685090000000002},{"key":"ea17498fc8f1ee10ccde7d5207d959cb8f2fd7095ee234897659fb05d1422118","facility":"Brigham and Women's Hospital","city":"Boston","region":"Massachusetts","country":"United States","lat":42.358429999999998,"lon":-71.05977},{"key":"c0770de3d29c4c5f32a2af8475f2c25f664dc150eb0612e3bad6f32b5afb5313","facility":"Oregon Health & Science University","city":"Portland","region":"Oregon","country":"United States","lat":45.523449999999997,"lon":-122.67621},{"key":"463b7eaf2831972976c6ab2249631d9a0d7323ad764555861eab134acf615949","facility":"M Health Fairview DBT Program","city":"Minneapolis","region":"Minnesota","country":"United States","lat":44.979970000000002,"lon":-93.263840000000002},{"key":"3999afea2dfc9e525a89b295c634b8873c7c49f65315ca0aa8ba0398d13bf73b","facility":"M Physicians St. Louis Park Clinic","city":"Saint Louis Park","region":"Minnesota","country":"United States","lat":44.948300000000003,"lon":-93.348010000000002},{"key":"7ce22b002e53ab5c3978b99f32427c645bc1173311a77a8658068ba9bbf879bc","facility":"University of Alabama at Birmingham","city":"Birmingham","region":"Alabama","country":"United States","lat":33.520659999999999,"lon":-86.802490000000006},{"key":"20f0c712ea58b6615610fe11e7cff939bcc55adfffcd8761309ca251e8acfc7d","facility":"GHU Paris Psychiatrie and Neurosciences","city":"Paris","region":"","country":"France","lat":48.853409999999997,"lon":2.3488000000000002},{"key":"43d57f1d479805418491a2b4e825f4a61463da217d6483cb15a9c517f345d284","facility":"University of California San Francisco (UCSF) Department of Neurology","city":"San Francisco","region":"California","country":"United States","lat":37.774929999999998,"lon":-122.41942},{"key":"0473ab642c74b3812c946daf78fe3c51c20132227d55cd3b18f186955bf391f2","facility":"University of Colorado Anschutz Medical Campus","city":"Aurora","region":"Colorado","country":"United States","lat":39.729430000000001,"lon":-104.83192},{"key":"2392816208ad8a6692839d858f70a09054f7ea063608cc805707f539d666e13b","facility":"Emory University Brain Health Center","city":"Atlanta","region":"Georgia","country":"United States","lat":33.749000000000002,"lon":-84.387979999999999},{"key":"6f007287e1a63fa09fd71b03e4e4b72f285c5af84c8385a3eed252bc9a13b363","facility":"Dana-Farber Cancer Institute","city":"Boston","region":"Massachusetts","country":"United States","lat":42.358429999999998,"lon":-71.05977},{"key":"22268aacd3575a268c889e749c8576127c9bff8a9e8343b4058a94d77d976383","facility":"University of Nebraska Medical Center","city":"Omaha","region":"Nebraska","country":"United States","lat":41.256259999999997,"lon":-95.940430000000006},{"key":"bf586d38e3cc5e261d1c6e575c24ec47a2175ffd3a3a156c666afe314b54f80c","facility":"New York University Langone Health, Center for Psychedelic Medicine","city":"New York","region":"New York","country":"United States","lat":40.714269999999999,"lon":-74.005970000000005},{"key":"94f32ec7d881a5dcad883b92fb978930f07259cffee3dda1527eba86a2d3e8bc","facility":"University Health Network","city":"Toronto","region":"Ontario","country":"Canada","lat":43.706429999999997,"lon":-79.39864},{"key":"fdeccc6664a6555feb9443c7f9547c8dc94264e878e864489fd4b43c0a16451a","facility":"Center for Psychedelics and Consciousness Research in the Behavioral Biology Research Center","city":"Baltimore","region":"Maryland","country":"United States","lat":39.290379999999999,"lon":-76.612189999999998},{"key":"f013c15d8112693910d9bf055f39dc54c2a9c3749b21ac7dacc4c09c7de423df","facility":"NYU Langone Health","city":"New York","region":"New York","country":"United States","lat":40.714269999999999,"lon":-74.005970000000005},{"key":"b080767d21c0ebe8aea0aba1c3f1a88355bed0e01997cb41cb5704abd0b086dc","facility":"Djavad Mowafaghian Centre for Brain Health","city":"Vancouver","region":"British Columbia","country":"Canada","lat":49.249659999999999,"lon":-123.11933999999999},{"key":"aa8f99cb753e6ee68d3c63b2cdb1b7e7d90b1680cb84bc239d625d80bd4e6c8b","facility":"Department of Psychiatry, University of Ottawa, The Ottawa Hospital","city":"Ottawa","region":"Ontario","country":"Canada","lat":45.411169999999998,"lon":-75.698120000000003},{"key":"ab54d44984a52b7a2aba12f9808b881d3f2fa4a702669885a0a10983ba498e39","facility":"Department of Psychiatry, University of Toronto, University Health Network,","city":"Toronto","region":"Ontario","country":"Canada","lat":43.706429999999997,"lon":-79.39864},{"key":"5694dcf845a6c481e3dda16b85afa7a73d3936087eefe461fcc9694177d080de","facility":"Center for Psychedelics and Consciousness Research","city":"Baltimore","region":"Maryland","country":"United States","lat":39.290379999999999,"lon":-76.612189999999998},{"key":"43d6a4c1bec6b0da7fbcdcf29f22e29eb9ee146f88b69aa1d4bc718a46bed666","facility":"University of Calgary","city":"Calgary","region":"Alberta","country":"Canada","lat":51.050109999999997,"lon":-114.08529},{"key":"52bc2180526f10b62a5aca748b84f9b3b723aee40e4b7ba311fbe63f85e74ca8","facility":"University of California San Francisco, Sandler Neuroscience Building","city":"San Francisco","region":"California","country":"United States","lat":37.774929999999998,"lon":-122.41942},{"key":"43285f7204d9fc6f3ca9d5dde05a28e488488aa9f5a73593374801c5dfe5dfe0","facility":"The University of British Columbia - Okanagan Campus","city":"Kelowna","region":"British Columbia","country":"Canada","lat":49.883069999999996,"lon":-119.48568},{"key":"b1b7385307b2710c76b5175c36619a7edcaff39e015a0a2e8cb2e1b125a2f6bb","facility":"Johns Hopkins University School of Medicine","city":"Baltimore","region":"Maryland","country":"United States","lat":39.290379999999999,"lon":-76.612189999999998},{"key":"9d73c96f237ac68fbda3d911e4b1f4df70d78bffe439fcbd3af6fdd7e0b5b445","facility":"Outpatient CTRC","city":"Aurora","region":"Colorado","country":"United States","lat":39.729430000000001,"lon":-104.83192},{"key":"26536ff41048bd47e18a2ae19bf7955b33e3305e2417d2a442cc3e762d6f37db","facility":"University of Colorado Cancer Center","city":"Aurora","region":"Colorado","country":"United States","lat":39.729430000000001,"lon":-104.83192},{"key":"7f09a842484186a75c6232177464293472d56c43d4d49f24f37efcb6c9cbbbb8","facility":"University of California, San Francisco","city":"San Francisco","region":"California","country":"United States","lat":37.774929999999998,"lon":-122.41942},{"key":"69ac64288af5cb5338ec5bcb6ba08a6b7fa1b82e6ac1e239ced6fb2bbb2fb97e","facility":"Arthur Child Comprehensive Cancer Centre","city":"Calgary","region":"Alberta","country":"Canada","lat":51.050109999999997,"lon":-114.08529},{"key":"dc3875179cb830724fc5f84413b98d92146b4b6cbbf28f85a160567e32905d2c","facility":"Providence Care Hospital","city":"Kingston","region":"Ontario","country":"Canada","lat":44.229759999999999,"lon":-76.480980000000002},{"key":"2e7548466e831b567e38ef1e8fdd7baae3817e9b4e2a89bc35dca43d64edbecb","facility":"UC San Diego","city":"San Diego","region":"California","country":"United States","lat":32.715710000000001,"lon":-117.16472},{"key":"51a9a92a0508b764f9a4517d8d60933b3ee3ba0964375b23c07f442f64b82278","facility":"MacAnxiety Research Centre","city":"Hamilton","region":"Ontario","country":"Canada","lat":43.250109999999999,"lon":-79.849630000000005},{"key":"3a56bfcfdf7e421572987bf0738f148704d0626c5f1a8add94a738b0edf2d3c0","facility":"ARQ National Psychotrauma Centre / ARQ Centrum'45","city":"Oegstgeest","region":"","country":"Netherlands","lat":52.18,"lon":4.4694399999999996},{"key":"2af82304b750e5e49e9f89c722d44575fe6978541c1a1e315e0c160897006053","facility":"Clinical Research Facility, King's College Hospital","city":"London","region":"London","country":"United Kingdom","lat":51.50853,"lon":-0.12573999999999999},{"key":"61ce79cfaa08fedbb10711df8d7c73a357fd5df0b146e4b4ff109a1f1ba7fd39","facility":"Toronto Western Hospital (University Health Network)","city":"Toronto","region":"Ontario","country":"Canada","lat":43.706429999999997,"lon":-79.39864},{"key":"27df3ff2008239e64bf38e6c56f8f5e8652612b4aa9bff987d4ba0f94be975b1","facility":"Connecticut Mental Health Center","city":"New Haven","region":"Connecticut","country":"United States","lat":41.308149999999998,"lon":-72.928160000000005},{"key":"e6baef990fbeb7d39fe3ae6170b4504d185d11acfac4b251c03198f2bd0ccd03","facility":"Vail Health Behavioral Health","city":"Edwards","region":"Colorado","country":"United States","lat":39.64499,"lon":-106.5942},{"key":"277ec95effb37a499f97d6fb82da461e2d3790bb840eb8be0d307666a1a93593","facility":"Psykiatrikliniken, Baravägen 1","city":"Lund","region":"","country":"Sweden","lat":55.705840000000002,"lon":13.193210000000001},{"key":"e3da1ce8cb4b14f80a762b6f6cadb84535f4c69b15786b698ef1c7179aa721b3","facility":"5510 Nathan Shock Drive","city":"Baltimore","region":"Maryland","country":"United States","lat":39.290379999999999,"lon":-76.612189999999998},{"key":"1094674cfb576eb3aba9c610abfa1ec8007d88c3fc30323de895b78b257dc9ca","facility":"Birmingham VA Medical Center, Birmingham, AL","city":"Birmingham","region":"Alabama","country":"United States","lat":33.520659999999999,"lon":-86.802490000000006},{"key":"36ded30328be4e5de016f706a8efcb9e2ce3181d513bae1f031f8c88931e15dd","facility":"Tuscaloosa VA Medical Center, Tuscaloosa, AL","city":"Tuscaloosa","region":"Alabama","country":"United States","lat":33.20984,"lon":-87.56917},{"key":"673eee709be8746b7b99358264e9a830cab9eff575766127a823456961139800","facility":"VA Portland Health Care System, Portland, OR","city":"Portland","region":"Oregon","country":"United States","lat":45.523449999999997,"lon":-122.67621},{"key":"5bc04aa77be1370761183e8a64f2c2e1129ef67efc98b5f6610da73065ccb37c","facility":"Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA","city":"Philadelphia","region":"Pennsylvania","country":"United States","lat":39.952379999999998,"lon":-75.163619999999995},{"key":"cf2d4c3f9eed8457b9a5ca21d741ba54a1b036d130efd17e977384b0d89a5133","facility":"VA Puget Sound Health Care System Seattle Division, Seattle, WA","city":"Seattle","region":"Washington","country":"United States","lat":47.606209999999997,"lon":-122.33207},{"key":"72b096fd9021c9bfd550d9d949b2594137c212c14110e7c00e66d39b5f8101eb","facility":"UW School of Medicine and Public Health","city":"Madison","region":"Wisconsin","country":"United States","lat":43.073050000000002,"lon":-89.401229999999998},{"key":"41d7ef563025697eae67dcbab6ec20d0cf94934cb7a21f3999e9b581e150f205","facility":"The Parsons Research Center for Psychedelic Healing","city":"New York","region":"New York","country":"United States","lat":40.714269999999999,"lon":-74.005970000000005},{"key":"ae85e9f90db4bd1845b2a9817e008d4a625ffc046123c8a22344695349c7e230","facility":"Athinoula A. Martinos Center for Biomedical Imaging","city":"Charlestown","region":"Massachusetts","country":"United States","lat":42.377870000000001,"lon":-71.061999999999998},{"key":"7de3d89eed44865c013d4553fc6090d54c7c067dbeedefce79bfea681d8b54c2","facility":"University of Washington Center for Novel Therapeutics in Addiction Psychiatry","city":"Seattle","region":"Washington","country":"United States","lat":47.606209999999997,"lon":-122.33207},{"key":"cc8da94c896719bab57ed8dd47266c0ce0664ad555799300d442f1fe89aa2942","facility":"The University of Texas M. D. Anderson Cancer Center","city":"Houston","region":"Texas","country":"United States","lat":29.763280000000002,"lon":-95.36327},{"key":"da2bda06c1b463bdcf59130477fd36b92915811ee4ac0f0c25eafb7329fb0cb9","facility":"The University of Texas Health Science Center at Houston","city":"Houston","region":"Texas","country":"United States","lat":29.763280000000002,"lon":-95.36327},{"key":"d8fb28c671742199166f748836eb0aaf7f93725796222ed3a6857bd2ec7ed639","facility":"Roswell Park Cancer Institute","city":"Buffalo","region":"New York","country":"United States","lat":42.886450000000004,"lon":-78.878370000000004},{"key":"5e54e3832bb9c4f6cddd3eeefc9951bb04903d8e26aedf819b29aa11a2e0c418","facility":"Kingston General Health Research Institute","city":"Kingston","region":"Ontario","country":"Canada","lat":44.229759999999999,"lon":-76.480980000000002},{"key":"351f97e654e4dc3c5a6bc97464ad09c9791a304ed6d742edf0ae41f3b33c137a","facility":"UCSF at Zuckerberg San Francisco General Hospital","city":"San Francisco","region":"California","country":"United States","lat":37.774929999999998,"lon":-122.41942},{"key":"e9edfb74a78777f36bdfaa262be65a39985de4f9f95f1206871c1a7ff9a9c980","facility":"Lighthouse Psychiatry Scottsdale","city":"Gilbert","region":"Arizona","country":"United States","lat":33.352829999999997,"lon":-111.78903},{"key":"8c8cc924d99dc7a2acac00ca041c949244f6efbdaecea0e276cd138f1f9f4a45","facility":"Clinical Innovations, Inc.","city":"Bellflower","region":"California","country":"United States","lat":33.881680000000003,"lon":-118.11700999999999},{"key":"33cd083fccf6bfafedb17e1ca5bcb5536d1a7eb0d006049da3c7f262774714ec","facility":"M3 Wake Research","city":"Encino","region":"California","country":"United States","lat":34.159170000000003,"lon":-118.50118999999999},{"key":"3956987c0538c47320e7e3cb786388fb4df67930ced721b44fcf2ab583c65ac8","facility":"The Regents of the University of California - San Diego","city":"La Jolla","region":"California","country":"United States","lat":32.847270000000002,"lon":-117.27419999999999},{"key":"b1132fa91c6c49bf3a7b5fc89a57fb89b94ff271a2081e8352dd7bd5a7ea4f1c","facility":"Kadima Neuropsychiatry Institute","city":"La Jolla","region":"California","country":"United States","lat":32.847270000000002,"lon":-117.27419999999999},{"key":"433890853c30fd15b198d52a519a62c71d8f0aa70ec3feaec3b4706dec634558","facility":"CalNeuro Research Group, Inc","city":"Los Angeles","region":"California","country":"United States","lat":34.052230000000002,"lon":-118.24368},{"key":"9d75c9d391d2e052ce5d2a8d26f61fee174796b13686fbc553967949c7f16d71","facility":"Catalina Research Institute, LLC","city":"Montclair","region":"California","country":"United States","lat":34.077509999999997,"lon":-117.68978},{"key":"0bce40827ee3d733ae9e503a880619077ca6e8de0dd17a87c7648da3a2ea4f92","facility":"Piedmont Hospital Neuroscience Centre","city":"Oakland","region":"California","country":"United States","lat":37.804369999999999,"lon":-122.27079999999999},{"key":"0ecf4347c0490c2eb9d05276c5439c505d2af8ab93b342747f51f471f3f2f8b5","facility":"ATP Clinical Research, Inc.","city":"Orange","region":"California","country":"United States","lat":33.787790000000001,"lon":-117.85311},{"key":"2d348620aff9bffb0740d1c6f653cba6346fb9e4be97ffcdd65f37a4facef711","facility":"CITrials","city":"Riverside","region":"California","country":"United States","lat":33.95335,"lon":-117.39615999999999},{"key":"f716f4334d80fcccdf2abeb47aec4330b37ff6c101c75c28a0c50d78e79fe16e","facility":"Lumos Clinical Research Center","city":"San Jose","region":"California","country":"United States","lat":37.339390000000002,"lon":-121.89496},{"key":"04fc45375356ec7e141d1e661bbe958521ad9595143bf914dac40e8e4038f89b","facility":"Syrentis Clinical Research","city":"Santa Ana","region":"California","country":"United States","lat":33.745570000000001,"lon":-117.86783},{"key":"50c13e63ee1fe4325b40dc6b409f9002d59ae4e7e4879bf350dcad72bc996f6d","facility":"Stanford University","city":"Stanford","region":"California","country":"United States","lat":37.424109999999999,"lon":-122.16607999999999},{"key":"f3f64a43e6e1393672512aff6e67e13509591b6e56ca2fda56ce8c242f43e72d","facility":"ASCLEPES Research Centers","city":"Thousand Oaks","region":"California","country":"United States","lat":34.170560000000002,"lon":-118.83759000000001},{"key":"a827f194bf451373f242dff28ca06d6f968576ec23131c98663006604196ff34","facility":"Pacific Clinical Research Management Group, LLC","city":"Upland","region":"California","country":"United States","lat":34.09751,"lon":-117.64839000000001},{"key":"1d86b7161c444a07e40f263de72732b54d755691bf3a60669016463f215c75dd","facility":"Innovative Clinical Research, Inc.","city":"Lauderhill","region":"Florida","country":"United States","lat":26.140360000000001,"lon":-80.213380000000001},{"key":"a61751b7d865072b2f31bf6e4ab9c9ce7ae37384fb363d60648104de17c1289c","facility":"Central Miami Medical Institute, LLC","city":"Miami","region":"Florida","country":"United States","lat":25.774270000000001,"lon":-80.193659999999994},{"key":"9e85535b6cebd5a4a1d90f25b70eda855eeb4de9eac52adb675e9c49740bdea8","facility":"Behavioral Clinical Research, Inc.","city":"Miami Lakes","region":"Florida","country":"United States","lat":25.908709999999999,"lon":-80.308660000000003},{"key":"69ca07bfacaf4b2aa725899b657d5f8cab7f1c88c3d64b1257c6f236ea3cd818","facility":"Health Synergy Clinical Research","city":"Okeechobee","region":"Florida","country":"United States","lat":27.243929999999999,"lon":-80.82978},{"key":"d254863966539613f9cf8b8bbf09c480ffe63cbd290d96eff3edb91423fba06c","facility":"Clinical Neurosciecne Solutions, Inc. dba CNS Healthcare","city":"Orlando","region":"Florida","country":"United States","lat":28.538340000000002,"lon":-81.379239999999996},{"key":"8b79eabaace5e2d9634e903d05c134f3463c515b9149f7f1110f7075f2855415","facility":"APG Research, LLC- Advanced Psychiatric Group","city":"Orlando","region":"Florida","country":"United States","lat":28.538340000000002,"lon":-81.379239999999996},{"key":"886add41555cb1260c6a674de26b8977c2837edb5094cf381bd33852ca06f8d6","facility":"University South Florida","city":"Tampa","region":"Florida","country":"United States","lat":27.947520000000001,"lon":-82.458430000000007},{"key":"e8272b61efc64a56598c46b640aaa7fe71b04a3bc669ca520458edb6dd768d81","facility":"Stedman Clinical Trials","city":"Tampa","region":"Florida","country":"United States","lat":27.947520000000001,"lon":-82.458430000000007},{"key":"96291c327c4e7434938b601c55622ac50098458d497e0741666ccdbb17afbff1","facility":"Health Synergy Clinical Research, LLC","city":"West Palm Beach","region":"Florida","country":"United States","lat":26.715340000000001,"lon":-80.053370000000001},{"key":"4e53967735fae7ab4ea818a325ed6321cb8d90d0439b5d344989cf76f7773501","facility":"Atlanta Center for Medical Research","city":"Atlanta","region":"Georgia","country":"United States","lat":33.749000000000002,"lon":-84.387979999999999},{"key":"2ee722b6641f2fb2181d7c449b187717e0152f3d6240301acbae668f2a017496","facility":"iResearch Atlanta","city":"Decatur","region":"Georgia","country":"United States","lat":33.774830000000001,"lon":-84.296310000000005},{"key":"6e7e87e6abd6f29f724f49ce28a3a34c25e5c1c49b95f77a93f8b41e6c15e026","facility":"Rush University Medical Center","city":"Chicago","region":"Illinois","country":"United States","lat":41.850029999999997,"lon":-87.650049999999993},{"key":"ddad76cc8ac3eabdf04d8d630a084814244b8b4bc8c26a47c3e9a8a5a1a06dea","facility":"Uptown Research Institute, LLC","city":"Chicago","region":"Illinois","country":"United States","lat":41.850029999999997,"lon":-87.650049999999993},{"key":"f7a1cbf92391beae3f7562af92296c53808e6d5b6e24800d0300caa67e059deb","facility":"Psychiatric Medicine Associates","city":"Skokie","region":"Illinois","country":"United States","lat":42.033360000000002,"lon":-87.73339},{"key":"694ca0b3448bdcdf992374f9b82f3bf5ea4a8de1d62177bd65c019ba6e3e7276","facility":"Harvard Medical School - McLean Hospital","city":"Belmont","region":"Massachusetts","country":"United States","lat":42.39593,"lon":-71.178669999999997},{"key":"0cbc44fd437f048ccec8b77bcab3642524094c01439c857c0d93b1df2c3c5792","facility":"Adams Clinical - Boston (Copley Clinical)","city":"Boston","region":"Massachusetts","country":"United States","lat":42.358429999999998,"lon":-71.05977},{"key":"3def80915b7bdc5d973f5b43fbe6e47d92c9a910c88c6ef98de29a0648309c43","facility":"University of Massachusetts Medical School","city":"North Worcester","region":"Massachusetts","country":"United States","lat":42.316760000000002,"lon":-71.817570000000003},{"key":"46862561f48050c28d5929604cd7310f7dd5b980451df606b91dec8b5a5e4842","facility":"Adams Clinical - Boston","city":"Watertown","region":"Massachusetts","country":"United States","lat":42.370930000000001,"lon":-71.182829999999996},{"key":"82a991cbba0edc55429e1bf37c9e8fb9198d616ade8204136d57fb15035be0c0","facility":"Michigan Clinical Research Institute PC","city":"Ann Arbor","region":"Michigan","country":"United States","lat":42.277560000000001,"lon":-83.740880000000004},{"key":"5077e7a11120073a05fb9c15ef1570a81e7dc68801a62a7c2dab56e77135317a","facility":"University Of Michigan Comprehensive Depression Center","city":"Ann Arbor","region":"Michigan","country":"United States","lat":42.277560000000001,"lon":-83.740880000000004},{"key":"1f57eba4506ead7dbe85ee58d44522b9adb00f7badf8acc2a19177cbd78523d7","facility":"Institute for Integrative Therapies","city":"Eden Prairie","region":"Minnesota","country":"United States","lat":44.854689999999998,"lon":-93.470789999999994},{"key":"bfc0abfee7b8d0aaf77701419fbafff26c77912e4386a5188e7182a2774725c2","facility":"St. Charles Psychiatric Associates - Midwest Research Group","city":"Saint Charles","region":"Missouri","country":"United States","lat":38.783940000000001,"lon":-90.481229999999996},{"key":"552a38e810ea599cab40e1a06262965439884f4f1ad26494072c517e71b41307","facility":"Alivation Research, LLC.","city":"Lincoln","region":"Nebraska","country":"United States","lat":40.799999999999997,"lon":-96.666960000000003},{"key":"ade48b4a9a79751c77c933de17f5be45d01a947eb4f6d0c0ae3d9779c9e993cc","facility":"Hassman Research Institute","city":"Berlin","region":"New Jersey","country":"United States","lat":39.791229999999999,"lon":-74.929050000000004},{"key":"0c6bbeedba8c2a5fa6e104bd9e3665edd400539cd709bc37e3b4c82a359254ae","facility":"Princeton Medical Institute","city":"Princeton","region":"New Jersey","country":"United States","lat":40.34872,"lon":-74.659049999999993},{"key":"4345cef85b3822f2a99a14204b9552b865c0a12a0081b0e155f454d8c0a0a130","facility":"Bio Behavioral Health","city":"Toms River","region":"New Jersey","country":"United States","lat":39.95373,"lon":-74.197919999999996},{"key":"bd484b86c9be7b53a1d38ad00e616619475eb6359e7b6f182f9ea4debf82b795","facility":"Dent Neurosciences Research Center, Inc.","city":"Amherst","region":"New York","country":"United States","lat":42.978389999999997,"lon":-78.799760000000006},{"key":"454515776b11d66402a152efa7f552f15b988e79b979ac8eed8fdeb01fb5a56e","facility":"Fieve Clinical Research, Inc","city":"New York","region":"New York","country":"United States","lat":40.714269999999999,"lon":-74.005970000000005},{"key":"99b8a84c837f6982e0917263a833f5aaea72f1851b9e6a259d714d169d25020a","facility":"Spectrum Neuroscience and Treatment Institute","city":"New York","region":"New York","country":"United States","lat":40.714269999999999,"lon":-74.005970000000005},{"key":"fb0809cdceec9619af9370ddd68999ba673fdb0632c5c9bc83beb431ea41f3e9","facility":"Adams Clinical - New York","city":"New York","region":"New York","country":"United States","lat":40.714269999999999,"lon":-74.005970000000005},{"key":"9f6dd6c250948ab5fb811774c2613bdc33238e29b80a54c99b31bd3b33684089","facility":"New York State Psychiatric Institute","city":"New York","region":"New York","country":"United States","lat":40.714269999999999,"lon":-74.005970000000005},{"key":"63cb8ba1c0094238eb4400cf5d93d9ae1b0820b3cd87f1ab2138f6949151ef5a","facility":"Richmond Behavioral Associates","city":"Staten Island","region":"New York","country":"United States","lat":40.562330000000003,"lon":-74.139859999999999},{"key":"8e138c4de81ac1f637dfa268b2b7800f8c82a961092c6100c7104b78ff3379a7","facility":"Adams Clinical - New York","city":"The Bronx","region":"New York","country":"United States","lat":40.849850000000004,"lon":-73.866410000000002},{"key":"987d4adb7e469b7ed36a06dbc91030981ca591af195c9a0ab2e02bba8a0d3972","facility":"University of Cincinnati, Department of Psychiatry & Behavirol Neuroscience","city":"Cincinnati","region":"Ohio","country":"United States","lat":39.127110000000002,"lon":-84.514390000000006},{"key":"40cbc17a430b6e762b1e9940acf93d8e293eda7f6847081b1ec74eccfcf6cd0c","facility":"Cleveland Clinic - Lutheran Hospital","city":"Cleveland","region":"Ohio","country":"United States","lat":41.499499999999998,"lon":-81.695409999999995},{"key":"be9155272f1c03899bfc66b211e217f90f72de646b7740cb75ea8391a13624e9","facility":"The Ohio State University","city":"Columbus","region":"Ohio","country":"United States","lat":39.961179999999999,"lon":-82.99879},{"key":"1c7438c2dd393f89a6984bc7c2d5a57e87c15ed5673114f3fdc806a7cb34c3cf","facility":"Suburban Research Associates","city":"Media","region":"Pennsylvania","country":"United States","lat":39.916780000000003,"lon":-75.387690000000006},{"key":"e95c6b8b499957a645809625007b3fd78455d1c8129ea67ceb51c5b53dd1fa04","facility":"The University of Texas at Austin - Dell Medical School","city":"Austin","region":"Texas","country":"United States","lat":30.267150000000001,"lon":-97.74306},{"key":"2acd481bb65f8fe1401b23689fc66e5da5978643601ea8445106082c8eabda7e","facility":"Houston Clinical Trials, LLC","city":"Bellaire","region":"Texas","country":"United States","lat":29.70579,"lon":-95.458830000000006},{"key":"02e37a9dd5948eceb65538ae90a46d1cc8b78982d21801b0bb6af3b10db5ed93","facility":"Relaro Medical Trials","city":"Dallas","region":"Texas","country":"United States","lat":32.783059999999999,"lon":-96.806669999999997},{"key":"7979f0993e76394286f5f03480f284ac50f3a19e17fd47d46e59665648ddf36d","facility":"Center for Depression Research and Clinical Care","city":"Dallas","region":"Texas","country":"United States","lat":32.783059999999999,"lon":-96.806669999999997},{"key":"0b557b40f24420f1abfb13544f507f9566ad0a580efeb5c49cb6773bccbd80ec","facility":"North Texas Clinical Trials","city":"Fort Worth","region":"Texas","country":"United States","lat":32.725409999999997,"lon":-97.320849999999993},{"key":"560f71dbdc782a70c5d785def2d529c405284ce56896efe30bc0b3d4f5029454","facility":"Brain Health Consultants and TMS Center","city":"Houston","region":"Texas","country":"United States","lat":29.763280000000002,"lon":-95.36327},{"key":"2028352f21415dc4d425b3e11ace95ea8cc08d2a2f26d289e61fe059c3ff3068","facility":"HCA Healthcare Research Institute - Medical City Green Oaks Hospital","city":"Plano","region":"Texas","country":"United States","lat":33.019840000000002,"lon":-96.698890000000006},{"key":"096867127180fe96e9a72bbcc7520d5592abe8032d4645482a93afa580e47078","facility":"Cedar Clinical Research","city":"Draper","region":"Utah","country":"United States","lat":40.52467,"lon":-111.86382},{"key":"fab2f83593e00e9a8526694e34435936cebf031dae3f2b19e723b5f14f9df830","facility":"The University of Utah - Huntsman Mental Health Institute","city":"Salt Lake City","region":"Utah","country":"United States","lat":40.760779999999997,"lon":-111.89105000000001},{"key":"852acd88a3554f9543812fc58a1da1761ef5d1428172d7159bdaf5ebc0afa09c","facility":"Seattle Neuropsychiatric Treatment Center","city":"Seattle","region":"Washington","country":"United States","lat":47.606209999999997,"lon":-122.33207},{"key":"ef60aa0dae20a9ed5c10cd4ce8482a706f4cbac6a5114b39c05228e620e8feb3","facility":"Diex Recherche Sherbrooke Inc.","city":"Québec","region":"B.C.","country":"Canada","lat":46.812280000000001,"lon":-71.21454},{"key":"7cb13038e1e3fe5eec551c8cb3f2e6cf8dc1c0100a214c236093feb7b9a1200f","facility":"Medical Arts Health Research Centre, Kamloops","city":"Kamloops","region":"British Columbia","country":"Canada","lat":50.66648,"lon":-120.3192},{"key":"b6145ff487ffb39fe26ce240998c399fbf6f9a455da2b4bd7a6baefc497639eb","facility":"Okanagan Clinical Trials","city":"Kelowna","region":"British Columbia","country":"Canada","lat":49.883069999999996,"lon":-119.48568},{"key":"fe34fdf0374170a77a8ea2f65e782f299897a6fc4f3888c7477dc463f4716995","facility":"Medical Arts Research Group - Penticton","city":"Penticton","region":"British Columbia","country":"Canada","lat":49.480620000000002,"lon":-119.58584},{"key":"3ea0145b1ddfed5da3fbe6e87c0d7cbfae4890db632cc0458ddbe08bcbd9e83c","facility":"Chatham-Kent Clnical Trials Centre","city":"Chatham","region":"Ontario","country":"Canada","lat":42.412239999999997,"lon":-82.184939999999997},{"key":"cbbb447c4fbad7764f06801cb01f1c736fa64961a1055d544bc07f4c33f05dc5","facility":"St. Michael's Hospital","city":"Toronto","region":"Ontario","country":"Canada","lat":43.706429999999997,"lon":-79.39864},{"key":"2846642b890b09da9f32cb5c27a53f14767c23a4d2f66d979dc0e0c46d5d4cb3","facility":"Centre for Addiction and Mental Health (CAMH)","city":"Toronto","region":"Ontario","country":"Canada","lat":43.706429999999997,"lon":-79.39864},{"key":"77dadecab9166a9daade5e3e4f5bab68b6201a9a4540a27546ed6ebd4bfbe01a","facility":"Centre for Neurology Studies","city":"Vancouver","region":"","country":"Canada","lat":49.249659999999999,"lon":-123.11933999999999},{"key":"cb8b817ff4fec9a087d8b86e30c73c54c24590b44ec0e883af2f7ceff9126dc6","facility":"Medical Arts Research Group","city":"Vancouver","region":"","country":"Canada","lat":49.249659999999999,"lon":-123.11933999999999},{"key":"d389d3900cc088a27974b2b5e13fc6f9ec37fc5b84a0948484673de1d44e47a5","facility":"National Institute of Mental Health","city":"Klecany","region":"","country":"Czechia","lat":50.175989999999999,"lon":14.411479999999999},{"key":"f91ac90932e665e7ecb3557e93b058f71655e686f92803689e1521f8dff9d84c","facility":"Neuroterapie KH Sro","city":"Kutná Hora","region":"","country":"Czechia","lat":49.948390000000003,"lon":15.26816},{"key":"b520016f9fb54cabf32fa9c005e80e49e6d316199594e35758680b6dc1ab5dc4","facility":"Psychiatric Ambulance","city":"Ostrava","region":"","country":"Czechia","lat":49.834650000000003,"lon":18.282039999999999},{"key":"d0f30b3dfe1a1430d239837af8087c86194996403bf342f41034f7cc173a8be4","facility":"A-Shine s.r.o.","city":"Pilsen","region":"","country":"Czechia","lat":49.74747,"lon":13.37759},{"key":"850755de8392406d920407e1a3c7b061e13ce0e6877ec4330e16e1b3581bfd9d","facility":"Psychedelicka klinika, s.r.o.","city":"Prague","region":"","country":"Czechia","lat":50.088039999999999,"lon":14.42076},{"key":"f17868226437efe220461a8dd69049d4795b3d7e10f0e247300b6f793eadf002","facility":"Institut Neuropsychiatricke Pece","city":"Prague","region":"","country":"Czechia","lat":50.088039999999999,"lon":14.42076},{"key":"bda21da2d259f22bc767e1bc16b14a0821d454f141c4df055bf56b1860147b38","facility":"Aalborg Universitetshospital-Psykiatrien Region Nordjylland","city":"Aalborg","region":"","country":"Denmark","lat":57.048000000000002,"lon":9.9186999999999994},{"key":"d6c34b0a3f2673cd992a7856bae0e50b1af86d935e249c027b580253ee59c5a0","facility":"Ghu-Centre Hospitalier Sainte Anne, Centre de Recherche Clinique","city":"Paris","region":"Paris","country":"France","lat":48.853409999999997,"lon":2.3488000000000002},{"key":"b0e7944fe5a90e12e71e461ffc91c42b04b7ae31031157eddab865ffef09f92a","facility":"Centre Hospitalier Universitaire de Nimes (CHU) - Hopital Universitaire Caremeau","city":"Nîmes","region":"","country":"France","lat":43.836649999999999,"lon":4.3578799999999998},{"key":"9a01801daca00ce24f1fab7f819e88260759bb8c60020463a724ade136a7c9f3","facility":"Universite Paris VI Pierre et Marie Curie - Hopital de La Salpetriere - Centre Emotion - USR 3246 (CNRS UMR 7593)","city":"Paris","region":"","country":"France","lat":48.853409999999997,"lon":2.3488000000000002},{"key":"a303bb5bfeff1483534543f03a9a65bedb06203041eed68e4ee3ff361dc4f99e","facility":"Centre Hospitalier Sainte Anne - Clinique des Maladies Mentales et de l'Encephale (CMME)","city":"Paris","region":"","country":"France","lat":48.853409999999997,"lon":2.3488000000000002},{"key":"13f3a02a08766157b3539561920a498408109806a88f798e97a5adb902b9ad83","facility":"Charite-Universitaetsmedizin Berlin","city":"Berlin","region":"","country":"Germany","lat":52.524369999999998,"lon":13.41053},{"key":"3d01600f8989a888092f754f642cc599a43330af3d400f38b4e840a702fe0dc5","facility":"Johann Wolfgang Goethe-Universitaet Frankfurt am Main - Klinik fuer Psychiatrie, Psychosomatik und Psychotherapie","city":"Frankfurt","region":"","country":"Germany","lat":49.683329999999998,"lon":10.533329999999999},{"key":"8b2daea5a7b3526bd77a6a99df1437437456f49d29ce3a49f27cc2d7918d1fd9","facility":"ZiP Campus Luebeck","city":"Lübeck","region":"","country":"Germany","lat":53.868929999999999,"lon":10.687290000000001},{"key":"1936d05fa8ae325b9934cffa0a0c3f08afa8e902d6fe3597cf7ffaec91b70308","facility":"Tallaght University Hospital","city":"Dublin","region":"","country":"Ireland","lat":53.333060000000003,"lon":-6.2488900000000003},{"key":"0f1e596cf73c48035fda8f4a649ac2cdba597ec02171f6c16aa85986f90c1399","facility":"La Nua Day Hospital Mental Health Centre","city":"Galway","region":"","country":"Ireland","lat":53.272449999999999,"lon":-9.0509500000000003},{"key":"27d7b4df35cb1e0b4d4349418e100597b52afe044578477ac7a1e36059b373ba","facility":"University Medical Center Groningen","city":"Groningen","region":"Provincie Groningen","country":"Netherlands","lat":53.219169999999998,"lon":6.5666700000000002},{"key":"c556803ea8e3be024939cd9c5b7ff7483d45f2a121453ccabc7afce367e79d59","facility":"Leids Universitair Medisch Centrum (LUMC) (Leiden University Medical Center) - Leiden Institute for Brain and Cognition (LIBC)","city":"Leiden","region":"","country":"Netherlands","lat":52.158329999999999,"lon":4.4930599999999998},{"key":"f27ca47bafc0beaaf1789d6d3ec8ed39dd2973eb988250dcf49e358e580ca35a","facility":"Universitair Medisch Centrum Utrecht (UMC Utrecht)","city":"Utrecht","region":"","country":"Netherlands","lat":52.090829999999997,"lon":5.1222200000000004},{"key":"65033108f2c921e6730b66e12ab86bd21a5830fe2456f05939665d6c1f15c600","facility":"Promente - Ośrodek Badań Klinicznych","city":"Bydgoszcz","region":"","country":"Poland","lat":53.1235,"lon":18.007619999999999},{"key":"d8588dddc2ec49af487209955c5c215697b2b789578db619a235a9fa0af36f7d","facility":"Uniwersyteckle Centrum Kliniczne, Klinika Psychiatrii Doroslych","city":"Gdansk","region":"","country":"Poland","lat":54.352269999999997,"lon":18.64912},{"key":"c96bda844dce2ee72d4741e6f70e1e7c3259ada70b947a164873839ebf52b359","facility":"Centrum Badan Klinicznych PI-House Sp. z o.o.","city":"Gdansk","region":"","country":"Poland","lat":54.352269999999997,"lon":18.64912},{"key":"59233ce7d6f2edef71f68bf51536799ac6a65f87692ff4369de3bf18f425914d","facility":"Hospital Clinic de Barcelona","city":"Barcelona","region":"","country":"Spain","lat":41.38879,"lon":2.1589900000000002},{"key":"46ad5618c3314b159e772e81bf17466910fb4af8aeb31aea469b663c4c645362","facility":"Parc Sanitari Sant Joan de Deu (Sant Joan de Deu Serveis de Salut Mental)","city":"Barcelona","region":"","country":"Spain","lat":41.38879,"lon":2.1589900000000002},{"key":"1ddb4bb3723fd7ceec0c9c2cdbafbb15107fe722952f9927a48a2eb3c1bff9d7","facility":"Hospital Universitario Fundacion Jimenez Diaz","city":"Madrid","region":"","country":"Spain","lat":40.416499999999999,"lon":-3.7025600000000001},{"key":"1e1b6ece04c7ea00924126f7b00e7cbae908840ee7eb0b316cb13e1cb711dd04","facility":"FIDMAG Hermanas Hospitalarias","city":"Sant Boi de Llobregat","region":"","country":"Spain","lat":41.34357,"lon":2.0365899999999999},{"key":"72b144f6dc83ba4a6ecf1f2ac2446fbfd27a9310097e956a77537b55d3eb07e0","facility":"Hospital Universitario Río Hortega de Valladolid","city":"Valladolid","region":"","country":"Spain","lat":41.655410000000003,"lon":-4.7235300000000002},{"key":"2b7b823bf3529da5f066168b504e02a29094c3ea0f7f9163307d91e79cff6fc8","facility":"Hospital Provincial de Zamora - Servicio de Psiquiatria","city":"Zamora","region":"","country":"Spain","lat":41.506329999999998,"lon":-5.7445599999999999},{"key":"f1a0a09fe583f21e302bf05e9ee655cd07aeca8a7eb5aac4b2cfec53e3a42234","facility":"Vuxenpsykiatrimottagningen","city":"Landskrona","region":"","country":"Sweden","lat":55.870800000000003,"lon":12.830159999999999},{"key":"c5c94dd70cd248ae3b8db5ad4cc50a4e910e3809eb4f086106edd7fb1c27a170","facility":"Lunds Universitet - Medicinska Fakulteten (Lund University Faculty of Medicine)","city":"Lund","region":"","country":"Sweden","lat":55.705840000000002,"lon":13.193210000000001},{"key":"1270a8c8958350af2f41db348de64da361ff0a6a3ae2b248ea8f4b4aa0810db6","facility":"ClinSmart Sweden AB","city":"Solna","region":"","country":"Sweden","lat":59.360039999999998,"lon":18.000859999999999},{"key":"8b7e818100b36f2a138b6da62aa3927916f36a260d8e14b9e1b511c61e7be21a","facility":"Hälsoklustret","city":"Stockholm","region":"","country":"Sweden","lat":59.32938,"lon":18.068709999999999},{"key":"502f7a9b486836f86f1c7723e897f8177e5e3b58de30c687b8695cd68684206a","facility":"Cornwall Partnership NHS Foundation Trust","city":"Bodmin","region":"Cornwall","country":"United Kingdom","lat":50.471510000000002,"lon":-4.7243000000000004},{"key":"ed7e594baca236a584b788fcf56a8d9d89ea2c9c1d9c2a2e93c47bb7892b1cbb","facility":"Abraham Cowley Unit - Surrey and Borders Partnership NHS Foundation Trust","city":"Chertsey","region":"","country":"United Kingdom","lat":51.388120000000001,"lon":-0.50782000000000005},{"key":"e1f0e3386129e61cb94fc070476723cc82a349226837177f359093b6504f5ede","facility":"St. Pancras Clinical Research","city":"Chester","region":"","country":"United Kingdom","lat":53.1905,"lon":-2.8918900000000001},{"key":"0e5481c54547720b8f9020635efd953371452d6d017f7f73c704a4b19a0ae2b1","facility":"Grounded Research Hub - Rotherham Doncaster & South Humber NHS Foundation Trust","city":"Doncaster","region":"","country":"United Kingdom","lat":53.522849999999998,"lon":-1.1311599999999999},{"key":"261e4850c7da0eb533cf912b4586297e7d085bcb73610f105b3bfd1c1af443bf","facility":"Clinical Research Facility, Royal Devon and Exeter Hospital","city":"Exeter","region":"","country":"United Kingdom","lat":50.723599999999998,"lon":-3.5275099999999999},{"key":"1a2807daf5cce5445b24431f5172ed03cbadc8702a144d7594f49f64b6a752a2","facility":"Fulbourn Hospital - Cambridgeshire And Peterborough NHS Foundation Trust","city":"Fulbourn","region":"","country":"United Kingdom","lat":52.182830000000003,"lon":0.22045999999999999},{"key":"2af6f49013d0328846d4ce8ee776c303f013ff687e95fd27fa857af0c681008b","facility":"St. Pancras Clinical Research","city":"London","region":"","country":"United Kingdom","lat":51.50853,"lon":-0.12573999999999999},{"key":"02475861c29cbd1b1474d35fe0bd7a2b64282baf79d491e44fc0514393cc6e2b","facility":"King's College London - Institute of Psychiatry, Psychology","city":"London","region":"","country":"United Kingdom","lat":51.50853,"lon":-0.12573999999999999},{"key":"8242b5f25a78f0691cea6b91e224fec590627e484a1125e0e6f474a7065690b8","facility":"Clerkenwell Health","city":"London","region":"","country":"United Kingdom","lat":51.50853,"lon":-0.12573999999999999},{"key":"d517f8dc8bece9df440ed5c67f9a803fdf173dc503e1a2699e9a50011514fa52","facility":"Cumbria, Northumberland, Tyne and Wear NHS Foundation Trust - Wolfson Research Centre","city":"Newcastle","region":"","country":"United Kingdom","lat":54.218040000000002,"lon":-5.8897899999999996},{"key":"01791a48325340ca7a8860be5bc049e6ef8d1bc9e07caf8546c3677942beff75","facility":"University Of Nottingham/Nottinghamshire Healthcare Trust, Institute Of Mental Health","city":"Nottingham","region":"","country":"United Kingdom","lat":52.953600000000002,"lon":-1.1504700000000001},{"key":"b2005f3755ff2b9b0e437b0c0a95409768810e849ab1c6907d0037e7560c4663","facility":"The Warneford Hospital- NIHR Clinical Research Facility","city":"Oxford","region":"","country":"United Kingdom","lat":51.752220000000001,"lon":-1.25596},{"key":"728ba7211bd103ada604bafdb7d6dd131aad2f3d1da71c9bffb43a70f1956e5a","facility":"Sheffield Health and Social Care NHS Foundation Trust","city":"Sheffield","region":"","country":"United Kingdom","lat":53.38297,"lon":-1.4659},{"key":"1b2819d4a8ca62168bb131d84bf5a2039f0800c02db6394dd76a4e6af80edf2c","facility":"James J. Peters Department of Veterans Affairs Medical Center","city":"The Bronx","region":"New York","country":"United States","lat":40.849850000000004,"lon":-73.866410000000002},{"key":"24261169bb3b882e44d0ce9b6db12a1a4ae03b8ce73f9ae22b19e94bba90d4a6","facility":"ProScience Research Group","city":"Culver City","region":"California","country":"United States","lat":34.021120000000003,"lon":-118.39646999999999},{"key":"53861f064c1a9f43fa47a00fa75810394fc0ced2e11c6ce351983a26424f1a9c","facility":"Collaborative Neuroscience Network, LLC","city":"Garden Grove","region":"California","country":"United States","lat":33.773910000000001,"lon":-117.94145},{"key":"1a66f6c1641f91b527ea1da596b436f437b6ca8cc333273f5ca35ea9e309b7aa","facility":"University California San Diego","city":"La Jolla","region":"California","country":"United States","lat":32.847270000000002,"lon":-117.27419999999999},{"key":"121fe8aeeee077fbeb52e9f1471bca271c42bfce67b02ad50d65b709ab003cf0","facility":"California Center for Psychedelic Therapy","city":"Los Angeles","region":"California","country":"United States","lat":34.052230000000002,"lon":-118.24368},{"key":"d7932aa60824f8d82cc579d74b2be467daab59ad9a4864aedfc27e57410e1e44","facility":"Clarity Clinical Research, LLC","city":"Los Angeles","region":"California","country":"United States","lat":34.052230000000002,"lon":-118.24368},{"key":"f9d7ad3ab662ab0b636e2440c3619194c78a3ee16acda243a8d5fab2004d0226","facility":"Artemis Institute for Clinical Research","city":"San Diego","region":"California","country":"United States","lat":32.715710000000001,"lon":-117.16472},{"key":"f8afd960bd569f417d33b370afd03dc4522d769a952965e6473c16317b2cbbcc","facility":"Comprehensive Psychiatric Care","city":"Norwich","region":"Connecticut","country":"United States","lat":41.524259999999998,"lon":-72.075909999999993},{"key":"81ea1f75d333518f039c11053765aac0c019b1120b8bbb0f1ef8f6e0180d1a82","facility":"APG Research, LLC","city":"Orlando","region":"Florida","country":"United States","lat":28.538340000000002,"lon":-81.379239999999996},{"key":"d1d1c12c20d14ca7af6aae7288edc9b1215a68aef339f77dd7037ed8e1070490","facility":"DMI Health Care Group, Inc","city":"Tampa","region":"Florida","country":"United States","lat":27.947520000000001,"lon":-82.458430000000007},{"key":"f330e51df71fdf4b1b4b45c55554f01d0670d6ccd46b9114a1cb1c99138ec54b","facility":"Meridien Research/Accel Research","city":"Tampa","region":"Florida","country":"United States","lat":27.947520000000001,"lon":-82.458430000000007},{"key":"cbc52ccc3240d2384c67bd70f459ee87227d85c7f149a1d0d89c35f236bc92da","facility":"Psych Atlanta","city":"Atlanta","region":"Georgia","country":"United States","lat":33.749000000000002,"lon":-84.387979999999999},{"key":"dddfebfd7c55fd6887c90ed4c4d9ddf35cec45fa0565c30783730eb960b19056","facility":"Emory University","city":"Atlanta","region":"Georgia","country":"United States","lat":33.749000000000002,"lon":-84.387979999999999},{"key":"bc376e1e0a696ea23f74184c3639e3209c4cf2754b05d49dcebccf226428bc05","facility":"Sheppard Pratt Health System","city":"Baltimore","region":"Maryland","country":"United States","lat":39.290379999999999,"lon":-76.612189999999998},{"key":"716580afddf6cd0f33cf716a44cfcca22ce21eaa4c95b49ed07b6271fd6f8d5f","facility":"CBH Health, LLC","city":"Gaithersburg","region":"Maryland","country":"United States","lat":39.143439999999998,"lon":-77.201369999999997},{"key":"aed5f3a3729fadb87eb9ddf7cf97e4496c94256c79003e4950aec06f92bd9335","facility":"Pharmasite Research, Inc","city":"Pikesville","region":"Maryland","country":"United States","lat":39.374270000000003,"lon":-76.722470000000001},{"key":"da66bed5e9f2c5007072da48565dcfb4c000c6aa0bc51cdf5c70ee46cf21fbda","facility":"University of Minnesota","city":"Minneapolis","region":"Minnesota","country":"United States","lat":44.979970000000002,"lon":-93.263840000000002},{"key":"cda828a419db240d879704c5ec8d0590c6dc6665b6cc951ea7d387b451349428","facility":"University of Missouri","city":"Columbia","region":"Missouri","country":"United States","lat":38.951709999999999,"lon":-92.334069999999997},{"key":"e4619be0239dcfaa6cf88391ac51a94bdeb892a639f37981575f1bfbbf8b4b7e","facility":"Midwest Research Group","city":"Saint Charles","region":"Missouri","country":"United States","lat":38.783940000000001,"lon":-90.481229999999996},{"key":"c3de2ce8933f517f3be34bd70e3809569645c3f60c38d874765d86ee599b4223","facility":"Washington University School of Medicine","city":"St Louis","region":"Missouri","country":"United States","lat":38.627270000000003,"lon":-90.197890000000001},{"key":"e92b0749ac676724df1bafae96e4d208c7b45c522933b2dbf2bc22c00aa8ea23","facility":"The Medical Research Network, LLC","city":"New York","region":"New York","country":"United States","lat":40.714269999999999,"lon":-74.005970000000005},{"key":"bd0345ed7184630e5724c893fe997cf750f7382cdd08f6d8cfaca4e419f0098c","facility":"Insight Clinical Trials, LLC","city":"Beachwood","region":"Ohio","country":"United States","lat":41.464500000000001,"lon":-81.50873},{"key":"2f1696f8b848ef33abde31d26e5190829ce43bc6881490782f854d8bae1ad054","facility":"Neuro-Behaviroral Clinical Research, Inc.","city":"North Canton","region":"Ohio","country":"United States","lat":40.875889999999998,"lon":-81.402339999999995},{"key":"c2ab64bad8cb6e1cd94fa26091c2b7967f3576497d9b5ba77fbedf8e1cbda0b8","facility":"Rivus Wellness & Research Institute","city":"Oklahoma City","region":"Oklahoma","country":"United States","lat":35.467559999999999,"lon":-97.51643},{"key":"3d2286af2ccca60c23d4793147a69fc14dabbc3ae3f9dd6f3cb7a1caea3d8f55","facility":"Global Medical Institutes, LLC, Scranton Medical Institute","city":"Moosic","region":"Pennsylvania","country":"United States","lat":41.353409999999997,"lon":-75.738249999999994},{"key":"abde1914156fb3a015069c2985bfbe52696b55acd78e453c5b11b7dad8ea18cb","facility":"UT Health Science Center at Houston (UTHSC-H)","city":"Houston","region":"Texas","country":"United States","lat":29.763280000000002,"lon":-95.36327},{"key":"b4d3e19100a06be7286fb663cf059a1979705efc30bbdaa0f7de176fb34503df","facility":"Core Clinical Research","city":"Everett","region":"Washington","country":"United States","lat":47.97898,"lon":-122.20208},{"key":"106844c26e5555241112f8f0d56e093d03f44485cef1b730bce4ccb7c71b295f","facility":"Toronto Western Hospital - University Health Network","city":"Toronto","region":"Ontario","country":"Canada","lat":43.706429999999997,"lon":-79.39864},{"key":"4c399ae21c1b15c1a76957dcb18c09f6ab07051151f994333e7109fd67ba663d","facility":"Johns Hopkins School of Medicine","city":"Baltimore","region":"Maryland","country":"United States","lat":39.290379999999999,"lon":-76.612189999999998},{"key":"da4eddfd2992562f2fa7a654929ec22b1272c672c077a5078fd4667df5e839c2","facility":"UPMC Presbyterian","city":"Pittsburgh","region":"Pennsylvania","country":"United States","lat":40.440620000000003,"lon":-79.995890000000003},{"key":"fe41ad3987d6de6fe68c69a1ba7b8083c49c8f7f3ed503bb29759b163851e03c","facility":"Univeristy of Southern California Brain and Creativity Institute","city":"Los Angeles","region":"California","country":"United States","lat":34.052230000000002,"lon":-118.24368},{"key":"1dd82fd9cc6558717200ae66d13a24d08c805492d49f67b2d8f9edc800d2c261","facility":"Department of Veterans Affairs","city":"West Haven","region":"Connecticut","country":"United States","lat":41.270650000000003,"lon":-72.947050000000004},{"key":"27055592446b9d587e53a6321150bf4888fc2ba23be8770451328b59a69e7dd8","facility":"Fred Hutch/University of Washington Cancer Consortium","city":"Seattle","region":"Washington","country":"United States","lat":47.606209999999997,"lon":-122.33207},{"key":"3590d22089fced0e188a9729567125a04d5a4db66af91f56a9d2d5c22d92597b","facility":"Toronto Western Hospital","city":"Toronto","region":"Ontario","country":"Canada","lat":43.706429999999997,"lon":-79.39864},{"key":"a9c873ac063d6e120c29fe3a990563df65d56f36d533e4becc50b462afacd39c","facility":"Tel Aviv Sourasky Medical Center","city":"Tel Aviv","region":"","country":"Israel","lat":32.080880000000001,"lon":34.780569999999997},{"key":"a702953addaa4dc3d8c52c701265782e11a96d5e3dba6aa4403c50eb6c2871a1","facility":"Scottsdale Research Institute","city":"Scottsdale","region":"Arizona","country":"United States","lat":33.509210000000003,"lon":-111.89903},{"key":"150ee05b89013f57afa3d4437262fc96492708dbef022aa3d4706d1b2f9b8bcd","facility":"University of Wisconsin - Madison","city":"Madison","region":"Wisconsin","country":"United States","lat":43.073050000000002,"lon":-89.401229999999998},{"key":"56dbd951047579f5e7cb6365abb06b654904e94f48585c22b28b8f01d8930412","facility":"Centro de Pesquisas Matteo Ricci","city":"Rio de Janeiro","region":"Rio de Janeiro","country":"Brazil","lat":-22.906420000000001,"lon":-43.182229999999997},{"key":"b7ce275dcf24ed96a64d133fef7a20f86f0b05456f00dfb40319b4e098140d69","facility":"The Clinical and Translational Sciences Research Center","city":"Tucson","region":"Arizona","country":"United States","lat":32.221739999999997,"lon":-110.92648},{"key":"8cd5c53de095e8abbdf7d2a81b2bc34a9a6968c44ae8f4eb45dc82ef2cf7b17c","facility":"South London and Maudsley NHS Foundation Trust","city":"London","region":"","country":"United Kingdom","lat":51.50853,"lon":-0.12573999999999999},{"key":"14e7954577ce525bd2e7710b02e39fdabf72f2c8d72262f82810220f9bbc7498","facility":"University of Alabama Clinical Research Unit","city":"Birmingham","region":"Alabama","country":"United States","lat":33.520659999999999,"lon":-86.802490000000006},{"key":"134624f1b3ebc995c482aef393a9d811e84fbfdd73e9884dfc7a181efcea7a1f","facility":"Preferred Research Partners-NWA, LLC","city":"Fayetteville","region":"Arkansas","country":"United States","lat":36.062579999999997,"lon":-94.157430000000005},{"key":"36ef6d1faa16c3ec487aae6864eb7b5265c820a39cc8d48cb8f9ee8d6d813e38","facility":"Preferred Research Partners, Inc.","city":"Little Rock","region":"Arkansas","country":"United States","lat":34.746479999999998,"lon":-92.289590000000004},{"key":"e0090c8e01843af348d108c015996af52250bb640aed2100a50bbf5478b2f43a","facility":"West LA VA Medical Center - Mental Health Department","city":"Los Angeles","region":"California","country":"United States","lat":34.052230000000002,"lon":-118.24368},{"key":"333ee8580c6de733d9a6b7d1c27943782b772607f8d8db5ad6d22a1f13cdbc38","facility":"Pacific Neuroscience Institute (PNI) at Saint John's Physician Partners","city":"Santa Monica","region":"California","country":"United States","lat":34.019489999999998,"lon":-118.49138000000001},{"key":"cd3b70cd42e414f693d2181817eaadd4560079c48ff673bea7aa12cd23f4a696","facility":"Psychedelic Science Institute","city":"Santa Monica","region":"California","country":"United States","lat":34.019489999999998,"lon":-118.49138000000001},{"key":"2fbe4fd0fc855904f5e7830f6c1af9e5e02f9eb69a12c4f076f653de81b52c55","facility":"Mountain View Clinical Research","city":"Denver","region":"Colorado","country":"United States","lat":39.739150000000002,"lon":-104.9847},{"key":"6aaffe1ee5c6e69eeb08d4ff968eff6bc874f659ee93212eeefddb37a646f777","facility":"Connecticut Mental Health Center, Yale University","city":"New Haven","region":"Connecticut","country":"United States","lat":41.308149999999998,"lon":-72.928160000000005},{"key":"dab11cb6c1feac91ad29ec450ae10d82f0c4d1351101be32a345ed9645f3e528","facility":"Clinical Neuroscience Solutions Inc.","city":"Jacksonville","region":"Florida","country":"United States","lat":30.332180000000001,"lon":-81.655649999999994},{"key":"1238ad629d3a9b7e22f2a3b74f5e654f316fbb433b79d619fbca7571e41b3e9b","facility":"Clinical Neuroscience Solutions, Inc.","city":"Orlando","region":"Florida","country":"United States","lat":28.538340000000002,"lon":-81.379239999999996},{"key":"37d6ce5812b7579b4de5e55e4c3cb57e1ee148c6b4602abf5d833c2e149ac515","facility":"CenExel iResearch, LLC","city":"Decatur","region":"Georgia","country":"United States","lat":33.774830000000001,"lon":-84.296310000000005},{"key":"845bec3dc316b3c2137f0d6c06c8372da8841a54f8dc62326a4964312161d387","facility":"Great Lakes Clinical Trials","city":"Chicago","region":"Illinois","country":"United States","lat":41.850029999999997,"lon":-87.650049999999993},{"key":"e28b64e754f83e37c6c04dd01732fe94b9a78655852692bd6f79cce0e822cb8d","facility":"Johns Hopkins School of Medicine, Center for Psychedelic and Consciousness Research","city":"Baltimore","region":"Maryland","country":"United States","lat":39.290379999999999,"lon":-76.612189999999998},{"key":"ee018f0ef7f8d9aa2c43156764d8851386a9cc2e57f50a485659f490014db48d","facility":"Sunstone Medical PC","city":"Rockville","region":"Maryland","country":"United States","lat":39.084000000000003,"lon":-77.152760000000001},{"key":"4fa1fba71596431dc1fafcac64c0506ff297f1f1a45eba4ca9b5603a69ef0512","facility":"VA Nebraska Western Iowa Health Care System","city":"Omaha","region":"Nebraska","country":"United States","lat":41.256259999999997,"lon":-95.940430000000006},{"key":"6821666350dba63b993707c9ef1bbd36cb7be5b3e36edac1be1401165a2912e1","facility":"Global Medical Institutes, LLC; Princeton Medical Institute","city":"Princeton","region":"New Jersey","country":"United States","lat":40.34872,"lon":-74.659049999999993},{"key":"558c7f9c59f7f0bcc99c2f9345254b29c79b0ad869836fb1621c4623c5996500","facility":"University of New Mexico (UNM) Interdisciplinary Substance Use and Brain Injury (ISUBI) Center","city":"Albuquerque","region":"New Mexico","country":"United States","lat":35.084490000000002,"lon":-106.65114},{"key":"45628f43bdfea032e58a89b43f8fb6c2bd63b4953aa6832c821a6edea255c9a0","facility":"NYU Clinical & Translational Science Institute","city":"New York","region":"New York","country":"United States","lat":40.714269999999999,"lon":-74.005970000000005},{"key":"6b9e755840736077e18d206704bd73d666a1c134ace71c56736b66d829529002","facility":"Bronx Veterans Research Foundation at the James J. Peters VAMC","city":"The Bronx","region":"New York","country":"United States","lat":40.849850000000004,"lon":-73.866410000000002},{"key":"7b63525882972dd6bf44fcfa835690c748540b4d1139f81fe71dd852856b83e7","facility":"AIM Trials, LLC","city":"Plano","region":"Texas","country":"United States","lat":33.019840000000002,"lon":-96.698890000000006},{"key":"37678407a2aea37d8b45c04bb4f789d0a48aefd9a52d1062eef70dd0656d3034","facility":"Clinical Trials of Texas, LLC","city":"San Antonio","region":"Texas","country":"United States","lat":29.424119999999998,"lon":-98.493629999999996},{"key":"4761e7e68f171ea984a7c8e123dd21a8e90a757c6e37951311684abce81485de","facility":"Cedar Clinical Research, Inc.","city":"Murray","region":"Utah","country":"United States","lat":40.666890000000002,"lon":-111.88799},{"key":"de6dacdebeab612d78b308723aa873619b88e755a446e145e96ac60d29e18b9f","facility":"Seattle Neuropsychiatric Treatment Center","city":"Bellevue","region":"Washington","country":"United States","lat":47.610379999999999,"lon":-122.20068000000001},{"key":"6020223d1dcc5a5283db6886bb3b4b8a3172b842608688b0cbdc5b7777ff0949","facility":"VA Portland Health Care System","city":"Vancouver","region":"Washington","country":"United States","lat":45.638730000000002,"lon":-122.66149},{"key":"53cdbf22033ee2308c3b87787fc126f7b960b463f408d5adce7f8bc3876c2e09","facility":"The Ohio State University Department of Psychiatry","city":"Columbus","region":"Ohio","country":"United States","lat":39.961179999999999,"lon":-82.99879},{"key":"9dd7a5cdc662ca608b61bdc5e24508a870c1b8317b7e9fbcad9af7befe4b01a2","facility":"BioPharma Services Inc.","city":"Toronto","region":"Ontario","country":"Canada","lat":43.706429999999997,"lon":-79.39864},{"key":"e80ae31010614821a2c0251a43cb105eb5afdf4210df2d02fbca62249b4812cb","facility":"Institute of Health Science, Khyber Medical University","city":"Islamabad","region":"Capital","country":"Pakistan","lat":33.72148,"lon":73.043289999999999},{"key":"482052fef0467a4bb441cf6e5d88301072e19c45a3a032776b1d48bce47e7a68","facility":"Hayatabad Medical Complex Peshawar","city":"Peshawar","region":"KPK","country":"Pakistan","lat":34.008000000000003,"lon":71.578490000000002},{"key":"54a0606875858be17f5c6f12f6ec10397681ed8e3c5b816b0964b25c06587ac1","facility":"Khyber Medical University","city":"Peshawar","region":"KPK","country":"Pakistan","lat":34.008000000000003,"lon":71.578490000000002},{"key":"ef06e3a474fd2949d20a68ee09bed05400191915922ddddc3e80085918c45336","facility":"VA Connecticut Healthcare System","city":"West Haven","region":"Connecticut","country":"United States","lat":41.270650000000003,"lon":-72.947050000000004},{"key":"104bc03ef1be3eb283fc88bf5fce3e5ff6c85007bff327791c7a04846f88d35a","facility":"William Osler Health System","city":"Brampton","region":"Ontario","country":"Canada","lat":43.683410000000002,"lon":-79.766329999999996},{"key":"6f7cb2e1921867a894d4f688041519f8adcacf7b68acf4348e2e37c6661d4cdf","facility":"St. Joseph's Healthcare","city":"London","region":"Ontario","country":"Canada","lat":42.98339,"lon":-81.233040000000003},{"key":"f934fa0d3d51d6c774793a28fc64efcf90b8e28198269a1250a0c3f99f3ed6f9","facility":"South Lake Regional Health Centre","city":"Newmarket","region":"Ontario","country":"Canada","lat":44.050109999999997,"lon":-79.466309999999993},{"key":"25666f03708722f78f57cf2a417d211304fca135b845052bac716c024043384f","facility":"Bruyere Health","city":"Ottawa","region":"Ontario","country":"Canada","lat":45.411169999999998,"lon":-75.698120000000003},{"key":"191b97d23002f5fc0aef25ec189e10d4d9cfe3306186fed0ac8629e958a94280","facility":"The Ottawa Hospital","city":"Ottawa","region":"Ontario","country":"Canada","lat":45.411169999999998,"lon":-75.698120000000003},{"key":"ef9bc15ff41fe07277a1de400fafab1b05a763305b6e78adf15926ff3f12ea42","facility":"McGill University Health Centre","city":"Montreal","region":"Quebec","country":"Canada","lat":45.508839999999999,"lon":-73.587810000000005},{"key":"49789f37aec7d28691c1a5e9cd381cbcd8b3460b042712987f08a6b62771c64a","facility":"Bruyere Continuing Care","city":"Ottawa","region":"Ontario","country":"Canada","lat":45.411169999999998,"lon":-75.698120000000003},{"key":"f03299e8c6bc2c4a865cc090ea047d3a962eb50dc47bdd65bf9ed339007f853b","facility":"University of California, Berkeley","city":"Berkeley","region":"California","country":"United States","lat":37.871589999999998,"lon":-122.27275},{"key":"20e312916f86cde9502fe213560fb5cb84834cd4665474a7d3a3ea662605a54d","facility":"Connecticut Mental Health Center","city":"Hamden","region":"Connecticut","country":"United States","lat":41.39593,"lon":-72.896770000000004},{"key":"a17b95243bab2667321a9c9da83c8ea1ac3e43c5e4a76ea01bb2eaf6e4cac641","facility":"West Haven VA Medical Center","city":"West Haven","region":"Connecticut","country":"United States","lat":41.270650000000003,"lon":-72.947050000000004},{"key":"6432b7631d0ccc20e148c4eddca2643abaa034857cab41344671f3fb747879b1","facility":"University of Pennsylvania","city":"Philadelphia","region":"Pennsylvania","country":"United States","lat":39.952379999999998,"lon":-75.163619999999995},{"key":"323f6a0d326702feb35e14a7b9184860791df3488ef3495f35a0de3236897eb0","facility":"Centre Hospitalier de la Côte Basque","city":"Bayonne","region":"","country":"France","lat":43.493160000000003,"lon":-1.4730000000000001},{"key":"5ffc1075f6bec0dadbe8bc3e065b0e1b877e363dbf6627b545bf4beffff70757","facility":"CHU Besançon","city":"Besançon","region":"","country":"France","lat":47.248779999999996,"lon":6.0181500000000003},{"key":"a6fd2e2e6ed56330ba623e90ee634f2d4915008c80b207dde3ed9faf47960e8d","facility":"CHU de Bordeaux","city":"Bordeaux","region":"","country":"France","lat":44.841239999999999,"lon":-0.58045999999999998},{"key":"14ea4a2b72ea454ee54e0e0774dcd9904223f73df3e3c531e7d5f0cfa141d839","facility":"CHU Brest","city":"Brest","region":"","country":"France","lat":48.39029,"lon":-4.4862799999999998},{"key":"f89e51a603fb7d3311c5aa5e1f5fa8b931a29eab96f579366c7020edef6d63eb","facility":"CH Le Vinatier","city":"Bron","region":"","country":"France","lat":45.73865,"lon":4.91303},{"key":"979bc0acd73468b3e9e5e478d1eb8b6146cdb655e43714015ace7d5e264ec03f","facility":"CHU de Nantes","city":"Nantes","region":"","country":"France","lat":47.21725,"lon":-1.5533600000000001},{"key":"4a89439659e3f06e4c831d2ab54c7949dfe24a09c19f411896d75ff90f0f0fde","facility":"CHU de Nîmes","city":"Nîmes","region":"","country":"France","lat":43.836649999999999,"lon":4.3578799999999998},{"key":"3f02e2b16edbfc081f5b9dfd08b8a203c4b47bf73ba2fa3f66915ff73cb56a9b","facility":"CHU Saint-Etienne","city":"Saint-Priest","region":"","country":"France","lat":45.696510000000004,"lon":4.9438500000000003},{"key":"8bf6e838a381bd54a71fab76ec32329ee9e85502264bce18bfd4dce5416f5ef3","facility":"Sunstone Medical, PC","city":"Rockville","region":"Maryland","country":"United States","lat":39.084000000000003,"lon":-77.152760000000001},{"key":"bc86403d1c9f2442271abec1230ce766e06c064f627db179acfcfde14e4f85e3","facility":"New York University","city":"New York","region":"New York","country":"United States","lat":40.714269999999999,"lon":-74.005970000000005},{"key":"b396510f76aa97e398e61aeedd81c7b5fcfd540d418138fc4fb60db60e0a0659","facility":"University Hospital Basel","city":"Basel","region":"Canton of Basel-City","country":"Switzerland","lat":47.558390000000003,"lon":7.5732699999999999},{"key":"dab33405eff5190f72da59b78efc1f976cb32567ca0ed993e0fa62358b51185e","facility":"The Ohio State University Medical Center","city":"Columbus","region":"Ohio","country":"United States","lat":39.961179999999999,"lon":-82.99879},{"key":"c2b8ac7cbe1dfe7dfd4a496dfe7196accedd01cd287918d4f9a3f24cacfa9649","facility":"Toronto General Hospital","city":"Toronto","region":"Ontario","country":"Canada","lat":43.706429999999997,"lon":-79.39864},{"key":"7d95aada95625af597e7f99db1d1499ad1edcc4815ba129bc332e93fab4f316e","facility":"University of Virginia","city":"Charlottesville","region":"Virginia","country":"United States","lat":38.029310000000002,"lon":-78.476680000000002},{"key":"3104f6716f75e5b945ffa549ff984557ea0e6967b3dba8f4b49a8f03caf190bf","facility":"Princess Margaret Cancer Centre","city":"Toronto","region":"Ontario","country":"Canada","lat":43.706429999999997,"lon":-79.39864},{"key":"bfd791b360bb10aa29e67bf9e59fc1b2f04b81de0d1e71a0170094e14bdf29df","facility":"The University of Texas at Austin Dell Medical School","city":"Austin","region":"Texas","country":"United States","lat":30.267150000000001,"lon":-97.74306},{"key":"4662514f893f3efe4da6f3a3a4ba0f9edfcd2d0e99897470f8dae3ff6d2f70fd","facility":"Enact Research Collaborative (40 Temple St, 4th Floor)","city":"New Haven","region":"Connecticut","country":"United States","lat":41.308149999999998,"lon":-72.928160000000005},{"key":"6c4e35a8a1d85d417c6c566904ebcd1766b91b815d9762c5e984afa8b2885908","facility":"Yale Program for Psychedelic Research","city":"New Haven","region":"Connecticut","country":"United States","lat":41.308149999999998,"lon":-72.928160000000005},{"key":"198d5bb2b7293acb85f77709d851433288e2bd94aaa3b81634c72028f5024289","facility":"UCSF Mission Bay","city":"San Francisco","region":"California","country":"United States","lat":37.774929999999998,"lon":-122.41942},{"key":"1a9055771782109a22253dda7644c3735bc7758f34ad52e7af1cb4208b995f4b","facility":"Interdisciplinary Substance Use and Brain Injury (ISUBI)","city":"Albuquerque","region":"New Mexico","country":"United States","lat":35.084490000000002,"lon":-106.65114},{"key":"d6737ae6c1d4e88b0250366ac1706c0eb50510292a7547d4474ad9750824e06e","facility":"UCLA Semel Institute","city":"Los Angeles","region":"California","country":"United States","lat":34.052230000000002,"lon":-118.24368},{"key":"39238c4b9e015bf29cc6e59ed247b7046f1b27b521fdf451030d1ab29482f72d","facility":"UAB Outpatient Clinical Research Unit","city":"Birmingham","region":"Alabama","country":"United States","lat":33.520659999999999,"lon":-86.802490000000006},{"key":"d57ba16f21b5e5513a5f85825fdee40ef908d80b41bdf65f0b98dc075445577b","facility":"Ohio State University Comprehensive Cancer Center","city":"Columbus","region":"Ohio","country":"United States","lat":39.961179999999999,"lon":-82.99879},{"key":"6185aa05c828ffdfd70299b8b961de62ec98b322b02bb5db160c13829b0a3b78","facility":"University of Arizona-Tucson","city":"Tucson","region":"Arizona","country":"United States","lat":32.221739999999997,"lon":-110.92648},{"key":"815dca1c51560a2771c70b436758dad26e0e7113577a98422d68f884f890d354","facility":"National Institute of Mental Health","city":"Prague","region":"","country":"Czechia","lat":50.088039999999999,"lon":14.42076},{"key":"34a79f541cea47ad7b374bfde6da99960b2120ed088ec92eaa3df41e96eb7390","facility":"Bispebjerg Hospital","city":"Copenhagen","region":"","country":"Denmark","lat":55.675939999999997,"lon":12.565530000000001},{"key":"0aaa8840c6965661f46de84dc613d0842e14dbd41f5597c5ec01c47dcbaabd26","facility":"Champalimaud Foundation","city":"Lisbon","region":"","country":"Portugal","lat":38.725090000000002,"lon":-9.1498000000000008},{"key":"d01e30cccc9c6ab8dac4908e28126c4f365239b13b07ded6735ea9cc343d434d","facility":"UNC Chapel Hill Medical Center","city":"Chapel Hill","region":"North Carolina","country":"United States","lat":35.913200000000003,"lon":-79.055840000000003},{"key":"025fc70936d18468a795a0604c0b4bc08e27cb12d5e5b43e1127d0c30c53c200","facility":"Innovative Clinical Research, Inc. (formerly Segal Trials)","city":"Lauderhill","region":"Florida","country":"United States","lat":26.140360000000001,"lon":-80.213380000000001},{"key":"b28ad4c1ff8ff143bf7c2827ef2d114686d3c82f734dbd59191da6544cce398b","facility":"University Hospital Basel, Division of Clinical Pharmacology and Toxicology","city":"Basel","region":"","country":"Switzerland","lat":47.558390000000003,"lon":7.5732699999999999},{"key":"2609712e4f7c93509e6b3bbd8713f3242d8e8886b7480458304bd6280a3610bb","facility":"University Hospital Geneva, Palliative medicine department","city":"Collonge-Bellerive","region":"","country":"Switzerland","lat":46.250610000000002,"lon":6.20174},{"key":"f23fcd3a56bf1387f2f4eb3ab67dce163cae1cad5a551f60baa5d5c5a6da894b","facility":"Spital Uster AG, Division of Internal Medicine","city":"Uster","region":"","country":"Switzerland","lat":47.34713,"lon":8.7209099999999999},{"key":"90de5e97b9c55b0ae303eb535137dc52bdcbaab9be856fa3b3812a38fcbc8990","facility":"University Hospital Zurich, Clinic for Radio-Oncology, Competence Centre Palliative Care","city":"Zurich","region":"","country":"Switzerland","lat":47.366669999999999,"lon":8.5500000000000007},{"key":"4e446ae220965839316b16732aaafbe4ddf148f28c168186b043252417bda1e0","facility":"University of California San Francisco","city":"San Francisco","region":"California","country":"United States","lat":37.774929999999998,"lon":-122.41942},{"key":"c4162229ed6f67b102ed1a6e733b6496859b57b83054c37e22f1710b8c9ce433","facility":"Portland VA Health Care System","city":"Vancouver","region":"Washington","country":"United States","lat":45.638730000000002,"lon":-122.66149},{"key":"ce5773649410208756c8f157ae6af094b53dc7a89423f78b2c8c86f9f332def8","facility":"Pacific Neuroscience Institute","city":"Santa Monica","region":"California","country":"United States","lat":34.019489999999998,"lon":-118.49138000000001},{"key":"a5489b7d1d0b138d5597a0dd410270ad86c9c871bb9c486d957b24f6ec0dee05","facility":"Segal Trials","city":"Lauderhill","region":"Florida","country":"United States","lat":26.140360000000001,"lon":-80.213380000000001},{"key":"be5d63bf40aada157fda0af485fadeddd7eac0c079ecab26a1612289fb4c7fdb","facility":"Johns Hopkins University","city":"Baltimore","region":"Maryland","country":"United States","lat":39.290379999999999,"lon":-76.612189999999998},{"key":"4190340e2c4a95cd68e889c7c9dbfa57587443bfb24f2b6116c85564833f04c2","facility":"New York University School of Medicine","city":"New York","region":"New York","country":"United States","lat":40.714269999999999,"lon":-74.005970000000005},{"key":"176e9ccf5caf25b2aaa9d97e556d0fa794ccf156c4dbf22575b8a382ba3a6aed","facility":"Jewish General Hospital","city":"Montreal","region":"Quebec","country":"Canada","lat":45.508839999999999,"lon":-73.587810000000005},{"key":"5f5211b90f32857d4a2b3783ed0a8d299123b97980aecac0dc9fd0a8439396d7","facility":"region Västra Götaland","city":"Gothenburg","region":"Göteborg","country":"Sweden","lat":57.707160000000002,"lon":11.96679},{"key":"56f6973050dae2540f6877689b3512d938f70ee52e4bd51ebc6542c3a6adaa89","facility":"Norra Stockholms Psykiatri","city":"Stockholm","region":"Stockholm County","country":"Sweden","lat":59.32938,"lon":18.068709999999999},{"key":"384faadacad1af176bc642c675eb5c7bdc2ad01c26ea770b0702143798b59dfa","facility":"Psykiatriska Kliniken, Akademiska Sjukhuset","city":"Uppsala","region":"Uppsala County","country":"Sweden","lat":59.858820000000001,"lon":17.63889},{"key":"046953804b0a225af99cd7bd152e5969b25e38978f43961e75862c8ef2f53fc5","facility":"Örebro sjukhus","city":"Örebro","region":"Örebro County","country":"Sweden","lat":59.274120000000003,"lon":15.2066},{"key":"721cc70d44836b7fa9283632bc238d3076c232982cd2852343243f358edfbe43","facility":"University of California, Los Angeles","city":"Los Angeles","region":"California","country":"United States","lat":34.052230000000002,"lon":-118.24368},{"key":"3bd85f8d9169f9145f6dadbdc3b3147879111bb22b7030edc0ce62cf2445458e","facility":"Clinical Pharmacology & Toxicology, University Hospital Basel","city":"Basel","region":"","country":"Switzerland","lat":47.558390000000003,"lon":7.5732699999999999},{"key":"d8875f7f4d4e3f36b2235d0201354748ba8de08e94380e3b3cb5c9f3cfca0d9e","facility":"Sunnybrook Health Sciences Centre","city":"Toronto","region":"Ontario","country":"Canada","lat":43.706429999999997,"lon":-79.39864},{"key":"5d4ed4b3f6bae7820b0119284aa91b928890b70232a51d746a42e7bc415455f1","facility":"Goodman Hall, Dept of Psychiatry, Indiana University","city":"Indianapolis","region":"Indiana","country":"United States","lat":39.768380000000001,"lon":-86.15804},{"key":"260f0d35c8c3f36f16deaf88e7bddbffd9e05e866f4ee5850ef906d177f62a36","facility":"The Stark Neuroscience Building (Goodman Hall)","city":"Indianapolis","region":"Indiana","country":"United States","lat":39.768380000000001,"lon":-86.15804},{"key":"0baab4fede4fc6054da41261b4cd831dfa37af046f4a5adc5c2912ab388dff0e","facility":"Federal University of Latin American Integration","city":"Foz do Iguaçu","region":"Paraná","country":"Brazil","lat":-25.547779999999999,"lon":-54.588059999999999},{"key":"89e2d67761ad37e19e964873766cfa07d5443f9dabbd7226a4f9fcb320860b0c","facility":"Psychiatric Center Copenhagen, Frederiksberg Hospital","city":"Frederiksberg","region":"","country":"Denmark","lat":55.679380000000002,"lon":12.53463},{"key":"e1f0adb91f843c24eebaa1127eb64810250131187c9a0be296d3c4b271f3acb7","facility":"Medical University of Vienna, Department of Psychiatry and Psychotherapy, Division of General Psychiatry","city":"Vienna","region":"State of Vienna","country":"Austria","lat":48.208489999999998,"lon":16.37208},{"key":"73be9e73a15b0a509c30e07498262eb93d5497d1e464edc1a0207267273a032a","facility":"Queen's University","city":"Kingston","region":"Ontario","country":"Canada","lat":44.229759999999999,"lon":-76.480980000000002},{"key":"57b51432bd54eead1665bf308d75c58452112099cecfea39a38a9a4ae8d6e95d","facility":"UAB Beacon Tower","city":"Birmingham","region":"Alabama","country":"United States","lat":33.520659999999999,"lon":-86.802490000000006},{"key":"53cb5faca3c60ecf068797736403edeb0302d95d0a85337b9536bbc345ef7916","facility":"Connecticut Mental Health Center - Yale School of Medicine","city":"New Haven","region":"Connecticut","country":"United States","lat":41.308149999999998,"lon":-72.928160000000005},{"key":"281c2eb56c8da95ba692a4789013f5bedb7069494aeb666eb410ca73d4c419da","facility":"Ohio State University Department of Psychiatry and Behavioral Health at the Davis Medical Research Center","city":"Columbus","region":"Ohio","country":"United States","lat":39.961179999999999,"lon":-82.99879},{"key":"60b561826ea1087d0a6075e09763aebb8728c09f0183a3d029f1558c69e69bd3","facility":"Mind Medicine Australia Clinic","city":"Abbotsford","region":"Victoria","country":"Australia","lat":-37.799999999999997,"lon":145},{"key":"bc24127b43b0f70565a09f33f689e5c1c9ef6f31ba136c7650ba0fd99b8289cb","facility":"Paratus Clinical Research Melbourne","city":"Northcote","region":"Victoria","country":"Australia","lat":-37.766669999999998,"lon":145},{"key":"adfbd3436ba3de0148122053ef79072e74006b058256ba9b8f2d0a035013fd6b","facility":"Empax Centre","city":"Leederville","region":"Western Australia","country":"Australia","lat":-31.93628,"lon":115.8419},{"key":"206ee54b8eec5bd83c44ff9bdf50d3c675f8537d8c74f1be1ba471dae964c101","facility":"Care Dimensions","city":"Danvers","region":"Massachusetts","country":"United States","lat":42.575090000000003,"lon":-70.930049999999994},{"key":"acb92468b8bdb8e495997bdcc5a1aab1cb194abab89bbb8f698d935f8a4f86a9","facility":"Hammersmith Medicines Research (HMR)","city":"London","region":"","country":"United Kingdom","lat":51.50853,"lon":-0.12573999999999999},{"key":"10c44137a9b4880068299ddcb07a1eb31ce3cb82a82abd191c04b907f1430cba","facility":"Johns Hopkins","city":"Baltimore","region":"Maryland","country":"United States","lat":39.290379999999999,"lon":-76.612189999999998},{"key":"429fe69d07db5cabcda31c9415fb3b7bade24763ccdfea22c895d8c381fdd472","facility":"Hadassah Medical Organization, Jerusalem, Israel","city":"Jerusalem","region":"","country":"Israel","lat":31.76904,"lon":35.216329999999999},{"key":"ea40aea40039489b09eb593dd7ca752f9e392333d283c9e911f6668d71b89b42","facility":"Massachusetts General Hospital","city":"Boston","region":"Massachusetts","country":"United States","lat":42.358429999999998,"lon":-71.05977},{"key":"97ab6774326b85ebb62ea5871bc0b94c44c9454e26b8d744944779b684f9004d","facility":"Nantes University Hospital","city":"Nantes","region":"","country":"France","lat":47.21725,"lon":-1.5533600000000001},{"key":"2efd177beb9722b60d05070a66389e71ae259668c4178f5411487061f62efb7c","facility":"Duke City Recovery Toolbox","city":"Albuquerque","region":"New Mexico","country":"United States","lat":35.084490000000002,"lon":-106.65114},{"key":"8fccc71c53b40f7dc5e28040c7be06eae1a4b7bb5a7209d9aca29d9c5f6643d0","facility":"University of New Mexico","city":"Albuquerque","region":"New Mexico","country":"United States","lat":35.084490000000002,"lon":-106.65114},{"key":"cb49fa24dfbf8e250086b9d17c0538ca82fa2466c8dd249c6067d4280ab1f354","facility":"StartCare","city":"Brooklyn","region":"New York","country":"United States","lat":40.650100000000002,"lon":-73.949579999999997},{"key":"cbc94afe933fcad9921964a6f0b6402d02a73d8e689068a95ac7f922a80f8c1f","facility":"VIP Community Services, Inc","city":"The Bronx","region":"New York","country":"United States","lat":40.849850000000004,"lon":-73.866410000000002},{"key":"e9371a41662463aee2a73b489b08fd54498561d5f98b540ab6947525b5b46514","facility":"Baylor College of Medicine","city":"Houston","region":"Texas","country":"United States","lat":29.763280000000002,"lon":-95.36327},{"key":"99eb38b713e3399c654ea67c21623804abe68f3e3b585ac71a2500aeee975686","facility":"University of California, San Diego","city":"San Diego","region":"California","country":"United States","lat":32.715710000000001,"lon":-117.16472},{"key":"6c0ef8e5236bcabb35a2af5615a610385af1e769f0b6c1dd1a8182e395efb066","facility":"Psych Research","city":"Toronto","region":"Ontario","country":"Canada","lat":43.706429999999997,"lon":-79.39864},{"key":"485cbb329a25d951a977ec15ee6793be07aa56a676a1928d2423d057bc2c5e59","facility":"University of Chicago","city":"Chicago","region":"Illinois","country":"United States","lat":41.850029999999997,"lon":-87.650049999999993},{"key":"bd9ef7ba5708708e271ac4223cd8f759659fe972f273d761152a6c0134e8622e","facility":"Imperial College London","city":"London","region":"","country":"United Kingdom","lat":51.50853,"lon":-0.12573999999999999},{"key":"ea083ab2fc2ae83a35a58fe8386ef0b69ef14561d64fefb0069b5be4bb994b97","facility":"University of British Columbia - Okanagan Campus","city":"Kelowna","region":"British Columbia","country":"Canada","lat":49.883069999999996,"lon":-119.48568},{"key":"7af9ac6392b1552d76cfb9c7864f12f879094bf439d72053786dd890245b723b","facility":"University of Colorado Anschutz Medical campus (CU AMC)","city":"Aurora","region":"Colorado","country":"United States","lat":39.729430000000001,"lon":-104.83192},{"key":"96f2bd88eed1d3818ed1f1051b3996f8f528fdb49be756ea1e8244ba9e93f7ba","facility":"University of Iowa Health Care","city":"Iowa City","region":"Iowa","country":"United States","lat":41.66113,"lon":-91.530169999999998},{"key":"6ca657d87e4528cc481a8c1baf8515a664bf591f795d28d79266623762f21568","facility":"University College London","city":"London","region":"","country":"United Kingdom","lat":51.50853,"lon":-0.12573999999999999},{"key":"15784c018ae70fcfb16f6b7f984cc9132fb865e356d99c82ce788fa1bede4b39","facility":"Health Discovery Building (HDB), 1601 Trinity St., Bldg B., Z0600","city":"Austin","region":"Texas","country":"United States","lat":30.267150000000001,"lon":-97.74306},{"key":"0ad263eeae1a75dac732ec21553e04d77ca0a990e5577d37801aa0cdfc72ee7c","facility":"Marin Cancer Care","city":"Greenbrae","region":"California","country":"United States","lat":37.948540000000001,"lon":-122.5247},{"key":"332dc40567d170a508105ad5d90cc0c3fa47296c7aa99226e6588e8748f592ae","facility":"University of San Francisco","city":"San Francisco","region":"California","country":"United States","lat":37.774929999999998,"lon":-122.41942},{"key":"38d8694ffd1fa8f9e8c095acaf21b7bd718da3dd6a2d2a4642a6dce4e7784baa","facility":"Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center","city":"Torrance","region":"California","country":"United States","lat":33.835850000000001,"lon":-118.34063},{"key":"52db1aeead88bb42011a4764f5c07cbf6c76496768465bd5c4fcd8e25775a003","facility":"Sunstone Therapies","city":"Rockville","region":"Maryland","country":"United States","lat":39.084000000000003,"lon":-77.152760000000001},{"key":"963ff36be3d4be959779a50db385d5b17dd29d729076a98c276ec54e5bf5cfdd","facility":"Psychiatrische Universitätsklinik Zürich","city":"Zurich","region":"","country":"Switzerland","lat":47.366669999999999,"lon":8.5500000000000007},{"key":"f6e857b260b7429beba395444fac2f816d9d86eb9ae717988e7a361b734fead7","facility":"Mental Health Center Beer Sheva","city":"Beersheba","region":"","country":"Israel","lat":31.251809999999999,"lon":34.7913},{"key":"5b227dd2e6263d32525d87b3fb390db797275e595c1806af406b57648ac86736","facility":"Beer Sheva Mental Health Center","city":"Beersheba","region":"","country":"Israel","lat":31.251809999999999,"lon":34.7913},{"key":"097d4730cb01f99d9d2fa793ee390c7860c40b2cbc6537289fd39fa1de4c2ebc","facility":"University of Iowa","city":"Iowa City","region":"Iowa","country":"United States","lat":41.66113,"lon":-91.530169999999998},{"key":"97fa1d69e8603abe5a3ef3a9d6071788707797dc09d271650fc5589a2d7cd901","facility":"VA Connecticut Healthcare System, West Haven Campus","city":"West Haven","region":"Connecticut","country":"United States","lat":41.270650000000003,"lon":-72.947050000000004},{"key":"02631a4a6a3dbc51fd551af9bdf1e4a90d67561f5bc211248aa42c89119b55bc","facility":"Washington University","city":"St Louis","region":"Missouri","country":"United States","lat":38.627270000000003,"lon":-90.197890000000001},{"key":"80808de48757f3ab86bdc23356fb96e401f106b134925f19370a66e24bdd35b1","facility":"LSU Health Shreveport","city":"Shreveport","region":"Louisiana","country":"United States","lat":32.525149999999996,"lon":-93.75018},{"key":"17373296f16c3a4efdaa8068b534d498ee273ea3e341911c48b8927bb2cf1330","facility":"Geneva University Hospital","city":"Geneva","region":"","country":"Switzerland","lat":46.202219999999997,"lon":6.1456900000000001},{"key":"2e5a211e4aae826703cd0d478a5304735037ed9f6e5d1fffb9064c5fa43504bb","facility":"Innertrek Patient Service Center","city":"Portland","region":"Oregon","country":"United States","lat":45.523449999999997,"lon":-122.67621},{"key":"f26bee6a0a45781053d5dfa012f97c3db3997369bce9de3db4cd4cc54b57daa6","facility":"Maastricht University","city":"Maastricht","region":"Limburg","country":"Netherlands","lat":50.848329999999997,"lon":5.6888899999999998},{"key":"53531a82330e40fa414108ebaefe85390bc30ce9a2da6c9a7d1d8128d9c6c3a2","facility":"Leiden University Medical Center","city":"Leiden","region":"South Holland","country":"Netherlands","lat":52.158329999999999,"lon":4.4930599999999998},{"key":"84d3b2e5a3a8521c2be63f3b94f0d00d44e1ecaff45bb8e80b74fbc4dd66bb3c","facility":"King's College London Institute of Psychiatry, Psychology and Neuroscience","city":"London","region":"","country":"United Kingdom","lat":51.50853,"lon":-0.12573999999999999},{"key":"c7d0f9ad38775ee389ffdd32d7a11b15a481184b7eb272189d6f8312f3074323","facility":"Lady Reading Hospital, Pakistan","city":"Peshawar","region":"Khyber Pakhtunkhwa","country":"Pakistan","lat":34.008000000000003,"lon":71.578490000000002},{"key":"6c7782ed88077aba01acca89cafaa29ef044132bd5e6ac7264c2f146705cf434","facility":"CHU de Nîmes, Hôpital Universitaire Carémeau","city":"Nîmes","region":"","country":"France","lat":43.836649999999999,"lon":4.3578799999999998},{"key":"c99816974f0fb391132ed7769c5eb4ada168032749e3008faafa7d34aaedf88d","facility":"Behavioral Pharmacology Research Unit","city":"Baltimore","region":"Maryland","country":"United States","lat":39.290379999999999,"lon":-76.612189999999998},{"key":"8c60b612e34dd2ffc6608ca0a06d7e3d5b026f9298fdb849106297822e4ca75d","facility":"Clinical Neuroscience Solutions Inc","city":"Jacksonville","region":"Florida","country":"United States","lat":30.332180000000001,"lon":-81.655649999999994},{"key":"5094cd778f2393158194a4acd2f61f98cd406b23d443dab41e2f4a1fa2124035","facility":"Elixia MA, LLC","city":"Springfield","region":"Massachusetts","country":"United States","lat":42.101480000000002,"lon":-72.58981},{"key":"1245c616ad9a5aafc72a46e45a4f8a7944fc567e32ee983414fa2a90dff5b99f","facility":"Aims Trial","city":"Plano","region":"Texas","country":"United States","lat":33.019840000000002,"lon":-96.698890000000006},{"key":"a2a4ed472d0c860a706d8a130661a9baa3742799c37bd96f2f64a1cdd0866b66","facility":"King's College London","city":"London","region":"","country":"United Kingdom","lat":51.50853,"lon":-0.12573999999999999},{"key":"18db5edcbdce2ce9d52632dc7fd86a8c0ad5c72075ddcbaef8ccbc091276d0ba","facility":"Emory University/Winship Cancer Institute","city":"Atlanta","region":"Georgia","country":"United States","lat":33.749000000000002,"lon":-84.387979999999999},{"key":"40311bdce25b868fa367c6b593e5197383e808ec7d37f412f45ff21e464e2ef8","facility":"Brain Health Center at Executive Park","city":"Atlanta","region":"Georgia","country":"United States","lat":33.749000000000002,"lon":-84.387979999999999},{"key":"6332cc00e1ef6b028ce5b2931bc428fb44a6e2eca82b5135ec346b7ceedf62ae","facility":"Icahn School of Medicine at Mount Sinai","city":"New York","region":"New York","country":"United States","lat":40.714269999999999,"lon":-74.005970000000005},{"key":"190dd76ab65ad7b28570cf2992585e62e7281887f8f4acc4cc7ee1b0ebcb7c7e","facility":"Kings College London, Institute of Psychiatry, Psychology and Neurology","city":"London","region":"","country":"United Kingdom","lat":51.50853,"lon":-0.12573999999999999},{"key":"a09e8186ba91aa1702e842c7ad40903a2cbce5c4b72a9493394ca5b209d4e052","facility":"CMAX Clinical Research","city":"Adelaide","region":"South Australia","country":"Australia","lat":-34.928660000000001,"lon":138.59863000000001},{"key":"3f8d5218d2ffc6ea8473ce2d358bca1e459782dafccddcfd64ae7296c5336987","facility":"National University of Natural Medicine","city":"Portland","region":"Oregon","country":"United States","lat":45.523449999999997,"lon":-122.67621},{"key":"ebda5e93566d65c5a0d08874906c8e63c9d620a77b25a4867b0465a3d920d8ef","facility":"Clinical Trial Unit","city":"Basel","region":"Canton of Basel-City","country":"Switzerland","lat":47.558390000000003,"lon":7.5732699999999999},{"key":"f728406bf268c1157eadcec1c17036ddef288c0c8a17b0883ee337abaeaac4bc","facility":"Neuroimaging Research Branch, NIDA-IRP","city":"Baltimore","region":"Maryland","country":"United States","lat":39.290379999999999,"lon":-76.612189999999998},{"key":"dfd44dbf58c7269a3dc9de0e69126ca81c5af72da9ff806f80dc2a90ae2be7f0","facility":"University of Wisconsin Hospital and Clinics","city":"Madison","region":"Wisconsin","country":"United States","lat":43.073050000000002,"lon":-89.401229999999998},{"key":"e61b82022d59d1b6f216840fa8e11fe15a6e63ddf70a4fefdcdd7e0f971a1974","facility":"Icahn School of Medicine at Mount Sinai, Center for Psychedelic Therapy Research","city":"New York","region":"New York","country":"United States","lat":40.714269999999999,"lon":-74.005970000000005},{"key":"38277cc33e9b01c0912117b90ec217a624b83ded19092f8b50f1fc25417f8e3f","facility":"Chronic Pain and Fatigue Research Center","city":"Ann Arbor","region":"Michigan","country":"United States","lat":42.277560000000001,"lon":-83.740880000000004},{"key":"403cf26dc1cd086ac357e6e0704cef6be00b732058ea333f56c4183c0c6738b6","facility":"University of Otago","city":"Christchurch","region":"","country":"New Zealand","lat":-43.533329999999999,"lon":172.63333},{"key":"de943dc53921b98b85839676ebd9bd35ab84bed7e937ec479cae02f2f56e5fd9","facility":"St. Michael's Hospital. Unity Health Toronto","city":"Toronto","region":"Ontario","country":"Canada","lat":43.706429999999997,"lon":-79.39864},{"key":"ac63a9b87b0d17c174df6cd33e9b23cdf05c23cc85c8cd317f6c08206a61f3ac","facility":"University Hospital","city":"Basel","region":"","country":"Switzerland","lat":47.558390000000003,"lon":7.5732699999999999},{"key":"715908c4979cbcb23bee4bb972336ab1530b5731718f5dd77546b6021989aad2","facility":"Department of Nuclear Medicine, Bern University Hospital","city":"Bern","region":"","country":"Switzerland","lat":46.948090000000001,"lon":7.4474400000000003},{"key":"b2f80bbc21f8f731c71b9ae4cd9db0e64fd8e3bd14ac7dbf1065c5b86be66a11","facility":"Psychiatric University Hospital Zurich","city":"Zurich","region":"","country":"Switzerland","lat":47.366669999999999,"lon":8.5500000000000007},{"key":"4fd62086c4d69458b7c2814650e353d5cc7313e840825f60e22f1fe59e5ab9b1","facility":"CHU","city":"Nîmes","region":"Nîmes","country":"France","lat":43.836649999999999,"lon":4.3578799999999998},{"key":"285f505708621e1f0fc9c6266c0110f7a1a84d0c2b08e83438836c81413008ad","facility":"University of Washington","city":"Seattle","region":"Washington","country":"United States","lat":47.606209999999997,"lon":-122.33207},{"key":"91c08ea7e8178d877e37065524d657f71f7f45eb4588c8396bf5ed6845e64c72","facility":"Harbor-UCLA Medical Center","city":"Torrance","region":"California","country":"United States","lat":33.835850000000001,"lon":-118.34063},{"key":"ca2d4ec9703fe3f5f146e1bd00eb9f0e2994b62836d9dfa60c94b7c30be1bf37","facility":"Charité Berlin, Campus Mitte, Department of Psychiatry and Psychotherapy","city":"Berlin","region":"","country":"Germany","lat":52.524369999999998,"lon":13.41053},{"key":"1c79f25f1e0ee6d8df07a3e5e4b5a843a34080ae32902e2e0c01f99d02b07a16","facility":"Central Institute of Mental Health (CIMH)","city":"Mannheim","region":"","country":"Germany","lat":49.489100000000001,"lon":8.4669399999999992},{"key":"194d419533160aa241e58316c109a3778e280f27677956060dac8d0bfae574c6","facility":"Neurobiology Research Unit, Rigshospitalet","city":"Copenhagen","region":"","country":"Denmark","lat":55.675939999999997,"lon":12.565530000000001},{"key":"b62c29cd779fd43501f426fef3293a64089108a0e7e17ae13b4044a87d256c81","facility":"Altman Clinical and Translational Research Institute","city":"San Diego","region":"California","country":"United States","lat":32.715710000000001,"lon":-117.16472},{"key":"44dff036ba0c252b89f384cafd7b6afe7f6dbbde33d112b5813eb8a58984f3ba","facility":"Dell Medical School","city":"Austin","region":"Texas","country":"United States","lat":30.267150000000001,"lon":-97.74306},{"key":"5770cc81f9352293b4571ef32e9013b2ee451488e071dd9fa0c99aebe3a521cb","facility":"University of Florida","city":"Gainesville","region":"Florida","country":"United States","lat":29.651630000000001,"lon":-82.324830000000006},{"key":"0c0bb514818072629295ef417bfbdcf56e7ac0531b9beee0971543a5f874732e","facility":"Huntsman Mental Health Institute","city":"Salt Lake City","region":"Utah","country":"United States","lat":40.760779999999997,"lon":-111.89105000000001},{"key":"cd53ff909631c02493009d6fa3e945541560209fce31bf8b65855864408557b7","facility":"CIPPRes Clinic","city":"London","region":"","country":"United Kingdom","lat":51.50853,"lon":-0.12573999999999999},{"key":"92f7e0cc003e9611ea48c068566e59f517929115533a6bed42bf34a1e382a8a8","facility":"Imperial College Hammersmith campus","city":"London","region":"","country":"United Kingdom","lat":51.50853,"lon":-0.12573999999999999},{"key":"dd2376bcaedbd8ec29b41fc08e574f0f48cfcd642bdbaf4b61cdc470ebcda7cc","facility":"CMAX Clinical Research Pty Ltd","city":"Adelaide","region":"South Australia","country":"Australia","lat":-34.928660000000001,"lon":138.59863000000001},{"key":"de5de4cd4a64693d58b4d482b491ab2adbd6db4602a86d03c76d0c7dfa1737de","facility":"Ghent University Hospital","city":"Ghent","region":"Oost-Vlaanderen","country":"Belgium","lat":51.049999999999997,"lon":3.7166700000000001},{"key":"5b68ee01102e7545497cccc1eed4861724cfdb4157ff64793fb872b22d1007f6","facility":"University of Arizona","city":"Tucson","region":"Arizona","country":"United States","lat":32.221739999999997,"lon":-110.92648},{"key":"7921922108da606383f02d461f4df4e14db71c279c22c13f6e0098569e6fc045","facility":"Sabi Mind","city":"Calgary","region":"Alberta","country":"Canada","lat":51.050109999999997,"lon":-114.08529},{"key":"f382a179650c2df27e8a44e5fbd93e67557feb21753716040410f9b7f60eb029","facility":"Centre for Neurology Studies","city":"Surrey","region":"British Columbia","country":"Canada","lat":49.106349999999999,"lon":-122.82509},{"key":"67a68181704a60b202e5bd17a9943b90ad9f4f4bae50a883bcee9366ae6b07ab","facility":"University of British Columbia, Department of Psychiatry, BRAIN Lab","city":"Vancouver","region":"British Columbia","country":"Canada","lat":49.249659999999999,"lon":-123.11933999999999},{"key":"48228a6e53745d2e5d9ebb9d9e380833b371fa7e760c88385827be732372c4f7","facility":"Centricity Research","city":"Halifax","region":"Nova Scotia","country":"Canada","lat":44.642690000000002,"lon":-63.576880000000003},{"key":"e6f14c804d63d788a9de79fa6c9092129f515985d376c7b8cc0020b9e61c1729","facility":"Department of Psychiatry, Queen's University","city":"Kingston","region":"Ontario","country":"Canada","lat":44.229759999999999,"lon":-76.480980000000002},{"key":"d06e48f11f12f9cf06e95d71a691ebf90c8fe98aefa9008cd221096d6eabb8b9","facility":"Research Center Oxidi Oy / Addiktum Oy","city":"Helsinki","region":"","country":"Finland","lat":60.169519999999999,"lon":24.935449999999999},{"key":"a967236f529970e305e31c0bb38c4df0951a3d9fa9defea114930d40bbcb3df8","facility":"A-Klinikka","city":"Kouvola","region":"","country":"Finland","lat":60.866669999999999,"lon":26.699999999999999},{"key":"097f01f888974a19c581a1a4a48207f44890c9eb5fc62fd738265f1e44166755","facility":"Mentacare Oy","city":"Oulu","region":"","country":"Finland","lat":65.012360000000001,"lon":25.468160000000001},{"key":"2b75d8f2d0990670d7c5884774f83a08cea77ea8701cbb5acf36b7aa6d726817","facility":"Addiktum Oy","city":"Turku","region":"","country":"Finland","lat":60.451479999999997,"lon":22.268689999999999},{"key":"ec5ea7fe39f9d8b779c8f5306f31a5e6e2852baac72dfa28060b9c9d1d8cf5c5","facility":"VA Palo Alto Healthcare System/Stanford Medicine","city":"Palo Alto","region":"California","country":"United States","lat":37.441879999999998,"lon":-122.14302000000001},{"key":"dafa3859e760931a703dbfafba7ca9060f6a965b188b8bd05bfcdce5b2f5f81d","facility":"Brugmann University Hospital","city":"Brussels","region":"","country":"Belgium","lat":50.850450000000002,"lon":4.3487799999999996},{"key":"480677b0a56d457be4a4efa8940d8eceb5f184eb3c10619dc4359584550e04e3","facility":"Psychiatric Center Copenhagen","city":"Copenhagen","region":"Frederiksberg","country":"Denmark","lat":55.675939999999997,"lon":12.565530000000001},{"key":"6732f25d9e7c5ee9eed300cdd40165c9c1b7f0ca5cc99960985a65e7da08f98b","facility":"Behavioral Biology Research Center, Johns Hopkins Bayview","city":"Baltimore","region":"Maryland","country":"United States","lat":39.290379999999999,"lon":-76.612189999999998},{"key":"ab3cd7771782c6f43e2834a6cc70a3c0c8ea89ffdaffe63af517b64058c9c50f","facility":"KGK Science Inc.","city":"London","region":"Ontario","country":"Canada","lat":42.98339,"lon":-81.233040000000003},{"key":"233b6ae11780c805724450c320e419d5b4e212f235659d5a9581ded7c6d5ea19","facility":"Universtity Hospital Basel","city":"Basel","region":"","country":"Switzerland","lat":47.558390000000003,"lon":7.5732699999999999},{"key":"08ca08bcbae798f4e6b61831eefcfb8b407b6ae9119e1caf821ef346cd1389e6","facility":"Northern Stockholm Spychiatry Clinic","city":"Stockholm","region":"","country":"Sweden","lat":59.32938,"lon":18.068709999999999},{"key":"be135dd6d3f7f605d0d633fc0bf5a818d78aa1bf95594c214d6c72a5b15b1206","facility":"Huntsman Cancer Institute","city":"Salt Lake City","region":"Utah","country":"United States","lat":40.760779999999997,"lon":-111.89105000000001},{"key":"bc118043aa3f26bbd3206be4e9c03a0fb0cffd4b4da900e4718d4e5764570ea5","facility":"University Hospital Basel, Clinical Trial Unit","city":"Basel","region":"Canton of Basel-City","country":"Switzerland","lat":47.558390000000003,"lon":7.5732699999999999},{"key":"4326182cc3c941409c93d0ef63691280ed9c41889de2f55922782d475630190d","facility":"Mount Sinai Comprehensive Cancer Center","city":"Miami Beach","region":"Florida","country":"United States","lat":25.790649999999999,"lon":-80.130049999999997},{"key":"27288850d009a8b31ead8ba5cf86982457592df2fa39c3adaf10d04517cf8a5c","facility":"Sheaf House, Tallaght Hospital","city":"Dublin","region":"","country":"Ireland","lat":53.333060000000003,"lon":-6.2488900000000003},{"key":"d761fe5f7a78138ff98cd1bb8712803a88c9a303339158053d3bf4cc3260d670","facility":"University of New Mexico Health Sciences Center","city":"Albuquerque","region":"New Mexico","country":"United States","lat":35.084490000000002,"lon":-106.65114},{"key":"372b3cad1815f00ae861323f9482b2ae015f778ad15ef5ae35dd9e54c31af368","facility":"Pharmaceutical Research Unit","city":"Amman","region":"","country":"Jordan","lat":31.955220000000001,"lon":35.945030000000003},{"key":"c1ae66a93c93e2e1e5f32a14c0f481e169db396e25ea7da6058e79087f8bffe5","facility":"Altasciences Clinical Kansas, Inc","city":"Overland Park","region":"Kansas","country":"United States","lat":38.982230000000001,"lon":-94.670789999999997},{"key":"25aca439e042e37bcb80c657bd30517c9daccd35fcab6328ee61c917337dfdd8","facility":"Canadian Rapid Treatment Centre of Excellence (CRTCE)","city":"Mississauga","region":"Ontario","country":"Canada","lat":43.578899999999997,"lon":-79.658299999999997},{"key":"a548c29a91f00e104ef28ac8ad761250fc7cefa257637d971bae85c1e19fc9fc","facility":"Centre for Neurology Studies x Upstream","city":"Abbotsford British Columbia","region":"British Columbia","country":"Canada","lat":49.057980000000001,"lon":-122.25257000000001},{"key":"d7257b7fd44162d83dfa116702665c090a51c6ae85a769c73bad67cf2d2ceb74","facility":"Halucenex Life Sciences Inc.","city":"Windsor","region":"Nova Scotia","country":"Canada","lat":44.983449999999998,"lon":-64.132040000000003},{"key":"9b630a2a90cc4073ef88d0ddbb37bf0acd68f69db35ab18518826ea459738714","facility":"Combat Stress","city":"Leatherhead","region":"Surrey","country":"United Kingdom","lat":51.296520000000001,"lon":-0.33379999999999999},{"key":"47a84d20902561e3e1fff1f955d9e2b25ff749b49e7a043201a36eaa8d67beee","facility":"UWHealth, 600 Highland Avenue","city":"Madison","region":"Wisconsin","country":"United States","lat":43.073050000000002,"lon":-89.401229999999998},{"key":"b902b2ed0312cb2a3cc5ba1cbae37f314afc33004604dfd9c9cef9895f4cf659","facility":"Altman Clinical and Translational Research Institute, University of California","city":"San Diego","region":"California","country":"United States","lat":32.715710000000001,"lon":-117.16472},{"key":"98e89c02051d49d5ecbaeeb42b54b85d2011fdba360a21f7bb381022221609db","facility":"Stanford Department of Psychiatry","city":"Stanford","region":"California","country":"United States","lat":37.424109999999999,"lon":-122.16607999999999},{"key":"4a761e46fb0059d7f502f97e7ff683ed2ef7e77e5bb9c131a2f074aa39eba6a4","facility":"Mood and Anxiety Disorders Program Emory University School of Medicine","city":"Atlanta","region":"Georgia","country":"United States","lat":33.749000000000002,"lon":-84.387979999999999},{"key":"f364e291f7f50ffe0211133728e04e54d4b08d8bbf7f1e2e84acca880af73791","facility":"Ray Worthy Psychiatry LLC","city":"New Orleans","region":"Louisiana","country":"United States","lat":29.954650000000001,"lon":-90.075069999999997},{"key":"bc6f21f5dce4d260a52c1cf80e4684418e2cef5172a8a249513f0bd649090cc4","facility":"UT Center of Excellence on Mood Disorders, University of Texas Health Science Center","city":"Houston","region":"Texas","country":"United States","lat":29.763280000000002,"lon":-95.36327},{"key":"4518bb99925a2afc34b082750c6bbd85e5a2401e5aedd715ecf330439d7becd3","facility":"Canadian Rapid Treatment Centre of Excellence","city":"Mississauga","region":"Ontario","country":"Canada","lat":43.578899999999997,"lon":-79.658299999999997},{"key":"fcbe4ef7ab96b23d49f2236d5eef4a63ae4ba8b1ef6fda33e2d4ecdfcd59a37c","facility":"National Institute of Mental Health Czech Republic","city":"Klecany","region":"","country":"Czechia","lat":50.175989999999999,"lon":14.411479999999999},{"key":"4325121d3f92a59587a95d740aec742f926476ae029c126cfb5dca75235c060c","facility":"Enhed for Psykiatrisk Forskning, Psykiatrien i Aalborg","city":"Aalborg","region":"","country":"Denmark","lat":57.048000000000002,"lon":9.9186999999999994},{"key":"acb48d7ccc1915a74261eb4d19980566f9e91227b002d29827c3b573468fca20","facility":"Charité - Universitätsmedizin Berlin, Department of Psychiatry and Psychotherapy, Campus Benjamin Franklin","city":"Berlin","region":"","country":"Germany","lat":52.524369999999998,"lon":13.41053},{"key":"4676f983baba50649c69d87e10227647f558552da403e1c02eb74db43f5954ef","facility":"Groningen University Medical Centre","city":"Groningen","region":"","country":"Netherlands","lat":53.219169999999998,"lon":6.5666700000000002},{"key":"e3f0197997fa9570956493b45ec7d746c6d8470a0084194ccfaca38d381335d5","facility":"Leiden University Medical Centre","city":"Leiden","region":"","country":"Netherlands","lat":52.158329999999999,"lon":4.4930599999999998},{"key":"8739aa2791a55723dbde929d6b1781e8da3c89797ac9f3c5cdcebc53f0be213d","facility":"Utrecht University Medical Centre","city":"Utrecht","region":"","country":"Netherlands","lat":52.090829999999997,"lon":5.1222200000000004},{"key":"0825127fed75b48491c482e72ff85f37b6d6a30ff270fa31a00aa738dfdab8b5","facility":"Unidade de Neuropsiquiatria, Centro Clinico Champalimaud","city":"Lisbon","region":"","country":"Portugal","lat":38.725090000000002,"lon":-9.1498000000000008},{"key":"8f7b027dc17f2a210264a5079ecaf11ec7851ea8acc52e06427fe3f08b1d2d69","facility":"Hospital de Dia Numancia","city":"Barcelona","region":"","country":"Spain","lat":41.38879,"lon":2.1589900000000002},{"key":"591cc23da3dbb467891a35aca8c18e00a3a00b36e679e2bc3a5c63f9cf912dff","facility":"Institute Hospital del Mar of Medical Research (IMIM)","city":"Barcelona","region":"","country":"Spain","lat":41.38879,"lon":2.1589900000000002},{"key":"4cb30a0cc2db1ef7bb013544a9f7756b74181b28b02d444b55518e6a7c5edd95","facility":"Clinical Research and Imaging Centre","city":"Bristol","region":"Avon","country":"United Kingdom","lat":51.45523,"lon":-2.5966499999999999},{"key":"ca5a318b9a8ab497d31d6e617a67f5536afaff42907d21d3392ac8c92cf5b910","facility":"Wolfson Research Centre, Campus for Ageing and Vitality","city":"Newcastle upon Tyne","region":"Tyne and Wear","country":"United Kingdom","lat":54.973280000000003,"lon":-1.6139600000000001},{"key":"49c938f65ac4e8234198d3d31829a1e4505a68760ed1739762448f71dbb85a8c","facility":"Greater Manchester Mental Health Foundation Trust","city":"Manchester","region":"","country":"United Kingdom","lat":53.48095,"lon":-2.2374299999999998},{"key":"abe2a0347c9a44ae241f4c2ee5f16cf0ec3542f9eaaaf340b9331c306c8d45ee","facility":"New York State Psychiatric Institute, 1051 Riverside Drive","city":"New York","region":"New York","country":"United States","lat":40.714269999999999,"lon":-74.005970000000005},{"key":"16d9ba9702f70f239da1a221cfefc364c6d5b87b4d0db3a5b080e4cd80046ae8","facility":"Pacific Treatment & Research in Psychedelics","city":"Santa Monica","region":"California","country":"United States","lat":34.019489999999998,"lon":-118.49138000000001},{"key":"187f9016fa20748a1f0b5436017e547660508fd4ed996a1485b5172a8705a463","facility":"Ross Allison NPI #1437519899 Administrator Of Study","city":"Bozeman","region":"Montana","country":"United States","lat":45.679650000000002,"lon":-111.03856},{"key":"2715c70c5a3cf61074816c8f4c0e3981b0c63530ec8157146313a3c8963e5794","facility":"Clinical and Translational Science Institute, NYU Langone Medical Center","city":"New York","region":"New York","country":"United States","lat":40.714269999999999,"lon":-74.005970000000005},{"key":"9676aa62be8612c7fce92ed8df2903ba93533215f56626938a83ac502dae0874","facility":"Sheppard Pratt","city":"Baltimore","region":"Maryland","country":"United States","lat":39.290379999999999,"lon":-76.612189999999998},{"key":"36cbadd08074d94fbe0a5b1b81e0701fcbda7798b24d5e8d9d9005fb9eb81047","facility":"Altman Clinical and Translational Research Institute","city":"La Jolla","region":"California","country":"United States","lat":32.847270000000002,"lon":-117.27419999999999},{"key":"67679966468a2018f1bdb6a74e7e4ef191ee055a3a28ed6d73618e92950f9177","facility":"FMS Department of Psychiatry","city":"Kingston","region":"","country":"Jamaica","lat":17.997019999999999,"lon":-76.793580000000006},{"key":"d1d8d084525b2d3486bf0c2b7d493ab1c682a967c30c20c77a945624472cd2ab","facility":"NYU Langone Medical Center/Tisch Hospital","city":"New York","region":"New York","country":"United States","lat":40.714269999999999,"lon":-74.005970000000005},{"key":"8f4b75aaf233d6bdd457e79d183df0aeecff4606794e577db9ad0470e8f822bd","facility":"Private Practice P.Gasser","city":"Solothurn","region":"Canton of Solothurn","country":"Switzerland","lat":47.207909999999998,"lon":7.53714},{"key":"45122612fb949f8500264d93f224a0323fcb7b1201661dbaff6914df06fb22b6","facility":"Instituto de Fisica de Buenos Aires (IFIBA)","city":"Buenos Aires","region":"","country":"Argentina","lat":-34.613149999999997,"lon":-58.377229999999997},{"key":"86fc9804485a03c3ff76195ce0de591aa8df52a325e697383b84e2beae895656","facility":"Behavioral Pharmacology Research Unit, Johns Hopkins Bayview Medical Center","city":"Baltimore","region":"Maryland","country":"United States","lat":39.290379999999999,"lon":-76.612189999999998},{"key":"6efaf5397268b87a303da006e78044c4e6a5b482459e0d1e7b74ca9c58ce0e0b","facility":"Maryland Oncology Hematology PA","city":"Rockville","region":"Maryland","country":"United States","lat":39.084000000000003,"lon":-77.152760000000001},{"key":"78b406395b11d45e5de52f1bd4997ed2ba1a3a3edbf561ff0ce4bc7bc43bb19f","facility":"NYU College of Dentistry Bluestone Center for Clinical Research","city":"New York","region":"New York","country":"United States","lat":40.714269999999999,"lon":-74.005970000000005},{"key":"6aef8b3e098d088faf66b099ff25db39f20cd48e8cf64e636833f68681dcc663","facility":"University of Wisconsin, School of Pharmacy","city":"Madison","region":"Wisconsin","country":"United States","lat":43.073050000000002,"lon":-89.401229999999998},{"key":"07a8178170a30179f640b9c70731e1d415c7038aab9705b99f55e89c1cc1fb21","facility":"Mitul Mehta","city":"London","region":"Camberwell","country":"United Kingdom","lat":51.50853,"lon":-0.12573999999999999},{"key":"8a9fa87413d480bac878c14fd3780e61a2c0f2573c87aa67b3913724f16cc960","facility":"Behavioral Pharmacology Research Unit, Johns Hopkins Bayview Campus","city":"Baltimore","region":"Maryland","country":"United States","lat":39.290379999999999,"lon":-76.612189999999998}],"enrollment":{"sum":15051,"known_trials":308},"registry_checked_at_utc":"2026-10-09 01:24:43"}